Form 10-Q

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

0001193125-14-403358.txt : 20141107 0001193125-14-403358.hdr.sgml : 20141107 20141107161328 ACCESSION NUMBER: 0001193125-14-403358 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20140930 FILED AS OF DATE: 20141107 DATE AS OF CHANGE: 20141107 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ORASURE TECHNOLOGIES INC CENTRAL INDEX KEY: 0001116463 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 364370966 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-16537 FILM NUMBER: 141205063 BUSINESS ADDRESS: STREET 1: 150 WEBSTER ST CITY: BETHLEHEM STATE: PA ZIP: 18015 BUSINESS PHONE: 5036416115 MAIL ADDRESS: STREET 1: 150 WEBSTER ST CITY: BETHLEHEM STATE: PA ZIP: 18015 10-Q 1 d811738d10q.htm FORM 10-Q Form 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2014.

¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to .

Commission File Number 001-16537

ORASURE TECHNOLOGIES, INC.

(Exact Name of Registrant as Specified in Its Charter)


DELAWARE		36-4370966
(State or Other Jurisdiction of Incorporation or Organization)		(IRS Employer Identification No.)

220 East First Street, Bethlehem, Pennsylvania		18015
(Address of Principal Executive Offices)		(Zip code)

(610) 882-1820

(Registrant’s Telephone Number, Including Area Code)

Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the Registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Indicate by checkmark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

Number of shares of Common Stock, par value $.000001 per share, outstanding as of November 4, 2014: 56,056,813 shares.


	Page No.
PART I. FINANCIAL INFORMATION

Item 1. Financial Statements (unaudited)

Consolidated Balance Sheets at September 30, 2014 and December 31, 2013		3

Consolidated Statements of Operations for the three and nine months ended September 30, 2014 and 2013		4

Consolidated Statements of Comprehensive Loss for the three and nine months ended September 30, 2014 and 2013		5

Consolidated Statements of Cash Flows for the nine months ended September 30, 2014 and 2013		6

Notes to the Consolidated Financial Statements		7

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations		17

Item 3. Quantitative and Qualitative Disclosures About Market Risk		32

Item 4. Controls and Procedures		32

PART II. OTHER INFORMATION

Item 1. Legal Proceedings		33

Item 1A. Risk Factors		33

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds		33

Item 6. Exhibits		33

Signatures		34

-2-

Item 1.

FINANCIAL STATEMENTS

ORASURE TECHNOLOGIES, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(Unaudited)

(in thousands, except per share amounts)


	SEPTEMBER 30, 2014			DECEMBER 31, 2013
ASSETS
CURRENT ASSETS:
Cash	$	93,855		$	93,191
Short-term investments		5,000			—
Accounts receivable, net of allowance for doubtful accounts of $288 and $299		14,920			12,957
Inventories		14,843			11,444
Prepaid expenses		1,089			1,712
Deferred income taxes		67			71
Other current assets		273			200

Total current assets		130,047			119,575
PROPERTY AND EQUIPMENT, net		17,958			17,933
INTANGIBLE ASSETS, net		18,831			22,226
GOODWILL		22,562			23,782
OTHER ASSETS		1,102			729

	$	190,500		$	184,245

LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES:
Accounts payable	$	4,510		$	4,834
Deferred revenue		11,540			1,119
Accrued expenses		9,203			13,032

Total current liabilities		25,253			18,985

OTHER LIABILITIES		1,090			677

DEFERRED INCOME TAXES		3,233			3,437

COMMITMENTS AND CONTINGENCIES (Note 6)
STOCKHOLDERS’ EQUITY
Preferred stock, par value $.000001, 25,000 shares authorized, none issued		—			—
Common stock, par value $.000001, 120,000 shares authorized, 56,052 and 55,632 shares issued and outstanding		—			—
Additional paid-in capital		342,865			338,674
Accumulated other comprehensive loss		(6,248	)		(3,797	)
Accumulated deficit		(175,693	)		(173,731	)

Total stockholders’ equity		160,924			161,146

	$	190,500		$	184,245

See accompanying notes to the consolidated financial statements.

-3-

ORASURE TECHNOLOGIES, INC. AND SUBIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

(in thousands, except per share amounts)


	Three Months Ended September 30,					Nine Months Ended September 30,
	2014		2013			2014			2013
NET REVENUES:
Product	$	24,447	$	24,524		$	73,610		$	69,549
Licensing and product development		3,398		147			4,173			623

		27,845		24,671			77,783			70,172
COST OF PRODUCTS SOLD		9,140		9,738			29,135			28,711

Gross profit		18,705		14,933			48,648			41,461

OPERATING EXPENSES:
Research and development		2,990		2,670			8,242			8,720
Sales and marketing		9,216		8,981			30,828			35,224
General and administrative		5,617		5,342			17,317			15,742
Gain on contract termination settlement		—		—			(5,500	)		—

		17,823		16,993			50,887			59,686

Operating income (loss)		882		(2,060	)		(2,239	)		(18,225	)
OTHER INCOME		268		41			244			36

Income (loss) before income taxes		1,150		(2,019	)		(1,995	)		(18,189	)
INCOME TAX EXPENSE (BENEFIT)		10		(127	)		(33	)		(786	)

NET INCOME (LOSS)	$	1,140	$	(1,892	)	$	(1,962	)	$	(17,403	)

EARNINGS (LOSS) PER SHARE:
BASIC	$	0.02	$	(0.03	)	$	(0.04	)	$	(0.31	)

DILUTED	$	0.02	$	(0.03	)	$	(0.04	)	$	(0.31	)

SHARES USED IN COMPUTING EARNINGS (LOSS) PER SHARE:
BASIC		56,018		55,592			55,897			55,534

DILUTED		56,666		55,592			55,897			55,534

See accompanying notes to the consolidated financial statements.

-4-

ORASURE TECHNOLOGIES, INC. AND SUBIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(Unaudited)

(in thousands)


	Three Months Ended September 30,						Nine Months Ended September 30,
	2014			2013			2014			2013
NET INCOME (LOSS)	$	1,140		$	(1,892	)	$	(1,962	)	$	(17,403	)
OTHER COMPREHENSIVE INCOME (LOSS)
Currency translation adjustments		(2,295	)		876			(2,451	)		(1,709	)

Other comprehensive income (loss)		(2,295	)		876			(2,451	)		(1,709	)
COMPREHENSIVE LOSS	$	(1,155	)	$	(1,016	)	$	(4,413	)	$	(19,112	)

See accompanying notes to the consolidated financial statements.

-5-

ORASURE TECHNOLOGIES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(in thousands)


	Nine Months Ended September 30,
	2014			2013
OPERATING ACTIVITIES:
Net loss	$	(1,962	)	$	(17,403	)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Stock-based compensation		4,284			4,187
Depreciation and amortization		4,732			4,846
Unrealized foreign currency loss		(73	)		—
Deferred income taxes		(33	)		(786	)
Changes in assets and liabilities
Accounts receivable		(2,111	)		3,127
Inventories		(3,444	)		745
Prepaid expenses and other assets		576			(554	)
Accounts payable		(284	)		497
Deferred revenue		10,433			(1,098	)
Accrued expenses and other liabilities		(3,734	)		3,297

Net cash provided by (used in) operating activities		8,384			(3,142	)

INVESTING ACTIVITIES:
Purchases of short term investments		(9,407	)		—
Proceeds from maturities of short term investments		4,432			—
Purchases of property and equipment		(2,353	)		(1,696	)

Net cash used in investing activities		(7,328	)		(1,696	)

FINANCING ACTIVITIES:
Proceeds from exercise of stock options		546			317
Repurchase of common stock		(639	)		(817	)

Net cash used in financing activities		(93	)		(500	)

EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH		(299	)		40
NET INCREASE (DECREASE) IN CASH		664			(5,298	)
CASH, BEGINNING OF PERIOD		93,191			87,888

CASH, END OF PERIOD	$	93,855		$	82,590

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for:
Income taxes	$	42		$	28

See accompanying notes to the consolidated financial statements.

-6-

ORASURE TECHNOLOGIES, INC. AND SUBSIDIARIES

Notes to the Consolidated Financial Statements

(Unaudited)

(in thousands, except per share amounts, unless otherwise indicated)

1.	The Company

We develop, manufacture, market and sell oral fluid diagnostic products and specimen collection devices using our proprietary oral fluid technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types. Our diagnostic products include tests that are performed on a rapid basis at the point-of-care and tests that are processed in a laboratory. We sell the first and only rapid point-of-care HIV test approved for use in the domestic consumer retail or over-the-counter (“OTC”) market. We also manufacture and sell oral fluid collection devices used to collect, stabilize and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic testing, academic research, pharmacogenomics, personalized medicine, and animal genetics markets. Lastly, we manufacture and sell medical devices used for the removal of benign skin lesions by cryosurgery, or freezing. Our products are sold in the United States and internationally to various clinical laboratories, hospitals, clinics, community-based organizations, public health organizations, research and academic institutions, distributors, government agencies, physicians’ offices, and commercial and industrial entities. Our OTC HIV and cryosurgical products are available at retail pharmacies and mass merchandisers, and our OTC HIV product is also sold to consumers over the internet.

2.	Summary of Significant Accounting Policies

Principles of Consolidation and Basis of Presentation. The consolidated financial statements include the accounts of OraSure Technologies, Inc. (“OraSure”) and its wholly-owned subsidiary, DNA Genotek, Inc. (“DNAG”). All intercompany transactions and balances have been eliminated. References herein to “we,” “us,” “our,” or the “Company” mean OraSure and its consolidated subsidiaries, unless otherwise indicated.

The accompanying consolidated financial statements are unaudited and, in the opinion of management, include all adjustments (consisting only of normal and recurring adjustments) necessary for a fair presentation of our financial position and results of operations for these interim periods. These financial statements should be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013. Results of operations for the three and nine months ended September 30, 2014 are not necessarily indicative of the results of operations expected for the full year.

Use of Estimates. The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Such estimates include the valuation of accounts receivable and inventories and assumptions utilized in impairment testing for intangible assets and goodwill, as well as calculations related to contingencies and accruals, among others. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis, using historical experience and other factors which management believes to be reasonable under the circumstances, including the current economic environment. We adjust such estimates and assumptions when facts and circumstances dictate. Illiquid credit markets, volatile equity and foreign currency markets, reductions in government funding and declines in consumer spending have combined to increase the uncertainty inherent in such estimates and assumptions. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic environment and other factors will be reflected in the financial statements in those future periods.

Short-Term Investments. We consider all short-term investments to be available-for-sale securities. These securities are comprised of guaranteed investment certificates with purchased maturities greater than ninety days. Available-for-sale securities are carried at fair value, based upon quoted market prices, with unrealized gains and losses, if any, reported in stockholders’ equity as a component of accumulated other comprehensive loss.

-7-

Our available-for-sale securities as of September 30, 2014 consisted of guaranteed investment certificates with amortized cost and fair value of $5,000. As of December 31, 2013, we had no available-for-sale securities.

Fair Value of Financial Instruments. As of September 30, 2014, the carrying values of cash, short-term investments, accounts receivable, accounts payable and accrued expenses approximate their respective fair values based on their short-term nature.

Fair value measurements of all financial assets and liabilities that are being measured and reported on a fair value basis are required to be classified and disclosed in one of the following three categories:

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

We offer a nonqualified deferred compensation plan for certain eligible employees and members of our Board of Directors. The assets of the plan are held in the name of the Company at a third-party financial institution. Separate accounts are maintained for each participant to reflect the amounts deferred by the participant and all earnings and losses on those deferred amounts. The assets of the plan are held in mutual funds and Company stock. The fair value of the plan assets as of September 30, 2014 and December 31, 2013 was $1,090 and $677, respectively, and was calculated using the quoted market prices of the assets as of those dates. All investments in the plan are classified as trading securities and measured as Level 1 instruments. The fair value of plan assets is included in other assets with the same amount included in other liabilities in the accompanying consolidated balance sheets.

All of our available-for-sale securities were classified and measured as Level 1 instruments as of September 30, 2014.

Inventories. Inventories are stated at the lower of cost or market determined on a first-in, first-out basis and are comprised of the following:


	September 30, 2014		December 31, 2013
Raw materials	$	6,772	$	6,700
Work in process		937		833
Finished goods		7,134		3,911

	$	14,843	$	11,444

Property and Equipment. Property and equipment are stated at cost. Additions or improvements are capitalized, while repairs and maintenance are charged to expense. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. Buildings are depreciated over twenty to forty years, while computer equipment, machinery and equipment, and furniture and fixtures are depreciated over two to ten years. Building improvements are amortized over their estimated useful lives. When assets are sold or otherwise disposed of, the related property amounts are relieved from the accounts, and any gain or loss is recorded in the consolidated statement of operations. Accumulated depreciation of property and equipment as of September 30, 2014 and December 31, 2013 was $30,603 and $28,390, respectively.

-8-

Intangible Assets. Intangible assets consist of the following:


		September 30, 2014
	Amortization Period (Years)	Gross		Accumulated Amortization			Net
Customer list	10	$	11,190	$	(3,370	)	$	7,820
Patents and product rights	3-10		10,449		(7,844	)		2,605
Acquired technology	7		8,692		(3,682	)		5,010
Tradename	15		4,289		(893	)		3,396

		$	34,620	$	(15,789	)	$	18,831


		December 31, 2013
	Amortization Period(Years)	Gross		Accumulated Amortization			Net
Customer list	10	$	11,795	$	(2,701	)	$	9,094
Patents and product rights	3-10		10,449		(7,466	)		2,983
Acquired technology	7		9,162		(2,952	)		6,210
Tradename	15		4,521		(715	)		3,806
Non-compete agreements	1-3		787		(654	)		133

		$	36,714	$	(14,488	)	$	22,226

Goodwill. Goodwill represents the excess of the purchase price we paid over the fair value of the net tangible and identifiable intangible assets acquired and liabilities assumed in our acquisition of DNAG in August 2011. Goodwill is not amortized but rather is tested annually for impairment or more frequently if we believe that indicators of impairment exist. Current U.S. generally accepted accounting principles permit us to make a qualitative evaluation about the likelihood of goodwill impairment. If we conclude that it is more likely than not that the fair value of a reporting unit is greater than its carrying amount, then we would not be required to perform the two-step quantitative impairment test. Otherwise, performing the two-step impairment test is necessary. The first step of the two-step quantitative impairment test involves comparing the fair value of the applicable reporting unit with its aggregate carrying value, including goodwill. If the carrying value of a reporting unit exceeds the reporting unit’s fair value, we perform the second step of the test to determine the amount of the impairment loss, if any. The second step involves measuring any impairment by comparing the implied fair values of the affected reporting unit’s goodwill and intangible assets with their respective carrying values.

We performed our last annual impairment assessment as of July 31, 2014 utilizing a qualitative evaluation and concluded that it was more likely than not that the fair value of our DNAG reporting unit is greater than its carrying amount. We believe we have made reasonable estimates and assumptions to calculate the fair value of our reporting unit. If actual future results are not consistent with management’s estimates and assumptions, we may have to take an impairment charge in the future related to our goodwill. Future impairment tests will continue to be performed annually in the fiscal third quarter, or sooner if a triggering event occurs. As of September 30, 2014, we believe no indicators of impairment exist.

The change in goodwill from $23,782 as of December 31, 2013 to $22,562 as of September 30, 2014 is a result of foreign currency translation.

Revenue Recognition. We recognize product revenues when there is persuasive evidence that an arrangement exists, the price is fixed or determinable, title has passed and collection is reasonably assured. Product revenues are recorded net of allowances for any discounts or rebates. Other than for our OraQuick^® In-Home HIV test, we do not grant price protection or product return rights to our customers, except for warranty returns. Historically, returns arising from warranty issues have been infrequent and immaterial. Accordingly, we expense warranty returns as incurred.

-9-

We began selling our OraQuick^® In-Home HIV test in the third quarter of 2012. From launch through November 2013, our revenue recognition practices with respect to the OraQuick^® In-Home HIV test were different than those customarily used in the consumer package goods industry. Under U.S. generally accepted accounting principles, product revenue cannot be recognized unless the amount of future returns can be reasonably estimated. Because our OraQuick^® In-Home HIV test was a new product for which we did not have a historical record of returns, we did not believe we could reasonably determine a return rate. As a result, initially we did not recognize revenue when we shipped to the retail trade. For these product shipments, we invoiced the retailer or distributor, recorded deferred revenue at gross invoice sales price, and classified the cost basis of the product held by the retailer or distributor as a component of inventory. We then recognized revenue upon the consummation of a sale to the consumer either in a store or over the internet. With the passage of time, however, we concluded that we have sufficient data and visibility into our distribution channel to develop a reasonable estimate of the level of expected returns. As such, commencing in December 2013, we recognized previously deferred revenue and its related cost of goods sold, and began to recognize revenue for this product upon shipment to the retailers or distributors. Accordingly, revenues in the first nine months of 2014 were recorded based upon shipments into the distribution channel, while revenues in the first nine months of 2013 were recorded based upon the consummation of a sale to the consumer.

Our net revenues recorded on sales of the OraQuick^® In-Home HIV test represent total gross revenues, less an allowance for expected returns, and customer allowances for cooperative advertising discounts, rebates, and chargebacks. All of these allowances are estimates established by management, based on currently available information and are adjusted to reflect known changes in the factors that impact those estimates. These allowances are recorded as a reduction of gross revenue when recognized in our statements of operations.

Royalty income from the grant of license rights is recognized during the period in which the revenue is earned and the amount is determinable from the licensee and is recorded as licensing and product development revenue in our statements of operations.

We record shipping and handling charges billed to our customers as product revenue and the related expense as cost of products sold. Taxes assessed by governmental authorities, such as sales or value-added taxes, are excluded from product revenues.

On June 10, 2014, we entered into a Master Program Services and Co-Promotion Agreement with AbbVie Bahamas Ltd., a wholly-owned subsidiary of AbbVie Inc. (“AbbVie”), to co-promote our OraQuick^® HCV Rapid Test in the United States. The product will be used to test individuals at-risk for the hepatitis C virus (“HCV”). We will be responsible for manufacturing and selling the product into all markets.

Under the terms of our agreement, we have granted exclusive promotion rights to AbbVie for the OraQuick^® HCV Rapid test in certain markets and we have agreed to develop, implement, administer and maintain a patient care database for the exclusive use of AbbVie. This patient care database will be used to compile patient information regarding new individuals who have tested positive for HCV using our OraQuick^® HCV Rapid test. We have also jointly agreed with AbbVie to co-promote our OraQuick^® HCV Rapid test in certain market segments, namely: healthcare providers such as primary care physicians, gastroenterologists, hepatologists and infectious disease specialists; employers and employee groups experiencing a high HCV prevalence rate, such as the long-haul trucking industry; and national retail pharmacies and retail clinics that perform routine healthcare screening services.

In exchange for these exclusive rights and other services, we will receive up to $75,000 in payments over the term of the agreement which expires on December 31, 2019. We will recognize revenues from these periodic payments ratably, over the life of the agreement. In addition, if certain performance-based milestones are achieved, we could be eligible to receive additional milestone payments. These payments would be based upon the aggregate number of new patients enrolled in the patient care database, in a given calendar year, after exceeding a baseline threshold, and could range from $3,500 to $55,500 annually over the life of the agreement. The first performance-based milestone period ends on December 31, 2015. The agreement also contains certain termination, indemnification and other provisions, typical of agreements of this type. Payments received under this agreement will be recorded as licensing and product development revenue in our statements of operations.

-10-

Customer Sales Returns and Allowances. We do not grant return rights to our customers for any product, except for our OraQuick^® In-Home HIV test. Accordingly, we have recorded an estimate of expected returns as a reduction of gross OraQuick^® In-Home HIV product revenues in our consolidated statements of operations. This estimate reflects our historical sales experience to retailers and consumers, as well as other retail factors, and is reviewed regularly to ensure that it reflects potential product returns. As of September 30, 2014 and December 31, 2013, the reserve for sales returns and allowances was $398 and $279, respectively. If actual product returns differ materially from our reserve amount, or if a determination is made that this product’s distribution would be discontinued in whole or in part by certain retailers, then we would need to adjust our reserve. Should the actual level of product returns vary significantly from our estimates, our operating and financial results could be materially affected.

Termination Settlement. On November 21, 2013, we terminated our assay development collaboration with Roche Diagnostics (“Roche”). Pursuant to a termination agreement, Roche paid us $8,300 which was recorded as a reduction of operating expense in our consolidated statement of operations for the quarter ended December 31, 2013. Roche agreed to provide certain transitional product support services to us and to continue to supply certain of the assays developed under the collaboration on a transitional basis for up to five years following the termination. We had the right to stop the supply of assays prior to the end of this five-year period and to receive an additional payment from Roche of up to $5,500 depending on how early in that five-year period the supply obligation was ended. During the second quarter of 2014, we issued our final purchase order for fully-automated assays previously developed under the terminated collaboration and as such, have recorded $5,500 as a reduction of operating expense in our consolidated statement of operations.

Deferred Revenue. We record deferred revenue when funds are received prior to the recognition of the associated revenue. Deferred revenue at September 30, 2014 and December 31, 2013 includes customer prepayments of $713 and $1,119, respectively. Deferred revenue also includes $10,827 which represents the $15,000 payment received in July 2014 under the terms of our HCV collaboration with AbbVie, less amounts recognized ratably in revenue.

Customer and Vendor Concentrations. We had no significant concentrations (greater than 10%) in accounts receivable as of September 30, 2014. One of our customers, AbbVie, accounted for approximately 12% of our net revenues for the three months ended September 30, 2014. We had no significant concentrations (greater than 10%) in net revenues for the nine months ended September 30, 2014 and the three or nine months ended September 30, 2013.

We currently purchase certain products and critical components of our products from sole-supply vendors, and if these vendors are unable or unwilling to supply the required components and products, we could be subject to increased costs and substantial delays in the delivery of our products to our customers. Also, our subsidiary, DNAG, uses two third-party suppliers to manufacture its products. Our inability to have a timely supply of any of these components and products could have a material adverse effect on our business, as well as our financial condition and results of operations.

Earnings (Loss) Per Share. Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings (loss) per share is computed in a manner similar to basic earnings (loss) per share except that the weighted average number of shares outstanding is increased to include incremental shares from the assumed vesting or exercise of dilutive securities, such as common stock options and unvested restricted stock, unless the impact is antidilutive. The number of incremental shares is calculated by assuming that outstanding stock options were exercised and unvested restricted shares were vested, and the proceeds from such exercises or vesting were used to acquire shares of common stock at the average market price during the reporting period.

-11-

The computations of basic and diluted earnings (loss) per share are as follows:


	Three Months Ended September 30,					Nine Months Ended September 30,
	2014		2013			2014			2013
Net income (loss)	$	1,140	$	(1,892	)	$	(1,962	)	$	(17,403	)

Weighted average shares of common stock outstanding:
Basic		56,018		55,592			55,897			55,534
Dilutive effect of stock options and restricted stock		648		—			—			—

Diluted		56,666		55,592			55,897			55,534

Earnings (loss) per share:
Basic	$	0.02	$	(0.03	)	$	(0.04	)	$	(0.31	)

Diluted	$	0.02	$	(0.03	)	$	(0.04	)	$	(0.31	)

For the three-month periods ended September 30, 2014 and 2013, outstanding common stock options and unvested restricted stock, representing 2,647 and 5,499 shares, respectively, were excluded from the computation of diluted earnings (loss) per share, as their inclusion would have been anti-dilutive. For the nine months ended September 30, 2014 and 2013, outstanding common stock options and unvested restricted stock, representing 3,313 and 5,324 shares, respectively, were similarly excluded from the computation of diluted earnings (loss) per share.

Foreign Currency Translation. The assets and liabilities of our foreign operations are translated into U.S. dollars at current exchange rates as of the balance sheet date, and revenues and expenses are translated at average exchange rates for the period. Resulting translation adjustments are reflected in accumulated other comprehensive loss, which is a separate component of stockholders’ equity.

Transaction gains and losses resulting from exchange rate changes on transactions denominated in currencies other than functional currency are included in income in the period in which the change occurs.

Accumulated Other Comprehensive Loss. We classify items of other comprehensive loss by their nature and disclose the accumulated balance of other comprehensive loss separately from accumulated deficit and additional paid-in capital in the stockholders’ equity section of our balance sheet.

We have defined the Canadian dollar as the functional currency of our Canadian subsidiary, DNAG, and as such, the results of its operations are translated into U.S. dollars, which is the reporting currency of the Company. The $2,451 and $1,709 currency translation adjustments recorded in the first nine months of 2014 and 2013, respectively, are largely the result of the translation of our Canadian operation’s balance sheets into U.S. dollars.

Recent Accounting Pronouncements. In May 2014, the Financial Accounting Standards Board (“FASB”) issued converged guidance on recognizing revenue in contracts with customers, ASU 2014-09 Revenue from Contracts with Customers. The intent of the new standard is to improve financial reporting and comparability of revenue globally. The core principle of the standard is for a company to recognize revenue in a manner that depicts the transfer of goods or services to customers in an amount that reflects the consideration which the company expects to receive in exchange for those goods or services. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2016, with no early adoption permitted. We will evaluate the effects, if any, which adoption of this guidance will have on our consolidated financial statements.

-12-

3.	Stockholders’ Equity

Stock-Based Awards

We grant stock-based awards under the OraSure Technologies, Inc. Stock Award Plan, as amended and restated (the “Stock Plan”). The Stock Plan permits stock-based awards to employees, outside directors and consultants or other third-party advisors. Awards which may be granted under the Stock Plan include qualified incentive stock options, nonqualified stock options, stock appreciation rights, restricted awards, performance awards and other stock-based awards. We recognize compensation expense for stock option and restricted stock awards issued to employees and directors on a straight-line basis over the requisite service period of the award. To satisfy the exercise of options or to issue new restricted stock, we normally issue new shares rather than purchase shares on the open market.

Total compensation cost related to stock options for the nine months ended September 30, 2014 and 2013 was $2,286 and $2,028, respectively. Net cash proceeds from the exercise of stock options were $546 and $317 for the nine months ended September 30, 2014 and 2013, respectively. As a result of the Company’s net operating loss carryforward position, no actual income tax benefit was realized from stock option exercises during these periods.

Compensation cost of $1,998 and $2,159 related to restricted shares was recognized during the nine months ended September 30, 2014 and 2013, respectively. In connection with the vesting of restricted shares, during the nine months ended September 30, 2014 and 2013, 106 and 122 shares, respectively, with aggregate values of $639 and $817, respectively, were withheld and retired in satisfaction of minimum tax withholding obligations.

4.	Accrued Expenses


	September 30, 2014		December 31, 2013
Payroll and related benefits	$	5,093	$	5,827
Royalties		1,703		4,374
Professional fees		484		749
Other		1,923		2,082

	$	9,203	$	13,032

5.	Income Taxes

During the three months ended September 30, 2014, we recorded foreign deferred tax expense of $10. During the nine months ended September 30, 2014, we recorded foreign deferred tax benefits of $33. During the three and nine months ended September 30, 2013, we recorded foreign deferred tax benefits of $127 and $786, respectively. The foreign deferred tax benefits are associated with certain Canadian research and development and investment tax credits. The income tax benefits associated with DNAG are considered realizable based upon the estimated scheduled reversal of the deferred tax liabilities recorded in connection with the acquisition of DNAG.

Deferred income taxes reflect the tax effects of temporary differences between the basis of assets and liabilities recognized for financial reporting and tax purposes, and net operating loss and tax credit carryforwards. The significant components of our total deferred tax liability as of September 30, 2014 relate to the tax effects of the basis differences between the intangible assets acquired in the DNAG acquisition for financial reporting and tax purposes.

In 2008, we established a full valuation allowance against our U.S. net deferred tax asset, and management believes the full valuation allowance is still appropriate as of September 30, 2014 and December 31, 2013 since the facts and circumstances necessitating the allowance have not changed. As a result, no U.S. federal or state income tax benefit was recorded for the three and nine month periods ended September 30, 2014 and 2013.

-13-

6.	Commitments and Contingencies

From time-to-time, we are involved in certain legal actions arising in the ordinary course of business. In management’s opinion, based upon the advice of counsel, the outcomes of such actions are not expected to have a material adverse effect on our future financial position or results of operations.

7.	Business Segment Information

We operate our business within two reportable segments: our “OSUR” business, which consists of the development, manufacture and sale of oral fluid diagnostic products and specimen collection devices and the manufacture and sale of medical devices used for the removal of benign skin lesions by cryosurgery; and our molecular collection systems or “DNAG” business, which consists of the manufacture, development and sale of oral fluid collection devices that are used to collect, stabilize and store samples of genetic material for molecular testing. OSUR revenues are derived primarily from products sold in the United States and internationally to various clinical laboratories, hospitals, clinics, community-based organizations, public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities. Revenues from OSUR’s OTC products result from sales to retail pharmacies and mass merchandisers, and to consumers over the internet. OSUR also derives revenues from licensing and product development activities. DNAG revenues result primarily from products sold into the commercial market which consists of companies and other entities engaged in consumer genetics, clinical genetic testing, pharmacogenomics, personalized medicine, and animal and livestock genetic testing. DNAG products are also sold into the academic research market, which consists of research laboratories, universities and hospitals.

We organized our operating segments according to the nature of the products included in those segments. The accounting policies of the segments are the same as those described in the summary of significant accounting policies (see Note 2). We evaluate performance of our operating segments based on revenue and operating income (loss). We do not allocate interest income, interest expense, other income, other expenses or income taxes to our operating segments. Reportable segments have no inter-segment revenues.

-14-

The following table summarizes segment information for the three and nine months ended September 30, 2014 and 2013:


	Three Months Ended September 30,						Nine Months Ended September 30,
	2014			2013			2014			2013
Net revenues:
OSUR	$	20,978		$	19,707		$	60,260		$	56,622
DNAG		6,867			4,964			17,523			13,550

Total	$	27,845		$	24,671		$	77,783		$	70,172

Operating income (loss):
OSUR	$	(987	)	$	(2,516	)	$	(5,177	)	$	(18,012	)
DNAG		1,869			456			2,938			(213	)

Total	$	882		$	(2,060	)	$	(2,239	)	$	(18,225	)

Depreciation and amortization:
OSUR	$	820		$	815		$	2,386		$	2,389
DNAG		804			810			2,346			2,457

Total	$	1,624		$	1,625		$	4,732		$	4,846

Capital expenditures:
OSUR	$	298		$	369		$	1,868		$	1,096
DNAG		67			235			485			600

Total	$	365		$	604		$	2,353		$	1,696


	September 30, 2014		December 31, 2013
Total assets:
OSUR	$	137,418	$	130,848
DNAG		53,082		53,397

Total	$	190,500	$	184,245

Our products are sold principally in the United States and Europe.

The following table represents total revenues by geographic area, based on the location of the customer:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2014		2013		2014		2013
United States	$	22,469	$	19,052	$	58,987	$	54,052
Europe		3,252		2,540		10,935		7,823
Other regions		2,124		3,079		7,861		8,297

	$	27,845	$	24,671	$	77,783	$	70,172

-15-

The following table represents total long-lived assets by geographic area:


	September 30, 2014		December 31, 2013
United States	$	16,802	$	16,925
Canada		1,139		975
Other regions		17		33

	$	17,958	$	17,933

-16-

Item 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Statements below regarding future events or performance are “forward-looking statements” within the meaning of the Federal securities laws. These may include statements about our expected revenues, earnings/loss per share, net income (loss), expenses, cash flow or other financial performance or developments, clinical trial or development activities, expected regulatory filings and approvals, planned business transactions, views of future industry, competitive or market conditions, and other factors that could affect our future operations, results of operations or financial position. These statements often include the words “believes,” “expects,” “anticipates,” “intends,” “plans,” “estimates,” “may,” “will,” “should,” “could,” or similar expressions. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that could cause actual performance or results to be materially different from those expressed or implied in these statements include, but are not limited to: ability to market and sell products, whether through our internal, direct sales force or third parties; ability to manufacture products in accordance with applicable specifications, performance standards and quality requirements; ability to obtain, and timing and cost of obtaining, necessary regulatory approvals for new products or new indications or applications for existing products; ability to comply with applicable regulatory requirements; ability to effectively resolve warning letters, audit observations and other findings or comments from the FDA or other regulators; changes in relationships, including disputes or disagreements, with strategic partners or other parties and reliance on strategic partners for the performance of critical activities under collaborative arrangements; ability to achieve financial and performance objectives under the HCV collaboration with AbbVie; failure of distributors or other customers to meet purchase forecasts, historic purchase levels or minimum purchase requirements for our products; impact of replacing distributors; inventory levels at distributors and other customers; ability of DNA Genotek to achieve its financial and strategic objectives and continue to increase its revenues; ability to identify, complete, integrate and realize the full benefits of future acquisitions; impact of competitors, competing products and technology changes; impact of negative economic conditions, high unemployment and poor credit conditions; reduction or deferral of public funding available to customers; competition from new or better technology or lower cost products; ability to develop, commercialize and market new products, including the OraQuick^® In-Home HIV test; market acceptance of oral fluid testing or other products; changes in market acceptance of products based on product performance or other factors, including changes in Centers for Disease Control and Prevention (“CDC”) or other testing guidelines, algorithms or other recommendations; ability to fund research and development and other products and operations; ability to obtain and maintain new or existing product distribution channels; reliance on sole supply sources for critical products and components; availability of related products produced by third parties or products required for use of our products; history of losses and ability to achieve sustained profitability; ability to utilize net operating loss carry forwards or other deferred tax assets; volatility of OraSure’s stock price; uncertainty relating to patent protection and potential patent infringement claims; uncertainty and costs of litigation relating to patents and other intellectual property; availability of licenses to patents or other technology; ability to enter into international manufacturing agreements; obstacles to international marketing and manufacturing of products; ability to sell products internationally, including the impact of changes in international funding sources and testing algorithms; adverse movements in foreign currency exchange rates; loss or impairment of sources of capital; ability to attract and retain qualified personnel; exposure to product liability and other types of litigation; changes in international, federal or state laws and regulations; customer consolidations and inventory practices; equipment failures and ability to obtain needed raw materials and components; the impact of terrorist attacks and civil unrest; and general political, business and economic conditions. These and other factors are discussed more fully in our Securities and Exchange Commission (“SEC”) filings, including our registration statements, Annual Report on Form 10-K for the year ended December 31, 2013, Quarterly Reports on Form 10-Q, and other filings with the SEC. Although forward-looking statements help to provide information about future prospects, readers should keep in mind that forward-looking statements may not be reliable. The forward-looking statements are made as of the date of this Report, and we undertake no duty to update these statements.

The following discussion should be read in conjunction with our consolidated financial statements contained herein and the notes thereto, along with the Section entitled “Critical Accounting Policies and Estimates,” set forth below.

-17-

Overview

We develop, manufacture, market and sell oral fluid diagnostic products and specimen collection devices using our proprietary oral fluid technologies, as well as other diagnostic products including immunoassays and other in vitro diagnostic tests that are used on other specimen types. Our diagnostic products include tests that are performed on a rapid basis at the point-of-care and tests that are processed in a laboratory. We sell the OraQuick^® In-Home HIV test, the first and only rapid point-of-care HIV test approved for use in the domestic consumer retail market. We also manufacture and sell oral fluid collection devices used to collect, stabilize, and store samples of genetic material for molecular testing in the clinical genetic testing, academic research, pharmacogenomics, personalized medicine, and animal genetics markets. Lastly, we manufacture and sell medical devices used for the removal of benign skin lesions by cryosurgery, or freezing. Our products are sold in the United States and internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, research and academic institutions, distributors, government agencies, physicians’ offices, and commercial and industrial entities. Our over-the-counter (“OTC”) HIV and cryosurgery products are available at retail pharmacies and mass merchandisers, and our OTC HIV product is also sold to consumers over the internet.

Recent Developments

HCV Co-Promotion Initiatives

During the third quarter, we initiated three co-promotion initiatives pursuant to our co-promotion agreement. The first initiative focuses on primary care and specialty physicians. In August 2014, AbbVie began detailing our OraQuick^® HCV test to physicians and we commenced a comprehensive product training program for these customers. As a result of these efforts, hundreds of physician offices have indicated an interest in our product. We expect that sales of our OraQuick^® HCV test to physician offices will begin to increase later in 2014 and throughout 2015.

The second initiative targets employers or employer groups with employees that are at high risk for HCV. Our initial focus has been on commercial long-haul truck drivers and we have been working closely with the Healthy Trucking Association of America (“HTAA”) and an organization known as Rolling Strong. We are promoting the use of our test in physician offices, health clinics and retail pharmacies where truckers receive their health care, driving schools where newly-hired drivers are required to take and pass a physical exam, and at health events sponsored by HTAA and Rolling Strong where truckers can take advantage of a variety of health and wellness services.

Lastly, we have identified national retail pharmacies and retail clinics as a major market segment. We and AbbVie have initiated discussions with several major retail pharmacies about increasing awareness and making our OraQuick^® HCV test and AbbVie’s patient support program available through retail outlets.

Launch of I2 Collection Device

We have completed development of a new version of our Intercept^® oral specimen collection device, which is called the “I2” collection device. In July 2014, we commercially launched the new I2 device into the U.S. criminal justice and forensic toxicology markets and into certain international markets. We eventually intend to market the I2 device with the fully-automated high throughput oral fluid drug assays being developed pursuant to our collaboration with Thermo Fisher. We expect to commercially launch the I2 device with a NIDA-5 panel of the Thermo Fisher assays into the U.S. criminal justice and forensic toxicology markets beginning in the fourth quarter of 2014.

-18-

Current Consolidated Financial Results

During the nine months ended September 30, 2014, our consolidated net revenues were $77.8 million compared to $70.2 million in the nine months ended September 30, 2013. Net product revenues during the nine months ended September 30, 2014 increased 6% when compared to the first nine months of 2013, primarily due to higher sales of our Oragene^®, OraQuick^® HCV, and cryosurgical systems products. Licensing and product development revenues for the first nine months of 2014 were $4.2 million compared to $623,000 in the first nine months of 2013. Licensing and product development revenues in 2014 represent the recognition of payments from AbbVie for exclusive promotion rights and certain services we provided under our HCV collaboration. Licensing and product development revenues for the first nine months of 2013 represent royalties related to sales of Merck’s OTC cryosurgical wart removal product pursuant to a license and settlement agreement that expired in August 2013.

Our consolidated net loss for the nine months ended September 30, 2014 was $2.0 million, or $0.04 per share, compared to a net loss of $17.4 million, or $0.31 per share, for the nine months ended September 30, 2013. Results for the nine months ended September 30, 2014 included a $5.5 million payment received pursuant to the termination of our oral fluid drug assay collaboration with Roche Diagnostics.

Cash provided by operating activities for the nine months ended September 30, 2014 was $8.4 million, compared to $3.1 million used during the nine months ended September 30, 2013. As of September 30, 2014, we had $98.9 million in cash and short-term investments compared to $93.2 million at December 31, 2013.

Economic Outlook

Many of our customers rely on public funding provided by federal, state and local governments. This funding has been and may continue to be reduced or deferred as a result of current economic conditions. These circumstances may adversely impact our customers and suppliers, which, in turn, could adversely affect their ability to purchase our products or supply us with necessary equipment, raw materials or components. In addition, these circumstances could adversely affect our access to liquidity that may be needed to conduct or expand our business, conduct future acquisitions or make other discretionary investments. Legislative, budgetary or regulatory changes may also be adopted which could adversely affect our ability to sell our current products or successfully develop and commercialize new products.

Business Segments

We operate our business within two reportable segments: our “OSUR” business, which consists of the development, manufacture and sale of oral fluid diagnostic products, specimen collection devices, and medical devices used for the removal of benign skin lesions by cryosurgery; and our “DNAG” or molecular collection systems business, which consists primarily of the development, manufacture and sale of oral fluid collection devices that are used to collect, stabilize, and store samples of genetic material for molecular testing. OSUR revenues are derived primarily from products sold into the United States and internationally to various clinical laboratories, hospitals, clinics, community-based organizations, public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities. Revenues from OSUR’s OTC products result from sales to retail pharmacies and mass merchandisers and to consumers over the internet. DNAG revenues result primarily from products sold into the commercial market, which consists of companies and other entities engaged in consumer genetics, clinical genetic testing, pharmacogenomics, personalized medicine, and animal genetic testing, as well as products sold into the academic research market which consists of research laboratories, universities and hospitals.

-19-

Results of Operations

Three months ended September 30, 2014 compared to September 30, 2013

CONSOLIDATED NET REVENUES

The table below shows the amount of total net product revenues (dollars in thousands) generated by each of our business segments and net revenues from licensing and product development activities for the three months ended September 30, 2014 and 2013.


	Three Months Ended September 30,
	Dollars							Percentage of Total Net Revenues
	2014		2013		% Change			2014			2013
OSUR	$	17,580	$	19,560		(10	)%		63	%		79	%
DNAG		6,867		4,964		38			25			20

Net product revenues		24,447		24,524		(0	)		88			99
Licensing and product development		3,398		147		NM	*		12			1

Net revenues	$	27,845	$	24,671		13	%		100	%		100	%

*	Calculation is not considered meaningful.

Consolidated net product revenues in the third quarters of 2014 and 2013 remained flat at $24.5 million. Higher sales of our molecular collection systems and OraQuick^® HCV products were offset by lower sales of our OraQuick^® professional HIV, cryosurgical systems, and OraQuick^® In-Home HIV products. Licensing and product development revenues were $3.4 million in the third quarter of 2014 and represent the recognition of payments from AbbVie for exclusive promotion rights and certain services provided under our HCV collaboration agreement. Third quarter 2013 licensing and product development revenues of $147,000 represent royalties received on sales of Merck’s OTC cryosurgical wart removal product, pursuant to a license and settlement agreement that expired in August 2013.

Consolidated net revenues derived from products sold to customers outside the U.S. were $5.4 million and $5.6 million, or 19% and 23% of total net revenues, in the third quarters of 2014 and 2013, respectively. Because the majority of our international sales are denominated in U.S. dollars, the impact of fluctuating foreign currency exchange rates was not material to our total net revenues.

-20-

Net Revenues by Segment

OSUR Segment

The table below shows the amount of total net revenues (dollars in thousands) generated by our OSUR segment in each of our principal markets and by licensing and product development activities.


	Three Months Ended September 30,
	Dollars							Percentage of Total Net Revenues
Market	2014		2013		% Change			2014			2013
Infectious disease testing	$	11,183	$	12,873		(13	)%		53	%		65	%
Substance abuse testing		2,149		2,092		3			10			10
Cryosurgical systems		3,241		3,649		(11	)		16			19
Insurance risk assessment		1,007		946		6			5			5

Net product revenues		17,580		19,560		(10	)		84			99
Licensing and product development		3,398		147		NM	*		16			1

Net revenues	$	20,978	$	19,707		6	%		100	%		100	%

*	Calculation is not considered meaningful.

Infectious Disease Testing Market

Sales to the infectious disease testing market decreased 13% to $11.2 million in the third quarter of 2014 from $12.9 million in the third quarter of 2013 primarily due to lower sales of our professional OraQuick^® HIV product in both domestic and international markets and lower sales of our OraQuick^® In-Home HIV test, partially offset by higher domestic sales of our OraQuick^® HCV product.

The table below shows a breakdown of our total net OraQuick^® revenues (dollars in thousands) during the third quarters of 2014 and 2013.


	Three Months Ended September 30,
Market	2014		2013		% Change
Domestic HIV	$	7,231	$	8,093		(11	)%
International HIV		491		1,157		(58	)
Domestic OTC HIV		1,368		1,762		(22	)

Net HIV revenues		9,090		11,012		(17	)

Domestic HCV		1,301		653		99
International HCV		470		924		(49	)

Net HCV revenues		1,771		1,577		12

Net OraQuick^® revenues	$	10,861	$	12,589		(14	)%

Domestic OraQuick^® HIV sales decreased 11% to $7.2 million for the three months ended September 30, 2014 from $8.1 million for the three months ended September 30, 2013. This decrease was primarily the result of some customer migration to automated 4^th generation HIV immunoassays performed in a laboratory, as recommended under new testing guidelines issued by the CDC. We anticipate that future sales of our professional HIV product will continue to be negatively affected as a result of the CDC’s guidelines and by reductions in government funding. International sales of our OraQuick^® HIV test during the third quarter of 2014 decreased 58% to $491,000 from $1.2 million primarily due to the timing of product shipments in support of a significant African testing program.

-21-

During the third quarter of 2014, we recorded $1.5 million in gross revenues from sales of our OraQuick^® In-Home HIV test. These revenues were partially offset by $177,000 in customer allowances, including cooperative advertising, cash discounts, and other allowances, which were netted against gross revenues in accordance with U.S. generally accepted accounting principles. Thus, net revenues from this product were $1.4 million for the third quarter of 2014 as compared to net revenues of $1.8 million in the second quarter of 2013 ($1.9 million in gross revenues, partially offset by $172,000 of allowances and discounts).

OraQuick^® In-Home HIV revenues recorded in the current and prior year periods are not readily comparable due to the December 2013 change in our revenue recognition policy related to this product. Since the product launch in late 2012, revenues had been recognized upon consummation of a purchase by consumers either in a store or over the internet. In December 2013, as a result of our growing experience with this product and improved ability to estimate potential product returns, we began recognizing revenues upon shipment of product to the retailers or distributors. Based on available point-of-sale data, consumer purchases of our OraQuick^® In-Home HIV test in the third quarter were flat when compared to the same period of 2013.

Sales of our OraQuick^® In-Home HIV test in the third quarters of 2014 and 2013 included approximately $48,000 and $217,000, respectively, of direct sales to public health customers. We anticipate that some public health entities may choose to use a portion of their funding to purchase our OTC product in lieu of professional rapid HIV testing products.

Domestic OraQuick^® HCV sales increased 99% to $1.3 million in the third quarter of 2014 from $653,000 in the third quarter of 2013, primarily due to the addition of new HCV customers, including certain clinics operated by the U.S. Department of Veterans Affairs, and higher sales to current customers who have expanded their HCV testing programs. International OraQuick^® HCV sales decreased 49% to $470,000 in the third quarter of 2014 from $924,000 in the third quarter of 2013, primarily as a result of lower sales to a multi-national humanitarian organization that purchased a large stocking order in the third quarter of 2013. We expect that purchases by this customer will continue at a reduced rate for the remainder of 2014.

We believe our OraQuick^® HCV product represents an opportunity for future sales growth, especially as new therapies for treating HCV come to market. We also expect that sales of our HCV product will be positively impacted as we implement awareness and testing programs in collaboration with AbbVie. However, demand for our HCV product, particularly in the public health marketplace, is somewhat tempered by the limited availability of government funding allocated to HCV testing efforts and the time and effort required to build awareness and demand for rapid HCV testing.

International orders for both our HIV and HCV products can be sporadic in nature and are often predicated upon the availability of governmental funding, the impact of competition and other factors. As such, there is no assurance that such sales will continue at the same levels in future periods.

Substance Abuse Testing Market

Sales to the substance abuse testing market increased 3% to $2.2 million in the third quarter of 2014 from $2.1 million in the third quarter of 2013, primarily as a result of higher sales of our Intercept^® drug testing system. The table below shows a breakdown of our total net Intercept^® revenues (dollars in thousands) generated in each market during the third quarters of 2014 and 2013.


	Three Months Ended September 30,
Market	2014		2013		% Change
Domestic	$	1,606	$	1,495		7	%
International		3		29		(90	)

Net Intercept^® revenues	$	1,609	$	1,524		6	%

-22-

Domestic Intercept^® sales for the third quarter of 2014 increased to $1.6 million compared to $1.5 million for the third quarter of 2013 largely due to the recovery of customers that were previously lost to competition. A new version of our Intercept^® collection device, known as the I2 collection device, was commercially launched into the U.S. criminal justice and forensic toxicology markets and into certain international markets.

Cryosurgical Systems Market

Sales of our cryosurgical systems products (which includes both the physicians’ office and OTC markets) decreased 11% to $3.2 million in the third quarter of 2014, compared to $3.6 million in the same period of the prior year.

The table below shows a breakdown of our total net cryosurgical systems revenues (dollars in thousands) generated in each market during the third quarters of 2014 and 2013.


	Three Months Ended September 30,
Market	2014		2013		% Change
Domestic professional	$	1,590	$	1,803		(12	)%
International professional		43		435		(90	)
International OTC		1,608		1,411		14

Net cryosurgical systems revenues	$	3,241	$	3,649		(11	)%

Sales of our Histofreezer^® product to physicians’ offices in the United States decreased 12% to $1.6 million in the third quarter of 2014 from $1.8 million in the third quarter of 2013 largely due to the merger of two of our large distributors who began selling a private label cryosurgical product in direct competition with our Histofreezer^® product. International sales of Histofreezer^® decreased to $43,000 in the third quarter of 2014 compared to $435,000 in the same period of the prior year, primarily due to delivery problems and inventory shortages associated with the transition to a new manufacturer of our international Histofreezer^® product and the introduction of a new competing product. Our long-term supply agreement for the Histofreezer^® product with Koninklijke Utermöhlen, N.V., the party from whom we acquired the Histofreezer^® business in 1998, terminated in late 2013, and Utermöhlen began promoting a competing product similar to Histofreezer^®. In order to remain competitive with this new product, we have decreased the per unit sales price of our Histofreezer^® product in certain international markets and we are transitioning the manufacturer of this product to a new supplier. While we expect the delivery problems and inventory shortages to be corrected in the fourth quarter of 2014, we expect the competing product from Utermöhlen will adversely affect revenues generated from our cryosurgical systems business.

Sales of our OTC cryosurgical products during the third quarter of 2014 increased 14% to $1.6 million compared to $1.4 million in the third quarter of 2013, largely due to higher sales to our European distributor, Reckitt Benckiser, partially offset by lower sales to our Latin American distributor, Genomma.

Current quarter sales to Reckitt Benckiser increased to $1.0 million, compared to $606,000 during the third quarter of 2013, primarily due to customer ordering patterns. Sales to Genomma decreased to $531,000 in the third quarter of 2014 from $754,000 in the third quarter of 2013, also due to customer ordering patterns.

Insurance Risk Assessment Market

Sales to the insurance risk assessment market increased slightly to $1.0 million in the third quarter of 2014 from $946,000 in the third quarter of 2013, as a result of the timing of orders by one of our large laboratory customers.

Licensing and Product Development

Licensing and product development revenues in the third quarter of 2014 were $3.4 million and represent the ratable recognition of revenues received for exclusive promotion rights and certain other services provided under our HCV collaboration agreement with AbbVie. Licensing and product development revenues in the third quarter of 2013 were $147,000 and represent royalties paid on domestic outsales of Merck’s OTC cryosurgical wart removal product, pursuant to a license and settlement agreement that expired in August 2013.

-23-

DNAG Segment

Molecular Collection Systems

Net molecular collection systems revenues, which primarily represent sales of our Oragene^® product line, increased 38% to $6.9 million in the third quarter of 2014 from $5.0 million in the third quarter of 2013. Sales of Oragene^® in the commercial market increased 16%, which was primarily due to higher sales to commercial customers specializing in pharmacogenomic testing. Sales of Oragene^® in the academic market increased 84% largely due to orders placed by two new international customers as well as higher sales to one of the Company’s larger existing academic customers.

CONSOLIDATED OPERATING RESULTS

Consolidated gross margin was 67% for the third quarter of 2014 compared to 61% for the third quarter of 2013. Gross margin for the third quarter of 2013 increased primarily due to the $3.4 million of licensing and product development revenues associated with our AbbVie collaboration, as well as a more favorable product mix driven largely by increased DNAG sales to higher margin customers.

Consolidated operating income for the third quarter of 2014 was $882,000, a $3.0 million improvement from the $2.1 million operating loss reported in the third quarter of 2013. The improvement in operating income was primarily the result of the $3.4 million of licensing and product development revenues recorded in the third quarter of 2014.

OPERATING INCOME (LOSS) BY SEGMENT

OSUR Segment

OSUR’s gross margin was 65% in the third quarter of 2014 compared to 58% in the third quarter of 2013. OSUR’s 2014 margin was positively impacted by the higher licensing and product development revenues.

Research and development expenses increased 15% to $2.3 million in the third quarter of 2014 from $2.0 million in the third quarter of 2013 largely due to higher laboratory supply costs. Sales and marketing expenses remained relatively flat at $7.3 million in the third quarter of 2014 compared to $7.4 million in the third quarter of 2013. The decrease in advertising and promotional costs for our OraQuick^® In-Home HIV test which totaled $280,000 in the third quarter of 2014, compared to $1.9 million in third quarter of 2013, was offset by an increase in sales and marketing costs associated with our OraQuick^® HCV co-promotion agreement with AbbVie. General and administrative expenses increased 7% to $4.9 million in the third quarter of 2014 from $4.6 million in the third quarter of 2013 due to higher legal expenses and consulting costs.

All of the above contributed to OSUR’s third quarter 2014 operating loss of $987,000, which included non-cash charges of $820,000 for depreciation and amortization and $1.3 million for stock-based compensation.

DNAG Segment

DNAG’s gross margin was 75% in the third quarter of 2014 compared to 70% in the third quarter of 2013. This improvement was directly attributable to an increased volume of higher margin sales experienced in the third quarter of 2014 when compared to the third quarter of 2013.

DNAG operating expenses rose to $3.3 million in the third quarter of 2014 from $3.0 million in the third quarter of 2013. Research and development expenses remained relatively flat at $650,000 in the third quarter of 2014 compared to $631,000 in the third quarter of 2013. Sales and marketing expenses increased 16% to $1.9 million in the third quarter of 2014 from $1.6 million in the third quarter of 2013 due to higher staffing costs. General and administrative expenses decreased 7% to $724,000 in the third quarter of 2014 compared to $775,000 in the third quarter of 2013, largely due to a decrease in legal fees partially offset by higher staffing costs.

-24-

All of the above contributed to DNAG’s third quarter 2014 operating income of $1.9 million, which included non-cash charges of $804,000 for depreciation and amortization and $112,000 for stock-based compensation.

CONSOLIDATED INCOME TAXES

We continue to believe the full valuation allowance established in 2008 against OSUR’s total U.S. net deferred tax asset is appropriate as the facts and circumstances necessitating the allowance have not changed. As a result, no U.S. income tax expense or benefit was recorded for OSUR’s pre-tax income or loss in the third quarter of 2014 or 2013, respectively. Canadian income tax expense of $10,000 was recorded in the third quarter of 2014. A Canadian income tax benefit of $127,000 was recorded in the third quarter of 2013, which was associated with certain Canadian research and development and investment tax credits and DNAG’s loss before income taxes. The Canadian income tax benefits are considered realizable based upon the scheduled reversal of the deferred tax liabilities recorded in connection with the acquisition of DNAG.

Nine months ended September 30, 2014 compared to September 30, 2013

CONSOLIDATED NET REVENUES


	Nine Months Ended September 30,
	Dollars							Percentage of Total Net Revenues
	2014		2013		% Change			2014			2013
OSUR	$	56,087	$	55,999		—	%		72	%		80	%
DNAG		17,523		13,550		29			23			19

Net product revenues		73,610		69,549		6			95			99
Licensing and product development		4,173		623		570			5			1

Net revenues	$	77,783	$	70,172		11	%		100	%		100	%

Consolidated net product revenues increased 6% to $73.6 million in the first nine months of 2014 from $69.5 million in the comparable period of 2013, primarily as a result of higher sales of our molecular collection systems, OraQuick^® HCV, and cryosurgical systems products. These increases were partially offset by lower sales of our professional OraQuick^® HIV, substance abuse and insurance risk assessment products. Licensing and product development revenues were $4.2 million in the first nine months of 2014 and represent the recognition of payments from AbbVie for exclusive promotion rights and certain services provided under our HCV collaboration agreement. Licensing and product development revenues were $623,000 in the first nine months of 2013 and represent royalties received on sales of Merck’s OTC cryosurgical wart removal product, pursuant to a license and settlement agreement that expired in August 2013.

Consolidated net revenues derived from products sold to customers outside the U.S. were $18.8 million and $16.1 million, or 24% and 23% of total net revenues, during the nine months ended September 30, 2014 and 2013, respectively. Because the majority of our international sales are denominated in U.S. dollars, the impact of fluctuating foreign currency exchange rates was not material to our total net revenues.

-25-

Net Revenues by Segment

OSUR Segment

The table below shows the amount of total net revenues (dollars in thousands) generated by our OSUR segment in each of our principal markets and by licensing and product development activities.


	Nine Months Ended September 30,
	Dollars							Percentage of Total Net Revenues
Market	2014		2013		%			2014			2013
Infectious disease testing	$	34,914	$	35,526		(2	)%		58	%		63	%
Substance abuse testing		6,187		6,455		(4	)		10			11
Cryosurgical systems		12,128		10,910		11			20			19
Insurance risk assessment		2,858		3,108		(8	)		5			6

Net product revenues		56,087		55,999		0	%		93			99	%
Licensing and product development		4,173		623		570			7			1

Net revenues	$	60,260	$	56,622		6	%		100	%		100	%

Infectious Disease Testing Market

Sales to the infectious disease testing market decreased 2% to $34.9 million in the first nine months of 2014 from $35.5 million in the first nine months of 2013, primarily due to lower sales of our OraQuick^® HIV professional product and OraQuick^® In-Home HIV test, partially offset by higher sales of our OraQuick^® HCV product.

The table below shows a breakdown of our total net OraQuick^® revenues (dollars in thousands) during the nine months ended September 30, 2014 and 2013.


	Nine Months Ended September 30,
Market	2014		2013		% Change
Domestic HIV	$	21,568	$	23,854		(10	)%
International HIV		1,897		2,457		(23	)
Domestic OTC HIV		4,991		5,196		(4	)

Net HIV revenues		28,456		31,507		(10	)

Domestic HCV		3,183		1,772		80
International HCV		2,341		1,409		66

Net HCV revenues		5,524		3,181		74

Net OraQuick^® revenues	$	33,980	$	34,688		(2	)%

Domestic OraQuick^® HIV sales decreased 10% to $21.6 million for the nine months ended September 30, 2014 from $23.9 million for the nine months ended September 30, 2013. This decrease was primarily the result of some customer migration to automated 4^th generation HIV immunoassays performed in a laboratory, as recommended under new testing guidelines issued by the CDC. We anticipate that future sales of our professional HIV product will continue to be negatively affected as a result of the CDC’s guidelines and by reductions in government funding. International sales of our OraQuick^® HIV test during the first nine months of 2014 decreased 23% to $1.9 million from $2.5 million in the first nine months of 2013 largely due to decreased order volume related to project work in Africa.

-26-

During the first nine months of 2014, we recorded $5.6 million in gross revenues from sales of our OraQuick^® In-Home HIV test. These revenues were partially offset by $584,000 in customer allowances, including cooperative advertising, cash discounts, and other allowances, which were netted against gross revenues in accordance with U.S. generally accepted accounting principles. Thus, net revenues from this product were $5.0 million for the first nine months of 2014 as compared to net revenues of $5.2 million in the first nine months of 2013 ($5.6 million in gross revenues, partially offset by $415,000 of allowances and discounts).

OraQuick^® In-Home HIV revenues recorded in the current and prior year periods are not readily comparable due to the December 2013 change in our revenue recognition policy related to this product. Since the product launch in late 2012, revenues had been recognized upon consummation of a purchase by consumers either in a store or over the internet. In December 2013, as a result of our growing experience with this product and improved ability to estimate potential product returns, we began recognizing revenues upon shipment of product to the retailers or distributors. Based on available point-of-sale data, consumer purchases increased 6% in the first nine months of 2014 as compared to the first nine months of 2013 due to increased awareness about the product.

Sales of our OraQuick^® In-Home HIV test in the first nine months of 2014 and 2013 included approximately $299,000 and $600,000, respectively, of direct sales to public health customers. We anticipate that some public health entities may choose to use a portion of their funding to purchase our OTC product in lieu of professional rapid HIV testing products.

Domestic OraQuick^® HCV sales increased 80% to $3.2 million in the first nine months of 2014 from $1.8 million in the first nine months of 2013, primarily due to the addition of new HCV customers and higher sales to current customers who have expanded their HCV testing programs. International OraQuick^® HCV sales increased 66% to $2.3 million in the first nine months of 2014 from $1.4 million in the first nine months of 2013, primarily as a result of purchases by a multi-national humanitarian organization which first began purchasing product in the third quarter of 2013. We expect that purchases by this customer will be at a reduced rate for the remainder of 2014. Also contributing to the increase in international sales is higher sales into certain Asian markets.

We believe our OraQuick^® HCV product represents an opportunity for future sales growth, especially as new therapies for treating HCV come to market. We also expect that sales of our HCV product will be positively impacted as we implement awareness and testing programs with AbbVie. However, demand for our HCV product, particularly in the public health marketplace is somewhat tempered by the limited availability of government funding allocated to HCV testing efforts and the time and effort required to build awareness and demand for rapid HCV testing.

Substance Abuse Testing Market

Sales to the substance abuse testing market decreased 4% to $6.2 million in the first nine months of 2014 from $6.5 million in the first nine months of 2013, primarily as a result of lower sales of our Intercept^® drug testing system. The table below shows a breakdown of our total net Intercept^® revenues (dollars in thousands) generated in each market during the nine months ended September 30, 2014 and 2013.

-27-


	Nine Months Ended September 30,
Market	2014		2013		% Change
Domestic	$	4,473	$	4,240		5	%
International		76		385		(80	)

Net Intercept^® revenues	$	4,549	$	4,625		(2	)%

Domestic Intercept^® sales for the first nine months of 2014 increased to $4.5 million compared to $4.2 million for the first nine months of 2013, primarily due to increased interest in oral fluid testing by customers who previously used alternative specimen types for drug testing. In addition, we added several new larger accounts. International Intercept^® sales decreased 80% to $76,000 in the first nine months of 2014 from $385,000 in 2013 largely due the discontinuance of purchases by our UK distributor who in 2012 began selling its own competing oral specimen collection device. Sales to this distributor were $286,000 in the first nine months of 2013.

Cryosurgical Systems Market

Sales of our cryosurgical systems products (which includes both the physicians’ office and OTC markets) increased 11% to $12.1 million in the first nine months of 2014, compared to $10.9 million in the same period of the prior year.

The table below shows a breakdown of our total net cryosurgical systems revenues (dollars in thousands) generated in each market during the nine months ended September 30, 2014 and 2013.


	Nine Months Ended September 30,
Market	2014		2013		% Change
Domestic professional	$	4,601	$	4,192		10	%
International professional		581		1,039		(44	)
International OTC		6,946		5,679		22

Net cryosurgical systems revenues	$	12,128	$	10,910		11	%

Sales of our Histofreezer^® product to physicians’ offices in the United States increased 10% to $4.6 million in the first nine months of 2014, compared to $4.2 million in the first nine months of 2013. This increase is largely due to market share gained by two of our larger distributors and the introduction of our product into a new market segment. These increases were partially offset by the impact of the merger of our two largest distributors who began selling a private label cryosurgical product in direct competition with our Histofreezer^® product, as well as a decrease in sales to our Canadian distributor due to delivery issues associated with our transition to a new Histofreezer^® manufacturer.

During the first nine months of 2014, international sales of Histofreezer^® decreased to $581,000, compared to $1.0 million in the same period of the prior year. Our long-term supply agreement for the Histofreezer^® product with Koninklijke Utermöhlen, N.V., the party from whom we acquired the Histofreezer^® business in 1998, terminated in late 2013, and Utermöhlen began promoting a competing product similar to Histofreezer^®. In order to remain competitive with this new product, we have decreased the per unit sales price of our Histofreezer^® product in certain international markets. In addition, we have experienced delivery problems and inventory shortages as we transitioned to a new manufacturer of our international Histofreezer^® product. While we expect the delivery problems and inventory shortage to be corrected in the fourth quarter of 2014 we expect the competing product from Utermöhlen will adversely affect revenues generated from our cryosurgical systems business.

-28-

Sales of our OTC cryosurgical products during the first nine months of 2014 increased 22% to $6.9 million compared to $5.7 million in the first nine months of 2013, largely due to higher sales to our European distributor, Reckitt Benckiser.

Sales to Reckitt Benckiser increased to $4.1 million, compared to $2.8 million during the first nine month of 2013, primarily due to the launch of our product into new geographic territories and new market segments. Sales to Genomma, our Latin American distributor, remained flat at $2.7 million in the first nine months of 2014 and 2013.

Insurance Risk Assessment Market

Sales to the insurance risk assessment market decreased 8% to $2.9 million in the first nine months of 2014 from $3.1 million in the first nine months of 2013, as a result of continued reduced demand in the domestic life insurance market, as well as the adoption by some underwriters of a “Simplified Issues” policy, pursuant to which testing for risk factors is replaced by having applicants respond to a questionnaire about their behaviors.

Licensing and Product Development

Licensing and product development revenues were $4.2 million in the first nine months of 2014 and represent the ratable recognition of revenues received for exclusive promotion rights and certain other services provided under our HCV collaboration with AbbVie. Licensing and product development revenues in 2013 were $623,000 and represent royalties paid on domestic outsales of Merck’s OTC cryosurgical wart removal product, pursuant to a license and settlement agreement which expired in August 2013.

DNAG Segment

Molecular Collection Systems

Net molecular collection systems revenues, which primarily represent sales of our Oragene^® product line, increased 29% to $17.5 million in the first nine months of 2014 from $13.6 million in the first nine months of 2013. Sales of Oragene^® in the commercial market increased approximately 25% in the first nine months of 2014 primarily as a result of overall market growth and more specifically, increased use of our Oragene^® product in pharmacogenomics testing. Sales of Oragene^® in the academic market increased 42% largely due to orders placed by two new international customers as well as higher sales to one of the Company’s larger existing academic customers.

CONSOLIDATED OPERATING RESULTS

Consolidated gross margin was 63% for the first nine months of 2014 compared to 59% for the first nine months of 2013. Gross margin for the third quarter of 2014 increased primarily because of the $3.4 million of licensing and product development revenues associated with our AbbVie collaboration, as well as a more favorable product mix driven largely by increased DNAG sales to higher margin customers.

Consolidated operating loss for the first nine months of 2014 was $2.2 million, a $16.0 million improvement from the $18.2 million operating loss reported in the first nine months of 2013. The operating results for the third quarter of 2014 include a $5.5 million payment received under the terms of the termination of our drug assay collaboration with Roche Diagnostics. Also contributing to this improvement in operating loss were higher licensing and product development revenues, higher product revenues and lower HIV OTC sales and marketing costs during the first nine months of 2014.

-29-

OPERATING INCOME (LOSS) BY SEGMENT

OSUR Segment

OSUR’s gross margin was 60% in the first nine months of 2014 compared to 57% in the first nine months of 2013. OSUR’s 2014 margin was positively impacted by the higher licensing and product development revenues recorded during the third quarter of 2014.

Research and development expenses decreased 7% to $6.3 million in the first nine months of 2014 from $6.8 million in the first nine months of 2013 largely due to lower clinical trial and staffing costs. Sales and marketing expenses decreased 16% to $25.3 million in the first nine months of 2014 from $30.1 million in the first nine months of 2013. This decrease was primarily the result of lower advertising and promotional costs for our OraQuick^® In-Home HIV test which totaled $7.7 million in the first nine months of 2014, as compared to $14.2 million in the first nine months of 2013. This reduction was the result of our decision to focus our marketing and promotional efforts at the retail outlet level and transition away from broad-based consumer advertising by June 30, 2014. The decrease in advertising and promotional costs were partially offset by higher sales and marketing costs associated with our OraQuick^® HCV co-promotion agreement with AbbVie. General and administrative expenses increased 11% to $15.0 million in the first nine months of 2014 from $13.5 million in the first nine months of 2013 due to higher legal, staffing and consulting expenses.

All of the above, along with the $5.5 million favorable payment from Roche, contributed to OSUR’s operating loss of $5.2 million for the first nine months of 2014, which included non-cash charges of $2.4 million for depreciation and amortization and $4.0 million for stock-based compensation.

DNAG Segment

DNAG’s gross margin was 73% in the first nine months of 2014 compared to 67% in the first nine months of 2013. This improvement was directly attributable to an increased volume of higher margin sales experienced in the first nine months of 2014 when compared to the same period in 2013.

DNAG operating expenses rose to $9.8 million in the first nine months of 2014 from $9.3 million in the first nine months of 2013. Research and development expenses remained relatively flat at $1.9 million in the first nine months of 2014 and 2013. Sales and marketing expenses increased 9% to $5.6 million in the first nine months of 2014 from $5.1 million in the first nine months of 2013 largely due to higher staffing and consulting costs. General and administrative expenses remained relatively flat at $2.3 million in 2014 and 2013.

All of the above contributed to DNAG’s operating income of $2.9 million for the first nine months of 2014, which included non-cash charges of $2.4 million for depreciation and amortization and $318,000 for stock-based compensation.

CONSOLIDATED INCOME TAXES

We continue to believe the full valuation allowance established in 2008 against OSUR’s total U.S. net deferred tax asset is appropriate as the facts and circumstances necessitating the allowance have not changed. As a result, no U.S. income tax benefit was recorded for OSUR’s pre-tax loss in the first nine months of 2014 or 2013. For the nine months ended September 30, 2014 and 2013, we recorded Canadian income tax benefits of $33,000 and $786,000, respectively, associated with certain Canadian research and development and investment tax credits and for the 2013 period, DNAG’s loss before income taxes. The Canadian income tax benefits are considered realizable based upon the scheduled reversal of the deferred tax liabilities recorded in connection with the acquisition of DNAG.

-30-

Liquidity and Capital Resources


	September 30, 2014		December 31, 2013
	(In thousands)
Cash	$	93,855	$	93,191
Short-term investments		5,000		—
Working capital		104,794		100,590

Our cash and short-term investment balances increased to $98.9 million at September 30, 2014 from $93.2 million at December 31, 2013. Our working capital increased to $104.8 million at September 30, 2014 from $100.6 million at December 31, 2013.

During the first nine months of 2014, we generated $8.4 million in cash from our operating activities. Our net loss of $2.0 million was offset by non-cash stock-based compensation expense of $4.3 million and depreciation and amortization expense of $4.7 million. An increase in deferred revenue of $10.4 million also contributed to the cash generated in the quarter. The deferred revenue increase is related to the receipt of $15.0 million from AbbVie in July 2014 reduced by the amounts ratably recognized in revenue during the period. Also contributing to the increase in cash was a decrease in prepaid expenses and other current assets of $576,000. These increases in cash were partially offset by a $3.7 million decrease in accrued expenses and other liabilities associated with payment of our 2013 management incentive bonuses, royalty obligations, and certain year-end accruals, a $3.4 million increase in inventory associated with our OraQuick^® HCV product, a $2.1 million increase in accounts receivable resulting from the timing of orders during the current quarter, and a $284,000 decrease in accounts payable.

We used a total of $7.3 million in investing activities during the first nine months of 2014 to purchase $9.4 million in short-term investments and $2.3 million to acquire property and equipment. These payments were offset by proceeds received from the maturities of short-term investments of $4.4 million.

Net cash used in financing activities was $93,000 for the nine months ended September 30, 2014, which resulted from the use of $639,000 for the repurchase of common stock related to the vesting of restricted shares, partially offset by $546,000 in proceeds received from the exercise of stock options.

Our current cash balance is expected to be sufficient to fund our current operating and capital needs through at least the next twelve months. Our cash requirements, however, may vary materially from those now planned due to many factors, including, but not limited to, the scope and timing of future strategic acquisitions, the progress of our research and development programs, the scope and results of clinical testing, the cost of any future litigation, the magnitude of capital expenditures, changes in existing and potential relationships with business partners, the timing and cost of obtaining regulatory approvals, the costs involved in obtaining and enforcing patents, proprietary rights and any necessary licenses, the cost and timing of expansion of sales and marketing activities, market acceptance of new products, competing technological and market developments, the impact of the current economic environment and other factors.

Summary of Contractual Obligations

A summary of our obligations to make future payments under contracts existing at December 31, 2013 is included in Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations, of our Annual Report on Form 10-K for the year ended December 31, 2013. As of September 30, 2014, there were no significant changes to this information, including the absence of any off-balance sheet arrangements.

Critical Accounting Policies and Estimates

This Management’s Discussion and Analysis of Financial Condition and Results of Operations discusses our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these consolidated financial statements requires that we make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of

-31-

contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. On an on-going basis, we evaluate our judgments and estimates, including those related to the valuation of accounts receivable, inventories and intangible assets, as well as calculations related to contingencies and accruals. We base our judgments and estimates on historical experience and on various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

A more detailed review of our critical accounting policies is contained in our 2013 Annual Report on Form 10-K filed with the SEC. During the first nine months of 2014, there were no material changes in our critical accounting policies.

Item 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We do not hold any amounts of derivative financial instruments or derivative commodity instruments and, accordingly, we have no material derivative risk to report under this Item.

As of September 30, 2014, we did not have any foreign currency exchange contracts or purchase currency options to hedge local currency cash flows. We have operations in Canada and Europe, which are subject to foreign currency fluctuations. As currency rates change, translation of revenues and expenses for these operations from foreign currencies to U.S. dollars affects year-to-year comparability of operating results. Sales denominated in a foreign currency comprised 7% of our total revenues for the nine months ended September 30, 2014. We expect our international business will continue to grow and our exposure to fluctuations in foreign currency exchange rates may increase.

Item 4.

CONTROLS AND PROCEDURES

(a) Evaluation of Disclosure Controls and Procedures. The Company’s management, with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934) as of September 30, 2014. Based on that evaluation, the Company’s management, including such officers, concluded that the Company’s disclosure controls and procedures were effective as of September 30, 2014 to provide reasonable assurance that material information required to be disclosed by the Company in the reports that we file or submit under the Securities Exchange Act of 1934 was accumulated and communicated to the Company’s management, including the Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure and was recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC.

(b) Changes in Internal Control Over Financial Reporting. There was no change in the Company’s internal control over financial reporting that occurred during the three months ended September 30, 2014 that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

-32-

PART II. OTHER INFORMATION

Item 1.

LEGAL PROCEEDINGS

Employment Termination Claim

In August 2012, DNA Genotek Inc. (“DNAG”) received a Statement of Claim filed by a former employee with the Ontario Superior Court of Justice alleging, among other things, that DNAG had wrongfully terminated this individual and had breached the terms of his employment. DNAG was also alleged to have violated this individual’s rights under the Ontario Human Rights Code. The Statement of Claim sought to recover in excess of $500,000 CDN in damages from DNAG. A Statement of Defense denying the allegations was filed by DNAG in October 2012. In September 2014, the matter was settled in exchange for the payment of an immaterial amount by DNAG to the complainant.

Item 1A.

RISK FACTORS

There have been no material changes to the factors disclosed in Item 1A., entitled “Risk Factors,” in our Annual Report on Form 10-K for the year ended December 31, 2013.

Item 2.

UNREGISTERED SALE OF EQUITY SECURITIES AND USE OF PROCEEDS

None

Item 6.

EXHIBITS

Exhibits are listed on the Exhibit Index following the signature page of this Report.

-33-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.


						ORASURE TECHNOLOGIES, INC.

						/s/ Ronald H. Spair
Date: November 7, 2014						Ronald H. Spair
						Chief Operating Officer and
						Chief Financial Officer
						(Principal Financial Officer)

						/s/ Mark L. Kuna
Date: November 7, 2014						Mark L. Kuna
						Senior Vice President, Finance and Controller
						(Principal Accounting Officer)

-34-

EXHIBIT INDEX


Exhibit

31.1		Certification of Douglas A. Michels required by Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended.

31.2		Certification of Ronald H. Spair required by Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended.

32.1		Certification of Douglas A. Michels required by Rule 13a-14(b) or Rule 15d-14(b) under the Securities Exchange Act of 1934, as amended, and 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2		Certification of Ronald H. Spair required by Rule 13a-14(b) or Rule 15d-14(b) under the Securities Exchange Act of 1934, as amended, and 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS		XBRL Instance Document

101.SCH		XBRL Taxonomy Extension Schema Document

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document

101.LAB		XBRL Taxonomy Extension Labels Linkbase Document

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

-35-

EX-31.1 2 d811738dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

Certification

I, Douglas A. Michels, certify that:

1.	I have reviewed this report on Form 10-Q of OraSure Technologies, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d –15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within the entity, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors:

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 7, 2014

/s/ Douglas A. Michels

Douglas A. Michels

President and Chief Executive Officer

(Principal Executive Officer)

EX-31.2 3 d811738dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

Certification

I, Ronald H. Spair, certify that:

1.	I have reviewed this report on Form 10-Q of OraSure Technologies, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors:

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 7, 2014

/s/ Ronald H. Spair

Ronald H. Spair

Chief Operating Officer and

Chief Financial Officer

(Principal Financial Officer)

EX-32.1 4 d811738dex321.htm EX-32.1 EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. §1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of OraSure Technologies, Inc. (the “Company”) on Form 10-Q for the quarter ended September 30, 2014 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Douglas A. Michels, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Douglas A. Michels

Douglas A. Michels

President and Chief Executive Officer

November 7, 2014

EX-32.2 5 d811738dex322.htm EX-32.2 EX-32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. §1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of OraSure Technologies, Inc. (the “Company”) on Form 10-Q for the quarter ended September 30, 2014 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Ronald H. Spair, Chief Operating Officer and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Ronald H. Spair

Ronald H. Spair

Chief Operating Officer and

Chief Financial Officer

November 7, 2014

EX-101.INS 6 osur-20140930.xml XBRL INSTANCE DOCUMENT

10827000

56056813

1709000

82590000

56052000

120000000

0.000001

25000000

0.000001

30603000

25253000

-6248000

4510000

-175693000

3233000

342865000

9203000

160924000

1090000

1923000

190500000

15789000

484000

11540000

5093000

1703000

288000

2451000

93855000

22562000

6772000

17958000

1089000

7134000

190500000

67000

14843000

5000000

14920000

18831000

937000

273000

1102000

130047000

34620000

1 1090000 0.10 0.10

1139000

16802000

17000

53082000

3370000

7820000

11190000

7844000

2605000

10449000

3682000

5010000

8692000

893000

3396000

4289000

713000

5000000

137418000

87888000

55632000

120000000

0.000001

25000000

0.000001

28390000

18985000

-3797000

4834000

-173731000

3437000

338674000

13032000

161146000

677000

2082000

184245000

14488000

749000

1119000

5827000

4374000

299000

93191000

23782000

6700000

17933000

1712000

3911000

184245000

71000

11444000

12957000

22226000

833000

200000

729000

119575000

36714000

677000 0

975000

16925000

33000

53397000

2701000

9094000

11795000

7466000

2983000

10449000

2952000

6210000

9162000

654000

133000

787000

715000

3806000

4521000

1119000

130848000

8300000

-0.31

-3142000

55534000

-0.31

5324000

55534000

-1709000

41461000

28000

69549000

-1709000

554000

-745000

-18225000

623000

-19112000

-18189000

817000

36000

70172000

1696000

-17403000

-3127000

4846000

40000

-1098000

59686000

8720000

35224000

-5298000

-786000

28711000

-500000

3297000

-1696000

317000

15742000

497000

4187000

122000

817000

2159000

317000

2028000

7823000

54052000

8297000

-213000

13550000

600000

2457000

-18012000

56622000

1096000

2389000

<div> <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%" valign="top" align="left">4.</td> <td align="left" valign="top">Accrued Expenses</td> </tr> </table>   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="63%"></td> <td valign="bottom" width="13%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="13%"></td> <td></td> <td></td> <td></td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"> September 30, 2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"> December 31, 2013</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Payroll and related benefits </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,093</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,827</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Royalties </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,703</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,374</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Professional fees </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">484</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">749</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,923</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,082</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,203</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,032</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> Principles of Consolidation and Basis of Presentation. The consolidated financial statements include the accounts of OraSure Technologies, Inc. (“OraSure”) and its wholly-owned subsidiary, DNA Genotek, Inc. (“DNAG”). All intercompany transactions and balances have been eliminated. References herein to “we,” “us,” “our,” or the “Company” mean OraSure and its consolidated subsidiaries, unless otherwise indicated. The accompanying consolidated financial statements are unaudited and, in the opinion of management, include all adjustments (consisting only of normal and recurring adjustments) necessary for a fair presentation of our financial position and results of operations for these interim periods. These financial statements should be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013. Results of operations for the three and nine months ended September 30, 2014 are not necessarily indicative of the results of operations expected for the full year. </div>

-0.04

<div> Earnings (Loss) Per Share. Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings (loss) per share is computed in a manner similar to basic earnings (loss) per share except that the weighted average number of shares outstanding is increased to include incremental shares from the assumed vesting or exercise of dilutive securities, such as common stock options and unvested restricted stock, unless the impact is antidilutive. The number of incremental shares is calculated by assuming that outstanding stock options were exercised and unvested restricted shares were vested, and the proceeds from such exercises or vesting were used to acquire shares of common stock at the average market price during the reporting period.   The computations of basic and diluted earnings (loss) per share are as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="68%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Three Months Ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Nine Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Net income (loss) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,140</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1,892</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1,962</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(17,403</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Weighted average shares of common stock outstanding: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Basic </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">56,018</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">55,592</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">55,897</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">55,534</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Dilutive effect of stock options and restricted stock </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">648</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Diluted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">56,666</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">55,592</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">55,897</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">55,534</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Earnings (loss) per share: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Basic </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.02</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.03</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.04</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.31</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Diluted </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.02</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.03</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.04</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.31</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> For the three-month periods ended September 30, 2014 and 2013, outstanding common stock options and unvested restricted stock, representing 2,647 and 5,499 shares, respectively, were excluded from the computation of diluted earnings (loss) per share, as their inclusion would have been anti-dilutive. For the nine months ended September 30, 2014 and 2013, outstanding common stock options and unvested restricted stock, representing 3,313 and 5,324 shares, respectively, were similarly excluded from the computation of diluted earnings (loss) per share. </div>

<div> Inventories. Inventories are stated at the lower of cost or market determined on a first-in, first-out basis and are comprised of the following:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="64%"></td> <td valign="bottom" width="12%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="12%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"> September 30, 2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"> December 31, 2013</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Raw materials </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,772</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,700</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Work in process </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">937</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">833</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Finished goods </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,134</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,911</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">14,843</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,444</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> Deferred Revenue. We record deferred revenue when funds are received prior to the recognition of the associated revenue. Deferred revenue at September 30, 2014 and December 31, 2013 includes customer prepayments of $713 and $1,119, respectively. Deferred revenue also includes $10,827 which represents the $15,000 payment received in July 2014 under the terms of our HCV collaboration with AbbVie, less amounts recognized ratably in revenue. </div>

<div> The following table represents total revenues by geographic area, based on the location of the customer:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="64%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"> Three Months Ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"> Nine Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> </tr>  <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> United States </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">22,469</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">19,052</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">58,987</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">54,052</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Europe </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,252</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,540</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10,935</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,823</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Other regions </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,124</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,079</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,861</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,297</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">27,845</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">24,671</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">77,783</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">70,172</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>   The following table represents total long-lived assets by geographic area:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="64%"></td> <td valign="bottom" width="12%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="12%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">September 30, 2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2013</td> <td valign="bottom"> </td> </tr>  <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> United States </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">16,802</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">16,925</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Canada </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,139</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">975</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Other regions </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">17</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">33</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">17,958</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">17,933</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>   </div>

10-Q ORASURE TECHNOLOGIES INC OSUR

<div> Accumulated Other Comprehensive Loss. We classify items of other comprehensive loss by their nature and disclose the accumulated balance of other comprehensive loss separately from accumulated deficit and additional paid-in capital in the stockholders’ equity section of our balance sheet. We have defined the Canadian dollar as the functional currency of our Canadian subsidiary, DNAG, and as such, the results of its operations are translated into U.S. dollars, which is the reporting currency of the Company. The $2,451 and $1,709 currency translation adjustments recorded in the first nine months of 2014 and 2013, respectively, are largely the result of the translation of our Canadian operation’s balance sheets into U.S. dollars. </div>

<div> Short-Term Investments. We consider all short-term investments to be available-for-sale securities. These securities are comprised of guaranteed investment certificates with purchased maturities greater than ninety days. Available-for-sale securities are carried at fair value, based upon quoted market prices, with unrealized gains and losses, if any, reported in stockholders’ equity as a component of accumulated other comprehensive loss.   Our available-for-sale securities as of September 30, 2014 consisted of guaranteed investment certificates with amortized cost and fair value of $5,000. As of December 31, 2013, we had no available-for-sale securities. </div>

<div> Customer Sales Returns and Allowances. We do not grant return rights to our customers for any product, except for our OraQuick® In-Home HIV test. Accordingly, we have recorded an estimate of expected returns as a reduction of gross OraQuick® In-Home HIV product revenues in our consolidated statements of operations. This estimate reflects our historical sales experience to retailers and consumers, as well as other retail factors, and is reviewed regularly to ensure that it reflects potential product returns. As of September 30, 2014 and December 31, 2013, the reserve for sales returns and allowances was $398 and $279, respectively. If actual product returns differ materially from our reserve amount, or if a determination is made that this product’s distribution would be discontinued in whole or in part by certain retailers, then we would need to adjust our reserve. Should the actual level of product returns vary significantly from our estimates, our operating and financial results could be materially affected. </div>

<div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left">7.</td> <td valign="top" align="left">Business Segment Information</td> </tr> </table>  We operate our business within two reportable segments: our “OSUR” business, which consists of the development, manufacture and sale of oral fluid diagnostic products and specimen collection devices and the manufacture and sale of medical devices used for the removal of benign skin lesions by cryosurgery; and our molecular collection systems or “DNAG” business, which consists of the manufacture, development and sale of oral fluid collection devices that are used to collect, stabilize and store samples of genetic material for molecular testing. OSUR revenues are derived primarily from products sold in the United States and internationally to various clinical laboratories, hospitals, clinics, community-based organizations, public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities. Revenues from OSUR’s OTC products result from sales to retail pharmacies and mass merchandisers, and to consumers over the internet. OSUR also derives revenues from licensing and product development activities. DNAG revenues result primarily from products sold into the commercial market which consists of companies and other entities engaged in consumer genetics, clinical genetic testing, pharmacogenomics, personalized medicine, and animal and livestock genetic testing. DNAG products are also sold into the academic research market, which consists of research laboratories, universities and hospitals. We organized our operating segments according to the nature of the products included in those segments. The accounting policies of the segments are the same as those described in the summary of significant accounting policies (see Note 2). We evaluate performance of our operating segments based on revenue and operating income (loss). We do not allocate interest income, interest expense, other income, other expenses or income taxes to our operating segments. Reportable segments have no inter-segment revenues.   The following table summarizes segment information for the three and nine months ended September 30, 2014 and 2013:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="63%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"> Three Months Ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"> Nine Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> </tr>  <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Net revenues: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> OSUR </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">20,978</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">19,707</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">60,260</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">56,622</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> DNAG </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,867</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,964</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">17,523</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">13,550</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">27,845</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">24,671</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">77,783</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">70,172</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Operating income (loss): </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> OSUR </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(987</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(2,516</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(5,177</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(18,012</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> DNAG </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,869</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">456</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,938</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(213</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">882</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(2,060</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(2,239</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(18,225</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Depreciation and amortization: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> OSUR </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">820</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">815</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,386</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,389</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> DNAG </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">804</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">810</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,346</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,457</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,624</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,625</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,732</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,846</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Capital expenditures: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> OSUR </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">298</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">369</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,868</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,096</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> DNAG </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">67</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">235</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">485</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">600</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">365</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">604</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,353</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,696</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="64%"></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">September 30, 2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2013</td> <td valign="bottom"> </td> </tr>  <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total assets: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> OSUR </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">137,418</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">130,848</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> DNAG </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">53,082</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">53,397</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">190,500</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">184,245</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Our products are sold principally in the United States and Europe. The following table represents total revenues by geographic area, based on the location of the customer:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="64%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"> Three Months Ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"> Nine Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> </tr>  <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> United States </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">22,469</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">19,052</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">58,987</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">54,052</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Europe </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,252</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,540</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10,935</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,823</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Other regions </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,124</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,079</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,861</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,297</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">27,845</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">24,671</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">77,783</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">70,172</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>   The following table represents total long-lived assets by geographic area:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="64%"></td> <td valign="bottom" width="12%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="12%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">September 30, 2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2013</td> <td valign="bottom"> </td> </tr>  <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> United States </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">16,802</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">16,925</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Canada </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,139</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">975</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Other regions </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">17</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">33</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">17,958</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">17,933</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>   </div>

Accelerated Filer

8384000

We could be eligible to receive additional milestone payments. These payments would be based upon the aggregate number of new patients enrolled in the patient care database, in a given calendar year, after exceeding a baseline threshold, and could range from $3,500 to $55,500 annually over the life of the agreement. The first performance-based milestone period ends on December 31,2015.

<div> Revenue Recognition. We recognize product revenues when there is persuasive evidence that an arrangement exists, the price is fixed or determinable, title has passed and collection is reasonably assured. Product revenues are recorded net of allowances for any discounts or rebates. Other than for our OraQuick® In-Home HIV test, we do not grant price protection or product return rights to our customers, except for warranty returns. Historically, returns arising from warranty issues have been infrequent and immaterial. Accordingly, we expense warranty returns as incurred.   We began selling our OraQuick® In-Home HIV test in the third quarter of 2012. From launch through November 2013, our revenue recognition practices with respect to the OraQuick® In-Home HIV test were different than those customarily used in the consumer package goods industry. Under U.S. generally accepted accounting principles, product revenue cannot be recognized unless the amount of future returns can be reasonably estimated. Because our OraQuick® In-Home HIV test was a new product for which we did not have a historical record of returns, we did not believe we could reasonably determine a return rate. As a result, initially we did not recognize revenue when we shipped to the retail trade. For these product shipments, we invoiced the retailer or distributor, recorded deferred revenue at gross invoice sales price, and classified the cost basis of the product held by the retailer or distributor as a component of inventory. We then recognized revenue upon the consummation of a sale to the consumer either in a store or over the internet. With the passage of time, however, we concluded that we have sufficient data and visibility into our distribution channel to develop a reasonable estimate of the level of expected returns. As such, commencing in December 2013, we recognized previously deferred revenue and its related cost of goods sold, and began to recognize revenue for this product upon shipment to the retailers or distributors. Accordingly, revenues in the first nine months of 2014 were recorded based upon shipments into the distribution channel, while revenues in the first nine months of 2013 were recorded based upon the consummation of a sale to the consumer. Our net revenues recorded on sales of the OraQuick® In-Home HIV test represent total gross revenues, less an allowance for expected returns, and customer allowances for cooperative advertising discounts, rebates, and chargebacks. All of these allowances are estimates established by management, based on currently available information and are adjusted to reflect known changes in the factors that impact those estimates. These allowances are recorded as a reduction of gross revenue when recognized in our statements of operations. Royalty income from the grant of license rights is recognized during the period in which the revenue is earned and the amount is determinable from the licensee and is recorded as licensing and product development revenue in our statements of operations. We record shipping and handling charges billed to our customers as product revenue and the related expense as cost of products sold. Taxes assessed by governmental authorities, such as sales or value-added taxes, are excluded from product revenues. On June 10, 2014, we entered into a Master Program Services and Co-Promotion Agreement with AbbVie Bahamas Ltd., a wholly-owned subsidiary of AbbVie Inc. (“AbbVie”), to co-promote our OraQuick® HCV Rapid Test in the United States. The product will be used to test individuals at-risk for the hepatitis C virus (“HCV”). We will be responsible for manufacturing and selling the product into all markets. Under the terms of our agreement, we have granted exclusive promotion rights to AbbVie for the OraQuick® HCV Rapid test in certain markets and we have agreed to develop, implement, administer and maintain a patient care database for the exclusive use of AbbVie. This patient care database will be used to compile patient information regarding new individuals who have tested positive for HCV using our OraQuick® HCV Rapid test. We have also jointly agreed with AbbVie to co-promote our OraQuick® HCV Rapid test in certain market segments, namely: healthcare providers such as primary care physicians, gastroenterologists, hepatologists and infectious disease specialists; employers and employee groups experiencing a high HCV prevalence rate, such as the long-haul trucking industry; and national retail pharmacies and retail clinics that perform routine healthcare screening services. In exchange for these exclusive rights and other services, we will receive up to $75,000 in payments over the term of the agreement which expires on December 31, 2019. We will recognize revenues from these periodic payments ratably, over the life of the agreement. In addition, if certain performance-based milestones are achieved, we could be eligible to receive additional milestone payments. These payments would be based upon the aggregate number of new patients enrolled in the patient care database, in a given calendar year, after exceeding a baseline threshold, and could range from $3,500 to $55,500 annually over the life of the agreement. The first performance-based milestone period ends on December 31, 2015. The agreement also contains certain termination, indemnification and other provisions, typical of agreements of this type. Payments received under this agreement will be recorded as licensing and product development revenue in our statements of operations. </div>

<div> Customer and Vendor Concentrations. We had no significant concentrations (greater than 10%) in accounts receivable as of September 30, 2014. One of our customers, AbbVie, accounted for approximately 12% of our net revenues for the three months ended September 30, 2014. We had no significant concentrations (greater than 10%) in net revenues for the nine months ended September 30, 2014 and the three or nine months ended September 30, 2013. We currently purchase certain products and critical components of our products from sole-supply vendors, and if these vendors are unable or unwilling to supply the required components and products, we could be subject to increased costs and substantial delays in the delivery of our products to our customers. Also, our subsidiary, DNAG, uses two third-party suppliers to manufacture its products. Our inability to have a timely supply of any of these components and products could have a material adverse effect on our business, as well as our financial condition and results of operations. </div>

<div> <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="63%"></td> <td valign="bottom" width="13%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="13%"></td> <td></td> <td></td> <td></td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"> September 30, 2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"> December 31, 2013</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Payroll and related benefits </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,093</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,827</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Royalties </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,703</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,374</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Professional fees </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">484</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">749</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,923</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,082</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,203</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,032</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> Intangible assets consist of the following:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="61%"></td> <td valign="bottom" width="5%"></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center">September 30, 2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center">Amortization Period (Years)</td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Gross</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Accumulated Amortization</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Net</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Customer list </td> <td valign="bottom">  </td> <td valign="bottom" align="center">10</td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,190</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(3,370</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,820</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Patents and product rights </td> <td valign="bottom">  </td> <td valign="bottom" align="center">3-10</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10,449</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(7,844</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,605</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Acquired technology </td> <td valign="bottom">  </td> <td valign="bottom" align="center">7</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,692</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(3,682</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,010</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Tradename </td> <td valign="bottom">  </td> <td valign="bottom" align="center">15</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,289</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(893</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,396</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">34,620</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(15,789</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">18,831</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="2"></td> <td height="16" colspan="12"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center">December 31, 2013</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center">Amortization Period(Years)</td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Gross</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Accumulated Amortization</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Net</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Customer list </td> <td valign="bottom">  </td> <td valign="bottom" align="center">10</td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,795</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(2,701</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,094</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Patents and product rights </td> <td valign="bottom">  </td> <td valign="bottom" align="center">3-10</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10,449</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(7,466</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,983</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Acquired technology </td> <td valign="bottom">  </td> <td valign="bottom" align="center">7</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9,162</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2,952</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,210</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Tradename </td> <td valign="bottom">  </td> <td valign="bottom" align="center">15</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,521</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(715</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,806</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Non-compete agreements </td> <td valign="bottom">  </td> <td valign="bottom" align="center">1-3</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">787</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(654</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">133</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">36,714</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(14,488</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">22,226</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> The following table summarizes segment information for the three and nine months ended September 30, 2014 and 2013:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="63%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"> Three Months Ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"> Nine Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Net revenues: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> OSUR </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">20,978</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">19,707</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">60,260</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">56,622</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> DNAG </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,867</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,964</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">17,523</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">13,550</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">27,845</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">24,671</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">77,783</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">70,172</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Operating income (loss): </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> OSUR </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(987</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(2,516</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(5,177</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(18,012</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> DNAG </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,869</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">456</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,938</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(213</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">882</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(2,060</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(2,239</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(18,225</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Depreciation and amortization: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> OSUR </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">820</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">815</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,386</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,389</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> DNAG </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">804</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">810</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,346</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,457</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,624</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,625</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,732</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,846</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Capital expenditures: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> OSUR </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">298</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">369</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,868</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,096</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> DNAG </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">67</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">235</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">485</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">600</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">365</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">604</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,353</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,696</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="64%"></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">September 30, 2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2013</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total assets: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> OSUR </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">137,418</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">130,848</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> DNAG </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">53,082</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">53,397</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">190,500</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">184,245</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> Use of Estimates. The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Such estimates include the valuation of accounts receivable and inventories and assumptions utilized in impairment testing for intangible assets and goodwill, as well as calculations related to contingencies and accruals, among others. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis, using historical experience and other factors which management believes to be reasonable under the circumstances, including the current economic environment. We adjust such estimates and assumptions when facts and circumstances dictate. Illiquid credit markets, volatile equity and foreign currency markets, reductions in government funding and declines in consumer spending have combined to increase the uncertainty inherent in such estimates and assumptions. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic environment and other factors will be reflected in the financial statements in those future periods. </div>

2014-09-30

<div> Goodwill. Goodwill represents the excess of the purchase price we paid over the fair value of the net tangible and identifiable intangible assets acquired and liabilities assumed in our acquisition of DNAG in August 2011. Goodwill is not amortized but rather is tested annually for impairment or more frequently if we believe that indicators of impairment exist. Current U.S. generally accepted accounting principles permit us to make a qualitative evaluation about the likelihood of goodwill impairment. If we conclude that it is more likely than not that the fair value of a reporting unit is greater than its carrying amount, then we would not be required to perform the two-step quantitative impairment test. Otherwise, performing the two-step impairment test is necessary. The first step of the two-step quantitative impairment test involves comparing the fair value of the applicable reporting unit with its aggregate carrying value, including goodwill. If the carrying value of a reporting unit exceeds the reporting unit’s fair value, we perform the second step of the test to determine the amount of the impairment loss, if any. The second step involves measuring any impairment by comparing the implied fair values of the affected reporting unit’s goodwill and intangible assets with their respective carrying values. We performed our last annual impairment assessment as of July 31, 2014 utilizing a qualitative evaluation and concluded that it was more likely than not that the fair value of our DNAG reporting unit is greater than its carrying amount. We believe we have made reasonable estimates and assumptions to calculate the fair value of our reporting unit. If actual future results are not consistent with management’s estimates and assumptions, we may have to take an impairment charge in the future related to our goodwill. Future impairment tests will continue to be performed annually in the fiscal third quarter, or sooner if a triggering event occurs. As of September 30, 2014, we believe no indicators of impairment exist. The change in goodwill from $23,782 as of December 31, 2013 to $22,562 as of September 30, 2014 is a result of foreign currency translation. </div>

<div> Intangible Assets. Intangible assets consist of the following:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="61%"></td> <td valign="bottom" width="5%"></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center">September 30, 2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center">Amortization Period (Years)</td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Gross</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Accumulated Amortization</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Net</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Customer list </td> <td valign="bottom">  </td> <td valign="bottom" align="center">10</td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,190</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(3,370</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,820</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Patents and product rights </td> <td valign="bottom">  </td> <td valign="bottom" align="center">3-10</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10,449</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(7,844</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,605</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Acquired technology </td> <td valign="bottom">  </td> <td valign="bottom" align="center">7</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,692</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(3,682</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,010</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Tradename </td> <td valign="bottom">  </td> <td valign="bottom" align="center">15</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,289</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(893</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,396</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">34,620</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(15,789</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">18,831</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="2"></td> <td height="16" colspan="12"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center">December 31, 2013</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center">Amortization Period(Years)</td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Gross</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Accumulated Amortization</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Net</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Customer list </td> <td valign="bottom">  </td> <td valign="bottom" align="center">10</td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,795</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(2,701</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,094</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Patents and product rights </td> <td valign="bottom">  </td> <td valign="bottom" align="center">3-10</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10,449</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(7,466</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,983</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Acquired technology </td> <td valign="bottom">  </td> <td valign="bottom" align="center">7</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9,162</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2,952</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,210</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Tradename </td> <td valign="bottom">  </td> <td valign="bottom" align="center">15</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,521</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(715</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,806</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Non-compete agreements </td> <td valign="bottom">  </td> <td valign="bottom" align="center">1-3</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">787</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(654</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">133</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">36,714</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(14,488</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">22,226</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> Property and Equipment. Property and equipment are stated at cost. Additions or improvements are capitalized, while repairs and maintenance are charged to expense. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. Buildings are depreciated over twenty to forty years, while computer equipment, machinery and equipment, and furniture and fixtures are depreciated over two to ten years. Building improvements are amortized over their estimated useful lives. When assets are sold or otherwise disposed of, the related property amounts are relieved from the accounts, and any gain or loss is recorded in the consolidated statement of operations. Accumulated depreciation of property and equipment as of September 30, 2014 and December 31, 2013 was $30,603 and $28,390, respectively. </div>

false --12-31 2014

55897000

-0.04

<div> Foreign Currency Translation. The assets and liabilities of our foreign operations are translated into U.S. dollars at current exchange rates as of the balance sheet date, and revenues and expenses are translated at average exchange rates for the period. Resulting translation adjustments are reflected in accumulated other comprehensive loss, which is a separate component of stockholders’ equity. Transaction gains and losses resulting from exchange rate changes on transactions denominated in currencies other than functional currency are included in income in the period in which the change occurs. </div>

<div> The computations of basic and diluted earnings (loss) per share are as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="68%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Three Months Ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Nine Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Net income (loss) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,140</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1,892</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1,962</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(17,403</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Weighted average shares of common stock outstanding: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Basic </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">56,018</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">55,592</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">55,897</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">55,534</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Dilutive effect of stock options and restricted stock </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">648</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Diluted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">56,666</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">55,592</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">55,897</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">55,534</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Earnings (loss) per share: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Basic </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.02</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.03</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.04</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.31</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Diluted </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.02</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.03</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.04</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.31</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left">2.</td> <td valign="top" align="left">Summary of Significant Accounting Policies</td> </tr> </table> Principles of Consolidation and Basis of Presentation. The consolidated financial statements include the accounts of OraSure Technologies, Inc. (“OraSure”) and its wholly-owned subsidiary, DNA Genotek, Inc. (“DNAG”). All intercompany transactions and balances have been eliminated. References herein to “we,” “us,” “our,” or the “Company” mean OraSure and its consolidated subsidiaries, unless otherwise indicated. The accompanying consolidated financial statements are unaudited and, in the opinion of management, include all adjustments (consisting only of normal and recurring adjustments) necessary for a fair presentation of our financial position and results of operations for these interim periods. These financial statements should be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013. Results of operations for the three and nine months ended September 30, 2014 are not necessarily indicative of the results of operations expected for the full year. Use of Estimates. The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Such estimates include the valuation of accounts receivable and inventories and assumptions utilized in impairment testing for intangible assets and goodwill, as well as calculations related to contingencies and accruals, among others. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis, using historical experience and other factors which management believes to be reasonable under the circumstances, including the current economic environment. We adjust such estimates and assumptions when facts and circumstances dictate. Illiquid credit markets, volatile equity and foreign currency markets, reductions in government funding and declines in consumer spending have combined to increase the uncertainty inherent in such estimates and assumptions. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic environment and other factors will be reflected in the financial statements in those future periods. Short-Term Investments. We consider all short-term investments to be available-for-sale securities. These securities are comprised of guaranteed investment certificates with purchased maturities greater than ninety days. Available-for-sale securities are carried at fair value, based upon quoted market prices, with unrealized gains and losses, if any, reported in stockholders’ equity as a component of accumulated other comprehensive loss.   Our available-for-sale securities as of September 30, 2014 consisted of guaranteed investment certificates with amortized cost and fair value of $5,000. As of December 31, 2013, we had no available-for-sale securities. Fair Value of Financial Instruments. As of September 30, 2014, the carrying values of cash, short-term investments, accounts receivable, accounts payable and accrued expenses approximate their respective fair values based on their short-term nature. Fair value measurements of all financial assets and liabilities that are being measured and reported on a fair value basis are required to be classified and disclosed in one of the following three categories: Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity). We offer a nonqualified deferred compensation plan for certain eligible employees and members of our Board of Directors. The assets of the plan are held in the name of the Company at a third-party financial institution. Separate accounts are maintained for each participant to reflect the amounts deferred by the participant and all earnings and losses on those deferred amounts. The assets of the plan are held in mutual funds and Company stock. The fair value of the plan assets as of September 30, 2014 and December 31, 2013 was $1,090 and $677, respectively, and was calculated using the quoted market prices of the assets as of those dates. All investments in the plan are classified as trading securities and measured as Level 1 instruments. The fair value of plan assets is included in other assets with the same amount included in other liabilities in the accompanying consolidated balance sheets. All of our available-for-sale securities were classified and measured as Level 1 instruments as of September 30, 2014. Inventories. Inventories are stated at the lower of cost or market determined on a first-in, first-out basis and are comprised of the following:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="64%"></td> <td valign="bottom" width="12%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="12%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"> September 30, 2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"> December 31, 2013</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Raw materials </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,772</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,700</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Work in process </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">937</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">833</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Finished goods </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,134</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,911</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">14,843</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,444</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Property and Equipment. Property and equipment are stated at cost. Additions or improvements are capitalized, while repairs and maintenance are charged to expense. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. Buildings are depreciated over twenty to forty years, while computer equipment, machinery and equipment, and furniture and fixtures are depreciated over two to ten years. Building improvements are amortized over their estimated useful lives. When assets are sold or otherwise disposed of, the related property amounts are relieved from the accounts, and any gain or loss is recorded in the consolidated statement of operations. Accumulated depreciation of property and equipment as of September 30, 2014 and December 31, 2013 was $30,603 and $28,390, respectively.   Intangible Assets. Intangible assets consist of the following:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="61%"></td> <td valign="bottom" width="5%"></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center">September 30, 2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center">Amortization Period (Years)</td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Gross</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Accumulated Amortization</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Net</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Customer list </td> <td valign="bottom">  </td> <td valign="bottom" align="center">10</td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,190</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(3,370</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,820</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Patents and product rights </td> <td valign="bottom">  </td> <td valign="bottom" align="center">3-10</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10,449</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(7,844</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,605</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Acquired technology </td> <td valign="bottom">  </td> <td valign="bottom" align="center">7</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,692</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(3,682</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,010</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Tradename </td> <td valign="bottom">  </td> <td valign="bottom" align="center">15</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,289</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(893</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,396</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">34,620</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(15,789</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">18,831</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="2"></td> <td height="16" colspan="12"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center">December 31, 2013</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center">Amortization Period(Years)</td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Gross</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Accumulated Amortization</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Net</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Customer list </td> <td valign="bottom">  </td> <td valign="bottom" align="center">10</td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,795</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(2,701</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,094</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Patents and product rights </td> <td valign="bottom">  </td> <td valign="bottom" align="center">3-10</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10,449</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(7,466</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,983</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Acquired technology </td> <td valign="bottom">  </td> <td valign="bottom" align="center">7</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9,162</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2,952</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,210</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Tradename </td> <td valign="bottom">  </td> <td valign="bottom" align="center">15</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,521</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(715</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,806</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Non-compete agreements </td> <td valign="bottom">  </td> <td valign="bottom" align="center">1-3</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">787</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(654</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">133</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">36,714</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(14,488</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">22,226</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Goodwill. Goodwill represents the excess of the purchase price we paid over the fair value of the net tangible and identifiable intangible assets acquired and liabilities assumed in our acquisition of DNAG in August 2011. Goodwill is not amortized but rather is tested annually for impairment or more frequently if we believe that indicators of impairment exist. Current U.S. generally accepted accounting principles permit us to make a qualitative evaluation about the likelihood of goodwill impairment. If we conclude that it is more likely than not that the fair value of a reporting unit is greater than its carrying amount, then we would not be required to perform the two-step quantitative impairment test. Otherwise, performing the two-step impairment test is necessary. The first step of the two-step quantitative impairment test involves comparing the fair value of the applicable reporting unit with its aggregate carrying value, including goodwill. If the carrying value of a reporting unit exceeds the reporting unit’s fair value, we perform the second step of the test to determine the amount of the impairment loss, if any. The second step involves measuring any impairment by comparing the implied fair values of the affected reporting unit’s goodwill and intangible assets with their respective carrying values. We performed our last annual impairment assessment as of July 31, 2014 utilizing a qualitative evaluation and concluded that it was more likely than not that the fair value of our DNAG reporting unit is greater than its carrying amount. We believe we have made reasonable estimates and assumptions to calculate the fair value of our reporting unit. If actual future results are not consistent with management’s estimates and assumptions, we may have to take an impairment charge in the future related to our goodwill. Future impairment tests will continue to be performed annually in the fiscal third quarter, or sooner if a triggering event occurs. As of September 30, 2014, we believe no indicators of impairment exist. The change in goodwill from $23,782 as of December 31, 2013 to $22,562 as of September 30, 2014 is a result of foreign currency translation. Revenue Recognition. We recognize product revenues when there is persuasive evidence that an arrangement exists, the price is fixed or determinable, title has passed and collection is reasonably assured. Product revenues are recorded net of allowances for any discounts or rebates. Other than for our OraQuick® In-Home HIV test, we do not grant price protection or product return rights to our customers, except for warranty returns. Historically, returns arising from warranty issues have been infrequent and immaterial. Accordingly, we expense warranty returns as incurred.   We began selling our OraQuick® In-Home HIV test in the third quarter of 2012. From launch through November 2013, our revenue recognition practices with respect to the OraQuick® In-Home HIV test were different than those customarily used in the consumer package goods industry. Under U.S. generally accepted accounting principles, product revenue cannot be recognized unless the amount of future returns can be reasonably estimated. Because our OraQuick® In-Home HIV test was a new product for which we did not have a historical record of returns, we did not believe we could reasonably determine a return rate. As a result, initially we did not recognize revenue when we shipped to the retail trade. For these product shipments, we invoiced the retailer or distributor, recorded deferred revenue at gross invoice sales price, and classified the cost basis of the product held by the retailer or distributor as a component of inventory. We then recognized revenue upon the consummation of a sale to the consumer either in a store or over the internet. With the passage of time, however, we concluded that we have sufficient data and visibility into our distribution channel to develop a reasonable estimate of the level of expected returns. As such, commencing in December 2013, we recognized previously deferred revenue and its related cost of goods sold, and began to recognize revenue for this product upon shipment to the retailers or distributors. Accordingly, revenues in the first nine months of 2014 were recorded based upon shipments into the distribution channel, while revenues in the first nine months of 2013 were recorded based upon the consummation of a sale to the consumer. Our net revenues recorded on sales of the OraQuick® In-Home HIV test represent total gross revenues, less an allowance for expected returns, and customer allowances for cooperative advertising discounts, rebates, and chargebacks. All of these allowances are estimates established by management, based on currently available information and are adjusted to reflect known changes in the factors that impact those estimates. These allowances are recorded as a reduction of gross revenue when recognized in our statements of operations. Royalty income from the grant of license rights is recognized during the period in which the revenue is earned and the amount is determinable from the licensee and is recorded as licensing and product development revenue in our statements of operations. We record shipping and handling charges billed to our customers as product revenue and the related expense as cost of products sold. Taxes assessed by governmental authorities, such as sales or value-added taxes, are excluded from product revenues. On June 10, 2014, we entered into a Master Program Services and Co-Promotion Agreement with AbbVie Bahamas Ltd., a wholly-owned subsidiary of AbbVie Inc. (“AbbVie”), to co-promote our OraQuick® HCV Rapid Test in the United States. The product will be used to test individuals at-risk for the hepatitis C virus (“HCV”). We will be responsible for manufacturing and selling the product into all markets. Under the terms of our agreement, we have granted exclusive promotion rights to AbbVie for the OraQuick® HCV Rapid test in certain markets and we have agreed to develop, implement, administer and maintain a patient care database for the exclusive use of AbbVie. This patient care database will be used to compile patient information regarding new individuals who have tested positive for HCV using our OraQuick® HCV Rapid test. We have also jointly agreed with AbbVie to co-promote our OraQuick® HCV Rapid test in certain market segments, namely: healthcare providers such as primary care physicians, gastroenterologists, hepatologists and infectious disease specialists; employers and employee groups experiencing a high HCV prevalence rate, such as the long-haul trucking industry; and national retail pharmacies and retail clinics that perform routine healthcare screening services. In exchange for these exclusive rights and other services, we will receive up to $75,000 in payments over the term of the agreement which expires on December 31, 2019. We will recognize revenues from these periodic payments ratably, over the life of the agreement. In addition, if certain performance-based milestones are achieved, we could be eligible to receive additional milestone payments. These payments would be based upon the aggregate number of new patients enrolled in the patient care database, in a given calendar year, after exceeding a baseline threshold, and could range from $3,500 to $55,500 annually over the life of the agreement. The first performance-based milestone period ends on December 31, 2015. The agreement also contains certain termination, indemnification and other provisions, typical of agreements of this type. Payments received under this agreement will be recorded as licensing and product development revenue in our statements of operations.   Customer Sales Returns and Allowances. We do not grant return rights to our customers for any product, except for our OraQuick® In-Home HIV test. Accordingly, we have recorded an estimate of expected returns as a reduction of gross OraQuick® In-Home HIV product revenues in our consolidated statements of operations. This estimate reflects our historical sales experience to retailers and consumers, as well as other retail factors, and is reviewed regularly to ensure that it reflects potential product returns. As of September 30, 2014 and December 31, 2013, the reserve for sales returns and allowances was $398 and $279, respectively. If actual product returns differ materially from our reserve amount, or if a determination is made that this product’s distribution would be discontinued in whole or in part by certain retailers, then we would need to adjust our reserve. Should the actual level of product returns vary significantly from our estimates, our operating and financial results could be materially affected. Termination Settlement. On November 21, 2013, we terminated our assay development collaboration with Roche Diagnostics (“Roche”). Pursuant to a termination agreement, Roche paid us $8,300 which was recorded as a reduction of operating expense in our consolidated statement of operations for the quarter ended December 31, 2013. Roche agreed to provide certain transitional product support services to us and to continue to supply certain of the assays developed under the collaboration on a transitional basis for up to five years following the termination. We had the right to stop the supply of assays prior to the end of this five-year period and to receive an additional payment from Roche of up to $5,500 depending on how early in that five-year period the supply obligation was ended. During the second quarter of 2014, we issued our final purchase order for fully-automated assays previously developed under the terminated collaboration and as such, have recorded $5,500 as a reduction of operating expense in our consolidated statement of operations. Deferred Revenue. We record deferred revenue when funds are received prior to the recognition of the associated revenue. Deferred revenue at September 30, 2014 and December 31, 2013 includes customer prepayments of $713 and $1,119, respectively. Deferred revenue also includes $10,827 which represents the $15,000 payment received in July 2014 under the terms of our HCV collaboration with AbbVie, less amounts recognized ratably in revenue. Customer and Vendor Concentrations. We had no significant concentrations (greater than 10%) in accounts receivable as of September 30, 2014. One of our customers, AbbVie, accounted for approximately 12% of our net revenues for the three months ended September 30, 2014. We had no significant concentrations (greater than 10%) in net revenues for the nine months ended September 30, 2014 and the three or nine months ended September 30, 2013. We currently purchase certain products and critical components of our products from sole-supply vendors, and if these vendors are unable or unwilling to supply the required components and products, we could be subject to increased costs and substantial delays in the delivery of our products to our customers. Also, our subsidiary, DNAG, uses two third-party suppliers to manufacture its products. Our inability to have a timely supply of any of these components and products could have a material adverse effect on our business, as well as our financial condition and results of operations. Earnings (Loss) Per Share. Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings (loss) per share is computed in a manner similar to basic earnings (loss) per share except that the weighted average number of shares outstanding is increased to include incremental shares from the assumed vesting or exercise of dilutive securities, such as common stock options and unvested restricted stock, unless the impact is antidilutive. The number of incremental shares is calculated by assuming that outstanding stock options were exercised and unvested restricted shares were vested, and the proceeds from such exercises or vesting were used to acquire shares of common stock at the average market price during the reporting period.   The computations of basic and diluted earnings (loss) per share are as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="68%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Three Months Ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Nine Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Net income (loss) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,140</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1,892</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1,962</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(17,403</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Weighted average shares of common stock outstanding: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Basic </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">56,018</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">55,592</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">55,897</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">55,534</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Dilutive effect of stock options and restricted stock </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">648</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Diluted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">56,666</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">55,592</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">55,897</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">55,534</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Earnings (loss) per share: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Basic </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.02</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.03</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.04</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.31</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Diluted </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.02</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.03</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.04</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.31</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> For the three-month periods ended September 30, 2014 and 2013, outstanding common stock options and unvested restricted stock, representing 2,647 and 5,499 shares, respectively, were excluded from the computation of diluted earnings (loss) per share, as their inclusion would have been anti-dilutive. For the nine months ended September 30, 2014 and 2013, outstanding common stock options and unvested restricted stock, representing 3,313 and 5,324 shares, respectively, were similarly excluded from the computation of diluted earnings (loss) per share. Foreign Currency Translation. The assets and liabilities of our foreign operations are translated into U.S. dollars at current exchange rates as of the balance sheet date, and revenues and expenses are translated at average exchange rates for the period. Resulting translation adjustments are reflected in accumulated other comprehensive loss, which is a separate component of stockholders’ equity. Transaction gains and losses resulting from exchange rate changes on transactions denominated in currencies other than functional currency are included in income in the period in which the change occurs. Accumulated Other Comprehensive Loss. We classify items of other comprehensive loss by their nature and disclose the accumulated balance of other comprehensive loss separately from accumulated deficit and additional paid-in capital in the stockholders’ equity section of our balance sheet. We have defined the Canadian dollar as the functional currency of our Canadian subsidiary, DNAG, and as such, the results of its operations are translated into U.S. dollars, which is the reporting currency of the Company. The $2,451 and $1,709 currency translation adjustments recorded in the first nine months of 2014 and 2013, respectively, are largely the result of the translation of our Canadian operation’s balance sheets into U.S. dollars. Recent Accounting Pronouncements. In May 2014, the Financial Accounting Standards Board (“FASB”) issued converged guidance on recognizing revenue in contracts with customers, ASU 2014-09 Revenue from Contracts with Customers. The intent of the new standard is to improve financial reporting and comparability of revenue globally. The core principle of the standard is for a company to recognize revenue in a manner that depicts the transfer of goods or services to customers in an amount that reflects the consideration which the company expects to receive in exchange for those goods or services. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2016, with no early adoption permitted. We will evaluate the effects, if any, which adoption of this guidance will have on our consolidated financial statements. </div>

0001116463

<div> Recent Accounting Pronouncements. In May 2014, the Financial Accounting Standards Board (“FASB”) issued converged guidance on recognizing revenue in contracts with customers, ASU 2014-09 Revenue from Contracts with Customers. The intent of the new standard is to improve financial reporting and comparability of revenue globally. The core principle of the standard is for a company to recognize revenue in a manner that depicts the transfer of goods or services to customers in an amount that reflects the consideration which the company expects to receive in exchange for those goods or services. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2016, with no early adoption permitted. We will evaluate the effects, if any, which adoption of this guidance will have on our consolidated financial statements. </div>

3313000

<div> Fair Value of Financial Instruments. As of September 30, 2014, the carrying values of cash, short-term investments, accounts receivable, accounts payable and accrued expenses approximate their respective fair values based on their short-term nature. Fair value measurements of all financial assets and liabilities that are being measured and reported on a fair value basis are required to be classified and disclosed in one of the following three categories: Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity). We offer a nonqualified deferred compensation plan for certain eligible employees and members of our Board of Directors. The assets of the plan are held in the name of the Company at a third-party financial institution. Separate accounts are maintained for each participant to reflect the amounts deferred by the participant and all earnings and losses on those deferred amounts. The assets of the plan are held in mutual funds and Company stock. The fair value of the plan assets as of September 30, 2014 and December 31, 2013 was $1,090 and $677, respectively, and was calculated using the quoted market prices of the assets as of those dates. All investments in the plan are classified as trading securities and measured as Level 1 instruments. The fair value of plan assets is included in other assets with the same amount included in other liabilities in the accompanying consolidated balance sheets. All of our available-for-sale securities were classified and measured as Level 1 instruments as of September 30, 2014. </div>

55897000

-2451000

48648000

42000

73000

73610000

398000

9407000

-4432000

-2451000

-576000

3444000

-2239000

4173000

-4413000

-1995000

639000

244000

77783000

2353000

-1962000

2111000

5500000

4732000

-299000

10433000

50887000

8242000

30828000

664000

-33000

29135000

-93000

-3734000

-7328000

546000

17317000

-284000

4284000

2019-12-31 <div> Termination Settlement. On November 21, 2013, we terminated our assay development collaboration with Roche Diagnostics (“Roche”). Pursuant to a termination agreement, Roche paid us $8,300 which was recorded as a reduction of operating expense in our consolidated statement of operations for the quarter ended December 31, 2013. Roche agreed to provide certain transitional product support services to us and to continue to supply certain of the assays developed under the collaboration on a transitional basis for up to five years following the termination. We had the right to stop the supply of assays prior to the end of this five-year period and to receive an additional payment from Roche of up to $5,500 depending on how early in that five-year period the supply obligation was ended. During the second quarter of 2014, we issued our final purchase order for fully-automated assays previously developed under the terminated collaboration and as such, have recorded $5,500 as a reduction of operating expense in our consolidated statement of operations. </div> 75000000 55500000

P40Y

P10Y

3500000

P20Y

P2Y

P3Y

106000

639000

1998000

546000

2286000

10935000

58987000

7861000

2938000

17523000

485000

2346000

P10Y

P7Y

P15Y

5500000

P5Y

-5177000

60260000

1868000

2386000

15000000

279000

P10Y

P3Y

P1Y

P10Y

P7Y

P15Y

-0.03

55592000

-0.03

5499000

55592000

876000

14933000

24524000

876000

-2060000

147000

-1016000

-2019000

41000

24671000

604000

-1892000

1625000

16993000

2670000

8981000

-127000

9738000

5342000

2540000

19052000

3079000

456000

4964000

235000

810000

-2516000

19707000

369000

815000

0.02

648000

56666000

0.02

2647000

56018000

-2295000

18705000

24447000

-2295000

882000

3398000

-1155000

1150000

268000

27845000

365000

1140000

1624000

17823000

2990000

9216000

10000

9140000

5617000

0.12

3252000

22469000

2124000

1869000

6867000

67000

804000

-987000

20978000

298000

820000

0001116463 us-gaap:ParentCompanyMember 2014-07-01 2014-09-30 0001116463 osur:DnagMember 2014-07-01 2014-09-30 0001116463 osur:OtherForeignCountriesMember 2014-07-01 2014-09-30 0001116463 country:US 2014-07-01 2014-09-30 0001116463 us-gaap:EuropeMember 2014-07-01 2014-09-30 0001116463 us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember 2014-07-01 2014-09-30 0001116463 2014-07-01 2014-09-30 0001116463 us-gaap:ParentCompanyMember 2013-07-01 2013-09-30 0001116463 osur:DnagMember 2013-07-01 2013-09-30 0001116463 osur:OtherForeignCountriesMember 2013-07-01 2013-09-30 0001116463 country:US 2013-07-01 2013-09-30 0001116463 us-gaap:EuropeMember 2013-07-01 2013-09-30 0001116463 2013-07-01 2013-09-30 0001116463 us-gaap:TradeNamesMember 2013-01-01 2013-12-31 0001116463 us-gaap:PatentedTechnologyMember 2013-01-01 2013-12-31 0001116463 us-gaap:CustomerRelationshipsMember 2013-01-01 2013-12-31 0001116463 us-gaap:NoncompeteAgreementsMemberus-gaap:MinimumMember 2013-01-01 2013-12-31 0001116463 us-gaap:IntellectualPropertyMemberus-gaap:MinimumMember 2013-01-01 2013-12-31 0001116463 us-gaap:NoncompeteAgreementsMemberus-gaap:MaximumMember 2013-01-01 2013-12-31 0001116463 us-gaap:IntellectualPropertyMemberus-gaap:MaximumMember 2013-01-01 2013-12-31 0001116463 2013-01-01 2013-12-31 0001116463 osur:AbbvieMember 2014-07-01 2014-07-31 0001116463 us-gaap:ParentCompanyMember 2014-01-01 2014-09-30 0001116463 osur:CollaborationAgreementMember 2014-01-01 2014-09-30 0001116463 us-gaap:TradeNamesMember 2014-01-01 2014-09-30 0001116463 us-gaap:PatentedTechnologyMember 2014-01-01 2014-09-30 0001116463 us-gaap:CustomerRelationshipsMember 2014-01-01 2014-09-30 0001116463 osur:DnaGenotekMember 2014-01-01 2014-09-30 0001116463 osur:DnagMember 2014-01-01 2014-09-30 0001116463 osur:OtherForeignCountriesMember 2014-01-01 2014-09-30 0001116463 country:US 2014-01-01 2014-09-30 0001116463 us-gaap:EuropeMember 2014-01-01 2014-09-30 0001116463 us-gaap:EmployeeStockOptionMember 2014-01-01 2014-09-30 0001116463 us-gaap:RestrictedStockMember 2014-01-01 2014-09-30 0001116463 us-gaap:IntellectualPropertyMemberus-gaap:MinimumMember 2014-01-01 2014-09-30 0001116463 us-gaap:MachineryAndEquipmentMemberus-gaap:MinimumMember 2014-01-01 2014-09-30 0001116463 us-gaap:ComputerEquipmentMemberus-gaap:MinimumMember 2014-01-01 2014-09-30 0001116463 us-gaap:FurnitureAndFixturesMemberus-gaap:MinimumMember 2014-01-01 2014-09-30 0001116463 us-gaap:BuildingMemberus-gaap:MinimumMember 2014-01-01 2014-09-30 0001116463 us-gaap:MinimumMember 2014-01-01 2014-09-30 0001116463 us-gaap:IntellectualPropertyMemberus-gaap:MaximumMember 2014-01-01 2014-09-30 0001116463 us-gaap:MachineryAndEquipmentMemberus-gaap:MaximumMember 2014-01-01 2014-09-30 0001116463 us-gaap:ComputerEquipmentMemberus-gaap:MaximumMember 2014-01-01 2014-09-30 0001116463 us-gaap:FurnitureAndFixturesMemberus-gaap:MaximumMember 2014-01-01 2014-09-30 0001116463 us-gaap:BuildingMemberus-gaap:MaximumMember 2014-01-01 2014-09-30 0001116463 us-gaap:MaximumMember 2014-01-01 2014-09-30 0001116463 2014-01-01 2014-09-30 0001116463 us-gaap:ParentCompanyMember 2013-01-01 2013-09-30 0001116463 osur:DnagMember 2013-01-01 2013-09-30 0001116463 osur:OtherForeignCountriesMember 2013-01-01 2013-09-30 0001116463 country:US 2013-01-01 2013-09-30 0001116463 us-gaap:EuropeMember 2013-01-01 2013-09-30 0001116463 us-gaap:EmployeeStockOptionMember 2013-01-01 2013-09-30 0001116463 us-gaap:RestrictedStockMember 2013-01-01 2013-09-30 0001116463 2013-01-01 2013-09-30 0001116463 osur:CollaborationAgreementMember 2013-11-21 2013-11-21 0001116463 us-gaap:ParentCompanyMember 2013-12-31 0001116463 us-gaap:UpFrontPaymentArrangementMember 2013-12-31 0001116463 us-gaap:TradeNamesMember 2013-12-31 0001116463 us-gaap:NoncompeteAgreementsMember 2013-12-31 0001116463 us-gaap:PatentedTechnologyMember 2013-12-31 0001116463 us-gaap:IntellectualPropertyMember 2013-12-31 0001116463 us-gaap:CustomerRelationshipsMember 2013-12-31 0001116463 osur:DnagMember 2013-12-31 0001116463 osur:OtherForeignCountriesMember 2013-12-31 0001116463 country:US 2013-12-31 0001116463 country:CA 2013-12-31 0001116463 2013-12-31 0001116463 2012-12-31 0001116463 us-gaap:ParentCompanyMember 2014-09-30 0001116463 osur:GuaranteedInvestmentCertificatesMember 2014-09-30 0001116463 us-gaap:UpFrontPaymentArrangementMember 2014-09-30 0001116463 us-gaap:TradeNamesMember 2014-09-30 0001116463 us-gaap:PatentedTechnologyMember 2014-09-30 0001116463 us-gaap:IntellectualPropertyMember 2014-09-30 0001116463 us-gaap:CustomerRelationshipsMember 2014-09-30 0001116463 osur:DnagMember 2014-09-30 0001116463 osur:OtherForeignCountriesMember 2014-09-30 0001116463 country:US 2014-09-30 0001116463 country:CA 2014-09-30 0001116463 2014-09-30 0001116463 2013-09-30 0001116463 2014-11-04 0001116463 osur:AbbvieMember 2014-07-31 iso4217:USD shares iso4217:USD shares osur:Customer pure osur:Securities osur:Segment

EX-101.SCH 7 osur-20140930.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 104 - Statement - Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - Consolidated Statements of Operations link:calculationLink link:presentationLink link:definitionLink 106 - Statement - Consolidated Statements of Comprehensive Loss link:calculationLink link:presentationLink link:definitionLink 107 - Statement - Consolidated Statements of Cash Flows link:calculationLink link:presentationLink link:definitionLink 108 - Disclosure - The Company link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - Summary of Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Stockholders' Equity link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - Accrued Expenses link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Income Taxes link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - Business Segment Information link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - Summary of Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - Summary of Significant Accounting Policies (Tables) link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - Accrued Expenses (Tables) link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - Business Segment Information (Tables) link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - Summary of Significant Accounting Policies - Inventories (Detail) link:calculationLink link:presentationLink link:definitionLink 121 - Disclosure - Summary of Significant Accounting Policies - Summary of Intangible Assets (Detail) link:calculationLink link:presentationLink link:definitionLink 122 - Disclosure - Summary of Significant Accounting Policies - Computations of Basic and Diluted Earnings (Loss) per Share (Detail) link:calculationLink link:presentationLink link:definitionLink 123 - Disclosure - Stockholders' Equity - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 124 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail) link:calculationLink link:presentationLink link:definitionLink 125 - Disclosure - Income Taxes - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 126 - Disclosure - Business Segment Information - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 127 - Disclosure - Business Segment Information - Summary of Segment Information (Detail) link:calculationLink link:presentationLink link:definitionLink 128 - Disclosure - Business Segment Information - Presentation of Total Revenues and Long-Lived Assets by Geographic Area (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 8 osur-20140930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 osur-20140930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 osur-20140930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Abbvie. Abbvie [Member] AbbVie [Member] Accounting Policies [Abstract] Accounting Policies [Abstract] Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accrued Expenses Accounts Payable, Current Accounts payable Accounts Receivable [Member] Accounts Receivable [Member] Accounts Receivable, Net, Current Accounts receivable, net of allowance for doubtful accounts of $288 and $299 Accrued Liabilities, Current Accrued expenses Accrued Expenses, Total Accrued Liabilities, Current [Abstract] Schedule of Accrued Expenses [Abstract] Accrued Professional Fees, Current Professional fees Accrued Royalties, Current Royalties Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Accumulated depreciation of property and equipment Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax Accumulated foreign currency adjustments included in other comprehensive loss amounted Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive loss Additional Paid in Capital, Common Stock Additional paid-in capital Adjustments Related to Tax Withholding for Share-based Compensation Restricted shares of common stock, aggregate values Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash provided by (used in) operating activities: Allowance for Doubtful Accounts Receivable, Current Allowance for doubtful accounts Amendment Flag Amendment Flag Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Number of anti-dilutive securities excluded from EPS computation Arrangements and Non-arrangement Transactions [Domain] Arrangements and Non-arrangement Transactions [Domain] Assets Total assets TOTAL ASSETS Assets [Abstract] ASSETS Assets, Current Total current assets Assets, Current [Abstract] CURRENT ASSETS: Available-for-sale Securities Available-for-sale securities, fair value Available-for-sale Securities, Amortized Cost Basis Available-for-sale securities, amortized cost Available For Sale Securities Number Of Securities Available For Sale Securities Number Of Securities Available-for-sale securities Award Type [Axis] Award Type [Axis] Basis of Accounting, Policy [Policy Text Block] Principles of Consolidation and Basis of Presentation Building [Member] Building [Member] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Business Acquisition [Axis] Business Acquisition [Axis] CANADA Canada [Member] Cash and Cash Equivalents, at Carrying Value CASH, END OF PERIOD CASH, BEGINNING OF PERIOD Cash Cash and Cash Equivalents, Period Increase (Decrease) NET INCREASE (DECREASE) IN CASH Collaboration Agreement [Member] Collaboration Agreement [Member] Collaboration Agreement [Member] Commitments and Contingencies COMMITMENTS AND CONTINGENCIES (Note 6) Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Common Stock, Par or Stated Value Per Share Common stock, par value Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Common Stock, Value, Issued Common stock, par value $.000001, 120,000 shares authorized, 56,052 and 55,632 shares issued and outstanding Comprehensive Income (Loss), Net of Tax, Attributable to Parent COMPREHENSIVE LOSS Comprehensive Income, Policy [Policy Text Block] Accumulated Other Comprehensive Loss Computer Equipment [Member] Computer Equipment [Member] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Concentration Risk, Percentage Percentage of concentration risk Concentration Risk, Supplier Number of third-party suppliers to manufacture DNAG's products Concentration Risk Type [Domain] Concentration Risk Type [Domain] Cost of Goods Sold COST OF PRODUCTS SOLD Current Federal Tax Expense (Benefit) U.S. federal income tax benefits Current Fiscal Year End Date Current Fiscal Year End Date Current State and Local Tax Expense (Benefit) U.S. state income tax benefits Customer Concentration Risk [Member] Customer Concentration Risk [Member] Customer Relationships [Member] Customer List [Member] Deferred compensation plan fair value of plan assets. Deferred Compensation Plan Fair Value Of Plan Assets Fair value of plan assets Deferred Foreign Income Tax Expense (Benefit) Foreign deferred tax expense (benefits) Deferred Revenue, Additions Deferred revenue payment received Deferred Revenue Arrangement Type [Axis] Deferred Revenue Arrangement Type [Axis] Deferred Revenue [Domain] Deferred Revenue [Domain] Deferred Revenue, Current Deferred revenue Deferred Tax Assets, Net of Valuation Allowance, Current Deferred income taxes Deferred Tax Expense from Stock Options Exercised Income tax benefit realized from stock option exercises during period Deferred Tax Liabilities, Net, Noncurrent DEFERRED INCOME TAXES Depreciation, Depletion and Amortization Depreciation and amortization Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] DNA Genotek Dna Genotek [Member] DNA Genotek [Member] DNAG. Dnag [Member] DNAG [Member] Document and entity information. Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Document Period End Date Document Period End Date Document Type Document Type Earnings Per Share [Abstract] EARNINGS (LOSS) PER SHARE: Earnings Per Share, Basic BASIC Earnings Per Share, Diluted DILUTED Earnings Per Share, Policy [Policy Text Block] Earnings (Loss) Per Share Effect of Exchange Rate on Cash and Cash Equivalents EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH Employee-related Liabilities, Current Payroll and related benefits Employee Stock Option [Member] Stock Options [Member] Entity Central Index Key Entity Central Index Key Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity [Domain] Entity [Domain] Entity Filer Category Entity Filer Category Entity Registrant Name Entity Registrant Name Entity Wide Accounts Receivable Major Customer Threshold Percentage Entity Wide Accounts Receivable Major Customer Threshold Percentage Concentration rate of accounts receivable Entity Wide Revenue Major Customer Threshold Percentage Entity Wide Revenue Major Customer Threshold Percentage Concentration rate of net revenues Equity [Abstract] Equity [Abstract] Estimated Annual Payments to be Received on Sale of Rights Estimated Annual Payments to be Received on Sale of Rights Additional annual payments to be received for sale of exclusive rights Europe [Member] Europe [Member] Fair Value of Financial Instruments, Policy [Policy Text Block] Fair Value of Financial Instruments Finite-Lived Intangible Assets, Accumulated Amortization Accumulated Amortization Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Gross Gross Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Asset, Useful Life Amortization Period (Years) Foreign Currency Transaction Gain (Loss), Unrealized Unrealized foreign currency loss Foreign Currency Transactions and Translations Policy [Policy Text Block] Foreign Currency Translation Furniture and Fixtures [Member] Furniture and Fixtures [Member] Gain (Loss) on Contract Termination Gain on contract termination settlement Gain on contract termination settlement General and Administrative Expense General and administrative Goodwill Amount of goodwill at period end GOODWILL Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Goodwill Gross Profit Gross profit Guaranteed Investment Certificates [Member] Guaranteed Investment Certificates [Member] Guaranteed Investment Certificates [Member] Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest Income (loss) before income taxes Income Statement [Abstract] Income Statement [Abstract] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Income Tax Disclosure [Text Block] Income Taxes Income Taxes Paid, Net Income taxes Income Tax Expense (Benefit) Deferred income taxes INCOME TAX EXPENSE (BENEFIT) Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accounts Receivable Accounts receivable Increase (Decrease) in Accrued Liabilities Accrued expenses and other liabilities Increase (Decrease) in Deferred Revenue Deferred revenue Increase (Decrease) in Inventories Inventories Increase (Decrease) in Operating Capital [Abstract] Changes in assets and liabilities Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other assets Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Dilutive effect of stock options and restricted stock Intangible Assets, Finite-Lived, Policy [Policy Text Block] Intangible Assets Intangible Assets, Net (Excluding Goodwill) INTANGIBLE ASSETS, net Net Intellectual Property [Member] Patents and Product Rights [Member] Inventory, Finished Goods, Gross Finished goods Inventory, Net Inventories Inventories Inventory, Net [Abstract] Inventories [Abstract] Inventory, Policy [Policy Text Block] Inventories Inventory, Raw Materials, Gross Raw materials Inventory, Work in Process, Gross Work in process Investment, Policy [Policy Text Block] Short-Term Investments Legal Entity [Axis] Legal Entity [Axis] Liabilities and Equity Total liabilities and stockholders' equity Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities, Current Total current liabilities Liabilities, Current [Abstract] CURRENT LIABILITIES: License and Maintenance Revenue Licensing and product development Machinery and Equipment [Member] Machinery and Equipment [Member] Major Customers, Policy [Policy Text Block] Customer and Vendor Concentrations Major Types of Debt and Equity Securities [Axis] Major Types of Debt and Equity Securities [Axis] Major Types of Debt and Equity Securities [Domain] Major Types of Debt and Equity Securities [Domain] Maximum [Member] Maximum [Member] Minimum [Member] Minimum [Member] Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] FINANCING ACTIVITIES: Net Cash Provided by (Used in) Investing Activities, Continuing Operations Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] INVESTING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net cash provided by (used in) operating activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] OPERATING ACTIVITIES: Net Income (Loss) Attributable to Parent NET INCOME (LOSS) NET INCOME (LOSS) Net loss New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Noncompete Agreements [Member] Non-compete Agreements [Member] Number of Reportable Segments Number of reportable segments of company Number of significant concentrations in accounts receivable. Number Of Significant Concentrations In Accounts Receivable Number of customers, accounted for significant concentrations Operating Expenses Total operating expenses Operating Expenses [Abstract] OPERATING EXPENSES: Operating Income (Loss) Operating income (loss) Operating income (loss) Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] The Company Other Accrued Liabilities, Current Other Other Assets, Current Other current assets Other Assets, Noncurrent OTHER ASSETS Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Currency translation adjustments Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] OTHER COMPREHENSIVE INCOME (LOSS) Other foreign countries. Other Foreign Countries [Member] Other Regions [Member] Other Liabilities, Noncurrent OTHER LIABILITIES Other Nonoperating Income (Expense) OTHER INCOME Parent Company [Member] OSUR [Member] Patented Technology [Member] Acquired Technology [Member] Payables and Accruals [Abstract] Payables and Accruals [Abstract] Payments for (Proceeds from) Short-term Investments Proceeds from maturities of short term investments Payments for Repurchase of Common Stock Repurchase of common stock Payments Received for Sale of Exclusive Rights Payments Received for Sale of Exclusive Rights Payments received for sale of exclusive rights Payments to Acquire Property, Plant, and Equipment Capital expenditures Purchases of property and equipment Payments to Acquire Short-term Investments Purchases of short term investments Preferred Stock, Par or Stated Value Per Share Preferred stock, par value Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Value, Issued Preferred stock, par value $.000001, 25,000 shares authorized, none issued Prepaid Expense and Other Assets, Current Prepaid expenses Proceeds from Stock Options Exercised Net cash proceeds from the exercise of stock options Proceeds from exercise of stock options Product Information [Line Items] Product Information [Line Items] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Net Long-lived assets PROPERTY AND EQUIPMENT, net Property, Plant and Equipment, Policy [Policy Text Block] Property and Equipment Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Useful Life Estimated useful lives of assets Range [Axis] Range [Axis] Range [Domain] Range [Domain] Reconciliation of Revenue from Segments to Consolidated [Table] Reconciliation of Revenue from Segments to Consolidated [Table] EX-101.PRE 11 osur-20140930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0"7#_[BQ`$``'(2```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,F%U/PC`4AN]-_`]+;\W6 MM2JB87#AQZ62B#^@K@>VL+5-6Q#^O=WXB"$((9)X;EA@[7D?FO"$O;W!HJZB M.5A7:I41EJ0D`I5K6:I)1CY&+W&71,X+)46E%61D"8X,^I<7O='2@(O";N4R M4GAO'BAU>0&U<(DVH,*=L;:U\.&MG5`C\JF8`.5IVJ&Y5AZ4CWTS@_1[3S`6 ML\I'SXOP\8K$0N5(]+A:V&1E1!A3E;GP@93.E=Q)B=<)2=C9KG%%:=Q5P"!T M;T)SY_>`];ZW<#2VE!`-A?6OH@X8=%'1+VVGGUI/D\-#]E#J\;C,0>I\5H<3 M2)RQ(*0K`'Q=)>TUJ46I-MP'\MO%CK87=F:0YONU@T_DX$@XKI%PW"#AN$7" MT4'"<8>$HXN$XQX)!TNQ@&`Q*L.B5(;%J0R+5!D6JS(L6F58O,JPB)5A,2O' M8E:.Q:PQNZC[,#_)Q]B",T`T.KC0L=B8733V%3@C2[8Q,&@?4E;&N0 M?77"-C'T*Z<'[O09T#0X$N2>;-HV1OUO````__\#`%!+`P04``8`"````"$` MM54P(_4```!,`@``"P`(`E]R96QS+RYR96QS(*($`BB@``(````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M`````````(R2ST[#,`S&[TB\0^3[ZFY("*&ENTQ(NR%4'L`D[A^UC:,D0/?V MA`."2F/;T?;GSS];WN[F:50?'&(O3L.Z*$&Q,V)[UVIXK9]6#Z!B(F=I%,<: MCAQA5]W>;%]XI)2;8M?[J+*+BQJZE/PC8C0=3Q0+\>QRI9$P4P>J/OH\^;*W-$UO>"_F?6*73HQ`GA,[RW;E0V8+ MJ<_;J)I"RTF#%?.&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;',@H@0!**`` M`0`````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````````"\6,MJPS`0O!?Z#T;W M1M[-HTF)DTLIY-JF'R!LQ3:Q)2.IC_Q]19HZ"83MQ>S%(`FOAMG=V;&7Z^^V M23ZU\[4UF8!1*A)M[%>W=\M7W6C0GS) M5W7GDQC%^$Q4(71/4OJ\TJWR(]MI$T]VUK4JQ*4K9:?RO2JUQ#2=27<90ZRN M8B:;(A-N4\3[MX'X<&CB\.\' MY^^:NI];\DC%XZX4LE"`G1J2&YP,62B]HSK72K]U,EDXH>J&6_!(O0-N-$#" M06Y7@[2M&=2!AOC9H,]5-`F]Y5RNG@++O[GN/0TE]M_326O M?G6L?@```/__`P!02P,$%``&``@````A`-J,GSKW`@``*0D```\```!X;"]W M;W)K8F]O:RYX;6R4EDUSFS`0AN^=Z7]@N#=\.9\3.Y.D[M27UC.XR5&C@&PT M$1)%HK;_?58XAL5JF>:$A="CW7??E7Q[MRN%]X?5FBLY]:.ST/>8S%3.Y6;J M_UI]^W+E>]I0F5.A))OZ>Z;]N]GG3[=;5;^^*/7J`4#JJ5\84]T$@5-263 MY@"IF:`&PM<%K[0_NUUSP9X.&7FTJG[0$N+>"=\35)MYS@W+I_XY#-66#5[4 M3?70<`&SUTF8^,&L2W)9>SE;TT:8%:1WI(->\22.+^R75HHGSK:Z7V2'WNZ9 MRUQM[:<@[;X;)1#`MIUZYKDI8#X,P^[==\8WA3F^!'R`^*V"L$_[]&2;WE$1 M`I4B60#QY1'$%$)GE.0B#Q0067& M2&J7:H2(P1(=(_X`@RPIQEPC3*OV/T-)#41D"ZZ)6I.?%4.8":),1H,94AY5 MB2B@?)?2^4T*4M:[VW6*=]( M#N:GTI#[+%.--!B#ZWKE8(S*7@LER\E"5H8A:%H.D/=%#(7!?14Y-AP3AJQ0(!/LS.B#U@1G=!E-L#S]"!L MU,AQZKC&8)<.9(_BKNE@<'(,CH/`,3T(IQ8[7D[=OB/W.=Q`<%M1N)!Z#LXL M=LSL%#W-"I8W@MF#X1YQ)K@C8\?.N"-1(.^]@3@Q[E$8G`@TZJ%!/`..8^91 M3HKCP6UZN'!;[=YOOU'.$G-PE\:MIX,6!-=I1D4&][Q]V).A=45P_)P,` M`/__`P!02P,$%``&``@````A`,AO-/KS!0``_Q@``!@```!X;"]W;W)K;\KA;FW__];`(3:/MLN,F.]3'8FV^%ZWY[?[GG^Y>Z^:IW1=%9X"'8[LV M]UUW6EE6F^^+*FN7]:DX@F5;-U76P*V[5M55AY-Y6'5 MS/%1;[=E7H@Z?ZZ*8Z><-,4AZV#][;X\M6=O53['794U3\^G15Y7)W#Q6![* M[KUW:AI5OOJQ.]9-]G@`W6_,S?*S[_[%Q'U5YDW=UMMN">XLM="IYLB*+/!T M?[Z?I+HCXU\"QZV)D\_]!'XHS$VQ39[/G1_UJ^_%N5NWT&X/5`DA:TV[Z)H M<]A1<+-4R\CK`RP`?AI5*5,#=B1[ZW^_EIMNOS8=?^D%ML,`-QZ+MGLHI4O3 MR)_;KJ[^51"3B[HXX8,3>&)PPOB2AQ[S_-M>++6B7J#(NNS^KJE?#<@:^,SV ME,D<9"OP?%:FUG'1^IE46)YT\EUZZ7V!BA;B\W(?L#OK!;8T'Y!8(8%IC`C' M2')&I&KI5IS?&)\A7M,S(:,'BBZR8+.H+`?"_G'`SBKD0UB%3SXOGB)4Q)0( M'*Q33!'B))T2FA,DU,%"KPN4,.2>'@,7KRU6B*LA'B:2FX2X2:37""0/%J+' M\;H\":]-V+LQQ6YTL2-9 M<-+FRY(PD>5?W/8')5:(W\MRG"C$YD29W=[,J&:A/^PR+=%ZWZG^L,_'7$:" M_*\(DC`11.(0*T0)XD'HDC@FR.[ZM-H(W1X$03@N6XE"=IL%XP%$LJ!MIW'PA M=\?:8?4-VSIY!F&SJFM3K M!;.GR&+4X%H1:5^T7EV#`CR*2!P(!GAV&)!%2#$1^.!X"'$?9WN>+ M4\,`BM_H>"@K^L`0TL.9R.]-4'J'P'#;)X$1!.`.Z3/U^2F@B0)++F MF.E3`V,>"4>"[`MN,Q(.@0$616,TAI.F?\*"A2P<76!QLM//%Z?F`B1N=#SD MHF*&R7VF3_4^0?0'`N/U]8HL)0*L)!9QQG[$VR+3YV,ZXT5C1U*Q9$#%`_,69SOCPVW#TZ"@8_$Z8.,YWT@#@-3<>J^65W'5D6S*Y+B<&B- MO'Z6=\DXZSM$O"*FP80O$6#IYE+*$Q3TXE MK90A$;0@"OR7.:MERU8F;Z$KB7@XU5<)+VN@.+""J>>&%*,R";\<*R[(H0#= M3^XU25KN9C&A+UDBN.29LH#.-HY.-=_8-S8P;=8I`P4Z[$C0+,)W;KA?8GNS M;N+SF]&S[#TCF?/S)\'2KZRB$&Q(DT[`@?,'#?V2ZBTX;$].WS<)^"Y02C-R M*M0/?OY,V3%7D.T%"-*ZPO0YIC*!@`*-Y2TT4\(+<`"^4V:I MRB/L+ZU%X/@NP-&!2G7/-"5&R4DJ7OXQ(/="94B\"PF>-VXQ^O.SRR;Q$Z?2"ITP71ZNMZ.5.M M^QJLW6_OW9H-X.[TC%V=(@)_Z%H\A8Q(]E-$CV0@QW^/'`V&$NM[[X^NWAK, M=0^S&+J_>Q41OXK8SR$&^L"1?KIT&?KPFLZG31^*,`2QRY*_`SM._Z]BO7"R:(>(#P_0E@/P`$JV4?,1`)[U=?Y+PX#1Z+&Q7_UF"N&W%C M83.V>,:V?]DVT+%\CPX-'NL8%Z/!F"2-=5"3(_U&Q)%5 M$A4T@ZL<*X!X"S-1S$+QNNG*!ZY@$C2/.0Q^"NW0L0"<<:[:A6YZW5^)S5\` M``#__P,`4$L#!!0`!@`(````(0`%MX6"\`(``"H(```9````>&PO=V]R:W-H M965T(M;DH M>+O+\.]?]U<)1DK3MJ"U:%F&7YC"U^O/GU8'(1]5Q9A&P-"J#%=:=RDA*J]8 M0Y4G.M:"I12RH1J6<_UB23%J\O1AUPI)MS7$_1S, M:/[*;1=G]`W/I5"BU![0$2?T/.8E61)@6J\*#A&8M"/)R@S?!.DFP62]LOGY MP]E!#;Z1JL3AB^3%-]XR2#:4R11@*\2C@3X49@N&*1/_2@`.-HRI>^YH<0HWRLMFK\.%!RI'$EX)(E`_=$>>F$R#^:+_[,0I\@& M>$$XX1FS<020\AH*\7":%_7*1Q&HL,XY[>QG'K(+%-LPEL,]@8 M"8#,#`6\GQT#ABP.(H_BZ]>:1JL5' M5!GP5-6RYW6J'&9F5G6SE295ZNP5QXO^,->*PJBJ?U&PO=V]R:W-H965T M+ZN/3W7E/1(N*&O6/IJ$OD>:@I6T MV:_]W[_N/Z2^)R1N2ERQAJS]9R+\CYOW[U8GQA_$@1#I`4,CUOY!RG89!*(X MD!J+"6M)`W=VC-=8PB7?!Z+E!)=Z45T%41@F08UIXQN&)7\-!]OM:$'N6'&L M22,-"2<5EJ!?'&@K+FQU\1JZ&O.'8_NA8'4+%%M:4?FL27VO+I9?]PWC>%M! MW$]HBHL+M[X8T->TX$RPG9P`76"$#F->!(L`F#:KDD($RG:/D]W:_X26.9KY MP6:E#?I#R4GT?GOBP$Z?.2V_T8:`VY`GE8$M8P\*^K54?\'B8+#Z7F?@!_=* MLL/'2OYDIR^$[@\2TCV#B%1@R_+YCH@"'`6:2:1E%*P"`?#IU525!CB"G_3W MB9;RL/;C9#*;AS$"N+E[Q5%(5O\U(*1$=231F20&]>?[T21*9VB6 MW&8)C"(=X!V6>+/B[.1!U<`S18M5#:(E,%\B,SJZ6%\*%>0IDD^*17-!%`+R M\[B)DV05/(*GQ1F3&T' M9D-,9"/R(6(>=Q!+))CGBIR^6"(7D6H1%$//DSA).W[M;68PTQYF9B/R,82E M$4CZ&L<-5."U#P9T^8J3A?WDS&!2G?%IE$[#,+01N85`Z;R/L+2!5WUMJA!O M)UDMHE`M'M;Z%6.RE[?,GWE M##)EAT*G7>?V[>A_C=CZKIP?K]!G.KW56^93NW-DR(",C4EL>60VKH5(1W8N M4FV\5X;C*=9HUSUG!V1GT%@!CD)L%U4'[^E3S>_V-D&F[\-GMT^'I\<9-*KS MU><'`IJ^SAL^*K3CXV"O:,JU;[(<1>F5_FQ#PLC:3[:/;SI$U"3GZAR<(F>0 M.>JN'B,6XNHY8N9+,W[5A.])3JI*>`4[JMD10?_O_C5S;:;F6CV9=C=@K&SQ MGGS'?$\;X55D!TO#R1QBX&8P-1>2M7KZV3()`Z7^>8`7"`+36C@!\(XQ>;E0 M\U;W2K+Y!P``__\#`%!+`P04``8`"````"$`5CSEB(X#```A#```&0```'AL M+W=O_1IR1^P7526 M@!8K#M7VF)=HF(HD"2T\8\8) M;5=NZ`6N@]N25J3=K]R?_ST^S%R'"]16J*8M7KFOF+N?UY_^6IXH>^('C(4# M"BU?N0H[+75Q4B^(26CG.Z$!W*^;G3L>>[/?5!:+RL"#N38 M'89W*_=+N"C"P/772S6@7P2?^."SPP_T]#C)@5,#W\D[),]@N`#EWIGNX^+U/:O@ M48I\D2I*"UQPR.=Y':>3I?\,,RW/G$QSIJYSX4PCD[+I*7*"4C?O;UQK0K.D MZ!DR/K!T\073LGW%D/O;B?4V9)%I([6^+QM3;!-CQC0VF\['%$ND&#,&(H;1 MV#1ZVZ`DP^$;9!"GB=E-#(.\[4^25RX,[W+& MYH%E3U-FZI"&X<2"-T/X(9S-K6!R$Y^G%EZ8^'027+,W;,&S-K0EG[O[YU,6 MF?%%`WWUR&2:`VU<1F#'=Y>1WV44MQB&S]3T>3L^2;;BL^:;:4JJXDO2()R9 M\6X,/$E&^9GX;#XUZPL33^+K6\RP!:^QC\"_HVS\>N)4WAAX?'U%\E("_:?#\2E MV)8OJ['LS'G7F(&_Y6Q$L*W9A)$WO9'IA:7!;(\WN*ZY4]*CW+8B&/GEKMX$ MLW`!6P0L`];]7&Z(:L>[`+"@=6B/OR.V)RUW:KP#R<";PJN-Z15/7PC:J9U@ M2P6L9NKC`59Q#/M)X`%Y1ZGH+^06\;`8``%(@```9````>&PO=V]R:W-H965TWA-,(Y1C;&`-.VWOUEF8W9V M\0+IBR8N?X8?LS/S7T,?/ORH3L[WHFG+^KQQV6KM.L4YK_?E^7GC_O/WY[O$ M==HN.^^S4WTN-N[/HG4_//[ZR\-KW7QKCT71.1#AW&[<8]==[CVOS8]%E;6K M^E*FB+;]R=5)\]?KR.ORLJSBQ'NFSDQZL.AS(M/=?Y2 M%><.@S3%*>N`OSV6E_8M6I7/"5=ES;>7RUU>5Q<(\52>RNYG']1UJOS^R_.Y M;K*G$]SW#Q9D^5OL_H,1OBKSIF[K0[>"<>JD'D1X?]B7<@4B[TQ2' MC?N1W>^"R/4>'_H$_5L6KZWRN],>Z]??FG+_1WDN(-NP3F(%GNKZFY!^V8M_ M@I,]X^S/_0K\V3C[XI"]G+J_ZM??B_+YV,%RAW!'XL;N]S\_%6T.&84P*S\4 MD?+Z!`#PMU.5HC0@(]F/_N=KN>^.&Y='JS!>'IGYUH/:` MO+UDHI+9/406^0ENY@<2(\[Y*$[J3P5U"XOZ_9$'\8/W'18BEYJMJ6%4L3,5 M?AI=-1X`7BDAX0M:@)%$UX)$-*F((P01&6TYT^(-RXDX,K&0CV!J$ED#43^6B,C MQZ.8!=?CA`LJ;CZ7$%,N'J37N)@SU$0]UQU@)YI@1P5!D`Q9)V31$C(AIF0L MU"Z\10V2L23A>E>HQWWX*BMU!8UL%[7U=:KS*8@.1/FJU"3:`7LU M)31[58IDZ3&6:B6PTP1Q.E0`9=-,8X(-Y[PZ1\Q^92B2#*;8,/QKK*9'CX9SG25C(<^K:=M'Q(, MV]*T5@G-'(11^<168+IMF3AKJF^ER,J)<<8EE'.168C-GM:[(YVAN@%;![J= M[&04V3I$0-D6V04S_6*D,U1#N(N38"@O-'\91;9.'$0W'(,MLHQ>K4\4W4BS]B[#8#CK:8<,5\!]@!2-EY6$G.T93#.-F1V" M4Q_Z^>JL/!AV&Y+3M`8CF38)R:>_R#MZ-5UI'@[3%?FD2,TC#_5*G!!11LU# MYN72'_&24$O45HI45DVRLTHHIQC^RM2>R8F685]S'T563IN$[=7Z[VK>YX4J>6D]ZY50OG>Y2<< M_<3>NU)DY<0XXQ+**2:ZXB?V%>8X_]45-KU9BM2+<_VQPVY"1!G%X)_/B#:A M,IJ]RU&$51CXQN,8>CST!R^B9'"3"\B$6JM"HWD M1<*9AC)(*)_F%/-LL?)\/R5 MLBWR#6[ZAOF]4XJL;!A'MDZD?!\@<,$BZ^C5M&G-1S)29(.3$GPTS?C0UI3M M7;81X+A7VY='P\C"K:D461EGVT8`UU('W[PFZ<^:>C@C159.D)C5# MF;GBZ!GVL2A>\-U<3LEID]`57V0O\*[7R*/Q942*K'DT[45]'H&$^%887W=> MLN?B:]8\E^?6.14'^)JQ7L5PDPV^$\8/77WI7Q@^U1V\R^U_/<*[^P+>>:Y7 M(#[4=??V0;QUOOYO@,?_`0``__\#`%!+`P04``8`"````"$`<(S:Z(L3.\?GW'ONO9G? M/ZF&',!8J=N<)E%,";1"%[*MK_X^&%^U&9G M:P!'D*&U.:V=ZS+&K*A!<1OI#EK\4FJCN,.MJ9CM#/"BOZ0:-HKC6Z:X;&E@ MR,PU'+HLI8"U%GL%K0LD!AKN,'Y;R\Z^LBEQ#9WB9K?O;H16'5)L92/=XW9_1*"J.M+EV$="P$>I[S';MCR+28%Q(S\+83 M`V5.ETFVFE"VF/?^_))PM"?OQ-;Z^-G(XJML`>>A#X8_P,CN[ MO>D+\,V0`DJ^;]QW??P"LJH=5GN""?F\LN)Y#5:@H4@3C?HPA&XP`%R)DKXS MT!#^U#^/LG!U3M/;:#*-TP3A9`O6;:2GI$3LK=/J=P`E/JB!9/1"@L\7DF02 MC4>3Z>P*%A8BZA-<<\<7[)6](3Z453@XE1E=EDG?(^/! M;V3"P:E,.AM?%AJ_1\B#L0M.7!J-XX$WI!@PN`Y.3@;$&R>QATZ=]-V98H__ MOY;^4D[1QH$]G?WE#Q$$S+BO]+_VAF$)O:3`5/`)FL82H?=^$!*\,YP.,[I, M^S$;/N",=+R"1VXJV5K20(E7XVB*NB9,6=@XW?6=NM4.IZ-_K?%G"-@(<83@ M4FOWNO%S//Q>%W\```#__P,`4$L#!!0`!@`(````(0"+>1UHX`4``'`9```9 M````>&PO=V]R:W-H965T&8QMM,98P.SL_GVJ*:N#AVNST<]O>MH;19.>\3)M-=51E;V5^;=%)G5_2%N)OSL6M&;R5V1IW M95I_>;L]955Y`Q>OQ:5HOW=.=:W,MI].UZI.7R_`^QNSTVSPW7V8N2^+K*Z: MZMANP)V!@7YT,!#(3L6IT?=_I'MDTXUXV7YTZ@OXO\O9G\K37G MZOV7NCA\+JXYJ`UY$AEXK:HO`OKI(+Z"Q<9L==)EX/=:.^3'].W2_E&]_YH7 MIW,+Z7:`D2"V/7R/\B8#1<'-ACO"4U9=(`#XJ96%*`U0)/W6_7XO#NUYIUON MQO%,BP%<>\V;-BF$2UW+WIJV*O]!$.M=H1/>.W$A^M[.-]QWF..JO1@844
!Z881PCU_^B"AR%DX_"2^<+6#20GZ\OEN\^ M&U]!TZS'[!'CZ=J(\;@,"0>(4%#XC88O[FN8O"0>$,.2!+_HI#.`XT@4Y*-$ M+2B$QRD<>(E%,B_NR0'L'T!D1#A'>)8,B>80(DT\1U`GR1S"_?$YDA;6_]%" M+(+"G>3/\JD8B+$G&&>,H,MHJ$1$2D2L1"1+"$D)"'5:%*]CR M[PIW_/:(\;L]P#W?IOPEN^UZI)ZCJ=WS/)]42BS934:W4()V^#G&>(]`8@X' MSWKF`BPSGVUOA-@=<=\GY1NBU>VL3]QT3;DL(MG.K4"VQY*=^9S?676Z)\/C ME;SAD%O/6X!EWLRDYQIBD!ISN2U''A(SB3N:FFW/(KK%DMFWR;,3-*_(-AR[ MZUD+L,S:\DE"]HC!=%LN815.K:Y))(G0BHIQRZ$E/C4S-Z"V`!/.`2G2/6+Z3`>F8Q)`B(#'Z<"&IG(1*UTDD@O?YI,C1MK@P8_0%V!* MGQQ->\0LL`N5B$B)B)6(9`DA*<"@OT\K0`PWZI[?K5(UNAZT)(8:$JDAL1J2 M+$)D0<1PM'I+,!REEOM=#^HWLQEXI"&&$H`%GDEFAD@"N":GO2&6`([K-G],C438STBBBWCST`BIO3.VD M#26C>S5U*(\?H"[0Y$"<]4"&(*3.@UGE3\V62T*/^M5]._%=LCR6[>:L#XY/ M5U,7P]'ZK.,H-/_)],5`M9X^CE]3^O34WC/$C$<; M.?K"WHX'I^W,6N)T.0^L^X;N2BB6EC]Q1K1)1ON]5.]]1Z+.R82XG/D.+3>% M>3_L07T_I.\^H6QF)&M1;T;EN$5?^&+9;CNDKI+1O9KZ#\V"_-$L2-*Z[T%( M?5;RDA5>^^3WY$@RVSXQQY+9I6]>R6A6\X;*75_M<*L\FP-FS;`'X:6/8YFS MVX\>\'@O8B]4^8C5/L05N`AVB,,*[M6!58\7W'C_6^;U*0_SRZ71LNI-7%YS MN)T9O\6+]3W;PJ4LW*V2[R.VA9M7^-X8#7#??4M/^6]I?2JNC7;)C^#2W'@P M*-1X8XX?VNK6W:B^5BW<='=_GN$_&SE<]YH;`!^KJAT^B`>,_RMY^1<``/__ M`P!02P,$%``&``@````A`,#?L'8D!0``M18``!D```!X;"]W;W)K&ULG%A=CZLV$'VOU/^`>+\!0Q(@2G)U`[B]TJU45?UX)L1) MT`8<`;O9_?<=,P2PD\6T+]D-#UY_?<\OQALKJXP7&Y/,;--@1;7[<\_K6^\?*G.C-4&,!35QCS7]75E M655Z9GE2S?B5%1`Y\C)/:OA:GJSJ6K+DT`S*+Y9CVTLK3[+"1(95.86#'X]9 MRB*>ON:LJ)&D9)>DAOE7Y^Q:W=GR=`I=GI0OK]<6/]0SH+)SHH^;`"BQ@VJX/&2@0MALE M.V[,;V1%26!:VW5CT-\9NU6#_XWJS&^_E-GA1U8P;W4?_#;KRP[G6M8[@4H$L)6AX^(52DX"C0S9R&84GZ! M"<"GD6\L.]7ECNLO9PK-=`G!CSZJ:9H+2--+7JN;Y/P@B+162 M."W)$F;?QIV9XR_(8JEGL7!&C<`HJ9/MNN0W`[(&?K.Z)B('R0J8[\IP'IW6 MSZ2"1D'R3;`T7*"B@O5YV[J!N[;>P-.TQ>P0XYE&A_$<&1+>(<)!P1O='_1C MB#PDOB/N0R@^:*RS0&,G%.Q3A;J0",^7\*Y+#))U.9X\@=T3B(P('Q&>XDWT M"%&LB1\1*@E]A#A^-Q7)"_?_>"$&0>(.UL\-YAU_LUX[Q,P'F(6,"+6(2(N( MM0@ZAI"<@*D.LV(\&P1X8X+-70:[@:)OAQB_V0..Y\^5>"C%YTM/R>=H&/<\ MSU_`408#47^OV%-1`QN`\< M9[X,Y'T2#N,DL!=*I8^&\84?^$JNQ5)\_C">8OSY"DC*@_^B7(!5Y6H%0$Q; M`9:^K2@+,?Y\9E@!-`RQEH'*#('3KXZDG<#1/WW9&[2J7JEONQ8T(B_40R(] M)-9#Z"A$-D+T2X/\GU8)"'99<,QVQ\QC,]""1@U!GA%(I&>)]1`Z"I$-$6W4 MP)#Q@D"PZ1KO"5H0;@S747=\*,6=Q=R6*T8DQ8D=N'U2-]LFE@">[_3'7A.G M;?RYS;)ZT3E-5X]]EJQ>J7<[,M:,-?,+]9!(#XGU$#H*D8T`LX9&3-P78I3N MB"0(>KX:K2%:2*1GB?40.@J1#1&]U?3,P$Y,S@PE;7?B%1K<:H]*XBAO$Z$4 M=VU/R:Q(BGO^4NFE8RGN.X%RDM(V_GPA9/&BL9HN'MLP6;QZ6))[KR;>EHDR MM;"+]@56<2_J(,\(XB[Z*0'M(,W[>E\S9.6BD9JN'-NNH?*YK92S'1GKS=K\ MUT(B/4NLA]!1B&R$Z*L&1DPL"-B-:0[*L9:M-40+B8@6$NLA=!0B&R):K8$A MFH,2&[-A9KC!PYY`$+X]$^(J&SZ$.SY1,)YOV,:HJ(5\1A'K*<1-HO@5I`B\ M?M^A?+PEQ$NTG)4G%K++I3)2_BIN`!UX_^V>XNWDCJS@9@LNJ)3G$5G!]14\ MM[H`7!I>DQ/[+2E/65$9%W8$2GOF0:$L\=H1O]3\VEQ+[7D-UX7-OV>X'F9P M9V;/`'SDO+Y_$3_073AO_P4``/__`P!02P,$%``&``@````A`"!S_$2C!0`` M[!8``!@```!X;"]W;W)K& M9_`^?OA>GYQOJNVJYKQUQ>?'E^;]FMW5*IW(,*YV[K'OK]L/*\KCZHNNE5S46=8V3=M7?3PL3UX MW:55Q6ZXJ#YYTO?77EU49QI_#$%=IRXW7P[GIBV>3[#O[R(LRFOLX<,L M?%V5;=,U^WX%X3P$G>\Y]5(/(CT][BK8@4Z[TZK]UOTH-GD@7>_I<4C0/Y5Z M[2;_=[IC\_I+6^U^J\X*L@UUTA5X;IJO6OIEI[^"B[W9U9^'"OS1.CNU+UY. M_9_-ZZ^J.AQ[*'<$.](;V^Q^?%)="1F%,"L9Z4AE$@T;/!3T1=/CVWSZD#7P#V[2Z%[4&P@\ML[@JUH[453[X@`)"0*<#M&VLQ`$YWGK(;HR2<2"*JR&\I"!H$68ZFQ5L7=CD6 M)?#IC3.4)$-1TR").!A=%ZD8KR=8T,[+L;288=FP6"J4K`>LR/<9=8[+P#9N MS'(3KC7E6M9*^B+&)\=M(Q]*D$^$J>2`9%VFD6U%@@?/R_*T:3'#"A@62JY8 M2GXM-@'08FM;GV$QGR[&MCD)D`!/6IZF0_!R-'1L@L;Z.A.H,6A)$MA&PBXC`@E_;$-0-.W"R]'0LZ=H M(?.G3*`&T:2$5XG1"0P:$01Q8@44[2[GUR]/[+D,65(RHS%9$[Z]L2&[FK]^ M#XFE33KE8LY_>X:+N>6'[+Z9T1BNU(>QQ'-&7#\)9?C>4W"7[PMT;6BF<=IQ M8\^,!HHV:NR]3=XPS-L2FKN[_%_,!\!DK@SWSHP&=-@T'-R)C99T:#9#*2T0R-S(LD36PK4C1M[XMM36HU0V-> MGQF-J9:?\CXSZ]>A;W=&N>Z:!'(^"4+;)::8TTD0R,D(,L4DZV'P'I@VY4G" MEKW.2K3RZ3R(6&(RHR'FP(PYOZVA&;QK*NB?L5!9R($U+]O-)H-7UY]HF/V: M,&0/HX3BL>&P,(_S(<%;/Y.H(0RS/-[44%`V*#1H")FX/;+U^<;TR;Y=X$%-K7#R"Q,+;#28OP<11^N4 M^S27!/'D#95D,+AKB`QJAL<2DQF-<>JUGTI;/"PO4P@Q&9$4CHV19>6%7J=.JZC.G7-2>PCIKV)PB!9/*_%#WUR&H['G MIH=3QN&_1SA55G`&YJ]`O&^:_OI!GX>.Y]1/_P$``/__`P!02P,$%``&``@` M```A`,=3H(HV`P``2`H``!@```!X;"]W;W)KH MI3U>N2^8NS?KCQ^6>\H>>8.Q<$"AYRNW$6+(?)^7#>X0]^B`>WA34]8A`8]L MZ_.!852I25WK1T&0^!TBO:L5,C9%@]8U*?$=+7<=[H468;A%`OSSA@S\5:TK MI\AUB#WNAJN2=@-(;$A+Q(L2=9VNS!ZV/65HTT+JD2])O@/3_Z[O"&[C\S M4GTE/89L0YUD!3:4/DKTH9)#,-D_F7VO*O"=.16NT:X5/^C^"R;;1D"Y8XA( M!I95+W>8EY!1D/&B6"J5M`4#\.ET1"X-R`AZ5O_WI!+-RITE7CP/9B'@S@9S M<4^DI.N4.RYH]T=#*J)1)#J(S,#]X7WD18LXC)/_J_C:D0KP#@FT7C*Z=V#5 MP&_R`CPQ"DG-NY20U%6@.Y7A:)\'2?X(,E@976Y-)(J2ZF7FG_QIZNYR1?3><-V_WABW82M.S*6'+5F)F)]<(%')<`[&U/XJSB&%.-KJC4^3\ MZI.P9SANVTTML2]BR;6V+7".ZU"'TZ)-:GP$,8R$U)OGP&AO<1+$UEE4F$"(_/I?/TS&V;M\7HZ*Z>_O[>_NWR\_1>5B[ZTV%_7$SSW]^[S+R?C+@[V]QU].^J/I MO6Q0+*>+W]\[>'+XY%ZVG([^LLR/_:>'>_OWGG]=CIY_O7C^LA@L)_ETD3&/ MK#-=C!:WV>G4!V#>7W^Y>/[UEVKJS9]EWQ;3Q4U)TV$^;#[MYK/=['!O.SO8 MVW_8?'A6O-O-]AZN?YBF<;1V&ME_'%V6BWE_L/C/9K=?-'](7?5N9WGSX1?[ M>SM_;/YX!`&&1H23%2#?,7O87F]N=C,I!?YS] M*>_/LQ.(7K;&64>T-$QX/8RVOH,_'C;[[,W[8K>L>SNY+,;-IU^<=]]>-'\, M/'"17X]$<3CCK#]I+>N+\XLC7NYDO<[Q-V?GK\]?G7:ZV>G9\8;NCF&Q.,AH_+6AF^-B,BFF67=1#'[8SKHW_7E>9N?+ MA4DS]&Z^=EQ,RV(\&EK'+_KC_G20\QHB6V9;;[LOL_L/FJ^<3K/>3;$L$=M3M=GK= MKYIC'O?+F^9OW9MBOMA9Y/-)-IJ^R\N%Y*1LMH)P4BUE-L\'^>A=_W*<;V?3 M?)$55UE_/"[>VXK1*MFP6%XNKI;CK!]?H&?3//9_W1,,L_H!?+]O.7^54.[PR9^J"8Y-FB_Z'=Z%Q$S0:!R?IER:XT MY]`K%C#OW6W>7)R_Z5ST_I0=G;W,.G]\>_KF6VAM9&AV=WK6.SI[=?KB=2=L MQ=I6K\[/7WY_^OIU\^WSWC>=B_!B\UGOO'?T>L.SX[#[KT^/7IR^/NTAL2T6 M2!LYZ]]J%YO])XK.Z?;;,23;T][VH>N;.6 M['WQ\T\__]3LJML[/_[#-^>O7W8NNE_8_O;^U&P#/P:&*UTUS%#V[_KC99[= MWT7!H>(0S$?;_)&5KC7ZRP42-OHQ'\(#P(!L5)80L-EST#AW=+M_L+>IWT>/ MM_<>'9B`/7JT_?CP(`[N8]F#8K/V.AH.V:)BB@1(VG9&TVS0GXV0B.8LV?WE M9#DV-6>Z"A`R`9_<()VC=WDV+LJ6:-7?&>97H\%HT>S6F<;6?E.,AR"J+[+\ M+TN@ROJ6-;:RM7W*FW>JZ#%!/OAAAPA]\FLK./PSRV2+#8+N!R-#^_<_1 MY-T%=#14@H8\&4U1H2.VX$U1VF[<`8F.[M:X3:)MYMJ/MFPQ\:>^\5EUS3]E`J'G.T1CA6O2AF&HK[+SF8`$8K/1Q!]^,I8^;%+@K-/++CK? M=<[>KM'A;^;%<#EH2='KT4!B"!H4U)]YHVR('A\7,_%921EG'7^_4WGK+MF(1=Y"5H>W-B$ M[YAHMP\ZLD:3_OP'I+2-P%[E4[8#U,'2^\/):&K@=H%2:LT9YRD#W`WP<^1P M9,(^2)^V,@,;+,8FE,W7G%CX9]IT:+S)``:VH$7`)%M2BBT3Y.;/35MSJ%,' M,_YB=ID#JS`;=R"@<79RQ:UA/ M>YRQC5GWFZ.+3@M+O#CJGAXW)__R]/7;7J?%*=9#-WO;-8.>8;??O'7F^.3A M[I!%-$#-"KT64VZ`W4F&)<*KKP6R;_9$?<\T]8O.-W#TZ7>=NTGICLW@-I.? M56(VQ6+]X9^7&U!V0*HKB[F3BU;GHOUJ;L==1,,;R$[`[AN)58GPT7'O]+OU MB/(,+V"MW:_6F2V*#,>AP,"-]&1!RRR]ML:UD:I'^0 M5>*&H([>&9!LL6%74&SGLJ^7!M`.)6B4;I+B90Z/8&)]%Z0G)K@^HQ_7-GX[ M)>HR%FS+)'ZC:Q2&>1#LYKK5'M_TI]QBFB6I`I3F;!,0KCZK9!+N] MXOU8EPZ[UGLQ37!>>^&.F6@#/W,/FC,]/?NNTS5QOH-1WBQ1]>R26<]2;J>I M7DBVT>W$T@WR?%AF5_-BDA$26\Z-!R2\G]A#?5"8#/U-`$Q60@!SK5E,]`AL M&"9HAC5Q89,")Z=G1S@=6+N[*+"RG/Q#/A_(U]=BQ,.PN^&)9M\7^2RL0DUA M<<4F[(UFR];4KQQ6"A-LG'KGY*1S;+;^Y/RB<_KJ#"-R_`W^:R?#@'R07]EW.")HY@C`/+?#S. M"J&6J_&210Q'_>MI4>*$1/3FH,=B00`XMGX\SME'MA^T!-PKLZ4!OF(YURLS M8BB+_ORVWNDB']Q,BW%QS3JVT4W9>XW*_[LB63/FMK#&>&EQQ=%DLIP6:)O^ MK<_%WW(>8/7Z[PW_,_J2`/*/)J9Z#!I+Z;0W4=:[?R;T^^L\ZP_DWEV4ZCUJF?U,23F9NR*:2_),LRS.?PW M$E-GM)_OT&C'`H<\VOK;7__W>>_X;W_]/P^"$-B$B+T7=0E9*QEK&9_Y@"#" MHVUE6A1K^M&)@GJ$/&5_,I/K@-J\QD&09&%$".A+YICDI$">B&?`J%J(@79; M65I0>&T[&XSQ*13@CQV%-Y"I07^83^A:PB]W9CN;$?N9]`<%;0N>('AL;*D( MBR$*]A>],D4;F+LR'4VJ?LM`''CG=;]+/2!6&+M#?S?%(@ MCEKZ93X5?BE_8-N@AKFLP*S!_+8HE_/K?,X8$.-JGN<_0@-G6G9<3B9\)SH2 ME8F;_G8Z4OC<@+3K!!@RG[L#12P8M%L@QB1-EF5%M<2&IH9NBM+B2Q#&Z:H_ ML&MDL1:W`F.T>42QJ"[:_'GU*(O?79)6E[;=ENR,6#UO_WUOZ`8>!\D)K+.&J\9?Y>_YFCBX;13$[3ID0\W58R`O37G3]1KLT M)>C%DS2+7\&`5$N.@_VJEJ.',$J=I/Q0P&2P#BK+(X#R&V1RL0>T[MUEQ[@)\NF2T9EMOK957\DQ%<)E(:7:J@F/XMQ9-&/ELLQO*%6'L+2EJHO M&,X,NJSB1&:*9#>V!Q+Q<]5;C55QO):8@TO9F+Z9!9;TY^74^"1[/T(]BXO7 MOJNYB`&%G^`0V",POO6C!1Q-ITMH@<\C!Q&ZGD"8H@!`E;TX+U1Y8!8>G>AUL&L(!-/ M&R&L&IA,B0_HJC6O)[-"A0.Q3:!W1GITG&GZ@3MC^87IT[?N$79@$6&5D$^1 MZOKEL78E+7&P7UU5PM2SO@?61=6/2R9B2"-(.U%IB[%?4*"2(ERB:)T$W'"V MV#B>:XLW0!I&I6!DCOY@/PD2L*DUR99*F_1_R#,!1ML@XR*L]7+B[GL&XEXN MV&0Y?)G2J%3R!(%:?6D)\\['MR;M]?>OKN`78RA"5$NEW9F3AWQLL%HPARE* M4)1=!"4,"$TQ*,K:I@!=I&>8P(:W'5+$+A00BZ.%K("K_1CKWLVZ2Z+UU2*" M\-I4E0;UV)HF&TU8%=VRF2O6$W+]+;(!U!P>LZ,C5/,(/XB91V0NX<$Z$68; M&7"R/+YUC\9C55.XM4%W(WFW7/.;[WV!,2##+-=$^$0)0\8E&=(]4D0<@+[!@ MQ-Y5\V2.XQ'<:7%85^8E'HIH:WQIFSH8S8]#,UV#6*T/"U`.!I-WL=#RFP@UO M>$"]QVC!0I0)8D[O"NTRL_:,L:T<7ED-V:;6O(Q78X`&-JMY`527:%-,M[MKBV7L+PSZ`ATN:&$LA!5A"U+:(@ATDQ$B."64TFLK(02'ZN9L( M@"_,<5UCV#KH$#N?FS[`F>I/98+8JV&.N09V,;XI/)0FD416!0\39X(5HB7" M^\96#T=T,<_*"MRC!2VFR@A,/#'>;E8+9%.X4'\6^A21[%77+DO]6TY*B'Z+ M!NL88AU'(K,.(ZX4UJKT\5KH``U]0H%,$:I\;16,V*L$\/A[\;QK=4T]U36I MP&@EXR+C]@]O3`GVL$.`?S9>(-3BY:U"+ZE$&"HYI#N(SDY)OI5($?(=/-N> M<4GUB\$AX>`S9&1)Q1"JBH[QN7CZ+/G"947&D#11+H1)8<<6\G*$X_[($<&H\*0P! M`E-E-IMEE>6Y1F3=VBF]8\H.,S;%;4KF45*L.'VH45&,(.H_<#8O=XJBO`:FVWZ46^QD[$K)@O#0@]NSJ4]Z%$5(= MW;=Z)M-0_*L-M2U`=8,G,"WNGODZM'NBH;ZS"BHZ/TE5,*?$;N:$%`$_2<#_ M\646(P`5UFSMMAM<>-W0HNV-M57BCMCGVB).&8,U99OIQU`":%MN(`@>B%#/ M8[X?#.%J;'8)DR(_1NY.)6E`'2P?#&?.,*UJ4R$D"!A=R^6V[15HJDW589,IC8#KS7JC_09CAK%J M6^L@`&FZ0^)5LL>>R*Q=$50:C51FIJD`AH=(AW"?BL[8',*1 M9D0#R6A1\Q-^YU(4/@P^=J<>+1=$8M8<"3BHL4 METIZ>4UPCON/)A_B-0T(7BNN+#?9_[5M\U;H!D"Y('A*`R.L_&$AFDAI6X+> MC2NX_9UV9OT:#K\BM&C),%X03[D7LE#$3(DG:E\"D^O(2!;1 M)E4IP3KYQ6&DQ-*2LZW1;KZ+""YG[HBI@H&25\J(M`!T8C`\1D%V&7@$YI-&QS"PN'6N/;W)JXC_E/,!<6>./6@F<]N' M3*/Y<`=W'7M=B6PM[([#Z-X\"".J(O6N`RS"R$B%.#GOXR"H&X+O,T6>V0(J M;04*;2NB7YH(`HFU1?57M&3!'*(J((CKNBEWY20LFSH(/7X2"2;`X\C>W]_>>[9G+>X_?O)$."3J7R6% MM%XUBWXNI'1_4(19!WGBQ*)&M3DYHI9*$=B"?+5B#*DHH[(83KM65Y,(53AZ M4D>%QG91%9=9T()TE(SY.G+5244J8R4BR`20"R>C03;-B+0>#&7!BC6MH\Y0 M)B4L0Z=T13[8W\I/`=L M4=I,6D,[!WLD7T8LEFQ],.U0NP;2UYX?6`'D/_^T]K17/4YM30Z;-NVB_YYE M8`PQCP'Z5D;[?K/U]\7\!S$YF4!AAN9C\/0(SAX2Z""JO_K4N.I-O2*JLUH1 M]9M@L!4"R)N;6=!1/%'QFM@+]1B.2:`X`37P"\E51ZW&07YBP@]Z$&O#_`-$ MP1#!&LOBY:KQ1W.)X:@0N&9CL'0!S20I?@T`:MIMK>B,J?C53`*UE/!X*4BCU&BZ@] M5Z$#VVNA4SN(AS-`)DTDN'(G+!*-O2`$!1DB.A'->*B8*JM3P:)V(.(>M]C* MJBK2H#&L!A8=Q)X7\R'O!&,E+SXEBXT)C25EAAC0(]IP8^TH3MJID(>LIE8G M^V9[8]NS"89PW/?QWJ$UX1C?]N$S4F)U*!*,55U!FFHYK6+U1\9?KGYJ6N67 MR2T])U9<#1WV-D1&(@:Z6[NO\;]75>?B^5%-,IO/WJ"[B^'//VW]2?+1JJ^W M,Q/-=VJ[V7Q$36?SI^,ET%/E5F-B_\V'6X?;AT_VFK\^:!]X>X/L*[+[U9/OIPX?-+H\&EAQ#A\7:A%8M)7-Y_/2@^6(/Y(@J;!\Z MWGKZ[+#9>&O_T?:3I\^:/SN1-Y!XZV#[R5[KB#"K>/CX<;,CVCY[U)KBUI/] M1\V69\648C8\,?SO/B%+5_[-5EN/'[4HM;7_K34U(7H74525$D@]5 M5/XRPK&ANC%.`\&>(=O&%F8^..-&&5)T#D/LUF.H*DNS\O2H9NNAEO`&D5S. MY,:,'7SF,8LKCH5B'^4#QF?!48HL)9ZLXWC$F&"@!V268'&U"\?D&$HE+-*> M1\MK)$.7$^SO9FE-J-BI(A@NLG1"#1CUCJP/,XX?@VW@1W(K>'E*B[AUQW*[ MVE65()J=ZCAB"5/%-$976GM(GZ'D0:.A%$!Y-N93RU[F'Q!1LBHA5?9VM[MK M%82-1'2P$HHM@4-CQAIU3U(;TRWC9TGG/JX=X0%28HHRAM+XG?+5GX]$/ M&*$;&$M3$?!3;K0V)_2C+0"=&&N.M`+^(\^MI5H/\K#Q^T0Y6Z&Z7O5RE1Z? M`00T:17NZ?V52+Y2FE2I>LC2K:29T*G(]]X24^K^4F8SJI)")2AL@1O/Q?MB MA]V9:=4JL_-EU\BKS:/P3GLI:VUUEGI;<]*,4P>-=S375%,3?%(KB+71`O>F ME^\:G:TG`RE092ZFE>ZT::5?J**E@M$XOT$X?8$LKI`%FHLADY=E MW?K^1E51([=@#O.W9(I3NMYGHI['V+1OPDBU]XGUK%*69X`L(%8*T"4-U;=, M*<_6+#+2S>Q=6_7$X,)JH'N5MC$^@'JN.8.$[P+%&%B1`J+)J!NO8ZHM1%"D M+-V]L!G_VW)\FRJ6'F9>_V`4V"CE;$446^RN:9Z%A8$^1W`U1U.9JU3Z%/FU MM'[4?$BQY<(GF',HWB]#^0#\L:$R!JY)\2KCFFH/Q3F:V.J%@O+UQ,J&N^M;7(.]"53VHO-J6N9EGI3X1/\R330E%P7P&AJOXIAD>.(H7MUFL57Q`<4] MAQ;+,&88O[I+>TN>(%M/AJ"4?M M#&5`2S$N8DCJ0G2`O!QUJKD,"5ET`75+=8'E-"*EZ]&'Z3ER/"$$A1/^V"; M`72<[@,2HN8$IZ2ITG$EWDP*`H\9-$>V;I>\37`[XDS=AP[^L-"CK%F\[<`+ M5F4>E*$+I6K2&)=83'C?8("6XOD1"2PF3X+=)3+2;%AWY:!H1MAMH3B1X$-1"'01(Z",%\OKFXSKWBS# MJ":'&"@8)12-\O])!\-92GSB1KIU#I$CL9;TRC_E$U\(M>P%>L(PIKX\+>=R MA_S@VIDDSOF]55UQ]EF^)I[3JBX&J,5J MPV19B"+[/67:N@KP)V!F>D`OND\7`.%M%7TE;IL/^JSEGV)G<0>#[F3].0@; MR6^JU4IUP6M#ZEVEN`UF][-:J:_VQ//Y0<^ZG@_M:PC="T!KQC<:;G8PZ&@% M0ZBP!3I&`"9_$PAE\9#:-!(C)$DW9$&+\F8TF\&A0:R9DXZ!*D5,QR=8"SB& M78^+5'-A#"P*+\L'1$/(H1&,T:NPKS`&!B47_&+?0KB^;Q..M$O2'4II@-LTH'>$QH_5VHSQ8#G`R(&^ M[/MXXD;02^I`:^*`]79V0WZ43)`1F6XMVA/<1LAN3%4N=!9N[3'.:3F`-A.H.V86ED>7Y1XHVA:8UIA. ME=%^_!,H*I/,BJ,3$8P+LZT1=`9%=;H4M=CF!7"G(BG12?/,L,?!2DOO.$_PJC@((+Y%5X)O:92!#]W73]T MY%;VH1N"Q.6U`M8XM/H(`K9N.]CFD':T=7QTQ,/-(WXZEU:!ZQ01,9QU#AP0 M?D_+3PN#?UP^@^C]$P)`I)E'W6$NW4/IVBR2;EN'MM$YZ('H"7G55$.8@JH+ M8+UJ[&[3H`C90]R^_A"ML'!8#B>Y*R4-:XY4Z,<2U)<@#'&TE\'`%BCQ-`OF MA%("/89H#W_A#7K!`3JT"L3$" M_3#E3&OSK$$\WN+!,(I\!L)0*P<7+.K8GGCB2%/HZ6"(E-;*!KC[G/2$P3"A MW92:M6!>+3>;',`D$HOG%\4M!]>E4`EF*IL0TL/NDC$DH6%*_-!SEH&3JUT; M<4@E/HI18HGWKNN(T9%^H$>_1`)W15+5PK*,@@,6YT&0@;#O9VZ MNE3%G3@^=!445RB.W^D/E;:W"V80&LG"AV!CC<"-.<;H<:2#Z\EI]F_+:?[S M3_OAI*D9:\PQ7H%V&?;O0O5X,=YDGC+/V@+@8/[QQ&L^7^[]U/)PXD"[;V&%1 M#/9;!?#?''^77=BE++V:U[QR)8;G..+>6^SW,MP2(^/MKPVYS&Q()@\&7.P0 M(/G!-+HD]H:B(:)IR.(Q]][,EUS.QMEXQO4S^M^3.5,XF2[E2BOVK52J,`OZ M-EPS%`4JQCA,;P0PXRQ%#Z',>Y,!=Q]2;\)Z$U=Q"&%*?!N?&H0T%0:S&O-; M6-%Y1$@Q:#,6'CC+P=5OT?&O6"<&7&(!=RRXESA'7&YT1K;2*L40V1R=$Q(M"``=^>T$8!$QA$CC%6W2\[\]0+C* M&I9CMK1U_*># MJ*D.[]OE1T!KDJ($1W!ZB:40S"A_EX5#&J$L-![9$.)`&G=: MX_54*I"7^@B_AIN8P(T$5$)^,F-:I"UEEG3ODA&EY+1SKC,6D-:!R!H;LGA^ MRMTP'T+*,&A]:%%IH&`:-`&KMDR]F64QK0-(Y&,#&,^9%.'])WZQ.M"7DVL6 M/JH*766D8K@AV:@`D2&J7>*`/8IQA91V?V;2%D<+";3H>268SL0==W/(/8W- M1@"FR72D`BC.[7CT1<@[0C&5(Z*P.;/.'E@A1-3[@<:J"0YW7G$%'NJ1-*^[ M5BJ?)2C!W0Z8!0_D8??3>1]H$BD4^V>/4Q]IIM'_23/WVANZJ@49Q$A5^X%*Z3%B6X&LXOU#*` M7G&[:1Z[BPUD?3NS^QL@=^K=$)>%H723(*G2R/)ARQ6+1W$AK5CN]%8-'(9H M*;C_EW+DS(%)M:A="[I>>#+0MI"H@7\8)!24TE[__<+W15;**`[VJY92`M"' M]6PKRO6.C*K!'V6T80<5X*YD6'^;8*B9P&[$4R-`]@`"JHBX&#K3#RHC0,T0 ML]QVI37"M1]5=.>W!S/KE`W\!F&J8+$%6=8>/FA&N-Q?2&0/9S5I!7RO):D\ M7)(PC=4^.=@0XG(M'VXJ1.F3(5ZYFC;`DA#@-1*% MXBXV(F31QJ5--)K4ZWGEHK`='KX-10%&,(X"^[UQ!C3\DIJ4%VH2@.M#;^MG MLNL4B%P'^A9!0MPU1"FK4\@0RLH$$VRJ43.6B5:F(D5JS:;U5'<=O@C135^$ MJ%K_?S$LY]-49K)?/=#$;>U4B:D@01'(.(3>3V!C._1BIP`(5-WG=!"PS./2 M8O]*1[=T<+5M4@\*?,-FFKW2GQ\[_93B&:$\$NE7(+8MLMP":.NT*1MCPFER M^!(G6U6A07.@22B`>N36N`O(;Y8R:F6,&>4"^R/L;??EQVV@)E% MJ"847]\*45-9.4ON=-S)?_'SKSQ8W7]A$?E`H^&@`&3DWY2 M_D#3Q(_`;>*7,$>!2Y\7+B[]TT1/(9W[31J6P78T6,3"8<7)RZ@<&5'+$:GK M)JL.QML=HOQ<0"[)2;2IY99- M@E:V+\H!/Z[NI"C%-#V7;<&;Q/SRM]7!BIMM*J[7L9+(R[UV)<`_%8HN&7_X%_4J]Y76.&8]W"W9QC`7V6\-JGO'98Z;C$O);0K@H;DK&) MJ"#`"@<0`]VI1U2,K0S7Q24!2^T,[8."\IU@N_'1$`9V19(!WL=.@IC"KZ;1 MEGYS)ZM83A7-E,T5"'!\(KN:SMC5!E9W<=35(".7-/V9.+;Z0+6H?-!,GHZS MZ*7:'4XHV[&^#F)&G>`'T3RJ2^PR>3%&[%X]K;"8JDK*PD%\NLV;:*I.)NEN M4V*@',!CJ=4=0[::D7Q'.JO2G6!'IA4'@J$9%K,?2MAHZLD4*XJ#:VMXB,`+ M_.O4W$`6]DDW:(8NHA.!@\,B%<^V$V>"-UKK,\J/P2)-A#P4;' MZ*5(BHA-&MY96R?0B=<:;;WF/-V#ZK.329?^LB:74_4O@*:#ZGZE\'DZ9DT5 MAXPJ`%(TY!((JZ:PW)_84"(*#ZGL)7[2SJ]O>L\!GQM:[W"9_%R%BU74V7HT MP>"]]+DC:)P^P9P-*RC('*B)P3*/QC8Z*%/Y"7P:'3Y$#2[9H[2E.(B':HJ MN<2>6(+X2@C\KF4J>,UW/X-K33H^K(*"IDVKJ,T:(E7RQ&C!;ON/RFF@&<+B M4Y$.T-0./^M:3%S*MG:I8+K06790DD6*2ID,3U+X:9HF]V"$L1?%.H*,- M%=/:=J2*DWK9L<.N8HK\(`GV*L2EH\/U.^;_WK M9TU1;KZ[M;_]]%G[-H7][6>/U_SZ9/OA7NO"A^^;\K1A1VHLU+I^T515ZRY^L[_97G2NMW5!$K1EO[>VV2:$?VY=) M[.T>MNZV.(&MQ9^&978,<04?/KC.&Q%0/+U3*=;_CLI(?H8D_&#[\<,G1LU' MVP^?/0LBM1K^%-HP0:\7S&D%-<%(RNTN:3!3RXN@$M>T!#_OT?;AP<.[J!2L$]C%TN=#Z)&,P^?2*^#7 M*.Z@AL5SZ&%G;8^M.)A`FW*,E`+%2[?@'BX2>`,U(1D@6H7&`$S7[5&`)Q<6DC8;6-$WA,J] MG$%=A]2%+4;>UT>OD4:4[+R0C#088*:O9[@<44A``!?BF8EM75N]UI6QK=>1 M/<2H>2>VL`)!=:W`^&]EO:DPFQ>-/-Z)*H_U=0"/3X.Y?#?LZPM>]V&^*[=K MVIARC"(7BAH!'VEG];=`9'`TW,#J7U4A=-C?7NQGJ+::W'M'LW`93Q(@IJ,G8G%J#%S#WC_8?OAHW\A*?/') MWK-*WJ)2D^C7OC[%%$,M29"\S4>8M#HWE2PK7!9NE]7"+6CC:\KO;$:^:&DF MS:\^;I."B1Z6N5S9P'`C+[!+7,F3N4;HT\76[EHF)K6(8[HU5_?G+4?:&\()Y@N<0T$<7` MV]4%EM=\D\5NM81I8M171([!<.N*?48X]Y$28ZZ;RWDO`,;_IIJ M]$S(ZYUCE>G%Z/0;<;X99(9`?F`7(*QEDBHZH[S1;8/\KX5*?`;1VNAI,K9 ME-Q)86/Z0]0+.8H[<#TND)MQD']$61XRME3?;(PB6!]+L,4/N*HPB9'CMDI9 M6;6(M&X*G5@@A$0?E\^[8C1QOL*$,`==%&,^MVH`[!8`^DL,8/W0E=_D;!VE MP@U1`<:Q[Y>$-*"A'/_=%%JH]3'J,$F5<<:=_<, MY2-&[.:Z3IM3?1[/V%@D\"N>JFUP2**O/UV/IHI`A7K'*C%-_D4,_QC=+5$@ MXHV;CU+L#SW^(:>-*]^`LE5=:OQ&E.E*GR&BXQ=J11N0WC>5"L,DL;2EF4U# M0"T`6T^P5W%):!&^1;G6,'9K'S[Y(NMP7=NB==NC_[KQ8]E\DZ?6"?I\0S?6 M:@<7'NURQ(4AS8N++=SNY^;,[(?:V;XUK26O*/#J"J;TXO64=I3K5$>;;`CO M/'O#]>;F1%(=;M$1"1,&2O089EOB-Q2@OZ&V7A[1X^?JM[!MV'6M<'5",'RL M\F;;%+50_8%_$D'W!;KL4KXT1MX1(:0OXN(J\DVX>53:G?U.D8!Y)VCS2]A; M][HPV66H"%V96D#0?J78E2Y.XQ=4C44,-=T8>J-`OO[U`5M*]`RG:;9F[-&BG67F3X"BBZHVH7(%_Z<$+GY22FY M%*-B?C49,$G?H-,7CAH8:/&\9V>*5VAJ1R+C44FF5J>K5Y^([3\O/&)W68`N M#YX^-E+SYQ[W!4N4$A+-^EY:F"/BS6];D)_8.#3?$SS:$ZUV!79"+C5%D\/GSF?/IT M_\GJ.B2.V`U9:+L/Q`W"@C,D%H9P:0\A$GHBMC&:++FPE"VW=SC#(-M?I`JF M9D:/^Z/US4FZZWCQ6\":,2C'1[7[MSJH[=;!&NNLZ'\<\>4<(>G_7`UM6'N= MS`@ZT7<^L%^K;S^*CC%L=3(OKDA>XO[!QU=\1Z;9P"(FS1\QJ&)X.TZ]^1FY MN?AUTCN6\;)BA4^K'3#-*<-A%Z@CEQ;'Q'O/[<,YVI)H/[3G^WLK)62?I#P^ M88A(:>.KP\.5,7P=8J%/&>WPXC>6I*D^7HF*94X MN7L6SK&D(`:=`E)U`)YQZF6E^K>NOO%O*QK_4RE`=KMT>-U6A?!S55!EH]D] MI)I&Q/H(A>M*NZ@`D\P/Z>8<)>Z\7*^D?'6XU%$D^21S*K&C65[9_'H0.;$) MT)W16EIJS:72+>7[,G)6M3:$-#@MINN,Y:PHP-0,F)JPC,J9XQ5?N@KM,E^\ M5UY"RC&@#JO.7!?[3K#(*W`JQ%[Y'=H(C0LXT+<*2H]>K[%>L:%O$X:X,F9A MSU8+<)H5*GX]R5H*X\/8@E=SBUY0YK9(&$@+;E(HT6`3A?"^-MT3SE:J2^>B MVJ7@`HN?0JG6!F/!#O;V@"T@,OD`\3X3/B2GCY3)?K@WFBK]L2XZ_Z6<=KAS M381?H9%E-7Q3JDM18(+X_5U6L+%W$"E,+]4.]"YPW!78^3G77KN5/\$V/*N!DX,>"<%?YD`H(!%%` M7=.LA*2!A2I][1RQYF/L$?]XY>^=Z=M13TY8>GQ/KQ/&6L35#_P MG&8A!V1AQM(NZ$)6;=<5YE'L0S->6_(4+O^KA,U/]BO88*=5[!`&\TB!W#88 M>A&JIMAD.ZK-@5GDEW%961-1Q"87Z>KYS:"(8+Z/RO\CFY&.,7RCZC+7H69J MXCGQKZPQ+O]Y]^T%SGYZ#YU@$2BS5"J$8U62DYI)U"=OXB4<,`"LIR-":H@- M`%.-]0%K<@G74[XHI+/$?NK/89[<)'A(QBG=FTO?%C4SQ*XUKJ%TYRWM&E4:)I@B\8K5\#81"QFZ(>(S*U'HCC69!<#^$E[=B2< MRK%OB.JZOG*&`M:7Z,-9?+\6;\E=C+>^X8NW@7KO?:V>$S26U"R)GN(!\)(J^C&1< M4L3!-0;535!4M\6*5UZ0T.G.4[8TQF>TUF^/F(JS8 M/A<"`R>N8`D&M76\('I1PY?9`,FJ(>2&CZSC(ZD2:CN'T. MS(*`C2[Q8?11E<3KD@>C<&#ZL.#^H#_,&1""!R?!U[U.5Z8FJUP/=PO`&_%M M3DD,6G9="MU9G#5)157!F:B]E8/VRQI;(?2C8,A65`J`S,MBK?^AGU47 MUM/GC!%SK#TJ,6`WW6`0?@A^-"%LEFS%5B")^*_PT.Q"A?K@??_*"R9]_L@K+GW]:=8.:*.8,6?S<5W`JHE)JS4$*L#F&Y+?YFX6" MFS^>PUK8$U#_"GNT!MEZ]O1)\UV^GO5HO_U-K4?;^T_:;?>?;G.;>+N+_I3@I_$W.!5J5'E MB=P7CRQA]Q?FNA]P!DB59NI'IX#U2TF9@(L801/&+&QK)2L3;.Z,S[7YJP4& M8<]K`G4%YXKNJ*8Q/9CK;/RUAVX M#@A3Z+-%&4[$SQ<[/5*^N#PQCM9J=:+O''U'X,$A8^'-7^_"&4`%]6!R6:36$61=3]Z+4P5]18E M5"@H+JW.W3>[3C&X,(WF\S2T%O\=.5WP/AM8.S?7?*,JTU;]7^MP337!DX\6 MRE9MB=I_8JEA]0X$1;976'5-K5+5_G-8O2?KV/X<9:V+C_)#K4$04L%R;I.( M.B79XK:H@GJ7!(6D(-1:\H.:^G_L74UO$S$0_2L^("5(I#0%Q`TI2C]4*2E1 MTR*AG@`A5(1*U=!*2/QXWAN/=[WCG762`R>NN[;7ZX_QFS?C&HL/^%F M+PR9WON4'MHM,)=-CGW;'#ENT64G-72]_"F":+79HD]3MFBOJTNUR7KO`8ZQ MK^Z@:/G#L=*(N?E&N5GPD+B"DS*!CC$1XB^_D:?X$_-.H[U= M1I7*;9Z\G2K:P@(EQ`9.`70/;R9%6[9@@BRPO9F\X5'PV_*CUX4GZ=P-X193#.E\T^:7-PX4+YZ>&<6_0Q1OLE?A\L;.&<84!TXP?9= MY0O9)'$NC`:XQ.C"S?`'B&OX"D8_*%M[IB$?A6EA;MD4=4&4XL^D9?=H]82Q M+"-"`AH51)@":2;18SN2T!J^E\);@*=.D2;!#8&VH&&7K(5?_*?1)WEFP6'T3:$=7D+MZ(M#%G5=$WFQ18P`PN)!$M8Q,@`;H:6H M">JD^Z%8`V_Z=V4#QA]4)["A16Q#%TUDT2^/<(,BI0M6,IYLD(VD9W*2#`!S M`+BOP!4#`8`RI3SKE,6NW&C:O\[?MZW)-3#6TZ^G?4X1;GN-8>NI2$.O_G>A MM;7_N54$`[(UHS:(@?W^J*!-VO:!)MK+C;SRHK@)QKS\6`G;X&!(WCM4O7[9LO8)<9RFO?.,+_ML=K=';_IY<,9D90XC[-:>.D+SX>3?A)D'*U-!H M"#[.KQ3?9C2G\@]VN6S1<&4@LPU15S:C.K"7SE_=[PU;@/4<:8*A/9_=.TB7 M%\+>RK"0$C%;&BC=*T2UW&"[X!33N!DB%)F-/@9^I\N]G0AI0BVZ'*7&GS=7 M9:'ZY^4:;5=D1R069,'=T5D5;%J?RD$YN:LKMOV1\]+;>1=/YXB];:.` M-LFI?RVV24_T?$!!\;3E9:>FSD;]BCO^NXYC[L"G8S,15[0A:(!5O@%H(S(A MW)K)R18'?^SR>PUGXG4=QVV7Q)J$]0!=5=T/J;W%;;P!AC/S19CKQ7?_-$S5 MH%9@#;).KXE(I_E*4B;MO7$2>]KQC5/+81@GI]2"?.KXEJF)BCZ$J8*=0RGO M.:`5TS5(_%5_U7Y['6E`^[@%:ST.1[K$[G';SM:K="Z7QB7_6%TSVEG0233$ M^CB:]RVC2;S:]W?P$``/__`P!02P,$%``&``@````A`/#Y'Z^D"P``UV4```T```!X M;"]S='EL97,N>&ULS%UM;^.X$?Y>H/]!T+;%'=#$MBS'=B[.8>U$[0+;[>$V M10OTBD*QY407O;B2O)OFOSFQ_OWM;W]S M$R=OGO/YV7$2#40$\4Q_3I+-=:\7+Y\=WXXOPXT3P"?K,/+M!-Y&3[UX$SGV M*L9&OM$I M""/[T0.HKP/37N:RV9L]\;Z[C,(X7">7(*X7KM?NTME'.>U->R#I]B;8^I:? MQ-HRW`;)3#>*2UKZR8?53+_2M=3D1;@"$'_XSS9,OOM=^L^[/[Y[U__WM]_] M\T=G]:^?OMG_[*=O]5ZNAL@$#NIE7O9KQ<+'J>1>9L'MS3H,B"%3F&D)<`RV,>N!+;OI-]8V)[[&+GX MM;7MN]Y;>MG`"RPPLN_Y+M"$%WNIAO/J>40TN4T3A,'9-,0KU"8?3++Q8KU- M]L\';.)TC9IUG>(_3A>SHMXN:;KVXV+/AZ?H*K@B>J*GQYEN69!#!OT^NI42 MUI&RZ:(/^LZF[&IT-LN&UM`:2[6,B\5]WE#AT)+IR@:%UOOQW=G<*5]9E759 M&CY7#\`.)]>++G3=FOX]MO#O''%RY@&M&\:85"[ILZY7YL8'UW=B[9/S5?LQ M].T`'4L'-?9M;DSF`D^^>([^;L1O:83)5U$$+_JRSO62YD9L+M6]GOUID!,\3.]'.Y/#X_W.>O$,?1NU_.*%^GW&K[]%-EO`X,!%VL0AYZ[0A1/"[:.R.9QBZM[:W'/ M]!)DHB@JA%K68MR!T/OY="$?Z6(ZE2W4L.!/LM#W(_R3+-2"_RVD^30;R4U9 M(`MY6N+BNK]_.9Y.IY/!U60RF9K#@6DR)S]F$>T&*^?5P5*`-#?M(Q@!@NEP M,KTR`$C?G#!59T4P!`#CT6@R&DP-$_[/4E7W"&3[=*2K9I4@4,0J0:"(5;;T M[$G(_%E/@2J*V>5(%#$*D&@B%4V=Y?85Z&ZK;BO M$@2*6"4(%+$J;?*996#84E#,*D&@B%6"X-RLYLNJQ?V]QN[WQG'4"J\3(?7K&?Y-P`_]]#),$-M)N;U:N_10& MM@WF+_-^:EK#5"+N*,SUY=IL*W0=C!=R(OFTVG/@P*)1DX5!64WO(0D:?8`M&-6-:L`'$ M1!X2@BUDV%CN+(C:2%J(V4@:"-I(6HC:"%WG4.?*/;D*M[#+O4NP94WZ_;2( M*ZJG7B`!?B!B#H,@;?;]V=CD@$<;V[2U%?++7M^8&_C'9JP'+&UHL6]G0X,# M5C:T$+61CYN<74YX44[`]'P`R8Z_N:\?!P,4I0US/#M),,M/N+F4;B\)I[O# MYC:*)U:#A';#56[#CIOV;9"AI(TE.;#&-G4D9N,U#/]+Q_,^XX#\CW4Q!X!2 MU^W-ZYH<3H$30WAZ`\^^X$NH)V_NT]1^=R&+' MB)@*=A7KUN6[.9NHE._?>^Y3X#NL6*>G8GZ(PL19)NR8$]L$JL(SK,`SR`2) MX#E%OUFA'_PD[(]3]$,QZ"")X!>E^B&XA/7+C`<\T)4%-5!`@[H.CTP$L.3/ M$0`)*A#@`;3,!Q">*A#`4BI'``%:(@`X-5%Q2C\8D&P&,5"J!/U=J80S0RJKT"_IKK+2X]'N2FTF^A4`OW0QO:@"H_,)`H M@4"(&"@:?P<4@Z(1F$:#HB&80N#&X#/V"65!BJ4B2!H"I#4B94I4B*056.)%2H2I$$`GA$28:D M3*A*D12#JAQ94C%4E2()!%49DC`Q[#A%]FC9-"VBDOKIZ.JH^JGVNFXLI`ZJ M%DW`>]X\73VE*T?@@JVER%(:;_FS\]JI]AQ&[B^PR,1;_Y903'4B'6\53=PE MO?(ULC48*%4P8(KE M"@L\A\FG13;##5Z:R]KG$O165A$'T-P,A\]D.;J:'3!&+AF_6F`Y/(KFF2#E]0C/LD,F+><\)+4<1?PYTQ8=3!LS])%1)):L M&[H>!7H$*8;LB7IC&)-\7ZD<'NZQ,QGD`W:>[6TT)H,V:&BGDD)-V^&AHH/7 M8Q'IWY7#95?!@[LC=:F\$_[@SL_#TP?.&L=:X!/-Z&PQF2\LB?_.E#M.=6,]3#[W M=]8SNN:U[7``3EEGE-()>Q:/@!!M&HB'6@Z.VJ:@E.. MI4,0]U4SJ=6="%:&=4GX;-W%@-PK5J$5G+,U)AD@K)@$P:)2G7)HV$W7\"%V\-#=_N^U"^W] M$N>CQ:QD@*=%AN8[A==IY>S/:FZV05U1,#HH[*@KI]6UE% MZC`@B*@L6"6VE07JTS0T!&N)++@1J[4LF&]FLO!L4NDO$PJ2;7%!DTP6[_N1 MH._-0SRR4WPE+C19!!>55?((GB,VPL/56LLJ>03BJ"PPN2VNDD=`2&29H*2M MK))'8('*@G!K*ZO@T<0L5_I^).C[JX,\\K&*1VY$<%%9)8]\K`X%8Y7**GGD M8Q5-;HNKY!&D$G^9\$%;626/?)XP!?,$M;'DD??]2-#WNQF5CWA#,.)3*25W M\(KX""L7(CY*I92L\5$^%(SR5$K)%Q_?IF!\IU)*ID`>L`BW410'^&GRB` M7S_0P"^IA_@8QJI<&S%%7^#=@_>4M!$#K5,T?/SA.JN-&&B=BN&3*LZ?1,1\ M"#;;@B$^E^+0+2+BHQN\."L^\K+V3P M*2)]5G!^$WPV__P$MY'G3L1J#.D[.(<6`?[7;4+ MB3D1"$M(1`A'.PL1.QE%4,;?[2C`WL)UW9T8K;"H/"@+L__5:_F,`>;W!'_$ M@SU]H%@/@*-6SMK>>LE#\>%,+U__A3U8!X(I^]8/[IOGZ(SZQ"'HQ ME#`@W7R,X2DX\*^VC=R9_NO]?#R]N[>,BTE_/KDPA\[H8CJ:WUV,S,7\[LZ: M]HW^XK_@,OS%DVOXR8P3?E&$_?()')4=F->Q![\[$F7&9N`_E]=F.GF3PF>/ M*0'8<'XF-Z(7%[_(:9F66%.B0-))?1O:XX`!P[IAEP&[[3!L*]`"NW2?)EN' MK0/Z%?9(2K(8RTO2!AO6U8=$(G]\_]_C(W7UVH.(H4,B).5QVZM=KGJ(Q#X? MTSAH>W>&_4L;'I(*QV/,>$S:WIQ([]K6^^]=Q9LJ)!%!L#Z6F[CMA4HEFY6* M]&$8R\L\(3',3;B(L()7$53&`A\!W8A5UJK59B7"-/90C",@>WLRH3Y!0TW2 MV\J(]QB\QDKJ`9^)@29-G!4&.Y[6-$+.99<)=(A9VP,^8WXT)`^4AQB6"B;: M7M7\O,K6U0K>3!`6#?!TVM+$6:]?Y&K9/1+(#LXS+M;K51K;OX`OWU)9E;G4ZGT4IE ML40-R#[6E_`;U69]>\W!&Y#%-Y;P]?O/R\1?E>%G$ M__K#)[_\_'DY$#)H(=&++Y_\]NS)BZ\^_?V[QR7P;8%'1?B01D2B6^0('?`( M=#.&<24G(W&^%<,04V<%#H%V">F>"AW@K3EF9;@.<8UW5T#Q*`->G]UW9!V$ M8J9H"><;8>0`]SAG'2Y*#7!#\RI8>#B+@W+F8E;$'6!\6,:[BV/'M;U9`E4S M"TK']MV0.&+N,QPK')"8**3G^)20$NWN4>K8=8_Z@DL^4>@>11U,2TTRI",G MD!:+=FD$?IF7Z0RN=FRS=Q=U."O3>H<],9&R;,UM`?H6G'X#0[TJ=?L>FT1.[P:3?$45*&'=`X+&(_D%,(48SVN2J#[W$W0_0[^`''*]U]EQ+' MW:<7@CLT<$1:!(B>F8D27UXGW(G?P9Q-,#%5!DJZ4ZDC&O]=V684ZK;E\*YL MM[UMV,3*DF?W1+%>A?L/EN@=/(OW"63%\A;UKD*_J]#>6U^A5^7RQ=?E12F& M*JT;$MMKF\X[6MEX3RAC`S5GY*8TO;>$#6C\S210*:D`XD2+N&\:(9+:6L\]/[*GC8;^AQB*X?$ M:H^/[?"Z'LZ.&SD9(U5@SK09HW5-X*S,UJ^D1$&WUV%6TT*=F5O-B&:*HL,M M5UF;V)S+P>2Y:C"86Q,Z&P3]$%BY"<=^S1K..YB1L;:[]5'F%N.%BW21#/&8 MI#[2>B_[J&:+T5';:S76&A[R<=+V)G!4ALZ%8JNU'N_*J8E+\@58IA_#]31>\G<`6Q/M8>\.%V6&"D,Z7M<:%"#E4H M":G?%]`XF-H!T0)7O#`-005WU.:_((?ZO\TY2\.D-9PDU0$-D*"P'ZE0$+(/ M994FRE)")J(*X,K%BC\@A84-=`YMZ;_=0"*%NJDE:!@SN9/RY M[VD&C0+=Y!3SS:ED^=YK<^"?[GQL,H-2;ATV#4UF_US$O#U8[*IVO5F>[;U% M1?3$HLVJ9UD!S`I;02M-^]<4X9Q;K:U82QJO-3+AP(O+&L-@WA`E<)&$]!_8 M_ZCPF?W@H3?4(3^`VHK@^X4F!F$#47W)-AY(%T@[.(+&R0[:8-*DK&G3UDE; M+=NL+[C3S?F>,+:6["S^/J>Q\^;,9>?DXD4:.[6P8VL[MM+4X-F3*0I#D^P@ M8QQCOI05/V;QT7UP]`Y\-I@Q)4TPP:&PO=V]R:W-H965T&ULE)=;C]H\$(;O*_4_1+DOB<-I081JR6K;2JU4M=_AVB0&K$WB MU#;+[K_O3!Q"[,`J>P,YO'[G\=ACAM7GER+WGIE47)2Q3T:A[[$R%1DO]['_ M[S^/G^Y\3VE:9C07)8O]5Z;\S^N/'U8G(9_4@3'M@4.I8O^@=;4,`I4>6$'5 M2%2LA#<[(0NJX5;N`U5)1K-Z4)$'41C.@H+RTC<.2SG$0^QV/&4/(CT6K-3& M1+*<:N!7!UZILUN1#K$KJ'PZ5I]2451@L>4YUZ^UJ>\5Z?+;OA22;G.8]PN9 MT/3L7=_T[`N>2J'$3H_`+C"@_3DO@D4`3NM5QF$&F'9/LEWLWY-E0B9^L%[5 M"?J/LY/J7'OJ($Y?),^^\Y)!MF&=--W^9CE+-XCC!*T8;K7YY"/];+]E%[&=O28ZU_B])7Q_4%#I"FD`;.QS%X? MF$IA&2#6*)JB:RIRL(!/K^"XGR"-],70\4P?8G\\&TWGX9B`W-LRI1\Y6OI> M>E1:%/\;$6FLC$G4F,#WR;R/YJ,Y"1?C^7"3<6,"WXT)B8:2!&96=<(>J*;K ME10G#[8K<*N*XN8G2S"^GA5(!VKO41S[P-,_KO&+<*"P2RT`7!_3*&K?IV M9G`0Z#KSGK3NAM`H)AW%U%8D;RDL0C#I$KY-AN+8A]FW*S*SXVZ,HDLVMQ5) M7W%AM\A@,P\G0[%-=F?'W1A%EVQA*Y*^X@;9[#UD*+;)B+O1C61:%\&$+(B[ MWVQ]R0TV_.$/#"$G-D=X\0XM3AIM%T^2*G9)(KFEM\>%@/YS-'>Y'0EV@&@SJX_&Z2R*R\51^S$"`QMG[:M M9=/SM2^@2:OHGOV@5L!T/#$394TK1YYD:+JFYSMD)#>U9?'J"'9]`V MA",0[X30YQML2MI_!>N_````__\#`%!+`P04``8`"````"$`$XU7O=<"``"4 M!P``&0```'AL+W=O;?-\>]?]U<+C)0F74D:T;$?/ZWV0CZJ MFC&-@*%3.:ZU[C/?5[1F+5&>Z%D'E4K(EFBXE5M?]9*1TFYJ&S\*@KG?$MYA MQY#)2SA$57'*[@3=M:S3CD2RAFC0KVK>JR-;2R^A:XE\W/575+0]4&QXP_6+ M)<6HI=G#MA.2;!KP_1PFA!ZY[V7S^<+97HVND:K'_(GGYC7<,PH8VF09LA'@TT(?2+,%F M_]7N>]N`'Q*5K"*[1O\4^Z^,;VL-W9Z!(>,K*U_NF*(0*-!XT>[,TB$.`HPU3^IX;2HSH3FG1_G6@\$#E2*(#20SJ M#_7(BQ:S<#;_/XOO%%F#=T23]4J*/8)#`\]4/3%',,R`V3B+(9^WG8$EL^?& M;+);`:V@&T_K.)FM_">(D!XPMPZ38C1@HBFB>`.Q&"`^Z!M$@O6/BS2;IB*C M=*"W/FX=Q!X0\3N9G3W:89(0YRZ]X#S'1!B27 M:S/@'(/-H2MA<@K=I>(P"]O7>9J>MVU:#H+!V405G.O+51GPF:K9B=>I)TFAYE;36D8)]-R,2['R_"T>Y(4O"*7 M)V7`4U4CLTZ4@[CV07.34QBV#G/24!SJ89*<5#M9;@JZ(=$RN64%:QJ%J-B9 M"1>!V6'5#=_;,(,W":;>V7H!0]FN^T,!AF)/MNP[D5O>*=2P"B@#+X7V23=6 MW8T6O7UU-T+#.+27-7S]&`R?P`-P)80^WIC!/7Q/U_\```#__P,`4$L#!!0` M!@`(````(0``J+?'WA8``)>````9````>&PO=V]R:W-H965TVJ&]7DE.QQ.]OUMG=:\=1$M?$5LKV3&;^ M_0(DFDWT2X%*9FY&DT>-MUL$T`":E/7VWW\^?KOXX_#\\G!\>GW-]>7%X MNC]^>GCZ\N[R?_X3_&MS>?'R>O?TZ>[;\>GP[O*OP\OEO]__]W^]_7%\_NWE MZ^'P>J$4GE[>77Y]??U^U7_?/YR]?+] M^7#WJ6WT^.W*N[Y>73W>/3Q==@HWS^=H'#]_?K@_[(_WOS\>GEX[D>?#M[M7 M%?_+UX?O+Z3V>'^.W./=\V^_?__7_?'QNY+X^/#MX?6O5O3RXO'^)O[R='R^ M^_A-?>X_9XN[>])N_P'RCP_WS\>7X^?7-TKNJ@L4/_/V:GNEE-Z__?2@/H&^ M[!?/A\_O+C_,;IK5ZO+J_=OV`OWOP^''R^#_+UZ^'G^$SP^?LH>G@[K:JI]T M#WP\'G_3IO$GC53C*V@=M#U0/5]\.GR^^_W;:W/\$1T>OGQ]5=V]5)](?["; M3W_M#R_WZHHJF3?>4BO='[^I`-1_+QX?]-!05^3NS_;UQ\.GUZ_O+N>K-\OU M]7RFS"\^'EY>@P7EQ__O+Z_'Q_SJCF9'J1#PCHEY)9.YLH-YMO:I7T\![ MXVV6L^5*>W5X6IB&ZI4\G==0R;8>U:MI.%/1.CRM3`/UVH?87Q='N[5IIU[[ M=@MON=ZT%]314,W(-D+UVG^TV>)ZZHIL33/U2A]LQAWH\#=38ZWK>CWHNF[U MWIP5ZJP?->I_^J9G=:"^ZIU7'BSG>J51,^-AHRZ6ZR/2<)GQ>/'.NS@T7F;# M_C_OXM`(F/$0V+Q9SZZW\[5[<,]H".C_Z2^KR^E5-YO;Y+"_>[U[__;Y^.-" M95S5+R_?[W3^GMUH-4H+W<7J$\6I/*$2A%;YH&7>7:K/H5+`BTIN?[SWMM[; MJS]40KHW-K=H,[,M=F2ALX^6W4O@2Q!($$H021!+D$B02I!)D$M02%!*4$E0 M2]`,P)7JGKZ/U`3X)_I(R^@^HJM[2V#0::)#R(*:["7P)0@D""6()(@E2"1( M)<@DR"4H)"@EJ"2H)6@&P.H0E5;^B0[1,FH9'4Z:Q;7=`[>=C4YD_TJ+4/:NNT\A>BN76]$S?9`?"`!D!!(!"0& MD@!)@61`*,W*^YNT0WM;NG(TNL7HQV0 M/1`?2``D!!(!B8$D0%(@&9`<2`&D!%(!J8$T0V+U@=IB67W@OO#:VK[PA@PN M/)`]$!](`"0$$@&)@21`4B`9D!Q(`:0$4@&I@31#8EUXM3>V+OQ@\+]^?;C_ M[?:H$HS:P8UTR%QMB+MMLA:Q^\.0]N#?VNQZPAEKMA"KQ[XSFJN705I;V*N0 MWQM16@N`A$`B(#&0I"/JR$/**9"L;S4,47R.O#V+MR$J-L=X*NY:M*'(?48`H1!0ABA$EB%)$ M&:(<48&H1%0AJA$U%K)[3)]YA_6'B1[KCLAJ]TV7]%:7F-147`S[PENL98^9 MANI$Y^JQ4:NMK>4;C][*S-GM>F-;!,9"OYSV%I(5K\41HV%#$4!LK$P`L^WZ M6GSDX`RC)B@.H&#D"J.T`EJN5)XI- M#>F<"L`>A?J@/QR%O[2XZXJE6!0,6J@=]3 MPV[U6&U68AP$QL!3>;'W#\HAR;!RA"@FU#E;;%NF)):PXRUM).NRM0E03,M[FRZ48S\V4-WLXZ1K$<#A-)#53LA@FM0YY\[ZO M=[H$I$:70HZNW),5:_F(`D(L'R**"+%6C"@AQ%HIHHP0:^6("D*L52*J"+%6 MC:@AU&K9W:.+#".;DG M*WO!$EJ^L:*E:+V1!X6`=$[EP?;,$9(5[UXC0LX`8A'`8K46-?V$=)P!I&3% M`62$G`'D=@#K]7H#B<)TE#.`DKQQ`!4A9P"U".!ZMH:E:"(`>W#JZHMK]7S34-WB(X\!HI#ER2I"JQA1@BA%K0RM:KO3\1(^9PM"PQSHT=?(P#2=ZS%@YT\I8BXP;&2N^` M>8RL1%8*R8H37D1H*#^3ZU<\'H203TC+&41*5AQ$1L@91#X>!*1^#$-OBAK1.!6&/2EVV&H[*7]N;:!51V.C0U$FDLYI*+T:>K,2.Y7`&$R=1'K_G'_`66RTYEY[`%\L17DF.T#I8MEP M0$TL3*:V-DQS';+V#3T:9!BY]=RKP=!F*];R$06$>'T.$46$6"M&E!!BK111 M1HBU-E;W_-)\;U7L^6[0Q%F$&KH7)[(:#DM8 M%WQCI18G7LG,/TO%-) M*R/&J59NRQJ4&'?&:J+205:\8_<1!81X%H>((D*L%2-*"+%6BB@CQ%HYHH(0 M:Y6(*D*L52-J"(UD%S50K&YS)W^]KQ3;!D)J(]7O);VE6-QWQFIBVT!:O.#Y MB`)$(Z]#$ MJ80:3B1^(^_,-[[14A^J3?R>J)T&Y,O*-)CXC2].=Q$U=+J/A?N9V"XEI.)T MGY(5N\\(.=WGY-[<#9IOQ&ZT(!FG_Y*LV']%R.F_!O]BH$>.?MQ30QY_/J*`$*_! M(:*($&O%B!)"K)4BR@BQ5HZH(,1:):**$&O5B!I"(WL#72,<=L^OS72M(G9T M'9HZ>9B&ZN7TA-RK&QNMO#,%^L:*[H>O/)C]1N94"NQN@I`SGI$1(:?_&/S# M$G2._Y2N0=8"W:&ILX9I.)'JC94SU?A>9V7.&MY65#4"\[Y][P//&GU$W,GG MN(]M]W-9Y4[.;#1+A/HC054Q6G2MO+C<69_E*285]9>@K)ZO.UV(C?!5G^2I)A7U5Z*LF M*W,)K\41JIGR98\C-=I^(H_-M;D8,!U2)V7*!SMCI0_/_6($!\8]6?$JYB,* M"+%\B"@BQ%HQHH00:Z6(,D*LE2,J"+%6B:@BQ%HUHH90JV5WC\HI5O?\TD%# MG>RAUSHT<="@AN[5AZR<^<\W5F;UF:_$%`E(Y53Z,U/??!2>(A$U=+J/;?1(2,7I/B4K=I\1-:&B")"W#!& ME!!BK1111HBU%DGIG57FQD> M2^<&V84$\9CIO4*+_<]^W$KVE'`!%YX]D5$Z(`YEN139*I M`*Q^6,@B@SN;M.;VX="@X7:.D>/#[$(/T<^HH8L'R-*"(V,\/$C'OTEN+/_N-FB/^/QQ?"VXB;C+5DIXS[E MB@5RQS9TP?:(?$0!HA!1A"A&E"!*$66(1Q/&D MMS!(G3OZSO%6HH"Q8RONGKXA(1^M`D0AH@A1C"A!E"+*$.6("D0EH@I1C:BQ MD-T]\O`WV.M,]!2>`_7&1N6GP0%\AVB/R$<4(`H118AB1`FB%%&&*$=4("H1 M58AJ1(V%[&[1I\'A%G2B+[K#X_`@I4NKW:Z?!O\.T1Z1CRA`%"**$,6($D0I MH@Q1CJA`5"*J$-6(&@O9?:&/D<.^&$R1\VL%"W,8Y2W?+:%!K8`1YSJ\=6&L M]*&&,^)"+&H^6]$("!"%B")$,:+$(/4M/9)/&7%<$'W&6FP%^ZN9\.^QN@_B"[?3)74]2YYYU;ZQ._Z$A-J!K%;`R MH9`17W?HG8BUQO^F3\P&I)RP,J&4D<-9QEK&F1C#.1N00#T$$QF*B0$`ZSIBB<2L14TQ674PS=?X33\`E9\64DHXSIFS< M2L24DY6I8VRV&U''*,Z*J20=9TS5N)6(J28K$],"KE,S%9,U?)<_5UMIS>V3 MIT'Z&RS]P/3D;=4=-52'QMX*AR];T4?]TWH39._RE9.?UG;$7^<]N__L/BXD!:4"-G`"59.0.HV(H"J.T` MUAOY5WP::G/*OSW>E)65+G]I$[74*F(8&F1G4?%PTXX:.F?BGJWH*OB$3,J< MP?/)QF`B8Y*,TW_$5N0_)M3YGU^O15Y(SO*?DHS3?\96Y#\GU/E?;U;B5DQQ MEO^29)S^*[8B_S6ASO_&DQ7E9LJ_/0K5++!&H7O15@=9&&X=&M;;C-7$`P)D MQ1L`'U%`:%!O8^3(H!%9L7R,*"'$\BDCAWQ&5BR?(RH(L7S)R"%?D17+UX@: M0E@M7(Y7"]L_;WS^$:U5$=FE*Q^JKV+0B-R1E7O/3E9VVA63US=6IOCMC?P- M*-(YE62[VC=9.6.*R,H94RQB&OFS4*3CC"DE*V=,&5DY8\KMF,;^4A3I.&,J MR+8(EUD\-LE)69S65LHP5U_!] MTF(4$.))'S)R3/J(K%@K1I008OF4D4,^(RN6SQ$5A%B^9.20K\B*Y6M$#:&1 ME"4+KQ-+$59;EZ;:VOU,D_[-E1VB/2(?48`H1!0ABA$EB%)$&:(<48&H1%0A MJA$U%K+GGLH'/[,MT.9BG3!(=4E_S/'DX^6[96]%J\D>D8\H0!0BBA#%B!)$ M*:(,48ZH0%0BJA#5B!H+V=WC*,!.S!HLNBX[I/82U`<[1'M$/J(`48@H0A0C M2A"EB#)$.:("48FH0E0C:BQD=XO:S/_,K-'F8M88-.P+0/LE(!]1@"A$%"&* M$246LC^SK/K)5?JL1X.66`PD-"@.,^*<`@6.O;&R[@7@-:LWMH43(+@/(8BI9J1'5IVF\I.-6U&1P1PWM#;<(?<]6-*)\@^CAH=E<7)"`VIS:@G?')[)R^H_8BOS' MY+_[+M1V+4).J,DI]_;55NZMJ_U+N66E540G&&3/#5DBHX;.<;AG*[H(OD'J M&QSM,Z$B$03F[:E98&)T>H_0>VQ[GXO'0I(I[W8/R#*">W>QZHH#P[ON!@W/ M6HR<.<<4&K@"XE-#1@$A/JV$C!SR$5FQ5HPH(82GE=74Z?2L=:]5$6/3G#$' M!1:R4IME5Y+N&HJGFL7\]XT6)8CU=BER3T#>3DU1DR&,-V=,$6FIL3R(7,04 M0TPX:(VW4S'9@U8>)&7:.*]PL,(#ID'68.ZL)@H'U)#/QCZB@-!P,)\C'U%# MEH\1)81&!K,^A@UOW0ZNV,2,-P?=;X=GB<0[1'YB`)$(:((48PH M090BRA#EB`I$):(*48U(_TXV7Z]N('>_>]W]M.WCX?G+87?X]NWEXO[XN_Y- M:_5]LO=O>]S]X/;M?'&CO]&DUB#QSH?%_.:#\H'OJ(<\;_1SBF/O*#7UB-S8 M.TOU3IN;A)_;I7I'511&VBQ7ZIW1")9K]4X[:J7:2K49C5KM[V]\M7%&/VH? M?J-WV?B.^CGR#^V12GI1/U/>%HLD]VZ:47MUP<:NUX?%S0?UY"XZOM77<8SK M:S7&]:<>X?OYZD9_U0D]J"\MW>BO).$[^\7Z1C^FA.^H!XYN]"-`^(YZLN;& M5X]XX#OJ,1BE-O:.>F;E1C^6@FW4`R;*S]@[>R4VQC/58(SO59^/=6RD>GR, M9]L;]0->(Q%M;^J67_4]KGX6_OO=ET-^]_SEX>GEXMOALYIBU^V-DN?NA^6[ M?[R:GRKX>'Q5/PBOUFSU\]*'NT\'566\?J.R].?C\97^H1Q?Z1^T;W^A^OW_ M"P```/__`P!02P,$%``&``@````A`&%$<<\C`P``NPD``!@```!X;"]W;W)K MS[-@$_N)61 M'!]+^9.=OA)Z*"1D.X0%J77%V(IL?QEZX1SPUIX(>4\5)[+2HY"L^MNC>JZ.Q>]9X-ZSA';@AXNEITC> MF#CK)\*]GSB;V^'"G;TRT>GDMV[<88DW*\Y.%E08Z!,-5O7JQ4`VV-!]6AOS MFB]@B"+9*I8U6B`+5BP@ET\;WUNNG"=(0-IC=N<8;XI(!H3*&\C3&L&=*VA4 M+$JCRJ42O1L"(]&&H`%A"@*CKB!(L:P17$>F15,%NP[CC4'A%))HB*DRN(I* MQ0+%`;>13#.W/>@MF1IBRH1"'YMY>0,.A:;`K1J=Q3[BME4W,[S1+T?B?5># M)E4V_X@.!9[JZ"+AQ"??K'`-,DV`K3,V06U#WP6N#^Y#13.5U4?`B/_I\WWM M0+L3$@TR9:EF9YX.7F`O@.Z#RA335%D?F2HS$ZA!IK+H:LH4TU19'YDJ"PS/ M-$@KZWI-=[I6A!](0LI26"D[JC[BJ0K58=WCMKXZD(SX#GJ?=RGNQ\E%_"R& M8^"<9QO$V[:'FOQ!G`07\+MYG,POQ18F<'T$039`@B>G+A[__Z]O7 M-_^\?7B\N__^T]O%N[.W;VZ_?[S_=/?]MY_>_L\_XK]=O'WS^'3S_=/-U_OO MMS^]_??MX]N___S?__7AS_N'WQ^_W-X^O2$-WQ]_>OOEZ>G'U?OWCQ^_W'Z[ M>7QW_^/V.Y5\OG_X=O-$__OPV_O''P^W-Y\.E;Y]?;\\.]N\_W9S]_WMH.'J MX10=]Y\_WWV\W=]__./;[?>G0;)[+_\J^W3S\_L>/ MOWV\__:#5/QZ]_7NZ=\'I6_??/MXE?WV_?[AYM>O=-W_6JQN/K+NP_^`^F]W M'Q_N'^\_/[TC=>\'0_&:+]]?OB=-/W_X=$=7X+K]S_K*XZA=G9V_? M__SAT$/_>W?[Y^/DWV\>O]S_F3S_?7DB?Z_IDMR577WZ]_[V\2-U*:EYMUP[ M31_OOY(!]-\WW^[&[3T]?Z%^;=^OMV?F"Q-_\>OOX%-\Y ME6_??/SC\>G^V_\-0@NO:E"R\DKH;T#)3$5JXM`Z_?45EV3(3(6-KT!_?87M MN]5RO;TXF#M3<>LKTM_36J(9UM*"G'YHROUC;.MBO5YM M+K;4,S-7M6#WN7]P:^MWB]79QKEOKN:2&Z5_O+!1)>X?8VLG#9,%CQ/W#V[MM`[E`;.8CI@Y+[X?IN)A9N]O MGFY^_O!P_^<;BI?DR\/]/BB8?O_)/:./:-;\%3YR:IR/N'>O&8C3EL8A+,%5]A9$%L06 M)!:D%F06Y!84%I065!;4%C06M!9T%O03H!Q"(>&O<(A39 M!?T9A=9:9#>*C%X"$@&)@21`4B`9D!Q(`:0$4@&I@31`6B`=D'Y*E--H-?@K MG.;44+"D/Z-#,-1Y(;)E%+)>&T5&KP&)@,1`$B`ID`Q(#J0`4@*I@-1`&B`M MD`Y(/R7*:[00*Z^%]YJ\##GI@W.X4Z\].3NL23:\C87BIJDOE2&TO+_`$">M M#1G(FK9=XY!8G%N#1B&V?P\D`A(#28"D0#(@.9`"2`FD`E(#:8"T0#H@_90H M7]`^0_G";5J6ZW?DSA=N6YPB[29/2-7$3>:&3G!KMI(&8N;0R3AJ%1B6G^87P(*Z]X1%- M0.[I':(]H@A1C"A!E"+*$.6("D0EH@I1C:A!U"+J$/4*:5^X@]KTT'S$%\.Y MCK:,W/'7+H7B)HM>9C8F@HD45]PCBA#%B!)$*:(,48ZH0%0BJA#5B!I$+:(. M4:^0=H\[MKW`/<,I3[EG0"9R;:U[1BEQ#Z!H`2A&E"!*$66(H6T>]P)[07N\0>ZZ>SQ2,^>"^N>44K<`RAR)^MA)K)4C"A!E"+* M$.6("D0EH@I1C:A!U"+J$/4*:?>XH]@+W.-/;E/W>*3=8Q(;.W>"UAV_1Q0A MBA$EB%)$&:(<48&H1%0AJA$UB%I$':)>(>T>ZM67N,>)FWV`1\H]JS,[>T8I MGA=[MUIICT6(8D0)HA11ABA'5"`J$56(:D0-HA91AZA72+O'G5E?,'N&(RZY MFWOYVOV.,/3RY`2Z,KGTG4AQQ3VB"%&,*$&4(LH0Y8@*1"6B"E&-J$'4(NH0 M]0II][BSZM0]+G-P?N%^KGSIJ=3]:&-GUG@2GKK.YGBXXO`+Z?`SQUB1O1FA M5(PH090BRA#EB`I$):(*48VH0=0BZA#U"FG7N1/LU'5'-MW#@5?-+(]TX+.Y M'?T01HAA1@BA%E"'*$16(2D05HAI1@ZA%U"'J%=+N<2?7%[AG..@J M]XQGW^GLL5F=Q2C%4V6/*$(4(TH0I8@R1#FB`E&)J$)4(VH0M8@Z1+U"RCU+ MFSX8?N=]YW[SGY](AYIZ!^'1>CFN6CM$>T01HAA1@BA%E"'*$16(2D05HAI1 M@ZA%U"'J%=)N>5DF88F9!$937W@I07N4BA#%B!)$*:(,4:Z0OF9W()Y&BLE0 M?/IR]_'WZWM:E.D:`N/RG'[&&6XX6`['ZFD`8;29#$LO17LJ2>>O3`IR[RLN M*?)/I$PV)A(ICCPQMI@(FNHR+::B:RIE$@R92'&+N:@GI+O5'62GW1KH/MKF MC/WGS[V3G:>[K\:M?+09F72#/5:SE.XL M:UYWMCN?3F?`ZP*+TV+6.X_4Q%C;(YD[0[B*LZ-P+U+<"1&C8BB M0<,5(ZXH*&8DZA-!,^I3EA)=&:* MN9/P7$#PNO2\-2$Q8O6;0XQ8K"Y69IK&W-IST_2P9"LTF[AB;MK&O^KHR]G/,:#J83U&?H5TB-]7-[%)S?*![$]9CV:/I+ M,J(]H@A1C"A!E"+*$.6("D0EH@I1C:A!U"+J$/4*:5]0=%)QYX@OG+CQQ8#6 MM'>70+\V`7IW/DJ-4P51A"A&E"!*$66(H6T>V@1 M4NZ9["B/>,K5-)X:T#1K<@YHCRA"%"-*$*6(,D0YH@)1B:A"5"-J$+6(.D2] M0MHMZJA+VXDCOL"C[KE'PQM1J18?>O1X`[M:O*N)N+1F)^@I1 MS4A,;1"UC`ZZM(O4D9\Z[,A*A6?[C8CZIE;&>V0O+PU+&IL)+N7W%I"M-LJL, MVK4Q9\]*6N0150N:J%\9(QJ6\LF^BZ7IES;8_L25>GQ1OZ@0<&1\.7$SUP>D M\\L;.#_XBJKK)D8-3VNZ]974TY;"C:_58GMFPF?D)=S-@>("JR<6*>[S%A-$RNB\VEF;:I%S@6=/R5SEY#SHW)VE!X9"*,61++H!$X M2$8C^/)J;+%A-%SQ^FP!X610\^P5JT&R4JDA&B2OVE$+V"VY?5=R8"%IR164$#!Z6DG!2(VJXQ2'"G)]?FI':O"0U`O6 M(K>U-VN11]-AJ$+6,,&%/)R+MGM?-;:?%S.T!T3F%.W]W:,N]W65V$?!2](,I5XQ. MJAA+Q6GGF^F:L-00&L]7&[O52KW$L['13VA_?;,7DW-K>LTP-A5>RBP01JH, MVH5S?+2+NZ\^R8B&I8:.65QO-&K#'BI&@F8HQ2\FO8@FBE)%,V$S0C/J0HE9Y3.Z]U`1%B&)$":(4488H1U0@*A%5B&I$#:)6 M(;THNG34-!UG)\=)-[NMAJ36]&8W1I,DJJ"9,;@7*791)&BF8NREZ%J'T]WF MW,2M1"18=8HH0Y0C*A"5B"I$-:(&4>M1((&ZHCBO/'9D7CAQLR`.B+;FW`V[ M@U):$&DS/G,J\E)'$J@GZ8J]E-L/2(MKL^-.1(I-31G)UC$3--$U60X.ZV3. M4KI%LW\M1(I;+!E)BQ6BFI%6;X9@(U*LOO5H<(>>G"ZW]I]/3I^ADXW9]6I` M:@0`VK.42J!NS0$N8BD933$CV3@EB%)&4C%#E#-2^Y:U65`+D>)N+1F)^@I1 MS4A,;1"UC`ZZM(O(+N6B([/1B9O9Z!'UOTP$2*"NO!3]$2D[Q/=>ZKD$ZDE* MXK"4&<@)2_E-VF)[:7R2>HECN]=3+BSGUO3E&YL*+Z5WKUN;0`W:A;O7T2X> M4?5)1C0L-73,Y=FER<&UP?8GKM3CRZ5'QA!`-AT97SXI,YWK/L&BXA(D4%>^ M(NW9Y\;7(#630#U)3RQ2W+F)1S,)5*ZD+F32;_XT=,J%Y*Q+0GK!!J@>L#=\ MEUQ1&8 S2"KZ_FBM)BPRWZ!.KEAC7<92LQ>1BQ2W7W#[ MJN+6K`,E5U1&X"@9>Y+5UUQQ$DJX19\IO3BSF5*NHQJ;.$2'$C)/C)PC[FT@;;>G;T MJ'P;7?W\EL7=&6ICS)A$8Z-W7NI(7DVDN&(D:-*9$],/D2AF*=DW)8A21I(] MR@3-J,]92M07B$I&HKY"5#,270VBEA'FU=8JKT;N>=WDQG3;0;&[QU[2"AX= M>18QF<]HQ2]$8GX1Q2XX#CM+EIJU*6>I M69L*MDE);4V<*5F7L@NGN'>%9-IJKJC4VSL2&C;"[S^7RZ6),2WK409,)H]> M-50J,3"P3LNSKS&7Z-$TD2MHZGJSDNQ%2N+!H'X^D,1<49+7":*4D4S83-", M73E+B?H"4(:D:BJT'4,@K$`Y<-G)XP73QPVX47O@5S/605ISE@C]P. M5>;GUF3<=B+%3MHCBA#%B!)$*:(,48ZH0%0BJA#5B!I$+:(.4:^0GFXN86?] M]JH'G-9.D]GE>T239>(Y$UEW7%$B_AY1A"A&E"!*$66(H6TYR@V*L\=V2`Y<>,>CY1[+DQF=K<>I61B`8I0*D:4($H198AR1`6B M$E&%J$;4(&H1=8AZA;1[7/+FKYE8/@TD6[7K]8!T2+PPY].=2(GGQHJ,(I2* M$26(4D09HAQ1@:A$5"&J$36(6D0=HEXAY;G-RU)@!W$]L3RBY8][>8=HCRA" M%"-*$*6(,D0YH@)1B:A"5"-J$+6(.D2]0MH7M(.`6?2*;<7&Z3%.\DA'/W/Z MWW'%R>*$*$(4(TH0I8@R1#FB`E&)J$)4(VH0M8@Z1+U"VF]T9@"_O6I;L7&: MC.<\TIXSZ=,=5YQZ;JS(\S)"J1A1@BA%E"'*$16(2D05HAI1@ZA%U"'J%=*> M>UG>98-Y%T;:/>:TO!,I]L4>480H1I0@2A%EB')$!:(2486H1M0@:A%UB'J% MM'MLWF5^U[?!!`LC[1YSYMV)E+C'ZY()%:%4C"A!E"+*$.6("D0EH@I1C:A! MU"+J$/4*:?=0KZJX=\0]3MP$-X^T>TQ*9;<9I<0]@"*4BA$EB%)$&:(<48&H M1%0AJA$UB%I$':)>(>V>4);B=2]&W6"B@I%VG4G'[41*7.=U36<6H!@K)HA2 M1!FB'%&!J$14(:H1-8A:1!VB7B'MNE"BXI6NPTS%)I2IN+`Y)I$2UXT5&44H M%2-*$*6(,D0YH@)1B:A"5"-J$+6(.D2]0MIU+ETP/0H?"8H^NS`Y[VX&I`Y4 M@/8H%2&*$26(4D09HAQ1@:A$5"&J$36(6D0=HEXA[8M06N*5TPCS$ILQO3!) M^-DGC'8BQ7-FCRA"%"-*$*6(,D0YH@)1B:A"5"-J$+6(.D2]0LIU6YN7<"GV MU[GNH$KO.SS2*27[./-.I$;7(8H0Q8@21"FB#%&.J$!4(JH0U8@:1"VB#E&O MD'9=*(WQJN/P%A,9'AG/V62@2(GG!EU4D5&$4C&B!%&**$.4(RH0E8@J1#6B M!E&+J$/4*Z0]]Y,ZFH$2*W;1'%"&*$26(4D09HAQ1@:A$5"&J M$36(6D0=HEXA[3F;R'#A\G5S#G,<6X_45O_2IJ!$2CPW5F04H52,*$&4(LH0 MY8@*1"6B"E&-J$'4(NH0]0IIS]D\[E($[?Z;O7\IOTAT?3G3ZB/:((48PH M090BRA#EB`I$):(*48VH0=0BZA#U"FE?V%S'_*EKB_D,1CK(V4RA2,E4@>1% MA%(QH@11BBA#E",J$)6(*D0UH@91BZA#U"NDW1/*9RS6)WRJ8HOI"X_H!DOV MP0[1'E&$*$:4($H198AR1`6B$E&%J$;4(&H1=8AZA;1;7I:KV&*N@M'4%UY* MT!ZE(D0QH@11BBA#E",J$)6(*D0UH@91BZA#U"ND?6%S%4FFM1E M)5)L:HVH0=0BZA#U'@6>/KT(92U\G#O]_9H'+3IAX=&D=W:(]HQH!DX<:7+R MD4AQ[\2($D0IH@Q1SD@>(BT0E8QF3:U$BDVM$36(6D0=HIX1/J-Z$YD(L.9<-#,J$)52,7P9E0BPFAK5-(A:J1BVN1,!UMPK-2H<7X12(2\?`)@& M.2BF`4#[FLD)LI2:'C@FO'HM971%K&L8.8N%_2YH[`7FG\U)6(UNS&R0 MT["4,2GS4NJ9P"5\EB=HE[V7OY`6V:VEH$D?VWOYJ[`1)I58GV1$(RVR$:V@ M&2.ZL!$F*]8?,T(/W5`N:#IT3WNHX`(301Y-'RH0-+U*,RKV+"4WW$>(8D9R M\WXB:$9]RE*B/D.4,Q+U!:*2D>BJ$-6,1%>#J&4DNCI$/2-\SN#B^=S0_.[P M4-'L((94D'H(=7EFXOJ.*]*95J(3QAV?:9(M?L05!<6($D:SZE.6$ET9HAQ1 MP4@6UY*1Z*H0U8@:1J*K922Z.D2]0GIBOBQA=($)(X_>ECCRFR%(R8R*/Z*.';INV6<$( M\Q;1UGEL?F$C4,**IT:"5,I2841A"X;L M!%>4(1HABAG)@IP(FE&?LI2HSQ#EC$1]@:AD)+HJ1#4CT=4@:AF)K@Y1SRBP M=Z!].L2'Z2[PI+?473@M9B,Q(+,&F#QE[B MV!HTF#EO0,JMB0$9HS%.XQHTJ)XWH/!ZU!KD>U-:JVQK@37HE-8:;*UEU=): MQVB\-ER#CK2FHX+-6;HU:#K&3CQI8"[S8D`J6HQH9CKON:)LN2-$,2.9@HF@ M&?4I2XGZ#%'.2-07B$I&HJM"5#,270VBEI'HZA#UC#!:7-K$Y7Q\/XCKL."1 M.5^8U7W'%6?7[3U+3;8-B&)$":-9]2E+B?H,48ZH8"3+;\E(=%6(:D0-(]'5 M,A)=':)>(34=+_^2I.5!B_'MD,.WS%^8B[9_449\8-V,+F9B+6->P2 MS]Z=F8Q([`7F8W#":HZ,A^'RS%=^;6:D\J!=D+-B7>+\TJ-Y M(RJNJ(RP[[>J3S*B85UB1'N2$1U7U$:8Q%E_S`@]=%TFTYYF7KZ27#HU9NP. M:+J2>"E"XDG8W>]92D)JA"AF).$Y$32C/F4I49\ARAF)^@)1R4AT58AJ1J*K M0=0R$ET=HIY18"4YEGT\:=]YB+LC-^SU'0$!X+08(0_ MJH:"D+=R]M"6<&.S)J4L-6M2YJ7(I&DG0!`*V85!R$O)_"]/,J(*&H%!Z!0C M&FY1C&@93:\1G-.%C8`@=,0('81"Z=97!"&?'963V_6E3[[*U-L)$D\&@I"O M*+,QXHJ"8D:B/A$THSYE*=&5(T4&7 M]J3-M+[ZILI+3,(R4DG8A=F@[$2*,T%[1!&B&%&"*$64(H5TIZC**DV`D<.(D[<+/@#4O>\+A?VAX[+44K<`RA"J1A1@BA%E"'* M$16(2D05HAI1@ZA%U"'J%=+N>5D>\!+S@(ST[(&SA*\H#XGNI2)[+$(4(TH0 MI8@R1#FB`E&)J$)4(VH0M8@Z1+U"VCTN>S/=1A^9/4.R9_K^L,[KDKD6H52,*$&4(LH0Y8@*1"6B"E&-J$'4(NH0]0HISRW.;(+, M[2A>]SSBH$LO6LS,O+.GFXG8Z+X`BP(L#K`DP-(`RP(L#[`BP,H`JP*L#K`F MP-H`ZP*LUVSPYOO'+[>W3_N;IYN?/WR[??CM=G?[]>OCFX_W?WPG=]*R-\%O M'FX___3VFM1<'711AX]5?-EV>^7NK@Z47*ZOW"8G5+*ADL-IQVJ[)&T4VD-U M+JCDD,:'.I=4RM")52'7HL0*J'>H:?N0R74._0,>*B$>H<>,0Z4 M;,FI]`1KH&1-=>AU:8&2#=6AEW>%2JBOZ?50H1+J:WK]4*B$^IK>?!,JH;ZF MEZX$2L[)@O.@!>=D`7TX(%2'+*#[[`(E:^IK>E=FJ(3ZFM[%&"JAOJ;7``9* M%J1MN*O5CI`%::/;'4-U2-OPJ4"H0UY8!+VPI#Z@K&]`VY+JT'>6`B4+JK,( MUEE0ORV"_;:@?J-W\8>TD><60<\MR'/#9@JNAT;$C3B?UE<_1)NA2J$6B>S M@O)D5,BF7U97O[A(&+@.,C8XRMP4#,F3&X->)"<&1P2Y(^0-NO7[RMV,C1;1 MC?6D*E2ROUA.L.2:KN#T[*G$W\&.=/96XQR,")=1O[GY[+*%G M)Z[<;?=80H]07+F[[[&$GJ2XPL`Y]#.UJ%RR) MJ,1][PKKT.?,KMPWKK"$OE=VY3YUA27TV;(K]\4K+*%/E5VY#Y&%2K94$JI# M7RF[[NSP MC.'#W6]NOS[\S]/]#]I\OWWSZ_W3T_VWPS^_W-Y\NGUP`G1Z^GQ__\3_0UWY M_L_[A]\/^\:?_U\`````__\#`%!+`P04``8`"````"$`@RC+AM$"``#"!P`` M&````'AL+W=OC>,D%G$X-^_'N_F&&E#JI24LF()?F4:WZ\^?UH>I=KK@C&# M@*'2"2Z,J6/7U;1@@FA'UJR"-YE4@AC8JMS5M6(D;8)$Z0:>%[F"\`JW#+'Z M"(?,,D[9@Z0'P2K3DBA6$@/Z=<%KW;,)^A$Z0=3^4-]1*6J@V/&2F]>&%"-! MXZ>\DHKL2LC[Q0$[;F;S06]X%1)+3/C`)W;"KW,>>$N7&!:+5,.&5C;D6)9 M@M=^O(VPNUHV_OSA[*A/?B-=R.,7Q=-OO&)@-I3)%F`GY=Y"GU)[!,'N1?1C M4X`?"J4L(X?2_)3'KXSGA8%J3R$AFU>/%`#%DME3PBZ"]0IVMBN]6/@:PW MH54\V/(_5\`.2[*V+`F>803Y:JCD\\H/YDOW&>RG'69S!7..V/8(6S60-V@$ M;VZ@T;)8C;:25O2F/W@3'8P$]8BQ(##J!H(L2X+A>6+:XES!IL7XIZ#I.60[ M0,8JPYNHM"S0'+"?WZ]8UFP8V:H8K=B==VW5U\6==%IWKL#=A$H;V[G<7\<.WP3*=B^Q.@.K-Q(DW$CN`!H?:V=7>5\%4 MSK:L+#6B\F#GT@Q2'DZ'D;D.;(>/SC2PG.='N^["*=*\M#'#JIZ2H]KO\TP\5=E;(KSER(@['%8@9;=JL=_87]DJ\;CM;->=0/_D MXJ,9_&TUQ^KCESK?_9:7`M2&.LD*O%35JX1^V\E_PFK8J_D404ZDP"5=)/&"OXGS.PX`% MBQ]G<9!1M\"GM$VWZ[KZL*!KX)W-.94]R%:0N5\9\KBL]=Y288TRR5>9I(4L!]"X<8>64HP\&9C+.2H(I*[U:;#3$^-AH@ZW7 M19,^>JO*!J_H$5X2;/+R:`D1HFAY9'9&E!\:/#;9C#-&1D2BLB``AJ-N!Y.:M.7)?<;0Q(>. M1DL6*XQBYOD^W94*@"5?^KHA3&+2DJ<30P,?$F/,I9KU+B^':K#4S81;@`W# MLR#0O$UBTI&G$T/_'A*C@L0,,6H/7-N8$?>C>Y64-CR=%YJVP4M7`AU#'LM@ M^V(EF>O34B<&8`9-JG>1*=E#QL]N.#]M[UB!^BY;>KI:JII#\_?X7=6(^\NY M^>,#$;LQ!ACQ^5B!D&+H74TG(S[SF*\3F.H]-`H8.CGT\F5>,T9L-5:@47>; M/!'80R.A0Q-W8Z1XL0*IZD:^JWM>5;HWX/Y0 M(&3I^U>#7L5OJVR2?&A`#-[<&>76L0+>+IMAAGML04SO` M#/E-;#[Y%-60'@`X@G!H!(-3I.(X#'M,5\#D]]#,D%^-*2].AZP"J6&V\`CO MQ(R'=YD]-#+XC9'!R8DH5B#%++K:#YA#A0-7+\R4['\-#'YC8'#M]\I/$*08 M\.A*NF'4-*^%$F5B!D-=B0 M'2L0OCKR6$1JGAB`KL;594C?[A1QT_H'9IRH]-!@7IN84``B0$(>1#= MJ:CWT'#HT.3;#=?6CIVF0.`1ET/"%3L<,K*#+[_7OZ+-YXQW'AVUX/. M)0`7CN?T('Y/ZT->-M9)[.%1=[X$`ZSQRA(_M-6YNQ=[J5JX:NS^/,+5LH![ M/'<.X'U5M?T'>1-WN:S>_@<``/__`P!02P,$%``&``@````A`#W1#<)4`P`` M8PH``!@```!X;"]W;W)KX#JDREA.J]W<_?WK83!Q'2%QE>."563NOA+AWBT^?YH= M&7\2>T*D`PR5F+M[*>NI[XML3THL/%:3"B);QDLLX9'O?%%S@O,FJ2S\,`C& M?HEIY6J&*?\(!]MN:492EAU*4DE-PDF!)>Q?[&DM6K8R^PA=B?G3H1YDK*R! M8D,+*E\;4M. M%%/&"M@`_'5*JCH#"H)?FO]'FLO]W!V.O5$<#!'`G0T1\H$J2M?)#D*R\J\& MH1.5)@E/))!Q(D&A%TY&:#2^S>+K'34"4RSQ8L;9T8&F@7>*&JL61%-@;I7I M?71:WY,*&A7)O6)IN$"%`'N>%\EHYC]#2;,39*DAL>MTD#@T(:L6H@JH:--V MX9R#S)1UBU#N@:).%A3+EC4$V]\VK%6ADDP586R^;_D&Q$2L+A'QT(2DEQ"K M$NM+1(_$$#K\'Z$J"7JPYT4R-O>XU)"H![$,7=U$I#<1ZVL(0R9LI._G=1\5 M>.Y"#;M62P)+GH9,FE9%*++"JWYX@":)Y4]JQI.Q%5^;\3@*SBU@R((3UY>E M3M_M-E5)EGMVFVH([**K@.W>341Z$[&^AC!DCDV9U]U38,N]B>6>AHP;]P9A M:']K5CH>-?%);+5V:F9'(_N;8L11'"3=VPU1\"GK>W==E`);HLZTS<=NJ2'O MB]+Q]T29V9>BC/C[HM2%I3<.KHM28%,4"JR3M-08?=`&"(WL/C3C`;+-,N)1 MA,X'J:D:3'VUAY8_0>A\%+5;>JCKF5<2OB,K4A3"R=A!#>P0>J1;U7>))9K" M)(*!8JVG<,=HUOTN`#.^QCOR'?,=K813D"U0!EX,!X/K6X)^D*QNYLJ&29CN MS<\]7.8(S+C``_"6,=D^J$G670\7_P```/__`P!02P,$%``&``@````A`+&, M9*.:#```J&<``!D```!X;"]W;W)K&ULI-U=`L5O"WWAN M\M+\>$3@Z6ZZ$;_]^<_KR]FO^6J]6+[=G1L7M?.S^=O]\F'Q]G1W'D?.']?G M9^O-[.UA]K)\F]^=_SM?G__Y_;__^?9[N?I[_3R?;\Y$A+?UW?GS9O-^>WFY MOG^>O\[6%\OW^9M8\KAGVY-&NUJ\O7V>+M/(MP MNSHFQO+Q<7$_[RSO?[[.WS99D-7\9;81V[]^7KROBVBO]\>$>YVM_O[Y_L?] M\O5=A/BQ>%EL_MT&/3][O;]UG]Z6J]F/%_&^_S'JL_LB]O:?@_"OB_O5%L=)'H$?R^7?DKH/LDBL?'FPMK,]`L'J[&'^ M./OYL@F7OWOSQ=/S1ASNAGA'\HW=/OS;F:_OQ1X582[,AHQTOWP1&R!^GKTN MY*DA]LCLG^WOWXN'S?/=N75UT6C6+$/PLQ_S]<99R)#G9_<_UYOE:YHA(P^5 M!3'S();8^GRY>6%>-XS&U1>BU/,HXO?IFR(V>OM^Q.__8U.N\BCB=Q'EZJ)N M-IK77]DMS3R*R+73W]!-'D3\+C:E^?5-,<2)E1UG<22+C;$NKAN-^M5U\_@C M;12'VO@XUB><,$9QK.6I6KRMFQ,VISA0QL>1LL29_M53SR@.E?RCV#WUBZ91 MN[&^LG?$D<[V\MXAKYWPMHJ#;LKZ(,^HFZ^G99'/;Y2]1 MA=_GII49<:;M3--42;L@LL*6<3M%P<7*DK=0M3 MK-33"]RB8#]*4XW2+S/7JAD<&NT->(4HMF58%'R\M+Z?_(SL[THMZJ@01=1` M+QCK!:%>,-$+(KT@U@L2O2#5"Z9[!9?B'-R=B"+'#DY$2]0#Y2UZ<=[)M;3S M3CM*K1*B'J-V)O;W9M-220>#V!S$*0FBG2[=$J)N2:]$:$'<0V+5M$SKEYFZ M^E*#0Z-%\5`,4?@H1B@"%&,4(8H)B@A%C")!D:*85@DEZT23=$+6R;5DUA65 M2ZLH^*BRS)L;]6QJ9Z:Y6ZESQ$JVOI)SN))5JZFOU"TS6OW8.\*X94:K&/IE M1FOX!D<8K\QHK=:PS&BUG5]FM",Q.L($1YCQ$28\PDQ*C*'51=$1)C[")$>8 M]`@S+3,?QUW),=&K.B''Y%I*CND%[:Q@+Z$*\9&%![EAZRLYQ4I%+G?U@IY> MX.H%?;U@H!=X>L&P*-C?5JT=\PM3;-JH*-A;R="2/R@S6O*/RXS6M(5E1DO^ M26&*#8R*@HH-C,N,MH%)F=$V,"TSV@9."R,V4#DEQ>6GSUJ MR]#JIE9FQ.OM>MT?V;#MRK=1=%#8*!P4710]%"Z*/HH!"@_%$(6/8H0B0#%& M$:*8H(A0Q"@2%"F*:950TDR,SBAI)B^N^9I&KG5W+KIPNU2R#*V9;V6F*MU0 M=%#8*!P4710]%"Z*/HH!"B\3U]O1BT9-[U4.,8"/8H0B0#%&$:*8H(A0Q"@2 M%"F*:950+J')-:SS'M4K25 MF:H<0]%!8:-P"B%'KK4KBFZQ[*,]UKJV/10NBCZ*`0H/Q1"%CV*$(D`Q1A&B MF*"(4,0H$A0IBFF54!),3(!](<&DUA+,U$[>5F:R"E=,ZVF+V]GBBOSK5`>P M,8!3")E:5TVM(]LMEGZ>7"A<%'T4`Q0>BB$*'\4(18!BC")$,4$1H8A1)"A2 M%-,JH227O!G@"]FUY7IZ:0,UK1Q5)%";28>)S<1ATF728^(RZ3,9,/&8#)GX M3$8EQ#*U`;>@%&DC;N-C4'@,FI0@K=\1E1#+U$;.XU*D14J.0>DQ:%J"/EY, MS4,3(9I"5\1%3'X[,4=;N6;6KFG:$Y=)G\F`B<=DR,1G,F(2,!DS"9E,F$1,8B8)DY3)M)*H&2CGB?:XE9(=7:VG8/*S,M>Z-,8-L=PU.VPFM?:=G0Y M1H^)RZ3/9,#$8S)DXC,9,0F8C)F$3"9,(B8QDX1)RF1:2=3,D_/'^YEW9-N7 M33NK;9\^;BGO415I6I%@;2:=G&0YV#P<#[;>E0;0THY:2WZZ@E(/22>/TMC.5=6M:_UE M;'X9ATF728^)RZ3/9,#$8S)DXC,9,0F8C)F$3"9,(B8QDX1)RF1:2=3LD]/K M^]FW_?C'-=YV+S]WI+>`UL'8:-7UT^!HOR3X`<1K$L[5K. MYC@.DRZ3'A.729_)@(G'9,C$9S)B$C`9,PF93)A$3&(F"9.4R;22J*DH9^'U M5.2;Q>0G]PXR41OL;.6H(LW:3#H[(F?RK!OMLM/>+?XTEYT=V7Y`K*EUF;N[ MQ9]&Z#%QF?29#)AX3(9,?"8C)@&3,9.0R81)Q"1FDC!)F4PKB9I_$Y=)/R?9VQ&=:ZT3 M/U"6'UZ:>?P20R8^DQ&3@,F82?D@Z!A*;B<.DRZ3'Q&729S(H(9:E]="]$J21(1.?R8A)P&3, M)&0R81(QB9DD3%(FTTJB9*)\]H*2B=4#,ENNCH76M:/?RDU6U1M&HZ[5]>T< M5/1/.Q3#YAB.%L/0^Y^[$+)[VC2T7G0/5G?5Y;5K4YL:[>_B?]J_'3#QF`R9 M^$Q&3`(F8R8ADPF3B$G,)&&2,IE6$C7=])M@(-U*;GZQ])M?S`Q5I%.;28>) MS<1ATF728^+F)*]D#NEL3MN&EX^$.A@T$6K[5LYJF_G#[2QT?9NX:=-06='9&NDK6_O%GZZ MOL.DRZ3'Q&729S)@XC$9,O&9C)@$3,9,0B83)A&3F$G")&4RK21J[NFWP$#+ M5W+KBZ6-0;;D([9@YH])AXG-Q&'29=)CXC+I,QDP\9@,<]+(9DUK%X8V4^-S MC!&3@,F82+?**LGGGZ0$HK1Y]G'M_V`B'L?'E%\CI,NDQZ3%PF?28# M)AZ3(1.?R8A)P&3,)&0R81(QB9DD3%(FTTJB9E[972\\U6Z6W/12UR[,6CFJ M2(\VDPX3FXG#I,NDQ\1ETFC%+;GJI:\/UK1QE`X+F55T;GVDKRQMU_7F5'66Y9>G3`;:R MO''PN4LG7UY1$W29])BX3/I,!DP\)D,F/I,1DX#)F$G(9,(D8A(S29BD3*:5 M1,V]LAM>ZJ*#".,PAS>\6'5]REU\]8/LK&;/TC+K#:V5;"O+C69-NX+L*,L/ MU[>5Y8?K._GRRMS#.VYZ',5ETFYNWYR\OZ['[Y4WY9B1PUVY5F7Z32,F[% M4_'%\SNU\HYQ*QY]?UCNBR]>*2MOF[?B@;&'WC9OQ3-AY?-!=R\@OB?E??8T M'\Y63XNW]=G+_%%L6NU"?B'$*ONFE>R?S?)]^^CU'\N-^(:4[9_/XAMQYN*Y M_;4+@1^7RTWQCWR!W7?L?/\?````__\#`%!+`P04``8`"````"$`O5##&>8% M``#)%P``&0```'AL+W=O,+V$Z3]*I?FLZA?%QU MJFP77GQ_+T_&*ZKJ`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`K$;WK*OZLF1$X(8QT':\:S>7(0F8T;S>(L3WWY/<1?>]"J_/Q3-NK,ZE" M7S52W$ED=V9JX.D-=Z1,D/[L$ZEHS>5<,,B%CD=$[[HS6:(U'PCM@+#2L]%9 M\1H*.?VD%=^!;EAFCOB8_OP:\Y9;#W_>FR@&1\C$?S2_+3?K" M_BXR7/D.,5?D9I!<^TJ)K/G`X>+OK'BX(8,\MY7;GRG11NS]C5KOB`>R'7=6 M?/I$GG[J*W&EMZ:7Q2:]9U_LWGE\_Y;MT`X6NB?NY8I!S`!I3&*_@\2R`%E+'X>+TL=V< M%/L5N5"]8K]R`[ATT'E67@`?VCK^Z`>/$)?^8N4'\,UY!9\$\#D$N"4\@HO4 M2W9`?V;5H3C7Q@GM(7:[_3:HZ%4L_=&PLGG"#=RAMA5TA"MS!"O4'H&V>XP; M_H-,("[A'WX!``#__P,`4$L#!!0`!@`(````(0!?&-W7S0(``+`'```9```` M>&PO=V]R:W-H965T;GL-6C;: M)4H;J9&JJI=GKS%@!6-D>[/)WW?,30ML5XG4%XS-F<.9,\.PN7L5!7IA2G-9 M1MAW/(Q8267"RRS"OWX^W*PQTH:4"2EDR2+\QC2^VW[^M#E)]:QSQ@P"AE)' M.#>F"EU7TYP)HAU9L1*>I%()8F"K,E=7BI&D#A*%&WC>TA6$E[AA"-5[.&2: M:M),1(T?,Q* MJ]F=`+3I74,C4.T+F-T&G.M^ZM"TS;3<(A`VL[4BR-\,X/ MXR5VMYO:G]^87)VSW3%`P%&B=86"8J"Q``5R2X[0PPA+S6 MZXDG)H_P;.DL5M[,!S@Z,&T>N*7$B!ZUD>)/`_);JH8D:$E@;4D"9[U8S)?K M%9!<"9RU@;!>>/LTT&W4UV;<$T.V&R5/"!H,].F*V';U0R#K7&@8>E_^90OX M84EVEB7"*XP@8PVE?-D&L^7&?0'_:8O93S'^$!%W"%LVD-=K!'?^@T;+8C7: M4EK1^^[@3/1(4(<8"P*CQH)FT("76Z?SR`9!DPP\6@U?N&\P_CEH,83$/60L M:CX59?OY@Y6T+-`+L%PI90NZ)K.'C&6"I'/OKGMFP;6:OFCMB5QB<]9@9GP=A?!$_"Z&KICR[>;BK!_"89Q[&\POX M_;(=V&X?``.S(AE[(BKCI48%2R$5S['#334CM]D868&',#:E@5%9W^;P9V3P MF7JV)JF4IMM8P_I_[?8O````__\#`%!+`P04``8`"````"$`N>J5%)$%```= M%@``&0```'AL+W=O9GDRH$Y3T:>+_/,[3&V6N!SC45*=$IK:'_U3&_5%RMR.Z1 M*]+RY?7R+\U->_VQ$3:/(@N1PQF7Z?(*\/QP_S;AV\T.3+_*LQ!7> MUP.0LVA']9RGUM0"I<5LET,&Q':C1/NY^>0$6\C?'+U7G?^-ZHC? M-V6^^R,_(W`;QHF,P#/&+X2:[`@$C2VM==2,P%^EL4/[]/54_XW?8Y0?CC4, M]Q`R(HD%NY]K5&7@*,@,W"%1RO`).@!_C2(GI0&.I!_-\SW?U<>YZ=D#Q[=' MP#:>455'.5$TC>RUJG'Q'^4X3(EJN$P#GDS#]0:^.QQ/G`=4/*8"3Z;B#";# MH3^:C._OBL]$X,E$?)%-3P80H'$!GCRV8BDUP>++@WF`X MMKW&O)Y.3UD[>#[4:0>*C(XYJ38VH'=WVZ(%U-3C.JW3Q:S$[P9,B30#49N?E2;4)%%Y(C)S$PR%LJM@/KTMW*D]L]Y@#F2,L]0YCLQ8 M<08I>"*[5H%0!2(5V*A`K`*)"FP[@`6V"&]@9GR%-T2&>,.S6G*@8Y9B!&?P M)FL5"%4@4H&-"L0JD*C`M@-(1L#D_@HCB`RL5-TB<4=RYDO*@;6W-6;!9B8)Q?&7NA8+$W8Z$-D5IG`@2 MU]X*;4`D+V%?D;R\XAE\LG#3"%LVC2'2]N0J_5DQDFR1DMGZ*FDJ9Q8RTK39 M!X?VU)/?1_2]"[MM9S"42)NKD112?)6D=">1NS-1$]_>Z(XT$N#.`R-!V/)( M4,2%'5>D[KH3V9\5:P:[D2#I%2U(O'Q"ICUJ;'?@4TR6C5B+;FQ-=B-D>V+' M@L1C)U)LWQO[5;B4UNFV'@7P"0J+C8+'HP`^ M%G4<+NF>FG.`PE^2R[LK_*4;P`E7UUEZ`9SJ=/S)#YX@+_W%T@_@@`.X)2+# MY=PE/:`_T_*0GROCA/:0H]U,V))>[]$?-2N/9US#O5Q3*4>XAD4P$^T!'`WV M&-?\!PD@+G87OP```/__`P!02P,$%``&``@````A`'Z=/&#S%@``(GH``!D` M``!X;"]W;W)K&ULK)U;<]NXDL??MVJ_@\OOQ];= MLBK)J5CBG2(IU=G=9\=1$M?85LIVYO+MMT&BV4#_:8K)S,LX\V.CT4`##:!Y MT;M___GXWF]??I\ M^W!\.KP__^OP_SU\N7[\^'V\]UH<>'R\EHM+A\O+U_.F\TK)Z' MZ#A^^7)_=]@<[WX\'IY>&R7/AX?;5[+_Y=O]]Q?6]G@W1-WC[?-O/[[_Z^[X M^)U4?+I_N'_]JU9Z?O9XMTJ^/AV?;S\]4+O_',]N[UAW_3^@_O'^[OGXD'J+AM#L7I.G#N\_WU`+3[6?/AR_OSS^.5_O%Z/SRP[NZ@_[W_O#' MB_/OLY=OQS^BY_O/^?W3@7J;_&0\\.EX_,V()I\-HL*74#JL/5`]GWT^?+G] M\?"Z/_X1'^Z_?GLE=\^I1:9AJ\]_;0XO=]2CI.9B,C>:[HX/9`#]]^SQW@P- MZI';/]^?3ZCB^\^OW]Z?3Q<7\ZO1=$SB9Y\.+Z_AO5%Y?G;WX^7U^/A_C=#8 MJFJ43*T2^FN5C"^6\_ELL;PB)3T%9[8@_>6"DXO)+TSU/27I:FTW_;4E M%[WR=+66I[]%EW;@O27+1P/ MZXLQC9JZ3O,/6W8RK-(Q^]_\PQ9=#JR5ADQ3JXP=^E=/"\<\3LP_;&7]7AOS M`#'_X);UU\$#PTR"877PT!C_]-@8\^`P_^#*9/;T=04/D[&,D\[.NVSF:SW] M-[>OMQ_>/1__.*.82OYZ^7YK(O1X993PQ&\J;4/!6Y&`0H#1\M&H>7].YM,D M?Z'P]?N'R7+Q[O)W"CEW5N8&9<:^Q)HE3'PQ:C<:!!J$&D0:Q!HD&J0:9!KD M&FPU*#0H-:@TV&FP=\`EN:?U$7GTG_"146-\Q+U[P\!QFG((2W"1C0:!!J$& MD0:Q!HD&J0:9!KD&6PT*#4H-*@UV&NP=X#F$XLX_X1"CAA9*9]*,)]>^!VX: M&1/IVIDU]T76K4CK)2`!D!!(!"0&D@!)@61`<+VM=XOFBV"A=F;][O%E/0 M=TM#YI-V+5H#V0`)@(1`(B`QD`1("B0#D@/9`BF`E$`J(#L@>Y=X/J`=EN># M_HXWTG['6^)T/)`-D`!(""0"$@-)@*0N\1I*6U&OH_UV?_?;S9$F-&V8 M.CI@2OO/9E=JE/CMMV0A`Z\E;H10T7K3"$WHCQ-&U/XV:(4XC(2M;B912UQ% MJK:X5>0*7?E!*VF%6'?:ZB;B]24=!;V^[.@S.B9SIQEIO],L(5\YK5_Z]JRM M$!GA"*F6;3J%U)8GL$+7]3%B<74U\6L*F^L3/Z:KFJ+.FI10W"FDS$F4.:.1 M;TYZPAS/$^9D_1.NJ,5]7U@TH:$O_3Q7-JVY(&U@16JFFK\1*1Y#`:N?U)U_ M/56C+N0B7O5:<<12O=7'(L75)W[U2[VQ2KG(6]7[G4U27F?_4@PQ&0TU'QAY M$V(.AUE;L']&L*YE&Y$"1LT$N!I/U7XEM`(G9@"KZ:T_%BEQ@C6\J7]Z/58M M2T_5[WO!'*+<#$-_]!DW9R[:7[,]-Q9-IBU:"^H=WXVNB>@*N*"@D)&HCP3U MJ(]92G0EB%)&M7J_9\Q1Q>V97QN?]L`C5MR8TR(-68KIW(=KBTQNJB\@6%W^ MO%4!,6#UBSI&C&?+F3K_A%P;#:2W:XM8JM>FF*5Z;4J43;3'5Y,F93UOV>2[ MQAQ(^ESSG^/WM[8?SE)J3HDZ=C3(&\PMZNFMC=4UD?Q-@"ADY`[F(>IC+BCJ M$T0IHX[!;(X-V&.<9!V>2&R.'Z:B=NA,EFH9NC%96=.Q-%Y;*;6ZK46&9\$& M48`H1!0ABA$EB%)$&:(T150@*A%5B':(]A[R MW6-.3*Y[G$7CA*?L6+.7RY;CGA"R.N-O86.4=SWECI2;D7J>7U4XA&*0KM%(S;P,Y5SN3 M2*1:CS&2:9P(H%M),I+C&G)'4N$54,/+5J]U^*5*LOK*H<8?O M:M+EN?J7)JA);JCH:)$W`AHI!VU8RDL-S76>CJ5D-(6,Y!0>(8H92<$$4&GIB-S1G:W=]-+**=@DRJ MA4Y!L937#7J(;ZS4=-R<)9628)"2L%M*#>2(I9JTQG@\OE:UQ5;"#&]IF#8Y M83V]#4N[I91-F96:>H?;AJ MLWZG7_SQ97((/S&^;,K!68SI;&RFOQG"XH:%RC&LK91)KXB48U3S`(F5FII[ M`K]_F(VO1BI\!H/TA"+%G1M9-+%ID-%LICHVYD)>0[2)"4OU-B05*38@8P.\ M@@NUA)'((C\2*:/6E/^KEY/>";NQ4C82J64]&*0C%"EV4L2HF5S+Q;6:MK$5.!5T MAK0AY?A6W[*R<&.HD$JRBB_K[F@-\><`6VC3*-K.FM6,34`@T%*0I'BWHTLLB%F M-EE"A+'M>FN^U>8EHKDG5*8BQ?5G7+_7^H6*H#D7](S`P6--E7!2<$%!)=?8 M1)CI]%J-U(K+>)4Y#O$'S\_ELJB?890TB.(:=\K:2IE0U[?P0,%@4,&0I61! MC!#%C,2N1%"/72E+B?H,4B!->SVC7G>0Y]#&^3%@Q:YKE=KP,;J<@H&@GH*ABPE-V8B1#$CF;") MH![U*4N)^@Q1SDC4;Q$5C$17B:ABU!$/='KOQ-$4\W@FT6..#F+GVJ*9H`VB M`%&(*$(4(TH0I8@R1#FB+:("48FH\I"W*$YU.DY/CD&/5M5:_"P=(R>)*JAG M#&Y$BL-&(*BG8&BE9LV^:S9>3%7($D0IH@Q1CFB+J$!4(JHLZDB@ MTIG$#V?]\Z(65ZXQ&FCUD]32VDH1ZNGAC94RHTG6M;D*;L$@7:&5.I%`%2GQ M6&/]3/:)"4MY.U-G.:C7R92EO,WB7.U?,Y'B&G-&4N,64<'(5Z^&8"E2K+ZR MJ'&'/SFI0;TKU[#):;2H$=`@;P0`VIA=@!DG7@;L2AW@`I:2T10RDHU3A"AF M)`431"DC6E??'G.92'&WYHQ$_191P4A,+1%5C&I=OHM,JF1XVH)23^`+BVBW M)`V$!"H7]+I!#_&-E:(191)<^JP=#%(2=DNI@1RQE-VDC:^N51R(K<2)W2OK MZ6U8VBVE;,JLE/&6=.65VCSFG7;![E5JY!%5"'+4ZSQ?R5)-QUR/KE4.KNJL MWW&E/[Y,>N0GQI=-RL@A[(;R$&;(J=2&3J!:J1,)5"M%+7@K@3I(3RA2W+F1 M170^;(8N)E"YD!=@G7YK3D,LY8T!+96*%!N0L0%>0?VX<*2:G\Q$BQ&1AWI%CD1R(UK==TCJY#6.^$ MW5@I&XE4(BT8I",4*792Q,A.KK'N^=@*G`HZ0]J0M59V9N#Q"2B?F*0-'DK-YMB\&FG!("6A2,DHL38V$VLVGZ@E(.8R;TTL&TILZ[V(X/2LW5:V4EQ_9M6; M.V7..J36@;S3"!PEH+[@@FXH\5H\78YTII3+O-5B/Y28S(T[2G[M4-CD?[S! M8Y$78:Z4W]=3*W4BPC12)-RL18N9NID2#-(3BA3[+[*(9KE1?:4?.(WM]5-! M9D@S4JP^D^K=X:,\FG<:@<.G-8);5V"-I=183T3]ID75693!KF)&_-HE`D[_7EVD>+6!H*9.[071/ACM_;?()QK<4 MG200ZL[?L)3$LX!1;\&0I;PXJS?DD96R.\OIXFJL(G',>MX*CG8Y&-*8E'7U MVI2Q39[4E5I%<];EV853O+6+^[W@@IYZW3$E&V'WGY/)1,68BO5X!CC^\P;6 M[%0J<5B>O5;CQP.+W'@@J&]DB11W32"HIV#(4I*\CA#%C&3")H)ZU*HS M1#DC4;]%5#`2726BBA'&`Y.!ZX@'/_VN1JVG]INT'.Y1W["4&\?U^B\R[+4- MH@!1B"A"%"-*$*6(,D0YHBVB`E&)J$*T0[3WD#__:+9[CNQ?=RF!JM==1G0Z MDG"M\SIKD1+W6%T2^@.4"A%%B&)$":(4488H1[1%5"`J$56(=HCV'O+=8_)\ M;ZR[)SQE,X2RXM_0#2SC/.?%C#6B#:(`48@H0A0C2A"EB#)$.:(MH@)1B:A" MM$.T]Y#OEI]+L-'=)9@UD.Q9LY3L:#:(`D0AH@A1C"A!E"+*$.6(MH@*1"6B M"M$.T=Y#OB],6L:=(B?FAW&VLE%DFG="G M]D.!2+'Z$%&$*$:4($HM^$B")$,:($4V9B9U\/<=:1,0[B2UR'DTH*[KY$'12LV: M7.ADI`]R@0AP7X6BF5$DR!DB.B+$HLOD1*@RE>5-1(`UIZ*9488HEX)6LSJ/ M;D6`U12HID142<%NFW,V'8;H=+EQ2`C2JF1C:@$]1BQZS9"97/WIXSPAZ[) MB?0-W8&Y")M:<8-7@[Q<1(O<5JI3[8:BEMDYTJ.+W#T!HI"1G/DC03WJ8Y82 M]0FBE)&HSQ#EC$37%E'!2'25B"I&HFN':,\(TQ/F:WW@R(4D09(UE<PF3`B->@Q4(EHD(K<6H-:BSO-R#FVL2`A%$; MIW$-:E3W&Y!9/62`K$&V-Z6VK:ZM8PT:4EN)M56L6FK;,6K;AFO0B=K\J MBW__I#$W:M1&IT%>M&A1[XBR4K+E#JQZY_`1,I(I&`GJ41^SE*A/$*6,1'V& M*&H+1"4CT54QDH([1'L/ M^=/1Y!;[IN.@5R;F-D,I"\^-12KDP[&C*=@?<3>LWD\CJ=Q,8*7L4VBCBY'* MB(16H#\&1ZSFQ'BP+>XU*6%=M#]MA^YDI`Q/.^V"G!7K$N?G%O6_-[OE@IX1 M^K'88I`1)>L2(ZI!1NRXH&^$2ISM3QGA#UWJ^]ZA.RQG-3=J5%QJD+>2M$@\ MV;$WL5(24@.KWEM)6EV\RD=J"`^IBE1'V"*&4DT3]#E#,275M$!2/1 M52*J&(FN':(]HXZ5Q*3Z_GX0:A*&;N)\WB"3"FV[=3*"?:D1; MS>7`2MFC:E<0LI6=.*L.,2D>9%(B)KF=H`Q/69=G%P:AUBX>NCD7=&?V6#\[ MM^TT`H-05^=H(TJNT0U"MF"O$;MN(R`(G3#""T+TLX+]0W=8$*K5^$'((C<( M"1)/0I38L)3,Q@!1R$AF=B2H1WW,4J(^090R$O49HIR1Z-HB*AB)KA)1Q4AT M[1"9GX$TT;[IU<:3S<\Z-K_K]GAX_GI8'QX>7L[NCC_,3S;2F/GPKL7\>Y+S MU4=Z]('F@+I"WU9>F<\#=UU9T)5ZR$*9*[I2FZVN?)R-5Q_)X@YM=,4\VM9U M94)7ZNV@TD8/0=&5NA/5%?I]S(^=):B2SCJHBDYYJJ!3_VSUL0G+JN*;&5G4 MU0CJQ MF;O->(5N)9,%75?HW>>5>9,6R]`KT"OS]BQ>H7><5^8E6KQR0^VYZ6P//;BS M,@]X8!EZ6(?:T]6?]/0'7>DJ0\_6K,QC&:B-'K%9F:[[=?#]O;YZ_W3R]G#X_ M\=O\SZO]-8-/QU?Z;5Y:Q.EW0.FWF`]TZV!D;KM^.1Y?^7_(J,OVUYT__+\` M````__\#`%!+`P04``8`"````"$`MB7/Q@H#```C"0``&0```'AL+W=O[F%7(I"JH2JNY6VTFJU MEV<'#%@%C&RG:?]^Q^:BX&2K=M67$(;CP_&9\0SKF^>Z0D]42,:;&/N.AQ%M M4IZQIHCQKY]W5RN,I")-1BK>T!B_4(EO-I\_K8]5 M:4EK(AW>T@:>Y%S41,&M*%S9"DHRLZBNW,#S%FY-6(,[ADB\A8/G.4OI+4\/ M-6U41R)H113HER5KYP M[V<_).G`;6[.Z&N6"BYYKAR@9SH$B]VSU7PX;TOJ+LY9;*%`P%&B>8:Z:45R``?E'-=&6`(>397(\L M4V6,9YX3!O/ER@<\VE.I[ICFQ"@]2,7K/QW*[[DZEJ!G@6O/LG+\T%MHBE>6 MS?IEOG#F2V]FWGV^T.W$&R]NB2*;M>!'!/4%ZF1+=+7Z$9`-)G0,HRW_ M<@7LT"1;S1+C)4:P7PF9?-H$,W_M/H']:8_9G6,L1#(@=-9`WJ@1O/D`C9I% M:]29U*)W0^!$]%1R,B!L06#4!PC2+%`T$]."J8)=A_%/0?,I)!DAMLKP0U1J M%B@.N+R2VQ[TFLP18LN$0C\U\_+Q&PI-@XV:,8M]Q#-59WLS/KPL?E)EBZD. MFRD)+ MV0BRE>E1:'%CA$)K]!PP/N=<#3?:X/'S9O,7``#__P,`4$L#!!0`!@`(````(0#3 M8_9[5B0``#?<```9````>&PO=V]R:W-H965TD*C>1\Z#1P.`%>H`F9_C+?__[V]=W_WIX?GE\^O[Q(GI_>?'NX?NGI\^/ MW__X>/%__B?YK\W%NY?7^^^?[[\^?7_X>/&?AY>+__[U?_^O7_Y^>O[SY/%E]?7'[N'Q>7EZL.W^\?O%Z.'V^=3?#S]_OOCIX?]TZ>_OCU\?QV=/#]\ MO7^E_K]\>?SQPMZ^?3K%W;?[YS__^O%?GYZ^_2`7OSU^?7S]S\'IQ;MOGV[S M/[X_/=__]I6N^]_1U?TG]GWX'W#_[?'3\]/+T^^O[\G=A[&C>,TW'VX^D*=? M?_G\2%=@AOW=\\/O'R_NHMLABI87'W[]Y3!"__?QX>\7Y]_O7KX\_9T^/WZN M'K\_T'"34$:"WYZ>_C2F^6>#J/('J)T<).B>WWU^^/W^KZ^OP]/?V M2>]KNB1S9;>?_[-_>/E$0TINWB^NC:=/3U^I`_3?=]\>S=R@(;G_]\>+!37\ M^/GUR\>+Y>K]]?IR&9'YN]\>7EZ31^/RXMVGOUY>G[[]O]$HLJY&)TOKA/Y: M)YOW5XOK]>;@9*;BE:U(?P.MSU2DOAVZ37]MQ873[9F**UN1_I[7U;6M2'_/ M:Y&6VJ&K]/>\%F]L1?I[7HL1S:)#D^8?MNK-^^CJ#^0>W2"%HMR_?EVL;G[Y\"\*3)^LS19M(M]BQQ8F M"AFW>PUB#1(-4@TR#7(-"@U*#2H-:@T:#5H-.@UZ#08'?"!Y)HUHX?P3&ADW M1B,>W2T#1S0E"%MPE;T&L0:)!JD&F0:Y!H4&I0:5!K4&C0:M!IT&O0:#`SQ! M*"#]$X(8-W0[=19-M-"+9K0Q(7!:6==*I,ED4@E(#"0!D@+)@.1`"B`ED`I( M#:0!T@+I@/1`!I=XHM&MX)\0S;BA8$E_)D$6ZTM?DJTUHKY,1EJUR612#4@, M)`&2`LF`Y$`*("60"D@-I`'2`NF`]$`&EWBJT7W84RV\;>7;D+$^B,.#NAW) M->US)B6BY<*7:S<9<;4]D!A(`B0%D@')@11`2B`5D!I(`Z0%T@'I@0PN\;2@ MC8VGA=DK+*[?D_V9NP7CR)?)$G+ER+14,DU&DTQ`8B`)D!1(!B0'4@`I@51` M:B`-D!9(!Z0',KC$DXEV82"3V<^>*9)Q`X%.[=BVUF@NT$TFDVI`8B`)D!1( M!B0'4@`I@51`:B`-D!9(!Z0',KC$4XWVWJ#:->T(SU3-N/&7UDA4!+Q22VLR MFD0"$@-)@*1`,B`YD`)(":0"4@-I@+1`.B`]D,$EGDAT*`.1WK"TC!M86NJF MM+5&Z.8@C\HS'9-J!\RAO33:*%A2%2T8[1'M$,:($48HH0Y0C*A"5B"I$-:(& M48NH0]0CHH2S,UZ^%N;(>X86XPG9T\(B?RNW4O>;:+)BQ?:(8D0)HA11ABA' M5"`J$56(:D0-HA91AZA'-'C(E\><;EUYWIJN,W[@#J3VVUN3=3!6<[<@L1$A MIVJ,8K1*$*6(,D0YH@)1B:A"5"-J$+6(.D0]HL%#OI#FP.L*>23FV?.Q&_-& MI&Y):[W.)BO68F]2%R98'CXV.J198T0)HA11ABA'5"`J$56(:D0-HA91AZA' M-'C(EX>BUSGR&'.U8[#(#X,;+<]D)?(`BLT.T[@?/YXSB?$$48HH0Y0C*A"5 MB"I$-:(&48NH0]0C&CSDRV/.OF>L'GM4=E?/='IV$PXJ^;HS'^7X`[]'%"-* M$*6(,D0YH@)1B:A"5"-J$+6(.D0]HL%#OCSFD'N&//9,[,ICD;=ZKE26=6<^ M+M/R`(K1*D&4(LH0Y8@*1"6B"E&-J$'4(NH0]8@&#_GRF./M&?*,IV$*EARC MMN:#PG'@G=5SI7)#.['BBGM$,:($48HH0Y0C*A"5B"I$-:(&48NH0]0C&CSD MRV/.L:X\9H^WW)AO9YR;#(KLD=B5SB)_9:GD2#ASSI%N,B71R<:WGAZ6DP9"`E_2Z71EHWF#D]B(SI: MWX=OA(V[<[1*$*6(,D0YH@)1B:A"5"-J$+6(.D0]HL%#OH[G)2D6F*2PR#\\ M7>FDN%B)/*,O]_"$5@FB%%&&*$=4("H158AJ1`VB%E&'J$,B7QYS_]0TL MNGZ_IJ`V?\Q=V,R!<[^RZ'HQ[3YVB/:(8D0)HA11ABA'5"`J$56(:D0-HA91 MAZA'-'C(E\6<^UU9CF@QI@G<;=_"(E<+0'NTBA$EB%)$&:(<4>$A_YIIRGG7 M/$;\PU1\_?+XZ<_M$VVN*.0&QF))7V,;O]QF=EYFN^M.2XM6SK2^EK0#EH^Z;Y2Z=%8K#CR)-P):3$5Y/I2+6;BR[52B:)JWVO(DU,-L'ITNJ ML93=S'8I"UNI+N5LQ5VZ5`?,]6U/RNZD'I&Y\G&8;X?>K-44S!AQU[SVG'*5K/-9V+%S>=^\QN]82NX MRL^:]P?;G(#=P7Y;8#%>5&"QB(9/1O=:'ZU-^#`5Z8]8Z:':BQ4/0LQHG'+K M:*GV/(DU.+8*3FD_X\8V4Y#,&8WM+V\B=67%L?9]%?11.1#&*8I-<1R/PXL1 MT5V3AV@G:'9L;459/C%7%)0P$O>IH!GW&5N)KQQ1P>C@WAN9I3Z)OFE^'KSX M\],B&M5IP-B*HOS,9&0K?]VJD!BS^]4A1D17FRMUKDK8S\^6Z>&6G;+5;)\R MMIKM4Z[Z%%WI@T+!?G[6)U\:LIH-'?_S](/&/+@G<2;STKA1VHS(G6[X3%7%)0P+M8J M`F[9RATRM0O8B0VO@CVB&%&"*$64(H1#1[RIW[H M9/BF;Y`N\:1HD7^FOU:[O)U8B7*C+_=,CU8)HA11ABA'5"`J$56(:D0-HA91 MAZA'-'C(5TX?'M^8.EM.ITIW":KEM66KV25H/4DTVDLUUC9&E"!*$66(D2#AWPA]8EX?LNTQ*.O1=>N.-&UNDWOQ(JUV".*$26( M4D09HAQ1@:A$5"&J$36(6D0=HA[1X"%?'GVR=O9M1Y3"0_9R1&[N#-$>48PH M090BRA#EB`I$):(*48VH0=0BZA#UB`8/^;*8TZQ[W#NBA3W\RNY]NX3S\`[1 M'E&,*$&4(LH0Y8@*1"6B"E&-J$'4(NH\Y(^R.56ZH^Q,_M.S=4M[-G4'WR+) MG>W8:O:`L!7RE&E8L5=S1A)5CP7Y/C2O2_8RF]1Y4!+L>(6*T;28HVH8>2[5P?N5JS8 M?6<1_2'D27WUCV05#E[\DZM%8Y.'$_P.T9Z1EZ&]UKESMI+9E#"21%2**&,D M%7-$!2-_9:LY5XH5#VO%2-S7B!I&TM464<ZO5"=:MK(IW\U"C4L7 M;-^1T@\!.A=S9'Y-*1?N]?9J1/ZG#"M]?K!6YJOP,G1.IPY!8F^MZ-QJYM=5 MM+Y4X3,^R4\B5MS-U"+Z"&:4%JD(HRZ)5;!3N`DF3K!E]=@BRVC\8JO+W50[X*-_722A/-*9WY` M?S5EE;CG6XM4E%&Z[[BBM\:)W#R6`DDG#1<45#++8Y7 MO%S>J)G:<1VO,4<0/\*XG)H)F;SRC+Z=B?%+%A*WD=)HBRAA) M6>M3`9G;KLP5J2/S;EB?%+%A#OAQV>U7%.V&D/C\FJEMUJ9M3AV-[#7-WLQ M!;P7KO&I7SQ\S4F=:-EJ')AHLUFJ/7`7[,!/U[W)I;D[ M"YTG.NT3U"N;DI/YO;7(6=8[0;,S:_3E5(Q/JIBPE7PVFB+*&,F"S07-]*M@ M*W%?(JH8B?L:4<-(?+6(.D:!>$`SU9/MR-'!F*N%/R)GE'=7(Z)-!\_)/:(8 M48(H190ARA$5B$I$%:(:48.H1=1YR+\IZG2<7APG?>7Q"K-TC)PDJJ"9.;@7 M*Y8H%C13,;%6M"<83W>KI8I;J5BPZPQ1CJA`5"*J$-6(&D0MHLZB0`+5?&)] MQKHXF/OKPB(W?29H9H3WUNI(`O4D7XFU,MD$N05?JQUW*E:38HQDGY@+M'+1GY"50]V%%V$KUJ;16_NYU MK3:/5;!?L'N5%GE&-8*L$3AXK@]PQ&JXHJ.46;0+U9J-$Z;B.UYAS M+?Y,T;FQ(S,%DV#7%OF12"WK'5O-+MB]M?I)`O4D'XE8L4@I([NX(CWRF34X M%G3LE0\&-R;VAM$A%&*5;%>R$[FJ-[AM$+:/QBE<+2*`&&_OI)#DO!W:- M.3"+5#A1^[8=5_06D].I,5-JK7Z6*3W)22)6,DMLNLUF2J\7ZA:0<9V?+2P; M2NS5SUY$P;YD89<6F6<>9<^BOSE<<46O$SA+ID[PY35<45ILN46;*=U#[''O2GV8 M$G-KLWX2L>(!3MGU^.C1>J-F=V;+CP694RZCP.9+:=Z=/DK1*M@)G#Y3)_CJ M&FRQE18/'UGHAYVZ8%L_G3TFN>7.GB,W(F.NML0C[9J6@R?/ MVQ:W\:)4&Y'[K,^A+;*B22B!$%6SOB2>Q2=53-C*B[-Z0YY:*[NS7*[6D=J1 M9^SG9\'1W@YL-VU5K%F8I]>?W")3[UBR=]PQ4]]WI@6NZ$ MW7\N%@L58SKVXW7`T<^_:QQ+)9Z69[_&7*)%7CP8K0C-SJS)BHT0QH@11BBA#E",J$)6(*D0UH@91BZA#U",: M/.2MOQ6M4@CL)G-UYCO!#W[\T&Z1R51*'%^KU.E.K$0WTR?_[9%HE2!*$66( MD2#AWS=*$J#;F]ZS&UE/"GE+*)3A*.<2ISMN*)\ M1+Y'%"-*$*6(,D0YH@)1B:A"5"-J$+6(.D0]HL%#OG(FS7/Z3G=ELT*R<]LR M\N39Z.2O6,G"LKY$L1BM$D0IH@Q1CJA`5"*J$-6(&D0MH@Y1CVCPD"^/SHB] M]<"5C9;X,C7PB1'7"W,*GK+_G!,LKAYO95% MM$ADE[%1^;B=6+&4>T0QH@11BBA#E",J$)6(*D0UH@91BZA#U",:/.3K9L[W M6K>W13^;*7"7ET6^D2#AWSE=$;D2/3#S,?*(E\>E;_:B97(,U5D%*-5@BA%E"'*$16(2D05HAI1 M@ZA%U"'J$0T>\N19Z\S'O#P'<_]TQH1S1XR)H1#1[RI3/I`KT9-#]] MS\'E&,*$&4(LH0 MY8@*1"6B"E&-J$'4(NH0]8@&#_G2Z:3&&_.*ZRG;(:MKL58B;=EJ=@U:3_)) MX5ZJR1H$JP2M4D09HAQ1@:A$5"&J$36(6D0=HA[1X"%?R%!&Y(UK$),BZQ'Y M:U"_9F(G5JS3'E&,*$&4(LH0Y8@*1"6B"E&-J$'4(NH0]8@&#_G2F?3#/W$? MM&D,[SZH/X#9KJW5[!J<;$1(0+%X8JL$48HH0Y0C*A"5B"I$-:(&48NH0]0C M&CSD"ZES)&_.[:\Q?6*16H(ZMR]6K,D>48PH090BRA#EB`I$):(*48VH0=0B MZA#UB`8/>H/8+9L-;<$Q682$E&,*$&4(LH0Y8@* M1"6B"E&-J$'4(NH0]8@&#_E"ZD3+FY?@!G,P%JDEJ#\:$"M1;O1%%1G%:)4@ M2A%EB')$!:(2486H1M0@:A%UB'I$@X=\Y4(YF#=]-+#!%`PC.B1,A[_H1G\T M(%8LTQY1C"A!E"+*$.6("D0EH@I1C:A!U"+J$/6(!@_YRE$<^R?V+QOC!X*G M6EY;MIH-GM:3.J/?\2*9=HCBA$EB%)$&:(<48&H1%0AJA$UB%I$ M':(>T>`A7SF3_7"5F_]\83,F2]S/%RQROHBP0[1'%"-*$*6(,D0YH@)1B:A" M5"-J$+6(.D0]HL%#OA8ZI7)$BRESPC-^N['(OUOI9*58<<4]HAA1@BA%E"'* M$16(2D05HAI1@ZA%U"'J$0T>\N4))4I.^HV^#>9%+*+'H%F#':(]HAA1@BA% ME"'*$16(2D05HAI1@ZA%U"'J$0T>\F4Q^84S(IA-1[@W&(M<+0#M-X!B1`FB M%%&&*$=4("H158AJ1`VB%E&'J$,C70NVJ^FRP%BON:H.H M1=0AZA$-%HU=]42\":)_.([>)2/X08BP&/52*>&:6"9AK+Q)=M3)W: MO+MU*^8O8USIPHNE*/AR368/YQ])3=^(VI#7(6 MME)=RJV5]QJ,!?P>:;!?^O'54EID62M!SACKQU?K<"=4ATYZCO9DR0WQ)6XOI9L6>K>09TQA1 MPD@R2*F@&?<96XG['%'!2-R7B"I&XJM&U#`27RVBCI'XZA$-C`Z^?"5_GAN: MWQW>8"K((N^]*XM+%==W7/'(OES"ZP8211>8ER-/-8W&I\WG6ZLC;B=F] MO)TH9C3>*:Y7EY':62?6XMBM8NSY?`G_'NC!VJ\:)VJ",RKTAVYIB*Z+L;6]&U@M^EVK.5K)C8(ONSW*LKF&'6 M,>V3I^;!<_?5*+ M#?N:O>R6K:3%CI%<8W]2BX-4#%^C/]MT`N_(_0>S=C+#^0<8XT7%AQ&I>Y"*G+N;T6K^%K"W5NX;\AGQ/6BU4HFHQ%H=TH&, M6Y,XG3.:XC3>@T;7\QTHK1_O'C16="ZWUJT%[D&GM-9B:QV[EFOK&4W7AO>@ M(ZWY44'G+,=O\)Q]TL!*LN6.$26,9`FF@F;<9VPE[G-$ M!2-Q7R*J&(FO&E'#2'RUB#I&XJM'-##":!%=ZLSE?(`?[?W`P$P=,=0-?L=F M1U[J-9DY>X<`2P(LG=C\]F`RDR;R`"L"K)R8W(JKB8F_.L":`&LG)OZZB8F_ M/L`&GWDK-+K\1Q*9HQLM]YC*5#<"?1CAJD?N!&Q&L=%=?RIQ%+,998Y,EN_R M_:5*E=!\&+LU'YUIBHQF\]W*V&R^6S1KK#=*R#G;2M5[FDBAOD%&B\W<6P>S M^8[0=`MU1+_SE6;@*1VA26F]>9-R9/,=H7D:[(C*KM'4/=(1-9M-PE,?>MQ- MS6FIK>C2)DYE<[5EYMYR'":RPCE@/YE)]*6).C:Q$$93TS*)Y30/)S;3!,U# M<$>3#AC-L,D='T`H5`&C4`5U:>X`HXD"=6E6`*-0!75I"@`CO=VZ2MQC>F>R+="E3-XBG5ZF&3":V9-N,%191[0&'$?J MJ$U3Q)H=NYN=TBV:-5.WI-'%)8:J4-\"H6KJ&\\WFENG=(2F6Z@C@5!U2D=H M4D)':%*>TA&:I\&.8*@ZTA$UFT.YV[>$*DSE1I^D=KIT$;:5I5W MN-&M"!CI"XST!4;Z`B,Q@9&8P$A,8"0F,!(3&(D)C,0$1F("(S&!D9C`2$R7 M*3%-SDZ+^89'HJ-+F_RC>2.RZ1]EV$YF%$XF,Q7S25OK2[8*I"TPTA88:0N, MM`5&V@(C;8&1ML!(6V"D+3#2%AAI"XRT!4;:`B-M@9&V+E/:GI>WC"XQ<*`2/%@)%BP$@Q8*08,%(,&"D&C!0# M1HH!(\6`D6+`2#&7*<5,`LI=C<<2$6/"RH^?EM&:GU;80G]AAM;89.8H!HS6 M&#!2#!@I!HP4`T:*`2/%@)%BP$@Q8*08,%(,&"D&C!0#1HH!(\57%3V"D+3#2%AAI"XRT!4;:`B-M@9&VP$A; M8*0M,-(6&&D+C+0%1MH"(VU=YFL;G9D6/-BK/)%E*G["'4_,9#4BBR-D28"E M`98%6!Y@18"5`58%6!U@38"U`=8%6!]@@\^48B:AXL;/-S^,&45C;L8+K'A)%QI<.NR-381=R7K:JLT4E-:>JCIK`2$U@I"8P4A,8J0F,U`1&:@(C M-8&1FL!(36"D)C!2$QBI"8S4=-FHYH>7+P\/K_O[U_M??_GV\/S'P^[AZ]>7 M=Y^>_OI.6\_H\*,Q$W_W_/#[QXL[FA6W])_#NE!E9@G>'J8-C3R6+4U9J-X= M'8+()^W20O6HC.[RAR0^^+Q'NIG%)FRD,^[S=)\U"970^`7KW&TN;^_HH?!` M'2HQKV@(E="HTBL`0B4TU\+>UC2F]!(YK'.WOJ+K"5TIO>R-Z@1'>TW#$ZQS MMZ992R_IP7;HM554)ZC#FG0(UKE;F;Z%>DTOU[\U[XC\CEMPM M:0SHQWJP9$LE`_U48JB$QF`9'(,EC<'X,:1:07S+,2WQE7H,LP,"W$S(P+\CM9K M,,B0YL'%2HH'!3?1*N"?GK2[-<^^X82CYQAI`$,E^YOHUCQ/AG7HR;!;\_`7 MEM"37;?FX2TLH2>SJ`>ADOKZ\M;\J#K6::C$_)`ZEM#/W=^:WU/'DBU=SS9X M/?0<[*UY7A+K[*G$/(T:**%Q,X\W8@D]JGIKGG+$$GIB]=8\[(@E].#JK7F4 M%$N2JYO;EI[JPY(M7>DV>*4[*MD%2V(JB8,E"96DP9*,2K)@24XE>;"DH))R M/#.H\%)<1U02TJ>B.E6PI+@B;_3X,8Y!M;RYK8(E-974P9*&2MI@24R" M)3&5Q,&2A$K28$E&)5FP)*>2/%A24$EI'W>>+O7EUU]^W/_Q4-\___'X_>7= MUX??Z?CNY_/C'R;K-/[/Z],/.@A=O/OMZ?7UZ=OAGU\>[C\_/!L#2B/] M_O3TRO]#P__A[Z?G/P^'JE__OP````#__P,`4$L#!!0`!@`(````(0`U9VOC M;A<``+*%```9````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`#JOQ>/][IKJ#MR^^?Q[\_[+Z_?/UUZZP^+U60V5>87O^Y?7H-[+7EY MFH?K[IDBGJBNT MF=%]PMSU\V*==DE5B7E;M%.5PM9K+Y=G>J5D3CF;9]Y@D*"4H)*@EJ#I@2N5GBY':BS\ M$SG2,CI'='=O"/22)A)"%M1D)X$O02!!*$$D02Q!(D$J029!+D$A02E!)4$M M0=,#5D+4#/-/)$3+?+I4_^5!,Y_8&;AI;?3DUADM;)-M9])E"8@/)``2`HF` MQ$`2("F0#$@.I`!2`JF`U$":/K&2IN;V?R)I6D9-ENI/EQ"KGT@I$K>]6('JA7*@9^XT+I9:Q(S1$Q=+U%6\N M5\;.B%[8#H@/)``2`HF`Q$`2("F0#$@.I`!2`JF`U$":/K&2I#8@D"1O\4'= MVS>F20O9:3+$3I,G.E1GU*4)B`\D`!("B8#$0!(@*9`,2`ZD`%("J8#40)H^ ML=*D]IE6FMR#6EO;N6B)&GUTF[=`=D!\(`&0$$@$)`:2`$F!9$!R(`60$D@% MI`;2](EUX]51[@TW7EO;-]X0>Q#,Q"#HC"@[.R`^D`!(""0"$@-)@*1`,B`Y MD`)(":0"4@-I^L3*A3XF6\EHCUX?=/W`/2".+>W$&+3P>$@@VB'R$06(0D01 MHAA1@BA%E"'*$16(2D05HAI18R$[+?H4UC\1C^2B/;2I_2#U]AM=Q-#CII\+ M0#NT\A$%B$)$$:(848(H190ARA$5B$I$%:(:46,A.Q?Z`-;/16^(O'Z_O_OM MYJ#V3.K>#N1HIG9\IC;1'N.L%!FT[+*V5>DZ9DWM+;I]V'0N=NT[8S53,VQG MY[UAY]!?'>V^OBL1^1(;ENK^75;OYI,(:V=`=VK@)4)A8@B M@UA9+)DQ&Y!,@C(IHHP;'FMN$'/.!J16C)UM?<#K M9WM@Q*H">#=DS7FPGU:#U*:R-_*6]LC;ZG.YSG1_?`Z,XLZ*0O>Y(:$`48@H M0A0C2A"EB#)$.:("48FH0E0C:BQD9TQM0]Z2,6VN;GP_8RV:]W/AS>497%?0 MV]62\SJ0L4$K46'VC9:W-"/X>K6V^T=`WM2:T?4B\!:2%:_@$:-^0Q%`;`
PG'A+45`L2,<90$E6'$#%R!%`;0>P6"X] M<49N2.=4`'8OU$?]_KSQOAV`*1CT.V>+YJI?=1W!FXONLM4KQAG326=%BGX0&`-/'0(Z_P,=$90C4EYW6Y>84.ML?KT4"U=REK.49%@Y0Y03 M:IU-5PM/+`S%6=Y*TF%O%:*:D/$V6RQ$?V[&O-G=29G1A8M^>MXWVK6*6(I:-%?#J1MMWES,WEN]:]`-^U8P)G=D MI)0+2.34/'@\O(5GQ;C8BY`P@%@',ERM14TY(QQE` M2E8<0$;(&4!N![!:K=8P49C[[0R@)&\<0$7(&4`M`IA,5[`4C01@=TY=R7%U MSO\3W='U$`2$>NR&BB!!K MQ8@20JR5(LH(L5:.J"#$6B6BBA!KU8@:0CBGZ!762IM[RC^:VY,'(37-=P/> MD^O0UEC-W),':?&JYR,*$(4L3WN,"*UB1`FB%+4RM,H1%8A*U*K0JD;46,@: M:)X:0V_)F#87&6O1R,GCZ&=TNBDY0PB)2L.(B/D#"(?#D)._:3E#*(D*PZB(N0,HAX. M0FR+&](Z%83=*Y5'JU>^:V^B.XCLK"T:.8F8AF/3BY'O3R\&F1WT>BEV/8%1 MUN.1.Z7V:06M+)?4ZH?6'>]4P< MWHJSG)7HK")E=E:3E7K)W4WR%F(];@8]]L:WW:%T-;&_GQA9F-KB8[_`HD\< MJC/U]PV,.$[2N(WM@Y'H=2\LA!9(2<0>3# M08BJ3$%:SB!*LN(@*D+.(.KA(,2\U9#6J2#L64071EW=]+Q3B7[X7*Y++5(C MA*;UR#[5"(6]ZVJ/^B&8]L&H\4+GF\: M]A;<`%'(\M1'(K2*$26(4M3*T"I'5"`J4:M"JQI18R$[8[K*]X:,M45!:[EN MT=BIQ#14*7&-,6/EG&]\K[6BB=\3M=/`7-=OP)_V%9(53W<1(:?[6+B?BNU2 M0BI.]RE9L?N,D--]3N[-NT&SM=B-%B3C]%^2%?NO"#G]U^!?#,Z&9$[YM_N? MKE7U^]_[]B.FXM7?C[1H[/S16HU-)$:^/Y&8AF;S,1&'L,!KKX\=/SKW/-&` MK]AHS8ROJ>COR5F^4E+AA&<&]6;#G)`Y?LSFT+O.>6$E.JM(F6]B3<@XFR_$ MQJ4Q!B?OHMV59"5S9/'!BJ77E2@T-$$2'6BA$E MA%@K19018JT<44&(M4I$%2'6JA$UA'!O,),5RW>-]*.*O64P:.3D00W="Q!9 M.:=`WUBI556?/%2I2XY^DCDU!;9O@I`5C\B(D--_#/[E$D0R3O\I6;'_C)#3 M?V[[GZ]FXNA5D(S3?TE6[+\BY/1?"_]K.4DU)'/*OS5OS)25A_N(`D(\;D-$$2'6BA$EA%@K19018JT<44&(M4I$%2'6 MJA$UA`;F$]5'K+2YIWNU>LJS!B&UG>SVB?!DR=98C6P12(M7-Q]1@"AD>5IS M(K2*$26(4M3*T"I'5"`J4:M"JQI18R%[H+VM-#C#TJ!!(V<-:C@RU1MYYU3C M&RUSUO"N154C(%^G9AHSTQM?/--%U-#I/K;=SV25.R$5I_N4K-A]1LCI/B?W M9J%;+\7++TC&Z;\D*_9?$7+ZKX7_R;78C38D<\J_W?]T+>YOGS5FIJ+'^Z`; M@T;.&L9J;"(Q\OV)I$5J8.GM!CQS971/;I)-%S0BG(.(7@F[BBG&UI4W@XU% MJ^+VE9(*^\K05TY6K:_Y6O@JS'6WKY)4V%>%OFJR,K=P(HY0S9@ONQ_)XN3( MRH-%R!D6(1GQ8H1%2++BSN];054M7MSSSF&%*I#PZ;F:F'LK# M:LO(V0E-0]Z"^]2044"(Y4-$$2%N&"-*"+%6BB@CQ%HYHH(0:Y6(*D*L52-J M"!VU[+3I>M>)M(W,^Z:2U\]4B_J?9]2?N5)#O(=VB'Q$`:(0480H1I0@2A%E MB')$!:(2486H1M18R$[+VXI],RSV$>+/`FP1[1#YB`)$(:((48PHL9#UFN?_ M2`7MJ&(O;(1XAMPRV;)5[@CJTH=!]1 M@"ADQ$'`OB-B*Y*/$246LF^66C+?TF$W@.1YCX3X'AJ3C#"!B*^[^)B8* M8'8M9I-D+``[#_J$W-\OC,PF[8&Z_X;ZW)RQ>5^S9>0<#:8A;SA\:L@H(,3R M(2.'?$16K!4C2@CA3DKW(.O.O*^'XFGZ*/SIPC-7(^R)DQ9MY'U%`J-_#.X_.'FZL6#XF+48)H8$>KL]3 M_3LV,O;;XYM_C-WXB\A$%B$)$ M$:(848(H190ARA$5B$I$%:(:46,A.SWR2->;;T8&$I[NU)=2Z!STCM5;1#M$ M/J(`48@H0A0C2A"EB#)$.:("48FH0E0C:BQDI64A3YWN7!S-[5%#J'?21K1# MY",*$(6((D0QH@11BBA#E",J$)6(*D0UHL9"=B[4PFW-8+TA!8`1+T5X`C-65@4`OSF(K6C!"A"%B")$,:+$(+6U(_F4D2/ZC+78"G9- M.5N1?(&H1%0AJA$U!K71V^E6&[Y_(-U:18Q(@_B&;=5,>;126Z!NYS&0[M9* MS1;FZW/$DT^^D5$&=*\"5B84,G(XBUC+.!,+;_;V)*5 MVMYT5@-=Q&C95O($15JF(WES^6A#8"Q&COVD8WL31;5HV$K$%)-5&]-4G>K$ M1IJ<\J_W=]TS:5_2G_?)LI4;K@:=K,PR)Y%Q;LA M6[)RCL0=6]%=\`F9*7,*3QT;@[$9TT3I]!^1,Z[4QH1:_[/)2LP+R5G^4Y)Q M^L_8BEY_3JCUOUK+-UB*L_R7)./T7[$5^:\)M?[7GJP3-V/^[5ZH:TW]7CBR M:+>EJ7ZM:&&J55SFVC)R3G&F(7==GQHR"@BQ?,C((1^1%6O%B!)"+)\R%+ZI%; M@T9*VF1E3[MB\/HD;QZV&?AF)](Y-!]10(@'?W30]<$N-O&TE]^ZDU9Y,I\OU1!0N`V,Q4AH@'=N;+*8. M6XF88K*BF*X]H9.,Q62G15JD1%NBAR]\].R1:)(*!X$W!HK_0,/KK08 M>9XM?)(W'Y6;RM\)#4CYU!:\/3Z1E=-_Q%;4HV/RWWY4Y'H%=]N$?,J]?;=U MA:!_M]\WMV@5,U])MZM2L:\VQG0I_U^!D;Z>UL'EBWJG[48.3NW:&C`)"?%H) M&3GD([)BK1A10@A/*TO5*ZP[\[Z^J55$WVQ1O\!R]*6L5(]PS09&RQZS8D+T MC18],[BZ7HBY)R!OIX:HF2&,-V=,$6DY8XHA)NRTQMNIF.Q.*P^2,C7G%0Z6 M>,`TR.K,K=5(X8`:\MG81Q00ZG?F<^0C:LCR,:*$$'9F]4OT)SNS>\0?6]H= MV*#>X6&+:(?(1Q0@"A%%B&)$":(4488H1U0@*A%5B&I$C87:CGS5^RGQQ_WS MM_UV__#P?/W;XXGG_]=/ES>)ZH\_S:@V25Y:3C3Y*#EV9 MJBO'8HELLU)M5%P#;=:;YOAFC&RAW`]ZGRHE]7MP`THS):4VZ0-7YJN-?GYR MZ(IJHQ[=PRMJU[_1>WJ\HG;G&[WWQBN_3#>_'+=.\K6HVS)X5[Q-,V@_4R]D M2'^^^67X)L[5JQAH<+-4^1CBZGX,W8[=?++1'VO"EZ8^H+31'S_"*[O%=*,? M7L(KZC&DC7XP"*_L%MY&/U*#5]3#,4IMZ(IZDF6C'U;!-NJQ$^5GZ,K-7/6B M]ID=D1+UTW`;_6-MJ*9^B6VC?QL-K^RFJDNH'\W"*^HGPY3:T!7UDU\;_:M> MV$;]9)?R<[QRU07W\OGCC]MO^_SV^=O]T\O%P_ZK&IZ3XX],/M]_T\M.^X]7 M\^,%OQY>7P^/:KJ\O/B^O_VR?]8&:D?\]7!XI7\HUU<_#\^_':>`S_\O```` M`/__`P!02P,$%``&``@````A`&U?$@*0`@```0@``!``"`%D;V-0&UL(*($`2B@``$````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` MG%5;3]LP%'Z?M/\0Y1U2"H,)N4&E=`)I$Y42V*-EG)/&(K$SVZG:_7J.F[5- MJ->-OOEROG.^1RK/ M!8<[Q9L*I(V&@\%E!$L+,H/LI-XJ#%N-UPM[K-),<K&@G'9%S7I>#, MHI?Q#\&U,BJWP73)H211]Y,@NP1XHX5=Q0,2=:\DX:R$"2J.@'<*AT8\1O#-@R#%V;`T1F%"Z8%DQ9I.;'VLCZ7M;$Z_JGT MJRD`K"$1"K2/ZV-7MGL6%_'P:BV!I[ZDT]`RP8\^QU38$LQC/F/:^BA?=3FO M6;2,6T*;+%*L#3J5%N-%'V2;;:&ZS+<^3)0TJA09LY#16U8RR8$F>Y[^CSR= ML7^;2"Q:3*JS)I MJHKIE2.:B+D4V"A8(G3,N6JD]4.LXJ^%*C/L7CK]U6`&O'*H0S<8\>D2.]*` MG]\#-GT%-&7+OP@@^4K8-IHNY1@VB_6.PP)'@-?N;6.$!&-H`G.'ZY2']`(. MQ^#L",S0BWD?$/3Z!3O!*WO("9IZ(8?=.#\""$'<^.W7B^CVJ^TVWR""ENC)@1+ M,?:B`*=;P$7>7Z%-00N>>#X`$SM1$0C4HH):3]< M.P"DP-""!A,\)AG!W]T`3OL_+PS)65.KL+=QIE'WG"W%,9S:.Z^F8M_W65\. M&M&?X/7RX6D8-57FL"L!B!WVTW(?EG&5&P7R=L]V;ZY-O&\J_#NKI!CLJ'#` M`\@DOD>/=J?DI;R[7RT0*W(R2PE)\^M506@QH^7LM<*GUGB?34`]"OR;>`*P MP?OGG[,O````__\#`%!+`0(M`!0`!@`(````(0"7#_[BQ`$``'(2```3```` M``````````````````!;0V]N=&5N=%]4>7!E&UL4$L!`BT`%``&``@` M```A`+55,"/U````3`(```L`````````````````_0,``%]R96QS+RYR96QS M4$L!`BT`%``&``@````A`%-W#7NM`0``,Q$``!H`````````````````(P<` M`'AL+U]R96QS+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A M`!/5F!6Q`P``UPP``!D`````````````````K1D``'AL+W=O&PO=V]R:W-H965T\;`8``%(@```9`````````````````%HA``!X;"]W;W)K M&UL4$L!`BT`%``&``@````A`'",W*!H`@``HP4` M`!D`````````````````_2<``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`"!S_$2C!0``[!8``!@````````````` M````#C8``'AL+W=O&PO&PO&UL4$L!`BT`%``&``@````A`-%M2'J1`P`` M6@P``!@`````````````````49```'AL+W=O]UP(``)0'```9`````````````````!B4 M``!X;"]W;W)K&UL4$L!`BT`%``&``@````A``"H MM\?>%@``EX```!D`````````````````)I<``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@` M```A`/R00W6D'P``&+\``!@`````````````````E+$``'AL+W=O&PO=V]R M:W-H965T&UL4$L!`BT`%``&``@````A`#W1#<)4`P``8PH` M`!@`````````````````/-H``'AL+W=O&UL4$L!`BT`%``&``@````A`+U0PQGF M!0``R1<``!D`````````````````E^H``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`'Z=/&#S%@``(GH``!D````` M````````````@/D``'AL+W=O&PO=V]R M:W-H965T&UL M4$L!`BT`%``&``@````A`#5G:^-N%P``LH4``!D`````````````````>#@! M`'AL+W=O\5,@$``$`"```1`````````````````.-3`0!D F;V-0 XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 R25.htm IDEA: XBRL DOCUMENT v2.4.0.8

Business Segment Information - Additional Information (Detail)
9 Months Ended

Sep. 30, 2014

Segment

Segment Reporting [Abstract]

Number of reportable segments of company 2

X

- Definition

Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.

+ References

No definition available.

+ Details

Name: us-gaap_NumberOfReportableSegments

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 15 R9.htm IDEA: XBRL DOCUMENT v2.4.0.8

Stockholders' Equity
9 Months Ended

Sep. 30, 2014

Equity [Abstract]

Stockholders' Equity

3. Stockholders’ Equity

Stock-Based Awards

We grant stock-based awards under the OraSure Technologies, Inc. Stock Award Plan, as amended and restated (the “Stock Plan”). The Stock Plan permits stock-based awards to employees, outside directors and consultants or other third-party advisors. Awards which may be granted under the Stock Plan include qualified incentive stock options, nonqualified stock options, stock appreciation rights, restricted awards, performance awards and other stock-based awards. We recognize compensation expense for stock option and restricted stock awards issued to employees and directors on a straight-line basis over the requisite service period of the award. To satisfy the exercise of options or to issue new restricted stock, we normally issue new shares rather than purchase shares on the open market.

Total compensation cost related to stock options for the nine months ended September 30, 2014 and 2013 was $2,286 and $2,028, respectively. Net cash proceeds from the exercise of stock options were $546 and $317 for the nine months ended September 30, 2014 and 2013, respectively. As a result of the Company’s net operating loss carryforward position, no actual income tax benefit was realized from stock option exercises during these periods.

Compensation cost of $1,998 and $2,159 related to restricted shares was recognized during the nine months ended September 30, 2014 and 2013, respectively. In connection with the vesting of restricted shares, during the nine months ended September 30, 2014 and 2013, 106 and 122 shares, respectively, with aggregate values of $639 and $817, respectively, were withheld and retired in satisfaction of minimum tax withholding obligations.

X

- Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Article 4

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph d

-Article 4

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

EXCEL 16 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\Y-6-C.&9F9%]B930Y7S0Q93E?.&1F,%]D8S0T M8CEE83=D,#0B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I7 M;W)K#I7;W)K#I%>&-E;%=O'!E;G-E#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/DEN8V]M95]487AE#I.86UE/@T* M("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/D-O;6UI=&UE;G1S7V%N9%]# M;VYT:6YG96YC:65S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I% M>&-E;%=O#I.86UE/@T* M("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/E-U;6UA#I7;W)K#I%>&-E;%=O'!E M;G-E#I7;W)K#I7;W)K#I%>&-E;%=O5]O9E]3:6=N:69I8V%N=%]!8V-O=6YT-#PO>#I. M86UE/@T*("`@(#QX.E=O#I%>&-E;%=O5]!9&1I=&EO;F%L/"]X.DYA;64^#0H@("`@/'@Z5V]R M:W-H965T4V]U#I%>&-E;%=O'!E;G-E#I%>&-E;%=O&5S7T%D9&ET:6]N86Q?26YF;W)M/"]X.DYA;64^#0H@("`@/'@Z M5V]R:W-H965T4V]U#I%>&-E;%=O#I%>&-E;%=O M#I%>&-E;%=O#I%>&-E M;%=O#I!8W1I=F53:&5E=#XP/"]X.D%C=&EV95-H965T/@T*("`\>#I0#I% M>&-E;%=O7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^4V5P(#,P+`T*"0DR,#$T M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)U$S/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS M<&%N/CPO6UB;VP\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO'0^)T]205-54D4@5$5#2$Y/3$]'2453($E.0SQS M<&%N/CPO2!#96YT3PO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^)S`P,#$Q,38T-C,\2!&:6QE3PO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^)T%C8V5L97)A=&5D($9I;&5R/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA'0^)SQS<&%N/CPO'!E;G-E'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPOF5D+"!N;VYE(&ES'0^)R9N8G-P.R9N8G-P.SQS M<&%N/CPOF5D+"`U-BPP-3(@86YD(#4U+#8S M,B!S:&%R97,@:7-S=65D(&%N9"!O=71S=&%N9&EN9SPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO3PO=&0^#0H@("`@("`@(#QT M9"!C;&%S7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPOF5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XR-2PP,#`\'0^)R9N8G-P.R9N8G-P M.SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\Y-6-C.&9F9%]B930Y7S0Q93E?.&1F,%]D8S0T8CEE83=D,#0-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.35C8SAF9F1?8F4T.5\T,64Y7SAD M9C!?9&,T-&(Y96$W9#`T+U=O'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\Y-6-C.&9F9%]B930Y7S0Q93E?.&1F,%]D8S0T8CEE83=D M,#0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.35C8SAF9F1?8F4T M.5\T,64Y7SAD9C!?9&,T-&(Y96$W9#`T+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO2!L;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M/B@W,RD\'0^)SQS<&%N/CPO2`H=7-E9"!I;BD@ M;W!E'0^ M)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA3I4:6UEF4Z,3!P=#L@9F]N="UF86UI M;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!792!D979E;&]P+"!M86YU9F%C='5R M92P@;6%R:V5T(&%N9"!S96QL(&]R86P@9FQU:60@9&EA9VYO2P@=V4@;6%N=69A8W1U M0T*(&-R>6]S=7)G97)Y M+"!OFEN9RX@3W5R('!R;V1U8W1S(&%R92!S;VQD(&EN('1H92!5 M;FET960-"B!3=&%T97,@86YD(&EN=&5R;F%T:6]N86QL>2!T;R!V87)I;W5S M(&-L:6YI8V%L(&QA8F]R871O2UB87-E9"!OF%T:6]N7-I8VEA;G,F(W@R,#$Y.R!O9F9I8V5S+"!A;F0@8V]M;65R8VEA;"!A M;F0-"B!I;F1U7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA'0^)SQD:78^#0H@/'1A8FQE('-T>6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P M(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4@8F]R9&5R/3-$,#X-"B`\ M='(^#0H@/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#0E(&%L:6=N/3-$;&5F M=#X\8CXR+CPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1T;W`@86QI9VX],T1L M969T/CQB/E-U;6UA6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0G/@T* M(#QI/CQU/E!R:6YC:7!L97,@;V8@0V]N2UO=VYE9"!S=6)S:61I87)Y+"!$ M3D$@1V5N;W1E:RP@26YC+@T*("@F(W@R,#%#.T1.0465A$$P.S,Q+"`R,#$S+B!297-U;'1S(&]F(&]P97)A=&EO;G,@9F]R#0H@=&AE M('1H6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P M=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!-05)'24XM5$]0.B`Q,G!T)SX-"B`\:3X\=3Y56EN M9R!A2!A;F0@9F]R96EG;@T*(&-U7,N($%V86EL86)L92UF;W(M#(P,3D[(&5Q=6ET>2!A#L@ M34%21TE.+51/4#H@,3)P>"<^#0H@)B-X03`[/"]P/@T*(#QP('-T>6QE/3-$ M)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`P<'0G/@T*($]U MF5D(&-O'!E;G-E6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T)SX- M"B!&86ER('9A;'5E(&UE87-U6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@ M-"4[($U!4D=)3BU43U`Z(#9P="<^#0H@3&5V96P@,3H@56YA9&IU6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5& M5#H@-"4[($U!4D=)3BU43U`Z(#9P="<^#0H@3&5V96P@,CH@475O=&5D('!R M:6-E2P@9F]R#0H@2!T:&4@9G5L;"!T97)M M(&]F('1H92!A2!L:71T M;&4@;W(@;F\@;6%R:V5T(&%C=&EV:71Y*2X\+W`^#0H@/'`@2!A="!A#0H@=&AI$$P.S,P+"`R,#$T(&%N9`T*($1E8V5M8F5R)B-X M03`[,S$L(#(P,3,@=V%S("0Q+#`Y,"!A;F0@)#8W-RP@6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!- M05)'24XM5$]0.B`Q,G!T)SX-"B`\:3X\=3Y);G9E;G1O6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V M86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/"]T M6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ M96TG/@T*(%=O$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/CDS-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XX,S,\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z M("TQ96TG/@T*($9I;FES:&5D(&=O;V1S/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$T+#@T,SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T M>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ,2PT-#0\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^ M#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@2!T;R!F;W)T>2!Y96%R2!A;F0@97%U:7!M96YT M+"!A;F0@9G5R;FET=7)E(&%N9"!F:7AT=7)E65AF5D(&]V97(-"B!T:&5I2!G86EN(&]R M(&QO$$P.S,P+"`R,#$T(&%N9"!$96-E;6)E$$P.S,Q+"`R,#$S#0H@=V%S M("0S,"PV,#,@86YD("0R."PS.3`L(')E2X\+W`^#0H@/'`@ M#L@ M34%21TE.+51/4#H@,3)P>"<^#0H@)B-X03`[/"]P/@T*(#QP('-T>6QE/3-$ M)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`P<'0G/@T*(#QU M/DEN=&%N9VEB;&4@07-S971S/"]U/BX@26YT86YG:6)L92!A6QE/3-$)TU! M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T.R!-05)'24XM5$]0 M.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX] M,T1B;W1T;VT@8V]L$$P.S,P+"`R,#$T/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$ M15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$8V5N=&5R/CQB/D%M;W)T:7IA=&EO;CPO8CX\8G(@+SX-"B`\ M8CY097)I;V0F(WA!,#LH665A6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C M;VQO6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/C$P+#0T.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#XH-RPX-#0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(L M-C`U/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M8F=C;VQO$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU+#`Q,#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[ M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/B@X.3,\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,L M,SDV/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/ M3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T* M(#QT6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@Q-2PW.#D\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/C$X+#@S,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^ M#0H@/"]T6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO M$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@R+#6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C$P+#0T.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#XH-RPT-C8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(L.3@S M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF M(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C M;VQO$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XV+#(Q,#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X M03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/B@W,34\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,L.#`V M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF M(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C M;VQO$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,7!X M)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@Q-"PT M.#@\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/C(R+#(R-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R M/@T*(#QT"<^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T)SX- M"B`\:3X\=3Y';V]D=VEL;"X\+W4^/"]I/B!';V]D=VEL;"!R97!R97-E;G1S M('1H92!E>&-E2!F;W(@:6UP86ER;65N M="!O2!T:&%N(&YO="!T M:&%T('1H92!F86ER('9A;'5E#0H@;V8@82!R97!O6EN9R!V86QU92P@:6YC;'5D M:6YG#0H@9V]O9'=I;&PN($EF('1H92!C87)R>6EN9R!V86QU92!O9B!A(')E M<&]R=&EN9R!U;FET(&5X8V5E9',@=&AE#0H@2!C;VUP87)I;F<@ M=&AE#0H@:6UP;&EE9"!F86ER('9A;'5EFEN9R!A('%U86QI=&%T:79E(&5V86QU871I;VX@86YD M(&-O;F-L=61E9`T*('1H870@:70@=V%S(&UO$$P.S,P+"`R M,#$T(&ES(&$@2!T&ES=',L('1H90T*('!R:6-E(&ES(&9I>&5D(&]R(&1E=&5R M;6EN86)L92P@=&ET;&4@:&%S('!A$%%.SPO2P@=V4@97AP96YS92!W87)R86YT>2!R971U M6QE/3-$)TU!4D=)3BU" M3U143TTZ(#!P>#L@1D].5"U325I%.B`Q<'@[($U!4D=)3BU43U`Z(#$R<'@G M/@T*("8C>$$P.SPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P M<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@34%21TE.+51/4#H@,'!T)SX-"B!792!B96=A;B!S96QL:6YG(&]U M$%%.SPO6QE/3-$)T9/3E0M4TE:13H@.#4E.R!615)424-!3"U!3$E'3CH@ M=&]P)SXF(WA!13L\+W-U<#X@26XM2&]M92!(258@=&5S=`T*('=E2!A8V-E<'1E9"!A8V-O=6YT:6YG#0H@<')I;F-I<&QEF5D('5N;&5S2!D971E2!T:&4@ MF5D('!R979I;W5S;'D@9&5F97)R960-"B!R979E;G5E M(&%N9"!I=',@F4-"B!R979E;G5E(&9O'!E8W1E9`T*(')E='5R;G,L(&%N9"!C=7-T;VUEF5D(&EN(&]U6%L='D@:6YC M;VUE(&9R;VT@=&AE(&=R86YT(&]F(&QI8V5N&-L=61E M9"!F6QE/3-$)TU! M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T)SX-"B!/;B!* M=6YE)B-X03`[,3`L(#(P,30L('=E(&5N=&5R960@:6YT;R!A($UA2UO=VYE9`T*('-U M8G-I9&EA#(P,4,[06)B5FEE)B-X,C`Q M1#LI+"!T;R!C;RUP#(P,40[*2X@5V4@=VEL;"!B90T*(')E$%%.SPO6QE/3-$)T9/3E0M4TE:13H@.#4E M.R!615)424-!3"U!3$E'3CH@=&]P)SXF(WA!13L\+W-U<#X@2$-6(%)A<&ED M('1E6QE/3-$ M)T9/3E0M4TE:13H@.#4E.R!615)424-!3"U!3$E'3CH@=&]P)SXF(WA!13L\ M+W-U<#X@2$-6(%)A<&ED('1E2!C87)E('!H>7-I8VEA;G,L(&=A65E(&=R;W5P&-L M=7-I=F4@'!I6UE;G1S+B!4:&5S92!P87EM96YT&-E961I M;F<@82!B87-E;&EN92!T:')E$$P.S,Q M+"`R,#$U+B!4:&4@86=R965M96YT(&%L#L@34%21TE.+51/4#H@,3)P>"<^#0H@)B-X03`[/"]P/@T* M(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0 M.B`P<'0G/@T*(#QI/CQU/D-U$%%.SPO$%%.SPO'!E2!T;R!E;G-U M$$P.S,P+"`R,#$T(&%N9"!$96-E;6)E M$$P.S,Q+"`R,#$S+"!T:&4@2!F#(P,3D[ M#(P,40[*2X@4'5R$$P.S,Q+"`R,#$S+B!2;V-H M92!A9W)E960@=&\-"B!P7,@<')I;W(@=&\@=&AE(&5N9"!O9B!T:&ES(&9I=F4M>65A M6UE M;G0@9G)O;2!2;V-H92!O9B!U<"!T;R`D-2PU,#`@9&5P96YD:6YG(&]N(&AO M=PT*(&5A2UA=71O;6%T960@87-S87ES('!R979I;W5S;'D@ M9&5V96QO<&5D('5N9&5R('1H90T*('1E6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T)SX- M"B`\:3X\=3Y$969E$$P.S,Q+"`R,#$S(&EN8VQU9&5S(&-U M6UE;G1S(&]F("0W,3,@86YD#0H@)#$L,3$Y+"!R97-P M96-T:79E;'DN($1E9F5RF5D#0H@2!I;B!R979E;G5E+CPO<#X-"B`\<"!S='EL M93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3)P="<^ M#0H@/&D^/'4^0W5S=&]M97(@86YD(%9E;F1O$$P.S,P+"`R,#$T+B!/;F4@;V8@;W5R(&-U M2`Q,B4@;V8@;W5R(&YE="!R979E;G5E$$P.S,P+"`R,#$T+B!792!H860@;F\@ M6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM M5$]0.B`Q,G!T)SX-"B!792!C=7)R96YT;'D@<'5R8VAA2!S=7!P;&EE2!S=7!P;'D@;V8@86YY(&]F('1H97-E#0H@8V]M<&]N96YT&5R8VES97,@;W(@=F5S=&EN9R!W97)E('5S960@=&\-"B!A M8W%U:7)E('-H87)E6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I% M.B`Q,G!T.R!-05)'24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B M;&4@6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S M;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N M=&5R/CQB/E1H$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S M;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N M=&5R/CQB/DYI;F4@36]N=&AS/"]B/CQB$$P.S,P+#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@8F=C;VQO$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4 M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H M=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@ M.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/ M3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT M9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO M$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS M1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XU-2PU.3(\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#XU-2PX.3<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU-2PU,S0\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/ M3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$ M)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XP+C`R M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@P+C`S/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@ M.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH M,"XP-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG M/@T*($1I;'5T960\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XP+C`R/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/B@P+C`S/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,"XP-#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$6QE M/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM M5$]0.B`Q,G!T)SX-"B!&;W(@=&AE('1H2P@=V5R92!E>&-L=61E9`T*(&9R;VT@=&AE M(&-O;7!U=&%T:6]N(&]F(&1I;'5T960@96%R;FEN9W,@*&QO2!E>&-L=61E9"!F&-H86YG92!R M871E&-H86YG92!R871E6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M.R!-05)'24XM5$]0.B`Q,G!T)SX-"B!46QE/3-$ M)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T)SX-"B!7 M92!H879E(&1E9FEN960@=&AE($-A;F%D:6%N(&1O;&QA2!O9@T*(&]U#(P,3D[2`R,#$T M+"!T:&4-"B!&:6YA;F-I86P@06-C;W5N=&EN9R!3=&%N9&%R9',@0F]A#(P,4,[1D%30B8C>#(P,40[*2!I&-H86YG92!F;W(@=&AO$$P.S$U M+"`R,#$V+`T*('=I=&@@;F\@96%R;'D@861O<'1I;VX@<&5R;6ET=&5D+B!7 M92!W:6QL(&5V86QU871E('1H92!E9F9E8W1S+"!I9@T*(&%N>2P@=VAI8V@@ M861O<'1I;VX@;V8@=&AI'1087)T7SDU M8V,X9F9D7V)E-#E?-#%E.5\X9&8P7V1C-#1B.65A-V0P-`T*0V]N=&5N="U, M;V-A=&EO;CH@9FEL93HO+R]#.B\Y-6-C.&9F9%]B930Y7S0Q93E?.&1F,%]D M8S0T8CEE83=D,#0O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO3PO8CX\ M+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\<"!S='EL93TS1"=M87)G:6XM M=&]P.C9P=#L@;6%R9VEN+6)O='1O;3HP<'0[(&9O;G0M3I4:6UEF4Z,3!P=#L@9F]N="UF86UI M;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!792!G#(P,40[*2X@5&AE(%-T;V-K(%!L M86X@<&5R;6ET6QE/3-$)VUA3I4:6UE2X@3F5T(&-A2X@07,@ M82!R97-U;'0@;V8@=&AE#0H@0V]M<&%N>28C>#(P,3D[F5D(&9R;VT@F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N M)SX-"B!#;VUP96YS871I;VX@8V]S="!O9B`D,2PY.3@@86YD("0R+#$U.2!R M96QA=&5D('1O(')E$$P.S,P M+`T*(#(P,30@86YD(#(P,3,L(#$P-B!A;F0@,3(R('-H87)E7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA6QE/3-$9F]N="US:7IE.C$R<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN M+6)O='1O;3HP<'0^#0H@)B-X03`[/"]P/@T*(#QT86)L92!C96QL3I4:6UE3I4 M:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N M/3-$,B!A;&EG;CTS1&-E;G1E6QE/3-$)V)O6QE/3-$)VUA$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO M=&0^#0H@/"]TF4Z,3!P="<^#0H@/'1D('9A;&EG;CTS1'1O M<#X-"B`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD M96YT.BTQ+C`P96T[(&9O;G0M3I4:6UE M6%L=&EE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/C$L-S`S/"]T9#X-"B`\=&0@;F]W6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S M($YE=R!2;VUA;CL@9F]N="US:7IE.C$P<'0G/@T*(#QT9"!V86QI9VX],T1T M;W`^#0H@/'`@F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM M97,@3F5W(%)O;6%N)SX-"B!0$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C0X-#PO=&0^#0H@/'1D(&YO=W)A<#TS M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XW-#D\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R M87`@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]TF4Z,3!P="<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL M93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96T[ M(&9O;G0M3I4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]TF4Z,7!X.SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@"!S;VQI M9"`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=B;W)D97(M=&]P M.C$N,#!P>"!S;VQI9"`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O$$P.SPO<#X-"B`\+W1D/@T*(#QT M9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149& M('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US M:7IE.C$P<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$9F]N="US:7IE.CAP=#XF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XY+#(P M,SPO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-T>6QE/3-$9F]N="US:7IE.CAP=#XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ,RPP,S(\+W1D/@T*(#QT9"!N;W=R M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^ M#0H@/"]TF4Z,7!X.SX-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O6QE/3-$)V)O3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Y-6-C.&9F9%]B930Y7S0Q93E? M.&1F,%]D8S0T8CEE83=D,#0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O M0SHO.35C8SAF9F1?8F4T.5\T,64Y7SAD9C!?9&,T-&(Y96$W9#`T+U=O'0O:'1M;#L@ M8VAAF4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!$=7)I M;F<@=&AE('1H"!E>'!E M;G-E(&]F("0Q,"X@1'5R:6YG('1H92!N:6YE(&UO;G1H$$P.S,P+"`R,#$T+"!W92!R96-O"!B96YE9FET"!B96YE9FETF4Z,3!P=#L@9F]N="UF86UI M;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!$969EF5D#0H@9F]R(&9I;F%N8VEA;"!R97!O"!P=7)P;W-E"!L:6%B:6QI='D@ M87,@;V8@4V5P=&5M8F5R)B-X03`[,S`L(#(P,30@"!E9F9E8W1S(&]F('1H92!B87-I"!P=7)P;W-E$$P.S,Q+"`R,#$S('-I;F-E('1H92!F86-T"!B96YE9FET('=A3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Y M-6-C.&9F9%]B930Y7S0Q93E?.&1F,%]D8S0T8CEE83=D,#0-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.35C8SAF9F1?8F4T.5\T,64Y7SAD9C!? M9&,T-&(Y96$W9#`T+U=O'0O:'1M;#L@8VAA'0^)SQD:78^#0H@ M/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313I#3TQ,05!313L@9F]N M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z,3!P="<@8F]R M9&5R/3-$,"!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('=I9'1H M/3-$,3`P)3X-"B`\='(^#0H@/'1D('=I9'1H/3-$-"4@=F%L:6=N/3-$=&]P M(&%L:6=N/3-$;&5F=#X\8CXV+CPO8CX\+W1D/@T*(#QT9"!A;&EG;CTS1&QE M9G0@=F%L:6=N/3-$=&]P/CQB/D-O;6UI=&UE;G1S(&%N9`T*($-O;G1I;F=E M;F-I97,\+V(^/"]T9#X-"B`\+W1R/@T*(#PO=&%B;&4^#0H@/'`@F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!&#(P,3D[7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^ M)SQS<&%N/CPO'0^)SQD:78^#0H@/'1A8FQE('-T>6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E M;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4@8F]R9&5R/3-$,#X-"B`\='(^ M#0H@/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#0E(&%L:6=N/3-$;&5F=#X\ M8CXW+CPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1T;W`@86QI9VX],T1L969T M/CQB/D)U2`M+3X-"B`\<"!S M='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@-G!T M)SX-"B!792!O<&5R871E(&]U#(P,4,[3U-54B8C>#(P,40[(&)U M7-T96US(&]R("8C>#(P,4,[1$Y!1R8C>#(P,40[(&)UF%T:6]N#(P,3D[#0H@;V9F:6-E6QE/3-$)TU! M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T)SX-"B!792!O M2!O9@T*('-I9VYI9FEC86YT(&%C8V]U;G1I;F<@<&]L:6-I M97,@*'-E92!.;W1E(#(I+B!792!E=F%L=6%T90T*('!E6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@1D].5"U325I%.B`Q<'@[($U!4D=) M3BU43U`Z(#$R<'@G/@T*("8C>$$P.SPO<#X-"B`\<"!S='EL93TS1"=-05)' M24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,'!T)SX-"B!4:&4@9F]L M;&]W:6YG('1A8FQE('-U;6UA$$P.S,P+"`R,#$T(&%N9"`R,#$S.CPO<#X-"B`\<"!S='EL93TS1"=- M05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3)P=#L@34%21TE.+51/ M4#H@,'!T)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]2 M1$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP M861D:6YG/3-$,"!W:61T:#TS1#DR)2!A;&EG;CTS1&-E;G1E$$P.R8C M>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P M+#`L,"D@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.U-E<'1E;6)E$$P.S,P+#PO8CX\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ M(')G8B@P+#`L,"D@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.TUO;G1H$$P.T5N9&5D)B-X03`[4V5P=&5M8F5R)B-X03`[,S`L/"]B/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R M('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P="!S;VQI M9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R M/CQB/C(P,30\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P="!S;VQI M9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R M/CQB/C(P,3,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P="!S;VQI M9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R M/CQB/C(P,30\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P="!S;VQI M9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R M/CQB/C(P,3,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.SPO=&0^#0H@/"]T2`M+3X-"B`\='(@6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($YE M="!R979E;G5E$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$58 M5"U)3D1%3E0Z("TQ96TG/@T*($]355(\+W`^#0H@/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8P+#(V,#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$S+#4U,#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X M03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP M+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP M+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/ M3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XR-RPX-#4\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C6QE/3-$)T9/3E0M4TE:13H@ M.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XW M,"PQ-S(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R M9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q% M1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($]355(\+W`^#0H@/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#XH.3@W/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,BPU,38\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/B@U+#$W-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z M(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($1.04<\+W`^#0H@/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE: M13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/C$L.#8Y/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#XH,C$S/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T* M(#QT6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XX.#(\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4 M+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,BPR,SD\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/B@Q."PR,C4\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/ M3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(')G M8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1% M4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T M6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E M;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($1E<')E8VEA=&EO;B!A;F0@86UO MF%T:6]N.CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C@Q-3PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE M/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XR+#,X-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+#,X.3PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X M03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+#0U-SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X- M"B`\+W1R/@T*(#QT"<^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G M8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G M8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^ M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M4TE:13H@ M.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XQ+#8R-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#8R-3PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/ M3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#XT+#6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT+#@T-CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X M03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P M+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H M,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@8F=C;VQO6QE/3-$)T9/3E0M M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/ M3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T M9#X-"B`\+W1R/@T*(#QT$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(Y.#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T M>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XS-CD\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T M6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E M;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($1.04<\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@ M.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C8W/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/ M3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,V-3PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE: M13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XV,#0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I M;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$58 M5"U)3D1%3E0Z("TQ96TG/@T*(%1O=&%L(&%S$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/C$S,"PX-#@\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T M6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E M;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($1.04<\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XU,RPP.#(\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\ M+W1R/@T*(#QT6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ.3`L-3`P/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C$X-"PR-#4\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^ M#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP M+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@2!G96]G6QE/3-$)T9/3E0M4TE:13H@.'!T.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R M9V(H,"PP+#`I(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X] M,T0V(&%L:6=N/3-$8V5N=&5R/@T*(#QB/E1H$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$ M15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T M=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N=&5R/@T*(#QB/DYI;F4F(WA! M,#M-;VYT:',F(WA!,#M%;F1E9"8C>$$P.U-E<'1E;6)E$$P.S,P+#PO M8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M+W1R/@T*(#QT6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/C4T+#`U,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@ M/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(T+#8W,3PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/ M3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XW-RPW.#,\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^ M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$ M)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z M(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z M(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/"]T#L@34%21TE.+51/4#H@,3)P>"<^#0H@)B-X03`[ M/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)' M24XM5$]0.B`P<'0G/@T*(%1H92!F;VQL;W=I;F<@=&%B;&4@0T*(&=E;V=R87!H:6,@87)E M83H\+W`^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(')G8B@P+#`L,"D@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L M$$P.R8C>$$P.SPO M=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@ M,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\ M<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE M$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XQ+#$S.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XY M-S4\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG M/@T*($]T:&5R(')E9VEO;G,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XQ-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS M,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P M+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P M+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C$W+#DS,SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X- M"B`\+W1R/@T*(#QT"<^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L M,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP M+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA! M,#L\+W1D/@T*(#PO='(^#0H@/"$M+2!%;F0@5&%B;&4@0F]D>2`M+3X\+W1A M8FQE/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3 M25I%.B`Q,G!T.R!-05)'24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`- M"B`-"B`\+V1I=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0G/@T* M(#QI/CQU/E!R:6YC:7!L97,@;V8@0V]N2UO=VYE9"!S=6)S:61I87)Y+"!$ M3D$@1V5N;W1E:RP@26YC+@T*("@F(W@R,#%#.T1.0465A$$P.S,Q+"`R,#$S+B!297-U;'1S(&]F(&]P97)A=&EO;G,@9F]R#0H@=&AE M('1H'0^)SQD:78^#0H@/'`@'!E;G-EF5D(&EN(&EM<&%I'!E M'0^)SQD:78^#0H@ M/'`@F5D M(&=A:6YS(&%N9"!L;W-S97,L(&EF(&%N>2P@6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@1D].5"U325I%.B`Q<'@[ M($U!4D=)3BU43U`Z(#$R<'@G/@T*("8C>$$P.SPO<#X-"B`\<"!S='EL93TS M1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,'!T)SX-"B!/ M=7(@879A:6QA8FQE+69O$$P M.S,Q+"`R,#$S+"!W92!H860@;F\-"B!A=F%I;&%B;&4M9F]R+7-A;&4@'0^ M)SQD:78^#0H@/'`@6EN9R!V86QU97,@;V8@8V%S:"P@6QE/3-$)TU!4D=) M3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T)SX-"B!792!O9F9E M65E$$P.S,Q M+"`R,#$S('=A2P@86YD M('=A6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q M,G!T)SX-"B!!;&P@;V8@;W5R(&%V86EL86)L92UF;W(M$$P.S,P+"`R,#$T+CPO M<#X-"B`\+V1I=CX\6QE/3-$)TU!4D=)3BU"3U143TTZ M(#!P=#L@1D].5"U325I%.B`Q,G!T.R!-05)'24XM5$]0.B`P<'0G/@T*("8C M>$$P.SPO<#X-"B`\=&%B;&4@$$P.R8C>$$P.SPO M=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.S,P M+"8C>$$P.S(P,30\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P M="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&YO=W)A<#TS M1&YO=W)A<"!A;&EG;CTS1&-E;G1E$$P.S,Q M+"8C>$$P.S(P,3,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%)A=R!M M871E$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8L-S`P/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS M1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%- M24Q9.B!4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#XY,S<\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C,L.3$Q/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT M6QE/3-$)T9/3E0M4TE:13H@.'!T M)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XQ-"PX-#,\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@ M,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P M.SPO=&0^#0H@/"]T'0^ M)SQD:78^#0H@/'`@2!T;R!F;W)T>2!Y96%R2!A;F0@97%U:7!M96YT+"!A;F0@9G5R M;FET=7)E(&%N9"!F:7AT=7)E65AF5D(&]V97(-"B!T:&5I2!G86EN(&]R(&QO$$P.S,P+"`R M,#$T(&%N9"!$96-E;6)E$$P.S,Q+"`R,#$S#0H@=V%S("0S,"PV,#,@ M86YD("0R."PS.3`L(')E2X\+W`^#0H@/"]D:78^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^ M)SQD:78^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O M;&ED)R!V86QI9VX],T1B;W1T;VT@86QI9VX],T1C96YT97(^/&(^06UOF%T:6]N/"]B/CQB$$P.RA996%R$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O M;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P M="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$ M8V5N=&5R/CQB/D%C8W5M=6QA=&5D/&)R("\^#0H@06UOF%T:6]N/"]B M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@ M5$585"U)3D1%3E0Z("TQ96TG/@T*($-U$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1&-E;G1E$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C M>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@ M5$585"U)3D1%3E0Z("TQ96TG/@T*(%!A=&5N=',@86YD('!R;V1U8W0@$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@W+#@T-#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T M6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E M;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($%C<75I$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1&-E;G1E$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XX+#8Y,CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,RPV.#(\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C4L,#$P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1&-E;G1E$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T M$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/ M3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XS-"PV,C`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^ M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@ M8V]L6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P M,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$8V5N=&5R M/CQB/D%M;W)T:7IA=&EO;CQB$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED M)R!V86QI9VX],T1B;W1T;VT@8V]L$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S M;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N M=&5R/CQB/D%C8W5M=6QA=&5D/&)R("\^#0H@06UOF%T:6]N/"]B/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$58 M5"U)3D1%3E0Z("TQ96TG/@T*($-U$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1&-E;G1E$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P M.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$58 M5"U)3D1%3E0Z("TQ96TG/@T*(%!A=&5N=',@86YD('!R;V1U8W0@$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@W+#0V-CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@ M5$585"U)3D1%3E0Z("TQ96TG/@T*($%C<75I$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1&-E;G1E$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XY+#$V,CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#XH,BPY-3(\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/C8L,C$P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1&-E M;G1E$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@ M5$585"U)3D1%3E0Z("TQ96TG/@T*($YO;BUC;VUP971E(&%G$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1&-E;G1E$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T* M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS-BPW,30\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE: M13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@'0^)SQD:78^#0H@/'`@2!A8V-E M<'1E9"!A8V-O=6YT:6YG('!R:6YC:7!L97,@<&5R;6ET('5S('1O(&UA:V4@ M80T*('%U86QI=&%T:79E(&5V86QU871I;VX@86)O=70@=&AE(&QI:V5L:6AO M;V0@;V8@9V]O9'=I;&P@:6UP86ER;65N="X-"B!)9B!W92!C;VYC;'5D92!T M:&%T(&ET(&ES(&UO#(P,3D[2X-"B!4:&4@2!I;7!A:7)M96YT(&)Y(&-O;7!A#(P,3D[2!I;B!T:&4@9FES8V%L M('1H:7)D('%U87)T97(L(&]R('-O;VYE$$P.S,P+"`R,#$T+"!W M92!B96QI979E(&YO#0H@:6YD:6-A=&]R6QE/3-$)TU!4D=)3BU"3U14 M3TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T)SX-"B`\:3X\=3Y2979E;G5E M(%)E8V]G;FET:6]N/"]U/BX\+VD^(%=E(')E8V]G;FEZ92!P&-E<'0@9F]R('=A M2!I6QE/3-$)T9/3E0M4TE:13H@ M.#4E.R!615)424-!3"U!3$E'3CH@=&]P)SXF(WA!13L\+W-U<#X@26XM2&]M M92!(258@=&5S=`T*(&EN('1H92!T:&ER9"!Q=6%R=&5R(&]F(#(P,3(N($9R M;VT@;&%U;F-H('1H2X@56YD M97(@52Y3+B!G96YE$%%.SPO2!W92!D:60@;F]T(')E8V]G;FEZ92!R M979E;G5E('=H96X@=V4-"B!S:&EP<&5D('1O('1H92!R971A:6P@=')A9&4N M($9O2!I;G1O(&]U'!E8W1E9"!R971U6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T)SX- M"B!/=7(@;F5T(')E=F5N=65S(')E8V]R9&5D(&]N('-A;&5S(&]F('1H92!/ M$%%.SPO2!A=F%I;&%B;&4-"B!I;F9O6QE/3-$ M)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T)SX-"B!2 M;WEA;'1Y(&EN8V]M92!FF5D#0H@9'5R:6YG('1H92!P97)I;V0@:6X@=VAI8V@@ M=&AE(')E=F5N=64@:7,@96%R;F5D(&%N9"!T:&4@86UO=6YT(&ES#0H@9&5T M97)M:6YA8FQE(&9R;VT@=&AE(&QI8V5N6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T M)SX-"B!792!R96-O&5S(&%S&5S+"!A M#(P,40[*2P@=&\@8V\M<')O;6]T92!O=7(-"B!/$%%.SPO6QE/3-$)TU!4D=) M3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T)SX-"B!5;F1E6QE/3-$)T9/3E0M4TE:13H@.#4E.R!615)424-! M3"U!3$E'3CH@=&]P)SXF(WA!13L\+W-U<#X@2$-6(%)A<&ED('1E'!E6QE/3-$)TU!4D=)3BU"3U143TTZ M(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T)SX-"B!);B!E>&-H86YG92!F;W(@ M=&AE$$P.S,Q+"`R,#$Y+B!792!W:6QL(')E8V]G;FEZ92!R M979E;G5E2P@;W9E7!I8V%L(&]F#0H@86=R965M96YT6UE;G1S(')E8V5I=F5D('5N9&5R('1H:7,@86=R965M M96YT#0H@=VEL;"!B92!R96-O'0^)SQD:78^#0H@/'`@&-E<'0@9F]R#0H@;W5R($]R85%U:6-K/'-U<"!S='EL93TS M1"=&3TY4+5-)6D4Z(#@U)3L@5D525$E#04PM04Q)1TXZ('1O<"<^)B-X044[ M/"]S=7`^($EN+4AO;64@2$E6#0H@=&5S="X@06-C;W)D:6YG;'DL('=E(&AA M=F4@2X-"B!)9B!A8W1U86P@<')O9'5C="!R971U M2!F0T*(&%F9F5C=&5D+CPO<#X-"B`\+V1I=CX\6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!- M05)'24XM5$]0.B`Q,G!T)SX-"B`\:3X\=3Y497)M:6YA=&EO;B!3971T;&5M M96YT+CPO=3X\+VD^($]N($YO=F5M8F5R)B-X03`[,C$L(#(P,3,L('=E#0H@ M=&5R;6EN871E9"!O=7(@87-S87D@9&5V96QO<&UE;G0@8V]L;&%B;W)A=&EO M;B!W:71H(%)O8VAE#0H@1&EA9VYO#(P,4,[4F]C:&4F(W@R M,#%$.RDN(%!U'!E;G-E(&EN(&]U2!I;B!T:&%T(&9I=F4M>65A2!O8FQI M9V%T:6]N('=A6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)' M24XM5$]0.B`Q,G!T)SX-"B`\:3X\=3Y$969E$$P.S,Q+"`R M,#$S(&EN8VQU9&5S(&-U6UE;G1S(&]F("0W,3,@86YD M#0H@)#$L,3$Y+"!R97-P96-T:79E;'DN($1E9F5RF5D#0H@2!I;B!R979E;G5E M+CPO<#X-"B`\+V1I=CX\6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0 M.B`Q,G!T)SX-"B`\:3X\=3Y#=7-T;VUE$$P.S,P+"`R,#$T(&%N9"!T:&4@=&AR M964@;W(@;FEN92!M;VYT:',-"B!E;F1E9"!397!T96UB97(F(WA!,#LS,"P@ M,C`Q,RX\+W`^#0H@/'`@2!P=7)C:&%S92!C M97)T86EN('!R;V1U8W1S(&%N9"!C7,@:6X-"B!T:&4@9&5L:79E2!T;R!H M879E(&$@=&EM96QY('-U<'!L>2!O9B!A;GD@;V8@=&AE6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T)SX- M"B`\=3X\:3Y%87)N:6YG2!D:79I9&EN9R!N970@:6YC;VUE("AL;W-S*2!B>2!T:&4-"B!W96EG:'1E M9"UA=F5R86=E(&YU;6)E&-E<'0@=&AA="!T:&4-"B!W96EG:'1E9"!A=F5R86=E(&YU;6)E2!A#L@ M34%21TE.+51/4#H@,3)P>"<^#0H@)B-X03`[/"]P/@T*(#QP('-T>6QE/3-$ M)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`P<'0G/@T*(%1H M92!C;VUP=71A=&EO;G,@;V8@8F%S:6,@86YD(&1I;'5T960@96%R;FEN9W,@ M*&QO6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<] M,T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#DR)2!A;&EG;CTS1&-E;G1E M$$P M.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@Q+#@Y M,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/B@Q+#DV,CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/B@Q-RPT,#,\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$ M)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2 M1TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%=E:6=H=&5D M(&%V97)A9V4@6QE M/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T M)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@ M.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4V+#`Q.#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE M/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4U+#4Y,CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C4U+#@Y-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4U+#4S M-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/ M3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C8T.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T M)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[ M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[ M/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,7!X M)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C M>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@ M5$585"U)3D1%3E0Z("TQ96TG/@T*($5A6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ M96TG/@T*($)A6QE/3-$ M)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XH,"XP,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/B@P+C,Q/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X- M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T9/3E0M4TE: M13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#XH,"XP,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/B@P+C,Q/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#XI)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T* M(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\<"!S M='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3)P M="<^#0H@1F]R('1H92!T:')E92UM;VYT:"!P97)I;V1S(&5N9&5D(%-E<'1E M;6)E$$P.S,P+"`R,#$T(&%N9"`R,#$S+`T*(&]U='-T86YD:6YG(&-O M;6UO;B!S=&]C:R!O<'1I;VYS(&%N9"!U;G9E2P@=V5R92!S:6UI;&%R;'D@97AC;'5D960@9G)O;2!T:&4@8V]M<'5T M871I;VX@;V8-"B!D:6QU=&5D(&5A2!4'0^)SQD:78^#0H@/'`@&-H86YG92!R871E6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T)SX- M"B!4'0^)SQD:78^#0H@/'`@0T*(&ET96US(&]F(&]T:&5R(&-O;7!R96AE;G-I M=F4@;&]S2!T:&5I#(P,3D[(&5Q=6ET>2!S96-T:6]N(&]F(&]U2P@1$Y!1RP@86YD(&%S('-U8V@L('1H92!R M97-U;'1S(&]F(&ET2!O9B!T:&4@0V]M<&%N>2X@5&AE("0R+#0U,2!A;F0@)#$L-S`Y(&-U M2!T:&4@6QE/3-$)TU! M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T)SX-"B`\:3X\ M=3Y296-E;G0@06-C;W5N=&EN9R!02!O9B!R979E;G5E M(&=L;V)A;&QY+B!4:&4@8V]R90T*('!R:6YC:7!L92!O9B!T:&4@2!T;R!R96-O9VYI>F4@3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%\Y-6-C.&9F9%]B930Y7S0Q93E?.&1F,%]D8S0T8CEE83=D,#0- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.35C8SAF9F1?8F4T.5\T M,64Y7SAD9C!?9&,T-&(Y96$W9#`T+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^)SQS<&%N/CPO6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T)SX- M"B`\:3X\=3Y);G9E;G1O6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L M$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE. M+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%=O$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CDS-SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XX,S,\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P M.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2 M1TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($9I;FES:&5D M(&=O;V1S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P M.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\ M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS M1'1O<#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C$T+#@T,SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@ M.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XQ,2PT-#0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q M,G!T.R!-05)'24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@ M6QE/3-$)T9/3E0M4TE:13H@ M.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.S,P+"`R,#$T/"]B/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R M('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$8V5N=&5R/CQB/D%M;W)T:7IA=&EO M;CPO8CX\8G(@+SX-"B`\8CY097)I;V0F(WA!,#LH665A6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@ M8V]L6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@8F=C;VQO$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS M1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%- M24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$P+#0T.3PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH-RPX-#0\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/C(L-C`U/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@ M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XU+#`Q,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0L,C@Y/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@X.3,\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/C,L,SDV/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@ M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[ M/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@Q-2PW M.#D\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/C$X+#@S,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R M/@T*(#QT"<^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L M6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@8F=C;VQO$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CDL,#DT/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O M<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9 M.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$P+#0T.3PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XH-RPT-C8\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C(L.3@S/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XV+#(Q,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0L-3(Q/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@W,34\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C,L.#`V/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XW.#<\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$6QE/3-$ M)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R M/@T*(#QT6QE/3-$)T9/3E0M4TE: M13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/B@Q-"PT.#@\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(R+#(R-CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X M03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)TU!4D=)3BU" M3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`P<'0G/@T*(%1H92!C;VUP=71A M=&EO;G,@;V8@8F%S:6,@86YD(&1I;'5T960@96%R;FEN9W,@*&QO6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]2 M1$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP M861D:6YG/3-$,"!W:61T:#TS1#DR)2!A;&EG;CTS1&-E;G1E$$P.R8C>$$P.SPO M=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P M.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO M=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^ M#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O M;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@Q+#@Y,CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/B@Q+#DV,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@Q-RPT M,#,\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M4TE: M13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z M(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%=E:6=H=&5D(&%V97)A9V4@ M6QE/3-$)T9/3E0M M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE M/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/"]T9#X-"B`\+W1R/@T*(#QT6QE M/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4V+#`Q.#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/C4U+#4Y,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/C4U+#@Y-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4U+#4S-#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X M03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M4TE:13H@ M.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C8T.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX] M,T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T M9#X-"B`\+W1R/@T*(#QT"<^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\ M+W1R/@T*(#QT$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^ M#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1% M3E0Z("TQ96TG/@T*($5A6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($)A M6QE/3-$)T9/3E0M4TE: M13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#XH,"XP,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/B@P+C,Q/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#XI)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T* M(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^ M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH M,"XP,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@P+C,Q/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X M03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\+V1I=CX\'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA'!E;G-E6%B;&5S(&%N9"!!8V-R=6%L6QE/3-$)T)/4D1%4BU# M3TQ,05!313I#3TQ,05!313L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N M.R!F;VYT+7-I>F4Z,3!P="<@86QI9VX],T1C96YT97(^#0H@/'1R/@T*(#QT M9"!W:61T:#TS1#8S)3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED M=&@],T0Q,R4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E/CPO=&0^ M#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]TF4Z.'!T)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E$$P.S,Q+"8C>$$P.S(P,3,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T'0M:6YD96YT.BTQ+C`P M96T[(&9O;G0M3I4:6UE7)O;&P@86YD(')E;&%T960@8F5N969I=',\+W`^#0H@/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C4L.#(W/"]T9#X-"B`\=&0@;F]W6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US M:7IE.C$P<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!2 M;WEA;'1I97,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#
$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT+#,W-#PO M=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$ M)VUA$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XT.#0\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)V9O M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.C$P<'0G/@T* M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@F4Z,3!P=#L@ M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!/=&AE$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L.3(S/"]T9#X-"B`\=&0@;F]W M6QE/3-$9F]N="US:7IE.C%P>#L^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)V)O$$P M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@3I4:6UE$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1&9O;G0M6QE/3-$9F]N="US:7IE.C%P>#L^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O6QE/3-$)V)O$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"=B;W)D97(M=&]P.C,N,#!P>"!D;W5B;&4@(S`P,#`P,"<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"=B;W)D97(M=&]P.C,N,#!P>"!D;W5B;&4@(S`P,#`P,"<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^)SQS<&%N/CPO2!O9B!396=M96YT($EN9F]R;6%T:6]N M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX-"B`\<"!S M='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,'!T M)SX-"B!4:&4@9F]L;&]W:6YG('1A8FQE('-U;6UA$$P.S,P+"`R,#$T(&%N9"`R,#$S.CPO<#X-"B`\ M<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3)P M=#L@34%21TE.+51/4#H@,'!T)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I M;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#DR)2!A;&EG;CTS1&-E M;G1E$$P.TUO;G1H$$P.T5N9&5D)B-X03`[4V5P=&5M M8F5R)B-X03`[,S`L/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L M$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/C$Y+#$$P.R8C>$$P.SPO=&0^#0H@ M/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z M(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($1.04<\+W`^#0H@/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#XV+#@V-SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#XT+#DV-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XQ-RPU,C,\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\ M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS M1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%- M24Q9.B!4:6UE$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(W M+#@T-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XR-"PV-S$\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C"<^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/ M3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/B@Y.#<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@R+#4Q-CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,3@L,#$R/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T M9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XT-38\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+#DS.#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/ M3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/B@R,3,\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T* M(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@ M/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C@X,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,BPP-C`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/B@R+#(S.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2 M1TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($]355(\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$ M)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XX,C`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/C(L,S@V/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(L,S@Y M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF M(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C M;VQO$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XX,3`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+#,T M-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(L-#4W/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M$$P M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@ M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L-C(T/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/C$L-C(U/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0L-S,R/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C0L.#0V/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R M('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1% M3E0Z("TQ96TG/@T*($-A<&ET86P@97AP96YD:71U$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O M<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9 M.B!4:6UE$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/C,V.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#@V.#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T M>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XQ+#`Y-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R M/@T*(#QT$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR,S4\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS M1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XT.#4\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XV M,#`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P M.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#5E;3L@5$58 M5"U)3D1%3E0Z("TQ96TG/@T*(%1O=&%L/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^ M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C8P-#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@ M.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR M+#,U,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#8Y-CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X- M"B`\+W1R/@T*(#QT"<^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO M='(^#0H@/"]T86)L93X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P M<'0[($9/3E0M4TE:13H@,3)P=#L@34%21TE.+51/4#H@,'!T)SX-"B`F(WA! M,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C M;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T M:#TS1#6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S M;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N M=&5R/CQB/E-E<'1E;6)E$$P.S,P+"8C>$$P.S(P,30\+V(^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T M=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/D1E8V5M8F5R)B-X M03`[,S$L)B-X03`[,C`Q,SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U) M3D1%3E0Z("TQ96TG/@T*($]355(\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4S M+#`X,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU,RPS M.3<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/ M3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/C$Y,"PU,#`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\+V1I=CX\6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#DR)2!A;&EG M;CTS1&-E;G1E$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/ M4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!T('-O;&ED)R!V86QI9VX],T1B M;W1T;VT@8V]L$$P.U-E<'1E;6)E$$P.S,P M+#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!T('-O;&ED M)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.TUO;G1H$$P.T5N9&5D)B-X03`[4V5P=&5M M8F5R)B-X03`[,S`L/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@ M.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]4 M5$]-.B!R9V(H,"PP+#`I(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O M;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,30\+V(^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$ M15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T M=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3,\+V(^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P="!S;VQI9"<@=F%L:6=N M/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,30\ M+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S M='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P="!S;VQI9"<@ M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB M/C(P,3,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO M=&0^#0H@/"]T2`M+3X-"B`\='(@6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%5N:71E M9"!3=&%T97,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C4X+#DX-SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS M+#(U,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+#4T M,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ,"PY,S4\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P M.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($]T M:&5R(')E9VEO;G,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR M+#$R-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS+#`W M.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XW+#@V,3PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XX+#(Y-SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[ M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\ M+W1R/@T*(#QT6QE/3-$)T9/3E0M M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#XR-RPX-#4\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C6QE/3-$)T9/ M3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XW,"PQ-S(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R M9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q! M4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$ M,"!W:61T:#TS1#6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%5N M:71E9"!3=&%T97,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C M>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@ M5$585"U)3D1%3E0Z("TQ96TG/@T*($-A;F%D83PO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/C$L,3,Y/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/CDW-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT M$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C$W/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/C,S/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R M('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T* M(#QT6QE/3-$)T9/3E0M4TE:13H@ M.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XQ-RPY-3@\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE: M13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L M,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1% M4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA&EM=6T@6TUE;6)E&EM=6T@6TUE;6)E M2!A;F0@17%U:7!M96YT(%M-96UB97)=/&)R/CPO=&@^#0H@ M("`@("`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`@("`@(#QT9"!C;&%S'0^)S(@>65A'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6UE;G1S(')E M8V5I=F5D(&9O'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO6UE;G1S('1O(&)E(')E8V5I M=F5D(&9O'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'!I'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6UE;G1S('=O=6QD(&)E(&)A'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!S97)V:6-E(&%G'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6UE;G0@'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA'0^)SQS<&%N/CPO3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Y-6-C.&9F9%]B930Y7S0Q M93E?.&1F,%]D8S0T8CEE83=D,#0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO.35C8SAF9F1?8F4T.5\T,64Y7SAD9C!?9&,T-&(Y96$W9#`T+U=O M'0O:'1M M;#L@8VAA'0^)SQS<&%N/CPOF%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M/B@S+#,W,"D\'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPOF%T:6]N/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M/B@W+#@T-"D\'0^)SQS<&%N/CPO M'0^)SQS M<&%N/CPO'0^)S,@>65A'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO MF%T:6]N(%!E65A65A'0^)S<@>65A'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPOF%T:6]N(%!E65A65A'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%\Y-6-C.&9F9%]B930Y7S0Q93E?.&1F,%]D8S0T8CEE M83=D,#0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.35C8SAF9F1? M8F4T.5\T,64Y7SAD9C!?9&,T-&(Y96$W9#`T+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S("T@ M0V]M<'5T871I;VYS(&]F($)A'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'1087)T7SDU8V,X9F9D7V)E-#E?-#%E.5\X9&8P7V1C-#1B.65A-V0P M-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\Y-6-C.&9F9%]B930Y M7S0Q93E?.&1F,%]D8S0T8CEE83=D,#0O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2`M($%D9&ET:6]N86P@26YF;W)M871I;VX@*$1E M=&%I;"D@*%531"`D*3QB6UE;G0@07=A'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO6UE;G0@07=A'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%\Y-6-C.&9F9%]B930Y7S0Q93E?.&1F,%]D8S0T8CEE83=D,#0-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.35C8SAF9F1?8F4T.5\T,64Y M7SAD9C!?9&,T-&(Y96$W9#`T+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'!E;G-E'0^)SQS<&%N/CPO7)O;&P@86YD(')E;&%T960@8F5N969I=',\+W1D M/@T*("`@("`@("`\=&0@8VQA'!E;G-E7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA"!$:7-C;&]S=7)E(%M!8G-T'0^ M)SQS<&%N/CPO"!B96YE9FET3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Y-6-C.&9F9%]B930Y7S0Q M93E?.&1F,%]D8S0T8CEE83=D,#0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO.35C8SAF9F1?8F4T.5\T,64Y7SAD9C!?9&,T-&(Y96$W9#`T+U=O M'0O:'1M M;#L@8VAA3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%\Y-6-C.&9F9%]B930Y7S0Q93E?.&1F,%]D8S0T8CEE83=D,#0-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.35C8SAF9F1?8F4T.5\T,64Y M7SAD9C!?9&,T-&(Y96$W9#`T+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPOF%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,#0\'0^)SQS<&%N/CPO'!E;F1I='5R97,\+W1D/@T*("`@("`@ M("`\=&0@8VQA'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`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` end XML 17 R8.htm IDEA: XBRL DOCUMENT v2.4.0.8

Summary of Significant Accounting Policies
9 Months Ended

Sep. 30, 2014

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Principles of Consolidation and Basis of Presentation. The consolidated financial statements include the accounts of OraSure Technologies, Inc. (“OraSure”) and its wholly-owned subsidiary, DNA Genotek, Inc. (“DNAG”). All intercompany transactions and balances have been eliminated. References herein to “we,” “us,” “our,” or the “Company” mean OraSure and its consolidated subsidiaries, unless otherwise indicated.

The accompanying consolidated financial statements are unaudited and, in the opinion of management, include all adjustments (consisting only of normal and recurring adjustments) necessary for a fair presentation of our financial position and results of operations for these interim periods. These financial statements should be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013. Results of operations for the three and nine months ended September 30, 2014 are not necessarily indicative of the results of operations expected for the full year.

Use of Estimates. The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Such estimates include the valuation of accounts receivable and inventories and assumptions utilized in impairment testing for intangible assets and goodwill, as well as calculations related to contingencies and accruals, among others. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis, using historical experience and other factors which management believes to be reasonable under the circumstances, including the current economic environment. We adjust such estimates and assumptions when facts and circumstances dictate. Illiquid credit markets, volatile equity and foreign currency markets, reductions in government funding and declines in consumer spending have combined to increase the uncertainty inherent in such estimates and assumptions. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic environment and other factors will be reflected in the financial statements in those future periods.

Short-Term Investments. We consider all short-term investments to be available-for-sale securities. These securities are comprised of guaranteed investment certificates with purchased maturities greater than ninety days. Available-for-sale securities are carried at fair value, based upon quoted market prices, with unrealized gains and losses, if any, reported in stockholders’ equity as a component of accumulated other comprehensive loss.

Our available-for-sale securities as of September 30, 2014 consisted of guaranteed investment certificates with amortized cost and fair value of $5,000. As of December 31, 2013, we had no available-for-sale securities.

Fair Value of Financial Instruments. As of September 30, 2014, the carrying values of cash, short-term investments, accounts receivable, accounts payable and accrued expenses approximate their respective fair values based on their short-term nature.

Fair value measurements of all financial assets and liabilities that are being measured and reported on a fair value basis are required to be classified and disclosed in one of the following three categories:

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

We offer a nonqualified deferred compensation plan for certain eligible employees and members of our Board of Directors. The assets of the plan are held in the name of the Company at a third-party financial institution. Separate accounts are maintained for each participant to reflect the amounts deferred by the participant and all earnings and losses on those deferred amounts. The assets of the plan are held in mutual funds and Company stock. The fair value of the plan assets as of September 30, 2014 and December 31, 2013 was $1,090 and $677, respectively, and was calculated using the quoted market prices of the assets as of those dates. All investments in the plan are classified as trading securities and measured as Level 1 instruments. The fair value of plan assets is included in other assets with the same amount included in other liabilities in the accompanying consolidated balance sheets.

All of our available-for-sale securities were classified and measured as Level 1 instruments as of September 30, 2014.

Inventories. Inventories are stated at the lower of cost or market determined on a first-in, first-out basis and are comprised of the following:

 September 30, 2014 December 31, 2013

Raw materials
 $ 6,772 $ 6,700

Work in process
 937 833

Finished goods
 7,134 3,911





 $ 14,843 $ 11,444





Property and Equipment. Property and equipment are stated at cost. Additions or improvements are capitalized, while repairs and maintenance are charged to expense. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. Buildings are depreciated over twenty to forty years, while computer equipment, machinery and equipment, and furniture and fixtures are depreciated over two to ten years. Building improvements are amortized over their estimated useful lives. When assets are sold or otherwise disposed of, the related property amounts are relieved from the accounts, and any gain or loss is recorded in the consolidated statement of operations. Accumulated depreciation of property and equipment as of September 30, 2014 and December 31, 2013 was $30,603 and $28,390, respectively.

Intangible Assets. Intangible assets consist of the following:

 September 30, 2014

 Amortization
Period (Years) Gross Accumulated
Amortization Net

Customer list
 10 $ 11,190 $ (3,370 ) $ 7,820

Patents and product rights
 3-10 10,449 (7,844 ) 2,605

Acquired technology
 7 8,692 (3,682 ) 5,010

Tradename
 15 4,289 (893 ) 3,396





 $ 34,620 $ (15,789 ) $ 18,831





 December 31, 2013

 Amortization
Period(Years) Gross Accumulated
Amortization Net

Customer list
 10 $ 11,795 $ (2,701 ) $ 9,094

Patents and product rights
 3-10 10,449 (7,466 ) 2,983

Acquired technology
 7 9,162 (2,952 ) 6,210

Tradename
 15 4,521 (715 ) 3,806

Non-compete agreements
 1-3 787 (654 ) 133





 $ 36,714 $ (14,488 ) $ 22,226





Goodwill. Goodwill represents the excess of the purchase price we paid over the fair value of the net tangible and identifiable intangible assets acquired and liabilities assumed in our acquisition of DNAG in August 2011. Goodwill is not amortized but rather is tested annually for impairment or more frequently if we believe that indicators of impairment exist. Current U.S. generally accepted accounting principles permit us to make a qualitative evaluation about the likelihood of goodwill impairment. If we conclude that it is more likely than not that the fair value of a reporting unit is greater than its carrying amount, then we would not be required to perform the two-step quantitative impairment test. Otherwise, performing the two-step impairment test is necessary. The first step of the two-step quantitative impairment test involves comparing the fair value of the applicable reporting unit with its aggregate carrying value, including goodwill. If the carrying value of a reporting unit exceeds the reporting unit’s fair value, we perform the second step of the test to determine the amount of the impairment loss, if any. The second step involves measuring any impairment by comparing the implied fair values of the affected reporting unit’s goodwill and intangible assets with their respective carrying values.

We performed our last annual impairment assessment as of July 31, 2014 utilizing a qualitative evaluation and concluded that it was more likely than not that the fair value of our DNAG reporting unit is greater than its carrying amount. We believe we have made reasonable estimates and assumptions to calculate the fair value of our reporting unit. If actual future results are not consistent with management’s estimates and assumptions, we may have to take an impairment charge in the future related to our goodwill. Future impairment tests will continue to be performed annually in the fiscal third quarter, or sooner if a triggering event occurs. As of September 30, 2014, we believe no indicators of impairment exist.

The change in goodwill from $23,782 as of December 31, 2013 to $22,562 as of September 30, 2014 is a result of foreign currency translation.

Revenue Recognition. We recognize product revenues when there is persuasive evidence that an arrangement exists, the price is fixed or determinable, title has passed and collection is reasonably assured. Product revenues are recorded net of allowances for any discounts or rebates. Other than for our OraQuick^® In-Home HIV test, we do not grant price protection or product return rights to our customers, except for warranty returns. Historically, returns arising from warranty issues have been infrequent and immaterial. Accordingly, we expense warranty returns as incurred.

We began selling our OraQuick^® In-Home HIV test in the third quarter of 2012. From launch through November 2013, our revenue recognition practices with respect to the OraQuick^® In-Home HIV test were different than those customarily used in the consumer package goods industry. Under U.S. generally accepted accounting principles, product revenue cannot be recognized unless the amount of future returns can be reasonably estimated. Because our OraQuick^® In-Home HIV test was a new product for which we did not have a historical record of returns, we did not believe we could reasonably determine a return rate. As a result, initially we did not recognize revenue when we shipped to the retail trade. For these product shipments, we invoiced the retailer or distributor, recorded deferred revenue at gross invoice sales price, and classified the cost basis of the product held by the retailer or distributor as a component of inventory. We then recognized revenue upon the consummation of a sale to the consumer either in a store or over the internet. With the passage of time, however, we concluded that we have sufficient data and visibility into our distribution channel to develop a reasonable estimate of the level of expected returns. As such, commencing in December 2013, we recognized previously deferred revenue and its related cost of goods sold, and began to recognize revenue for this product upon shipment to the retailers or distributors. Accordingly, revenues in the first nine months of 2014 were recorded based upon shipments into the distribution channel, while revenues in the first nine months of 2013 were recorded based upon the consummation of a sale to the consumer.

Our net revenues recorded on sales of the OraQuick^® In-Home HIV test represent total gross revenues, less an allowance for expected returns, and customer allowances for cooperative advertising discounts, rebates, and chargebacks. All of these allowances are estimates established by management, based on currently available information and are adjusted to reflect known changes in the factors that impact those estimates. These allowances are recorded as a reduction of gross revenue when recognized in our statements of operations.

Royalty income from the grant of license rights is recognized during the period in which the revenue is earned and the amount is determinable from the licensee and is recorded as licensing and product development revenue in our statements of operations.

We record shipping and handling charges billed to our customers as product revenue and the related expense as cost of products sold. Taxes assessed by governmental authorities, such as sales or value-added taxes, are excluded from product revenues.

On June 10, 2014, we entered into a Master Program Services and Co-Promotion Agreement with AbbVie Bahamas Ltd., a wholly-owned subsidiary of AbbVie Inc. (“AbbVie”), to co-promote our OraQuick^® HCV Rapid Test in the United States. The product will be used to test individuals at-risk for the hepatitis C virus (“HCV”). We will be responsible for manufacturing and selling the product into all markets.

Under the terms of our agreement, we have granted exclusive promotion rights to AbbVie for the OraQuick^® HCV Rapid test in certain markets and we have agreed to develop, implement, administer and maintain a patient care database for the exclusive use of AbbVie. This patient care database will be used to compile patient information regarding new individuals who have tested positive for HCV using our OraQuick^® HCV Rapid test. We have also jointly agreed with AbbVie to co-promote our OraQuick^® HCV Rapid test in certain market segments, namely: healthcare providers such as primary care physicians, gastroenterologists, hepatologists and infectious disease specialists; employers and employee groups experiencing a high HCV prevalence rate, such as the long-haul trucking industry; and national retail pharmacies and retail clinics that perform routine healthcare screening services.

In exchange for these exclusive rights and other services, we will receive up to $75,000 in payments over the term of the agreement which expires on December 31, 2019. We will recognize revenues from these periodic payments ratably, over the life of the agreement. In addition, if certain performance-based milestones are achieved, we could be eligible to receive additional milestone payments. These payments would be based upon the aggregate number of new patients enrolled in the patient care database, in a given calendar year, after exceeding a baseline threshold, and could range from $3,500 to $55,500 annually over the life of the agreement. The first performance-based milestone period ends on December 31, 2015. The agreement also contains certain termination, indemnification and other provisions, typical of agreements of this type. Payments received under this agreement will be recorded as licensing and product development revenue in our statements of operations.

Customer Sales Returns and Allowances. We do not grant return rights to our customers for any product, except for our OraQuick^® In-Home HIV test. Accordingly, we have recorded an estimate of expected returns as a reduction of gross OraQuick^® In-Home HIV product revenues in our consolidated statements of operations. This estimate reflects our historical sales experience to retailers and consumers, as well as other retail factors, and is reviewed regularly to ensure that it reflects potential product returns. As of September 30, 2014 and December 31, 2013, the reserve for sales returns and allowances was $398 and $279, respectively. If actual product returns differ materially from our reserve amount, or if a determination is made that this product’s distribution would be discontinued in whole or in part by certain retailers, then we would need to adjust our reserve. Should the actual level of product returns vary significantly from our estimates, our operating and financial results could be materially affected.

Termination Settlement. On November 21, 2013, we terminated our assay development collaboration with Roche Diagnostics (“Roche”). Pursuant to a termination agreement, Roche paid us $8,300 which was recorded as a reduction of operating expense in our consolidated statement of operations for the quarter ended December 31, 2013. Roche agreed to provide certain transitional product support services to us and to continue to supply certain of the assays developed under the collaboration on a transitional basis for up to five years following the termination. We had the right to stop the supply of assays prior to the end of this five-year period and to receive an additional payment from Roche of up to $5,500 depending on how early in that five-year period the supply obligation was ended. During the second quarter of 2014, we issued our final purchase order for fully-automated assays previously developed under the terminated collaboration and as such, have recorded $5,500 as a reduction of operating expense in our consolidated statement of operations.

Deferred Revenue. We record deferred revenue when funds are received prior to the recognition of the associated revenue. Deferred revenue at September 30, 2014 and December 31, 2013 includes customer prepayments of $713 and $1,119, respectively. Deferred revenue also includes $10,827 which represents the $15,000 payment received in July 2014 under the terms of our HCV collaboration with AbbVie, less amounts recognized ratably in revenue.

Customer and Vendor Concentrations. We had no significant concentrations (greater than 10%) in accounts receivable as of September 30, 2014. One of our customers, AbbVie, accounted for approximately 12% of our net revenues for the three months ended September 30, 2014. We had no significant concentrations (greater than 10%) in net revenues for the nine months ended September 30, 2014 and the three or nine months ended September 30, 2013.

We currently purchase certain products and critical components of our products from sole-supply vendors, and if these vendors are unable or unwilling to supply the required components and products, we could be subject to increased costs and substantial delays in the delivery of our products to our customers. Also, our subsidiary, DNAG, uses two third-party suppliers to manufacture its products. Our inability to have a timely supply of any of these components and products could have a material adverse effect on our business, as well as our financial condition and results of operations.

Earnings (Loss) Per Share. Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings (loss) per share is computed in a manner similar to basic earnings (loss) per share except that the weighted average number of shares outstanding is increased to include incremental shares from the assumed vesting or exercise of dilutive securities, such as common stock options and unvested restricted stock, unless the impact is antidilutive. The number of incremental shares is calculated by assuming that outstanding stock options were exercised and unvested restricted shares were vested, and the proceeds from such exercises or vesting were used to acquire shares of common stock at the average market price during the reporting period.

The computations of basic and diluted earnings (loss) per share are as follows:

 Three Months
Ended September 30, Nine Months
Ended September 30,

 2014 2013 2014 2013

Net income (loss)
 $ 1,140 $ (1,892 ) $ (1,962 ) $ (17,403 )





Weighted average shares of common stock outstanding:


Basic
 56,018 55,592 55,897 55,534

Dilutive effect of stock options and restricted stock
 648 — — —





Diluted
 56,666 55,592 55,897 55,534





Earnings (loss) per share:


Basic
 $ 0.02 $ (0.03 ) $ (0.04 ) $ (0.31 )





Diluted
 $ 0.02 $ (0.03 ) $ (0.04 ) $ (0.31 )





For the three-month periods ended September 30, 2014 and 2013, outstanding common stock options and unvested restricted stock, representing 2,647 and 5,499 shares, respectively, were excluded from the computation of diluted earnings (loss) per share, as their inclusion would have been anti-dilutive. For the nine months ended September 30, 2014 and 2013, outstanding common stock options and unvested restricted stock, representing 3,313 and 5,324 shares, respectively, were similarly excluded from the computation of diluted earnings (loss) per share.

Foreign Currency Translation. The assets and liabilities of our foreign operations are translated into U.S. dollars at current exchange rates as of the balance sheet date, and revenues and expenses are translated at average exchange rates for the period. Resulting translation adjustments are reflected in accumulated other comprehensive loss, which is a separate component of stockholders’ equity.

Transaction gains and losses resulting from exchange rate changes on transactions denominated in currencies other than functional currency are included in income in the period in which the change occurs.

Accumulated Other Comprehensive Loss. We classify items of other comprehensive loss by their nature and disclose the accumulated balance of other comprehensive loss separately from accumulated deficit and additional paid-in capital in the stockholders’ equity section of our balance sheet.

We have defined the Canadian dollar as the functional currency of our Canadian subsidiary, DNAG, and as such, the results of its operations are translated into U.S. dollars, which is the reporting currency of the Company. The $2,451 and $1,709 currency translation adjustments recorded in the first nine months of 2014 and 2013, respectively, are largely the result of the translation of our Canadian operation’s balance sheets into U.S. dollars.

Recent Accounting Pronouncements. In May 2014, the Financial Accounting Standards Board (“FASB”) issued converged guidance on recognizing revenue in contracts with customers, ASU 2014-09 Revenue from Contracts with Customers. The intent of the new standard is to improve financial reporting and comparability of revenue globally. The core principle of the standard is for a company to recognize revenue in a manner that depicts the transfer of goods or services to customers in an amount that reflects the consideration which the company expects to receive in exchange for those goods or services. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2016, with no early adoption permitted. We will evaluate the effects, if any, which adoption of this guidance will have on our consolidated financial statements.

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for all significant accounting policies of the reporting entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18726-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18861-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18743-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18854-107790

+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 18 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8

Consolidated Balance Sheets (USD $)
In Thousands, unless otherwise specified

Sep. 30, 2014

Dec. 31, 2013

CURRENT ASSETS:

Cash $ 93,855 $ 93,191

Short-term investments 5,000

Accounts receivable, net of allowance for doubtful accounts of $288 and $299 14,920 12,957

Inventories 14,843 11,444

Prepaid expenses 1,089 1,712

Deferred income taxes 67 71

Other current assets 273 200

Total current assets 130,047 119,575

PROPERTY AND EQUIPMENT, net 17,958 17,933

INTANGIBLE ASSETS, net 18,831 22,226

GOODWILL 22,562 23,782

OTHER ASSETS 1,102 729

TOTAL ASSETS 190,500 184,245

CURRENT LIABILITIES:

Accounts payable 4,510 4,834

Deferred revenue 11,540 1,119

Accrued expenses 9,203 13,032

Total current liabilities 25,253 18,985

OTHER LIABILITIES 1,090 677

DEFERRED INCOME TAXES 3,233 3,437

COMMITMENTS AND CONTINGENCIES (Note 6)

STOCKHOLDERS' EQUITY

Preferred stock, par value $.000001, 25,000 shares authorized, none issued

Common stock, par value $.000001, 120,000 shares authorized, 56,052 and 55,632 shares issued and outstanding

Additional paid-in capital 342,865 338,674

Accumulated other comprehensive loss (6,248) (3,797)

Accumulated deficit (175,693) (173,731)

Total stockholders' equity 160,924 161,146

Total liabilities and stockholders' equity $ 190,500 $ 184,245

X

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3-4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph a(1)

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e681-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14A

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669686-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AdditionalPaidInCapitalCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 9

-Article 5

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 25

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 7

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 17

-Article 9

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.17)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.(a),19)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards expected to be realized or consumed within one year or operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31917-109318

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31931-109318

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31928-109318

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31958-109318

+ Details

Name: us-gaap_DeferredTaxAssetsNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of deferred tax liability attributable to taxable temporary differences, net of deferred tax asset attributable to deductible temporary differences and carryforwards net of valuation allowances expected to be realized or consumed after one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31917-109318

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31931-109318

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31958-109318

+ Details

Name: us-gaap_DeferredTaxLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph ((a)(1),(b))

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6386567&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 32

-Article 5

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 21

-Article 5

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Aggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.8)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

+ Details

Name: us-gaap_OtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 17

-Article 5

+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 24

-Article 5

+ Details

Name: us-gaap_OtherLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The cumulative amount of the reporting entity's undistributed earnings or deficit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Investments which are intended to be sold in the short term (usually less than one year or the normal operating cycle, whichever is longer) including trading securities, available-for-sale securities, held-to-maturity securities, and other short-term investments not otherwise listed in the existing taxonomy.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.2)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Subparagraph g

-Article 7

+ Details

Name: us-gaap_ShortTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 19 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8

Consolidated Statements of Cash Flows (USD $)
In Thousands, unless otherwise specified
9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

OPERATING ACTIVITIES:

Net loss $ (1,962) $ (17,403)

Adjustments to reconcile net loss to net cash provided by (used in) operating activities:

Stock-based compensation 4,284 4,187

Depreciation and amortization 4,732 4,846

Unrealized foreign currency loss (73)

Deferred income taxes (33) (786)

Changes in assets and liabilities

Accounts receivable (2,111) 3,127

Inventories (3,444) 745

Prepaid expenses and other assets 576 (554)

Accounts payable (284) 497

Deferred revenue 10,433 (1,098)

Accrued expenses and other liabilities (3,734) 3,297

Net cash provided by (used in) operating activities 8,384 (3,142)

INVESTING ACTIVITIES:

Purchases of short term investments (9,407)

Proceeds from maturities of short term investments 4,432

Purchases of property and equipment (2,353) (1,696)

Net cash used in investing activities (7,328) (1,696)

FINANCING ACTIVITIES:

Proceeds from exercise of stock options 546 317

Repurchase of common stock (639) (817)

Net cash used in financing activities (93) (500)

EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH (299) 40

NET INCREASE (DECREASE) IN CASH 664 (5,298)

CASH, BEGINNING OF PERIOD 93,191 87,888

CASH, END OF PERIOD 93,855 82,590

Cash paid for:

Income taxes $ 42 $ 28

X

- Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906

+ Details

Name: us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 20

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450189&loc=d3e30690-110894

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 20

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6450189&loc=d3e30700-110894

+ Details

Name: us-gaap_ForeignCurrencyTransactionGainLossUnrealized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

+ Details

Name: us-gaap_IncomeTaxesPaidNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Income Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6515339

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInDeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The net amount paid (received) by the reporting entity through acquisition or sale and maturities of short-term investments with an original maturity that is three months or less which qualify for treatment as an investing activity based on management's intention and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3095-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 9

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3098-108585

+ Details

Name: us-gaap_PaymentsForProceedsFromShortTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow to reacquire common stock during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3291-108585

+ Details

Name: us-gaap_PaymentsForRepurchaseOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquireShortTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (j)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 20 R22.htm IDEA: XBRL DOCUMENT v2.4.0.8

Stockholders' Equity - Additional Information (Detail) (USD $)
Share data in Thousands, unless otherwise specified
9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Total compensation cost $ 4,284,000 $ 4,187,000

Net cash proceeds from the exercise of stock options 546,000 317,000

Income tax benefit realized from stock option exercises during period 0 0

Restricted Stock [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Total compensation cost 1,998,000 2,159,000

Vesting of restricted shares, withheld and withholding obligations 106 122

Restricted shares of common stock, aggregate values 639,000 817,000

Stock Options [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Total compensation cost 2,286,000 2,028,000

Net cash proceeds from the exercise of stock options $ 546,000 $ 317,000

X

- Definition

The amount of adjustment to stockholders' equity associated with an employee's income tax withholding obligation as part of a net-share settlement of a share-based award.

+ References

No definition available.

+ Details

Name: us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of deferred tax expense from write-off of the deferred tax asset related to deductible stock options at exercise.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 20

-Section 55

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=32706628&loc=d3e11283-113907

+ Details

Name: us-gaap_DeferredTaxExpenseFromStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (j)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

For net-share settlement of share-based awards when the employer settles employees' income tax withholding obligations, this element represents the number of shares the employees use to repay the employer.

+ References

No definition available.

+ Details

Name: us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

ZIP 21 0001193125-14-403358-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-14-403358-xbrl.zip M4$L#!!0````(`+6!9T43'JWTKZH``&!0!P`1`!P`;W-U9)(&C<3P)HOL/_5F*_'0 MFOG1Q`_C2'[HO\BT__>/__YOO_X'0KWKZYX71Y$,0_G2^V,L0YGXF>Q]BM03 M8PD7Q[-'&67_W?ONIW+2BZ/>'^[UYQX]([W>0Y9-+\[/?_SX<98DD\77G(WC MQ_,>0HN?^&>QNHM>3YQ1V\"ZX!+F'!$",+B M&S8NF'&![?]=OCN>OB3!_4/6^\_Q?\'-V$#P!.M=GUV?+0'[N7<31RG<_3CU MHY>>$X:]:_54VKN6J4R>Y.1L_J7/WY.P!S2-T@_])7CJX[,XN3^'GV#GP9PZ M_>+."W4UW'!_&$1_*O*]WJ\^*-W_@^5W$]NVS_.KBUN#-.:4F)L64]SQ^MUI M4/7-<"LY_^/+YYOQ@WSTD8X`).7>]Z>O3][YZ??\N?F%\YP/F"!&%H],Y-L/ MY2M*Y?CL/GXZAPL5M\?I+"DM+$Y\^$CFTJ)NQS;#2\O)7J8RK5Q/?J7B%]0B M)EEY37/HQGEQL71K4'FK*&X-%K>FV32IQJFNJ&60\C+&(--9\E+]S/RB>HQI MC\V2!#1WW7/SJQ6PY?/XH?HA=:7B@<@/QFGU$_FE"DQ!]"33K/J9XEH%HC08 MKR%<,*[XC4C>@\9/UDJZ?9[$H3R?W_;ZU.RQ^HE)EIPK23F'.V02C%\?`*.P M_9DX0MISLRS9L#2XV@?ST>OE!B2\2',UNY9WO5R;+]2W?NBGP>,T5#J7?^8G M8X6HGMW(GWA(Y-V'OM(DM-"8L^=TLH=9J6^QS@M8/?@@RBUB_%X"(!)-;(9AAV?36 M'1@<<\:0&#(/<>(R9#%W@`8V,;@PAI;K\%L"F&YQ_R/!%C5A+;^>;\938`9# M=C&,LB![`ATK'+[$$FRF#N5WZEOA1&N:. MVYG\:Y9F*F;X*K/+NV_^\XX48DJN2Q2J+PTF!VD@V$5BQ`7B`X&1A0=#-&#$ M`R&AF+L>4$F)@HGMDB0T`+Q,V8&?/CC11/UO^'^SX,D/X=;4R09^DKP`'_[I MAS/9(JVP"S00HQ$2S'00-]D0.0/*T5"`BE!W(*@U5)I#;ZG9_VA10]%KB6"U M\&@DT,7P4YK.(*K8A9Q%5:Y!$7 M+,4M8X4*T3+8ZI5O@7>`F6@6(Z^%<:V16+G3F64/<1+\U35>4E!T!1)O!OJV M_+4XK_SD,KG)E'G(!?M*)OFS!^-=4MC;J4QNZ[F#N@0@_8_X+(=/*O&O@U6F MPU4R=Y/=9SFU^A^IH7-\,X!-8-\GWY7%7N5[/63;67]DJPTIZT440#B:)3.Y M-V)[)59=\NB>!%\^#G(_#7^',G?8T<1YC),L^"O__"J)@0_9RU7H1QE<4TYM M^KA/=+N_3R:NX-0A'L(4TC;.;8$<9MB(".XPSZ#N6_^-_#O2L"C4,G$!AP@V`=><7BRP"O9>8'D9P,_20">4U+ M1O8N&`<=!,O`_R-B&L(NVY7M6*K+/<#U)9/T-8[&764SA?2-45:&O0V&)M&3 M2:#^<'D4S3PIT'FATLVMWNPF0&P.;6$49;OK5!6E!DLYN1=.$[<_VC3 MU0"H>OUEF#GRASBEE:+D!?R^ZJM)SK)65 MU@.H`-H%>25#[AJ84<0'7-71.$:V.Q*(#2@?V(P18;J*GX#5IFP5:TV97;H. MP=.[D&!;0<:&EHMO`U*&/0I@??(S!")@OC(_N@_`3SMI*K-EY[6X,3*1/?0,I!(SCWC&R!T054(U;I6D&Z95+CGOCJW26D,:=R?3 M-#?S(]EA%0`B<(M7&>PU$!K9>VH^TE1R3PR.*V.0JIVFQ3W#QVD8OTAY+7/. MOP>S!E[8P%J4N15&I1A?QR]^V&FL)-\VJHPX],5K",,P_J'Z+49QXL6S[]G= M+%RD'M=R+(.G3J=.$%M22TL9=T'4M1W&0TA6:XQC3`0`GEF M&>7,98_=Q=_B>/(C",/N(200_%%JB/)^VV*]912?(O`/69R\7/L_OH"L)`'\ M>(N0G)$QQ*YP$6$4#*)M$60[`P/9Q'7=H>N8S!H5`BY,LPRH3=P^DS!>+<:EM6M.+(?>/>81HS+G*I:[MK977`;Q[:Q06LK< MK*OIZ`WF3Q^RMLN\[V4[H%2+33Z%GS5 MRJMW$M[BQRY+)%>,LVGU?D(5!%TJRPD_W#=\'HB0E.S6C=+2Z^J37;;S=L0DII5YI?+ MRD2I)L%T';:U^S[=9AA17:O`,&Y6N/9*?FVH+_Z6Q*WJ6_U**5$;64*SJ]N0 M%+A59_S%U]GC=YE)J>;7H(5`]X;3LF$;1N(.UP@T`$+#1UAN<*S''L@YI18 M;!'MCF>)#D4C_._!1*Z2ZXO_KSA9L/#;0R)3M2-Q)1-%9O_^;%Z?=##[:&'C6!-%V<@(#)9/#?,_R?<'._(RY<<.$) M;B-LXA'BU`,J"`\CT_(<8TBH,62.LIU%@9HP/76O7ZUH%#YD!,W!5^<;A`A MF`NQR"A)%-7J7<8-BB%6'0:?:.%7[@LZG$''.#-QHAY6QF>5)R MQ*WDYM+1EHD##L&TM.AQ]_RTF%7WJ,& M-4\%$J#,.>UNW8ZHD'PUWZ19EW*L-P'"?F; M=-\'M4`*T"!+V+7EI",*!)D::90P7"F0I;5-O0_]:8$VJH6?V:+S^M,"*4!_ M.*W?-EJA/\?LFGR;V`%Y+=\SGZTWL4,E\R:I/L:QJ872>?*#4-6_1G%RXX?R M1HYG2=Y[>`!D"XM\2(F%S3TK_,P3@Y&-#()M5>OTD&79+AIZ%O$(95BX2[FM MOG.Z'E)=Z'.;H8JFZ2&L;X\.>"GW MQ*-$VK"GJ@[)V=IC!Z<8)=(&P]4H$68)4Y/O$XT2:8/116>MEL.V-4ND#9;F MLT0(X>6:>FNS1-K@(Y5D'MU"B1%E1`=?#PE0'>[8X2:2/2M%][N$X[ M2:0%EJHM'WT\_TDFB;2`56WK,CW`.O4DD1;D64T2L36UW7^22",3]5L(5=2A M0F*7TZGVYEVT8;94A,),JZUY%X=`JG42E!;S+K2M@';G7;3!MV+>A38]\Y3S M+EH`K>9=F$0_-'**>110O`U+P+2%_63%Q9/99TO)D0+8!3!\^I;:R4Q$\W$Z(-%:1JN!6EA_9K M'F4F1`LF5+4TLS7S6IJ<"=$"*]5,""W&:6,F1!M""JII4GL=M"9&0K2!2A6N M"1B<*N_7QDB(=BI>:B2$,$GM\UKZ2(@F1R`<0H%:(Q#FJ4?A4PZ:@+"^?_9U MQL2^S=*K5'C[JNU]2#6:@O/(=4&`78`TG8ZU>L(_=SZVINTG.>!>A;[I`_[% M>QN%3;N(OX4#_D7VMF]N?HAU:_6`/RT.^#.]L^04!_R7\+=V<%LH-L/OD+KN M[E2'PTY#'`86$-MZ_GCBPV&G(45^P-^TC3WBHI-J4-,'M\UB>U"(]ZA!S1-' M%>=M2\]@.ZA!S9/B/1SPKZ!,XP>WK=P'V4;G#_B?ACB@08)V[8#_:4BA$A(B M.GW`OX(PG!G-%BVP4B!A='[$S&EHH]Z%M5)"[9[ZM$`)HB81F>]->YJ>>V`7 M<_EK![9=TI[F::/:TBW*+B-U$BSQQ_F+!H)H1WM'"JR$S@79MC%@!2=@ MT/T2$<*]H6M0BIAP7<095X*,&7(')C6XX=E$15#SV0]Y1E;JE]J$2FOWG!_" M61R\]8)PENURKA8$-@>_::#SFK/%J[-[A<<\U[5-A(EA(NZ*`7(Q-4&$70,[ M`X;)B-[RO+D5X3.V=*QX#8XR6+5][J;T/6#$Q%HBU3J)7U-2U.$.PS"T$W<[8MJL,:Z?!N..ZXNU55]R%)K! M!]&8*)*`0WS;%BN"`SD9)?&CVD><9;G47-[IWPCQU&P7?WB8/!C8=4U+4.0. M/0&>WZ5@,#E'F#L>HQP38GA`"=4JSK07(Q\%9RVE69&L8\G.456&[*`RU8@J M&CUV>&4AN*MB3,"1WMQX#&MLF#8=C3A235J(6YP@"[LVPH[P;`;4<@Q^FX_F M0V"V*YI%C@Y?"V-4>*K.K^QR#O@(=*DI4@8$VX2++_J@1=5`C54F88^O;J/NBV46C1-+E3MU%[A%#)BSSG^!;+43$;J!-?1.$E6$SNI7H M="\FEJZ\@XBGB4_^26(0`6RET]`"P@D52-2 M^5N*X]A?9/803_9Z]939>R6_C*:K4@J(I&O<127C='#67N*<*[#RI+GUNMRFON!X;-,QD%Z[.K[ MMC9Z&]NF"\^C@-60C@KEKLK0V M;0Q2'2Q:\?CN3HXA=AH^@P^+[N6UG\G+J/H(?Q>I0!49RIM-NT#:9A"T?<@N M4J#(>["]4OK9#&5-CC?7G6Y:>%4(MH4EJA.\Q=+U2"25/@1HP'L/D(=Q[MLZ M''F9:JR\]MJWC2"TFIX,0[6CIG+!Y$^Y1)@N@@57Q@RJ[7^LAU!G:,J53`*5 MA)3EOXN:2PW07(/:==X@4(VJVJ'/B_BO^=N<>*Z,9-OU^"&S!P"/(&_`;44) M&UF>)=#(2ZQLRHP%P+Y+P99B0G8/C" M%L%6Q6JF9T"*,?00'A&(U5R7(,M5QWLQ=AUJ>"XSC8+!RR*^&8%>LDK!F><5 M_ILX;#`4W9^7^=AQ4YM%HJV[5N/'*%"ENW?9^*%&S")#Z_LY#&:EV.>S^<$^ M?H['[T7X297P;\91(U'5QF-V42;R(A*U:R2J&IA:RE+4&=^ELN3]8BNEF<-P MKAP0'DLY24^0TA]@0]1XA-7W?F\&HC4>@/Z`3U$Y[^11#8'*%'F>NEQJ58,Q M#5/KF-N"HVXA:S["O8O,5MDI@.Q6"$',L=(3YR M&')@^F2KV(@Z M`'23JM0R853G$S'LG;6K,2>YC-\0ZBU,>\W4J5$&7^C3@6ZS.?:W`%^Q'VNM M;W78?^@FY?+(&"S8?H=DZ(AQ^#F*/*PZ(5QB(4L,"/*&F(TL$]():K^^0->T MM,Z/ZFW+8P+;>Q9.+6!4`5-]6AP;=39DCX?L@"DWM9"QQ:NQ]?RG&M@1FZR. M,N)F@"EQO)&#!I00Q`4VD3T:6:\MD,<'I<&T^ZN[;K\=5^\./--;" M3^=OMD?$PEIK7AN*WR9*Y9J$H-WH%6H9NZI+X"-U#S6L^&V21:@7`ECZ<>5= M%5^K:ZA[5ZJ@7I".0S4F4GX#LKCA/@V2?%';T*-K>T1_``+UK_ST0"_-7D+YH>]>7GO#:S2X M_/S9N;H97BS^^*5W!TM%=_YC$+Y0>>_RA^]Z_C1C^87T^`O>4'P-.OW MOL?)1"8?^K#2L0S#J3]1R>OKO].I/U[\^T?U]\>)Y-RM^X_&3I.TM? M,^=C;]&.L.E+STN+/L\)N_3!=$'D)6K1:?;+HY_26+_SC]Y6_/#BY^>KK"0YVT.NGG-#3%3R4.'9?U=S-H;CW*@F3>I4A=0K2M^^O3W0`?>EFRK;=9=^MZ))$` M^J#1:+`/N\E5+>4%HL7W@X\G'-\1S093+FG9![25:];_&:+2YNX\*,8L*.7M M@K*@JKTA"!:"7?G75JO3Z79_>J'R&J65VIN8YGEKJNPEVG%"B8^^,MQ4=2_H M`Z)?].3+V5Z>-6M)1["?1Z'O,R?HLT@^D64]&=,5"T9XE_J"/W[<2+'4QPC? MIZ;;*AHX#4MO#<+'R!G_^T_R[T_;'N]!9+7-VFYE?:-U/C(%3XNZ[5V;7V@O M%Z;:T&JEDU/KMPIM:>6:M6?]/C>3GBO#R0;\!#7?LG>L`L9)V7Y3KOAS$^BMZ/;=E*GT=EH,\6Q36QD;^IF-1B==(7AM1FXW*8 M+E#<#%1;7C#\#;8A=RK_?P=AN+;=:%F=LEXKMPW=ZI:J>KU2J^MURZ[:C4:C M5+)KJ\)PZ7-_I/Z[^K_.%&=D7W<:O5]__ M]PM;V,A4$W9P/Y8A"P@SK+&KP+UDGY1J`?:MK^JZ[*OVU\_0'([7 M@Y8>[T/?G^KA8P!#$'%/>'W/B:8::U\WV#<>A!/^EVP6;III&"[X-M/J)6OX M/L,<3)$;CL9.,&63+(>BH"Y[CH_YF00T=N\\<-;C/&#<]R@?,N]?LEM\\Y'C M)0Q.9=P+V"1D^6X?N9;O%2X)G^6`!@@CKBB!%T4<-%LA1BVA&(T@B.&N6SX. MHPD@Q;H`$LR\_E_)D*&)`1ARN&C*G8CQ`.]>&LIB&,'"%95`,`>`,BJ3^XA+ MK0Z\@+,16/=[H=I='CC$ABW2#Q`&15+3!,>$1,\]6-O0(;8?+>V?/XVY2[J7 M#F00^U*HQ26RN.%MME5*W\"5S>H]L"+9FQW23;J/<*IN&J7?M2EVW MFMVJWK1;IMYIE)MFHV-5NAWSG=%-JMNAF^0F5*VNF4E]KH]-V2\" MW^15CQSQS00V@=^@81W_:NR1TXKR@H?0?Y`&P>71Q(&_/A^BG4RVT<@3("+M M*=(81S!_:"1A*42"UETOADM@35["SIVST-FV5O\J$B.N04L]?%F`Q>-0MNCT M'SR7&L+5);BOR8[B"1(;:2F+V+W/#8E+RY8M:[!MM,$[T#T:6!2@_\!Q?)QR MU*!Q(\,=3^)(6K4%"PX6;ZGUV,1`O&RQ[Z8.@_75ZEUW9*YW%E"R=UJ"I#MRE6+N1<`(YRO,\K_#_?V8W"I< MOM+#N62)-B\9Z9)Q>@$Y7@!=@+^#I^Z#VP'+N[=*7-4(?W+!>X">GTE?X\I&_TK>.""#BJ9+B'@$-ZC7QM&$^CD!V,.T,@C(T?7I>X^=N^!@PVVS<.[LD(& MY%1FTDI1YD5`T!W?C15O9BI%D9,'$.:AH7[)H94C?.2$=_+B7G[`,\.5'='5 M\E=-G01)/=1;YQ.BB.YT*NT44Y^.N,C2FH$?>'^(G53 M>7\1N;S8@=+3%YR3GF:-`'Z>6^5/&]!"=V5D2K/',#>K7T%PR76$L]!?NS#E M1NN@^^[[X:/X\GHAD$N[:IAKN;.JCQ>",N^_(JW/=\:"+SJ>*\BX=?/G!0)@ MYLZN]U"K]LOILP=DSQ9=[Y4RG%-G>YTV'Y0T/'L>3):X>A8-]D\Q7Q?"+!F/ MMKJ,>IZ>J^[HD<"O]"1@]A#5B]C?A([WL0>,N$]@.MQZ.;U_.8S0TLQGHO[Z=%-LGR0:UB^KW.T?[> MZ=[!#<@`O.O\SYU^==WN7,,W.GR5=',]?\I>?(ITG#Q]0S.LTD:WSM$LWCK> M`\CZR=#L^G(.R0;"?MXU)?%MDM6K9RI93;-6D*+>*MHF1BEWNE\-QAY4?MZ4 M*=M/I^O$\)=3[L@N>"K;[7''_DZ!X-86;H%;@=NKJ+^OL#XB MLOC`]#74V]DS]':YMX>\KI"QD.QPDIW^^;/\K+FB^/#QVY\WOJ)5J6HEPW[M M66";+T@<-4H5K?+Z8^[^4#H0-G9]>5Z"`AO0F_+R%YJWALVI.8F59ZUN.^%[ M)+2SP1)ZQSRGX^RM=-4Z:Q.]9MRO:&$10KPUY5-:KX;EM&Q8`6P![&YWEE-Z MF&LDKVKOZ\G0JSM\N3H5^&T5OV,0HD#M+%`[]^^LP*W`[=2>.S]/3NBL>HFKH"`4,IYV MH/Y\)3OWH_5I4!!>24,N799.X)QX$&@^`3:[X6IA2E+)A"DH[3CG)LWSZF'I2SW)/)N@MI/>&1C;";2UJ%Q_6 MX#:+6EDK&V6%6MFT$M0(W`7<5,91?YHBN`J_BP_K$=PD<_":A+BSV7.O0.9@ M$D8[JY)1Z[9+7;MV]:;1ZI;*5KG6*.V]2L9\VMS9,AD) M)$D&[H72%[D+*. M)+`"H*;^!6I*V33E*I:Y,E%%(LJ*JM+1R\R92U\%/^_!!92SO.<'=J#]+7I+X)H[^P_@G5Y6[7CX,;?V` M(MOE5S__WJ>&'Z\5[WJ!)^[!DQ^&UQB5Q7-&LF:Y`OF?$E$'UP^6"T[!75R@"RMJ[5J9 M75H_7#@MQCZ_&:B?!=9=[3R!"('CMQ3B6![T>Q@,OZ/<#2'X1#2GWW@XA,T/ M0'/\!M8@O,/EOOWHGEDOM4JEKJU;%;C;JG=J>KW>[NB==K-AETW#JIBE0Z[) MNWS$C,D`5EZ%0BQ@J&908-'"80HDY^G25Z_]ZB<>LKV>$8 M_T7769,/8960_K%?L.BXKL]X6;/;YAN"=<_]328/_ M?7Y]^;:+7+R-RMUE(U&UW-+/5+,M^W@4A>Z.`38L?'=4J!7J?I35T8Y!YGT7 MOCL&F8MYWK)%06\,S-JB+[;,56N&_>F\JW9N$;G?X1"&Y%OD[YT,K$T-:M: MW^C>(PK$O?:Q;UTK5=X+BZ1B:W7[Y'@%KQ76VOW,GA=GIA-'X9COW4R]/81N MGMX*?JO0IE8YO9*G;Q7:*&GU[8Y>X'AHD0HBRO'3CK$Q/L^1)_#Q'_LR,^6I9 M=L4]+;V0>NJ'P5#WB;'L$'67]:9P[QP+];V12]>G>DDT:F_DTB(3S'MGGIU) MYI>M8G+@3"\%H>D<"$U&5;,/E'?Z(,+6S1T_23HOVDO+"9R^LW=E?C,90C/* M[RY`6J^=A&H?KP$_;2:$<7+DQ3?3((Z`^7-B3R_/*HY6H%A$(_<>-C%J6KUB M'\34G@8XA55^[\^>"QR/^1G^VY]1R__HJX4L&[M+FR'3<_2Y]Z4=NC$F'+F; MCK>7X*96:U7*1J>A=ZU21;>J-4MO-LV2WFQ#,QW3*MD=0R;3P%;_[6_S`\F& MUPDFWF1Z"\<(,8F<8'+MC+8WS':S`W_;MMXJM6S=,AIUW:XT&WJKVZT9C6H5 MT_O#,(V?_N/FMO'C]]L.''=:OUS??+_Y=M7YP:ZN6W+HRP:9B7`7.1@6^#$= M]4)_WV,'B&]@Y'*<,R.9S=#2PNS\_)X'`K3H*G!!L62RI%U54RB9E;+5Z=JZ MV;!A_*;=T>N69>E54)RVV:BT;;-R7#F0&BXH:.Q3A01YNIT!C7T/Q8HR"W^" MROJ.$-X`0V+>A*N\/=2(.],(5LG`["U46X0%SB2..!51Z'O"A1^Y2O[CY`;3 M1%9KZ/_,OZ/&%8"].8FJ64P.5$R0''/^60QO=`^IA.F M@,JRH*18M@(SWM#S.,$8,?Q?2=2)5TP1Y6K`'#C*.*!.Y5%,%"4]!X1]X0' M_XJF&FM?-[YI$CQ`.G;O-97,2L2^3![E3;`T2SCF,CF33(&%MD+("?""2K8'1 ML^PF[)!VMZF7:[5JMU8W;,7B@Y1XF*W-\'V80 M[\6$96C_LKLQ[5L/[-N#X_GHG^B#,-*%@P%[#GH+=H@+TFN1_P:U-^*S!66& ML8,[+RL[4^B\\=S8DI$X4>3)NCD#!\PV^+\QUU2ZK7@,.O^/.,1EKLKGP+!=+$Z% M(X(FX@!Z]S$?&QLZGBI]A58;K_$&\'&J*0M`XFU@@,$..010&"`.`%#>W-,N M0\OZ!HM$85FF` MIFXM^UZ[5ND8=4.OMBI@#FOMAM[LM%IZM=DRJI99[YBEQK[-8>DY:Y@R',(NH#D/4(EC;>#>C1S]D$]'32/+Q"08SC#8`2TST M8W>B8?TU4%7\7GDE-Y'SW['G_H6]B'A9=,>N_/R5_=&YO;MJ-;[KC>]7WZZ_ ML/2)HE*VCER>T`(-]"K0?X$1L%^N_KC`=)-B`EKJHJL`CH@L"R>=JM1_`.,) M5WE8X065F3^A@T`9,0D>U%LT3!%'.90O,(S0/]V'!`J_+$LBN#N$-*QL?!CL MR#)Y\"=-^IEY;+@->2A!*F#$!SZ()Z@-^`WKJ,%IFPG2")0=-@7T7V!"`0!8 MKSB9,H,H=AGCY%(AP4<.>R3:(!4SPVO!2KC0HI!^I8=.VH/''U46U&$L*_%! MTV"]\8P`.]<$W,QL5&/8<>!CQ[P0(`J M*N6.P3Q/I;KMO1,S=I\]E1HXPHWJ4F\.&`X^PP&/$H+!ZDS#.&> M#4%F-]6P2AWNF6F-.NET`H`CIZ]@FL!L)9W,N)P76+@0*R;VXDE6SQ$\%#Q] MA5@S,99>\B/LO9RZ"N"4%$WPR(;6WZ'=.9UM@BG`=2);"G##@#F3SG=>@$L& M_A5>DASO"`@?--7'F9I'Y`'.'4QX8))QNPDF.4AR*BHTZD(I<3"4NP]`$K@> M90N5YQ,WD3(#&(<`F./B?5TZV/PNL2H7;)J6N45'E,F.,KO6[7:WW*YV]7*K MWM:M>KNKU[N=EEYIM4MFJ]*Q&]4C>])0U&T\43)O&D>9?1Y>L'7?%UNWJ-MX M8(R*NHU%W<:B;N.693TO,FY1M_'D*(I%W<:B;N,[3$]6U&WZ6*-IR/Y^ZD6^UEMXDWY7`9_J#!511N2X)$$8&T0&'XPRQC!SPC$E M&@E&O2/'9P,_]I!VZ@R#4$P\-XE!RM@0AFY!7HQVHNHIOB>TC\PFN@+[6]7! MB/V>,!:`<3?P$R/A?$G<18:S3%%3WDT?0K MM2S!&84P$@R-YP92)[$$F"9S,C0@%5^R5`O4I;# MA>2HP3)/RJV.G,A+`L;II(+_G?(_9Y(O*,:"%]!;!Y(8*YD'#]!.&`OF^EY` MTZFJCU)<4F/WH2#:L$!5D]?`MVXX&L70_E17U2BCH1-X_Y0D"XV-8>,!">^Y MXQ,W;N[G-#I/S(AA^`!CDC,`V+C4[?A^*CS7$+T('U0W!"&XM&$2/#Y1$XM-H&E9>64BHS/0ET#?$CH M4]'^A#B0T]8+HA=X#TI*7`=9$TJ(-5HR00H:%0W-8%0AYD7#XQ(_V5-F(>$> M)C##/X8P>:1[B>2)HJ.Z)+J5Z+Y2KX,A,7:3*^*:"RYK$KM/GT.4%L:"Y`].HY%]F>=-+ M9M8'&KT`1A()Q4&$D:5+YF`D>;7>>'^..9)L0\@CE02PI&2S>D=!FLB+#QEV MJO*QLBJAR/8R257'EN*`6A\C!='C(FLEZX^X31S-()<,?6RISX4+=B"CK(/> MC)`30ZR''#%F:2^?!.?L.H0-V/Q\B5)S9&."LHB];(2:W"6;.!EV>RD]H#:BP0< MP"3U-%._9(+E294!S[\=P;'"YEHV'4:=WQME9M?%E6BZS-E$17%E0\( M5E%2^2B5_.A*[1Y.TGT74B[F]/_9N_;>MHUE_U4(WU/`!98N'Q)))4T!2;9. MT_6[0(\-\](+0ZJZKIOI66:^M/M)#'V>NHM>N@Q0@H9 MF-5T-3L5B>J`F$K5!:CEDF@H1#.J/OFX7!+[!C&T&IQ:5&\CXFG!Q-.()[<= MCBPJ-8AE-&3W'DMJCPR,JHN&3T2J:I)^V0=XUX96G?3[-7CAI0G5>&UMMOM2 MO-AAUV'78=>>!MDO:?SUGS3^/N/19X=9?U[M"]Z;T)"M\KIR+8V. MLHZRL@31Z<1.62G<$XJ8`TW^RX%U<#[EQQ:Y/I<:Z:M&AP0@T0[`\_"47S3;6RLLNG-,N.S>41RZCF@.'R;81CL]?]@X5INX'1R$!OP,&1 M54!SJ:D'QV./%K8-BSFV*K?6Y24[[#KLFH5=TUS\,\Z'6U8US:1KZ]=I1#F\ M0+I5'JY&-/U@#Z952("OKVD'%XV8D:D=9\RAKFE=\OHEO2ZOF%=FZ.D"6VE7,;^9I M=*NE*:PC$"DYV]E\:Z[+BK^VE&I>6R[??#@6&+6E*N?XG+C>:ZFL/1Z:7K_D MA@CJT4_8)+=@J MKVMZYK6CK'F4-%Q\#E;7=G`@RK.?M=/_4$A11UB``VS25N6:NL2E1UZ'7I-1.^I M4Z@+QTR+2_';;;-.K@09L".?[] MW;OAAT]PDQ-XGKV,Z(7D4`^/_':8/WMSH8C/2]MUL\_WS(WG;RY,XX>')X)+ MMT'HTA"ORD!Y>#1WX>3N7%]M:GOJWOV'FK>.M!+ M.DHP[&T.;.[A4HZA_T27,5W!F%Q3YR$DZB8D M^LM"\I3,+.S_;>*A(%*/#`?4MRZ)!P@D.XIH?&@]TI&.4B77U7K.30M!M>>\ M>54W24^M^L#YTU&K$*M7,K5=34`9,NC(S&1?)TI%/3BKI5H?=.\NGW5ZIT.Q M2Y*=59),'2BD7W8A2G/1L7I$*_MHYA;JA)8%5CL<&Q2@WE_X<\(QH)W[HDDH M+]Y*8KX4SZGTA\]BZDJ?8CN&D6W?A9MODC!8 MTJM'()UBXI]A3M/`\X)[/&Q4Q-I#[,0:41](B7D4)Z1WU$]@P-N5-*/!#*34 MG#E(ITU@C%L[`I("0:`7.**%:S#EGYTD`BZBX>,84+L3!P.M=HF#)VYYJ>^[ M1Y_TT5VR!!,#QK;$0/H,'N[_/`\I7<_D-S`!Y]'Z,Z@2ZJX_[LBN>&W+IWP7 MMO?,KQ=J';M_/P]VCKF_ET_N-8+F;IV[)&ZY2=P-;^4@S[&"[).FD5Y%+RU7 MD&H;$*7?N(3+@<3V+7+$(>Y-([97_LHV+=S^M+02<923BZECLXV4JFNF(TS0E]@JQOJN1%M$:TK_CGOLI4.Q0[%#L4VH7@*SWCOM?-J M7^ZD@>8ON]JIN>#TB&%68Q;5'QS3)*;5@&8*U8"C$-6L00RP8;9ERXK?.AP[ M'#L(03+JN%/5*I#6RH$DUB*4TKD+@<&(' M99_)V*ZRE['MVZY]/+H.H0>5/ MPZ*7KX'S]!6Z6?G8I M>W7CQRQ>39A'P[$=TUD0KB0')!5<^9%.WUS0P/ORX<8T+-.095GMJ8K\'T51 MS"^?/E]_T4S]"X;]E(&N?%$N).:^N6#N%\/0^]9`^W(]NH%_KRUYK(PMN:<. M![+5'PWE\61BJD/#&-U8UA?U2^_BEZ'C4)B!C<$;/I>??]HQ.3'SC-3W-![; MT?Q#&-PQE[JCU1\1==_ZOR]Q+"!]Z,3LCL6,1F.@B?D)?)?^"/[%X80F/A-W ML2CH::KYY8]/UQ>22QVVL+WHS86L/P)#&:FF8DPFLJ&;0[EGZC?R<*SUY!O# M5!1M-#8TZP;`4`$-2[=Z\.CUBAY'YB9D'T6SCX_4"69`!5SP&^`;Q8%/?Z/Q M/'#SCR_'!]>3\7`X'@.MUZ;:,+/O@+'YIXKG1+ M)0K2@.$^BP-P"!W*[JB$J1*P.7(9W>`SF"P.&-)H'GDNP M0TQ*<6C[,RI-PV`A_4O'SEM(][_Z??ZG[?L);S,3W,&HO`\+F]*L!PO0$U** M)%^)K!L+HUB"]9\&(1B&#I4%_07(:,@"%\AT(VSLDH6Q)5TEL([]JS7K[<\N MWV.S#V`Y.ZM#)6)W+L>C61K:)JR:0VMWEB]'@\FR%W* MQ2\H+E-I67(:M-B"!Y_#,B61X!\I-E(!'"[)^8^B3Q"_0?H+,Z;\FO_2K/]0 MWJT'AKZ?4\[0P),LPD6-$CO"?4)13L#"PX]V#-PCV2'G+^018$H6Q1'!&V&, M9<@!\@AA,)J1T% M>,,*T[B@:=PKZ<.#^?*^24A.""(,MEN,[&MC?AA9%$5.4:I=;X1VA1'217OKR[\&"RK]^O9/"9X>$^D>]GT`)G,LS0#* M.,4-%B5.@0CR%E$Q0,RY@3*R.YZST)7^2>PP%GH())UV)4UPB3T[\9TYJHL@FA#2P)>TJZ9_$Y1, M+IM.X5_@1;YW06=$6=LP8&B0&$DD%"UO)P;V2@);!(2-\]6>X6QG0>`B)[IP M2[BZDO[P7?C]CZM/5]*,^F#DH%ZT'=Q/*)T<+CI@.85LPP9MH*#(0_$)^MK' MS7Q;$+%@(?AP;21LA`6.@RA/I6D">X+F^Q!N%??E0@_(9;C'0.R-J&,#167* MIZU0PVZUA1&3$LIERYP!`Z'H8BZ775Q*V-(\ER^I1`8J(=MV"T`&3X M56JHK,G.-`4.*>[%00`'D#,1_RY*O!C-)&!,ODZ%@=>:+5L2KL[N<\`F?XOE!2`3H%7L\GF5JW8 M.XN\/9^-0-K"@-[86Y1Q5S?*(+MR&D# M\4JD>7`/SP^)X`O?\1*7(P'FQCT5;!8ETREST&R&0=!FYKC=@0Z[91Y#S>6G MBC$'`F?N@)3PJ8>S=N$17K#DE.1L1_/=EMF_'EZ&'U"9.3''1JA29,,H<>8H M+0%BQBY,,B4,S%:;2F3\&7,&'F3\<%B@!5"$-<,$SU0Y;F5E0I2 MX0/XN#<7O+.78"FTHX58SKF_X!OE^T@L#8Y37!H$42P.0RA'FS^3D M/W[J5M[=RKG5]-#$YI]HKN;$YD0@9%PNI(QX,FF?UU&F991"5F43)!+78FCV M9^8UY[=L>Q0E/1=EJ5U:L,;Y]4X0B"`"][QAM\?<_A2,*"QTDMGGZ4AS.YS! M%\Y7Y$_/2X$!45T8VN:52$M;"%IX*6;<>Y6:H'Z.FOX,= M@6)`V+GHX7*FP<>CAV&[?P,Y0G>$=(INBO35#^Z%8)GEO(K^!IA)L).$U&(+ M,#GBU#S))Y?%%#:GGW.`L))1T>$>3GEW8S&$4BO(%G@ZBKP(2Y3X7A,F1I"' M:ZIA\H_!RO:X3':0U[B+@2PMG!V8(#COW%%(71H6%8A"CDA"7N8[SX,+0*@P M/X0@$VC`;=0&[2+YGD+ZY%3P%K8?0"]^XP$6WFLWDZ:IYN"R M-'_V0^3K@/M?&3,)FR>E!!2H[W*?1.RH2`*5Z0FFWO`D`8,"U44-)5`7&BIS M\NPH5U9Y-V/45^AR?K:_(7.#B\^]?&P%C":!CTCA24\)[(R0QQ@)5ZDX6"K\ M4#7=V5Y"9=OE5@`.1?A&`3]76`9\-1^&,"J2Y[[TOTFQ]:6J$*X8A4.,Y@_? MIX"U+?UF1^B8?0BQ('TA?:+A'1/1"@1Y',CPRR+@6W^81>&$VS6\O?V346ED MS^T%8/4N=J\`$]@3`1C",@@DOF^BY#9B+K/#%:Y*>L];W[F2+M,)PLS&K\4/ MZV^N7_](D!F<0%[R"93K\. M]3C""93``N*-?:5P14PJOED<$0`0* MT00;/8_LDMRLYA*9;VK86ACM$P(@9<)UQ"GEI0S#>=[:7D"G1RMYZ M]T,>1?^+<@L"W]3*(&+>;<(((4A*5&V': M7(@KH5D$Y%X42'\'3%A/`O^B@*I"BNQB%MBBL]21]^T%]5:O0"B`73+GZ[84 M^:\PRA20"/$L4'B*"^:K"#Q.&PW;&0CN,.#2//""F0AYUP)'I)]R&0;+$&:!R#5GJ66)H93;GE*(3 MB3DA,+XQ)++6FJ*-OC^3YW:"K<$M%C.LU?Y)OIYFN-/JQ!$M@88,_ M+28BOD67#&0:^KA;YR+=E8=R M\@V<23"D,>!QBFRZ7`3BEA5^)$\(`F]BFLSL$T51D)_RW%\>ST!YFCEHN3CE MR1,T3F'U6$@WLF`;+W.@83!8:YI'02N>MT@MU2BS?9FSGD>(P@8]]&VI.Y1X MZ]P=(),E.$$L3O.]\40F+_.F;&>.43J7K.-TSTBA).1^L[;E::FMC?T7I^>9Q'M^!I?L3>!6D[CCP M\86V=$EVII_G-@;KT4]A,\&&N'\W[I4N@74PORCR.ZKRPX]\2XM$3)0+:^[4 MVYP7MK]*R'VP*W#/:&;]KA.F,(HP5T@V,/J4&#=?`B]^X\$:V-:J]D-V[T;$ M+M4S/)@-?)X%)RF>&&R;`X^.HK>QYQ1R9U[,'`8IA%?1 M_/C.`'IE<8UUS&Z9A*#P,>V7:;3\+"64W!A60/&5IS_28'50/'6)2_0H\*@, MYN02!KWCC)P&'ED69TR_3=5B(D))`%KBHU3CWA\LI1A!A$C^25C(H_CYPPL2 MCG->4:6"O_YWFDQEOH-)B30#(&Y#=SX&#@'K$82C9Z\B(0]Y*)WBB^["T=\@ M[6%0!T.G44!26WP=(2#\T%B"[@K<=!^(Y+&\M,-X)6AB:*;"<&O?EV*J8ATB MPCJ*!%,_=IJ#B8,L)XAY'6^588,Q>'^5QV]%_F0;0"DTZ2!9H8&(%Z-=-T7K M<K0 M_QB!'?P*A<03)\WL:D&@']""X(E[7NK[ZIZ]JZ9^SV6P-@V`D[]LO_\+]!EA M@A=E<<,K]4I1LM?QI?]1^']%@IK9@N`DJ%3RV=O>0*23 MZEMYG+\@T3B^5LE@Q_$Q+>9LC2C6]HY/I^%MP5C+;Z_K^8YVZ@3!)A(>T+9J.(QX&:JOM$#(A6D25=>VA4G2AZ)Y[W MV>>ZV.>B^<*)9,N+/+-6`KJU*&YR^:,.&5MZ5^R=@=F5N9G@RV;T'=8WO/5C MV^<%,$/>6[JD%(XY,4QE9%S+H^'D6NX-3%VVQD-#-G5-'ZF*JFG*Y-0%`4JQ MWBI#(6NQC:_3,%$&'A>;=)];F^V!]KTVV[EXWMQI61)+?7X2J__\/-(+#M4] M^OO?-[X7^&F?MKW+=JI/]FJQK2H']!V77C[7U_B%/W@IGD!_N,`F4O^U\R8E M.=RWH?13X?G\^P^\''(]S/\WOLSWLGQ6QB<7,(UNWIS7F>*;$P?Y*P<75CQ>1G6OX^>/5:R' M1AA4H@[VFF"=FD4?2.RE3G3S8&)_/(6U<^CY?<322E[%=IUE\`&TRH,"TO1] MGZK%A2Z?1F`^ZB)#C4X*&TAT><91T&3II M+7],G;F/KWFNJA8K>QT(4?7NLH@Q:-SY0T>+%)T8.W+P;1$I?:+LI]2J%BEU M$2"?L<$M=A0]]($56^A'M&L\S-%K!UUU6V1&N"M#8SJI49=SH\XQ3,> M2KCB,0?K>-:)#KPY^H%'LVV'WTE2/.>%6C7.SW.DS*D.%JKCG`X,P.D]8I0= M@6LL.)=JGYB'&VB'&"O/`N6$4*@6L72U,VKJ9M2<[K2HXY]83[/FK!"L!17U MPVTOR?.PLGU.43J^N5"-W1*A<$TQ:?Z\Z]5=-S2^WJ9I=1_?*;0JG@(EG:!K M0-.6^Q3E585J&U%+U550-8_BKH*JJZ#J*JA*]NA48@Y*SI?7AMA+C9C*P>YK MG2NH!D09'%S7<8XIRJZ"JJN@.DB$F*1G')S6:T3B4B,#JP8'WS?9_N@JJ`Y5 M8ZIQ?A54L.'Z[:Z@,HC655!U%52E\5>/]+62TU+U(_K2W&]Q&BLU=&(I-:B@ M:K(A\C[P96PX3N/"D1F5NSBJO)=]6?4&,ZV]C*96R12CW^[70U2]!JY-5[[0 MUNJX#K_FE"ZT![53^#[/D2E=!>;S;5V#F&K)$?S&@G.I]DC/LDYIF#P+E!-" MH6E$TVK@%'4F3'OKX#H$FV3&M`FW(_I<[MVO3_V;NRWK:19?U^@/P'PL@`'H#T<)%(*C,)H'60BSE)[CB#X#X9--F2 M>(8B-5SLZ/SZ6U7=W"39D65K-5\22V)W5U5W5WV]L+[9S(G]_T(%@F:Z1N^= M\S,2SR)401S,)=7BADR->&^RR:/YQ#R:6Y#!M0Z7@;)I>B=-O][[P<5M2O,1 M(L5;_/LK^J92C'^39RH_#]%%E1\?H,M#V6^WQ*`O4V(/EOH$GONH#-4,[Q]< M%CX`>>.!U'SA%RN.57A4\?1#SNF`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`((YLW0)'86?U?$+\1")KHKH@Q4] M+"ZUMR4V%8;J?_[CC^Z7:RCD1D'@S!-V(;DL0%IKUP\G[R]4_GGN>%[^^=[W MTNG["\O\:9GU6KJ-8H_%^%0MMM2[490W6S]M'$#R,IKV<)F7^OYP;6\0DNTM M5S3/FM8;A^[Z)'QY(O5K-D_9[);%I1R&*I/Y) MUWQH'2XY2<+2UTD\?X0RG]I.S_G0I6N&);>T0_.E[T];5;9;.];V]!WH&9)N MMPU9/5`JRL-J;72:5WM?Z?E)8[_F_.F5G#]I'55N[_HNQ^E:QV[)^JY9AL\M M#IS3+F9CP9>-!2O[P+]X_AU^_.V7+%$FCC-_=^U.F9<%[//XFDUF+$S_9'/, MJAE./H;C*)Y10OSXE7U/>T'D_OT!*I1^RROY*X'RPR3UX7%P_"ZX"WCP M3S9^?\&BX.;+T#)MRU0416MIJO*_8`+KYOKKX$:WC!O<*5,[AGJC7DB^]_[" M]VY,TVC;'?U&-^R.,5('BJZU#*4ULOM*MS/L*5U]V&K;1E_KZ/J-!@4_H&Y" MM:?N>&\>O:@+<8>\VL]^[@LR_`,,(45CJ3`%V9Q^N:(_Z6GIZY1)\YC-G9CG M,H428#+"!E#(@YK'?NB$KN\$H`5\A:9/)#_$Q[!3_'0AW?OI5')<-\I"HO6< MQSZ4F`,Q M(X'!`61%)XK>0!/&S&7^'9V*8'-^B(:)8G^-`;,4)/LO[R%_-G?\>,;E3[%) ML!7T./R6.N'$I_I*M291Y-W[00`Z)=(]"W"_4'*=P,T"$HI+$N"@PIXLK.,6 M+8U(%S!S-?%=BX9T?1R'7]1N6=[S_9`D@L/IX M6C;M_92%)"G_J=8H5.+Y+D[>*^EC$/@P9^&)F'E^"NK$?\/(D*6["+L?9,Y83%+#K`Y)/:S`8V[@AS3\L1)X M.`//(27T$BH:W[D#&T2S6WB(1AM8!\W(YTD&PL>I`\-X`:7]$#H#&X#F'C?& ME=1-ZLY%]"=4ZL<2(]>!8SX,(^Q%$#-EX"!1!O*0E#(Z@:I@B+LIC'70-LD" MFJ0P6P-0S(=*0!&PCC^&P1.FX#;'<33#-JH^[$KJ3V$2D@G@MVAIAO!Z:<)B M83[9,OSL5HNQ8H!@Z7*(D.9+HQ2F-A^-XP#4+)UX$1Z@BGJ`(+%R@^$4B+SD M:A55K,"`>@3GT=UC_KM!!&,/*O]"50U#;P"_OUB`MZQ^V]"&76744MM*R[1: M2J^GJTIO`-4,]99J#S4(\/K%!ZQ$43N*H?[VRX-RU4')[\(Y=D/O8^$]N^0\ M\Y^^0,B%B?!2Z@R[FM$R]8&BC8RNTK),5>FT6Z9BCU2KK8YZFJY;QX57(*@Q@>'>P]_.."6T(_PX0HQ MC2(E$V6DD$&\+P(:36C?@_IA`I+371/N7((GW@H<(&=!4P.]?!;S)Q,_#\JX M#8PSHYM-T/="]VE7I69^(J'C$)GD"7O=`HX`8(83$7[%($RMAAGA*0K&1926 MX!,4!141/C%R'3YB%["!""F@KX..#MRV0[,:9*I4P+Y#T`+/(H+'7U?75^OQ MVUJHAU,/@_@115+9;`6&"8,![T3+P@=@0N.,9+CXV),;R@! M8L$HN*-E$OP2YZVO3A)G/@?WA/.!8%S-A!3;T&[.!$PY(:><6Y`JJ:`3'$_Y M/,=.);!2>WAM+^$L9UXBYGC]QSK,*T67:?)7NB7!8.?E=N)QFYL!^J^(U17L MGRM?L1I`?`1;(&*X$$N+6KV%06<`-[*8`Y9%M8;;1=W8O%=@>GH5V9/"[@0J MF/>HSKE%$=41P%]V6-1#'*6`[YQ#C3@;ZW9?$YKW$0>^%7V$\!U<9N`DJ7!Q M5;.A)DDB_N3=]S]9L*A=\4"'VA)K&++\@\X'H:SP)1S`<7=R[VSN3["'4%[T MZ:MS8@.W@CB\<,SD7`BVSAROAOD?QN:XBA+K*R9&TJIX=;EHS@GL*8"9@*"T MB`)5!9Z&0("FIH'ST(KJ0-_>BZ^&.`+ M+1%V:;WP5C=DR];Y3)/67J="30VP-M3T5M?EMID__8AA<%8X8L#AHVO6@6GL MA`G?,-ADJ;`QKJ[#\>5G1S[N1/T!7L)[81C>&]JM=GE9[8)BZH?;W#P62A]7`HIP$27L'D=!$-W#=%F] M'G;>]WT[^C/O^SYR?_:A.[?MIU^Y?<&JFJ9__/W)WUD^M0O!FKK%%6GIY6]& MGWS';]T5CUB_6^'&JYO[-I9^J;1/W_-MM%+,R_]C3IS\_*Q^.NQ]]-]C6#6^ M[#@[EAVQBWIALW(P9Z;F#=]H:2)FN=PUS?VK^REX9L6'OE@-^79I:\<\K#4[N4 M^;B'^.*D^=FK-(\C/"Z6R)S)H=V%H>S'83SWBKNFRJW681)K'E#K2YAIK:U3 MC.S%A3Q715TVU2.XLGK*^*.;G^VFS)V&(.-D<6BWLM'+*(>>7;9L=E[=NT*` M2LSMWY`Z"9?2EM5=TV.>%SSY&CL>"YT9.[3;V(PX^M!3J"7KNV8O/CZE+^W. MUIF]3L)KX#N43::NHWL_YWS>,VSL=SJYK<[':H=9_#S%RQPCA=*1O^EIM&1S MUSMP)VN<2ZTM6]L#M&W`RI.,LD=3:+9L&UH#:HX-U)S3*[.-!4\)V)R3W3;R M/.F2YYDR]([O+S3S88]0>:9Z:/ZTY[6'"IS\?9M3N_?Q@XM6^5UA*;\B3&+< M;ADOSJ^[]W&]JG+;AM^E:FY0G9[&S0VJY@9521Q=DMR?3Y?PPBV4]Z>67 M.)JS.%U\"9PP[8;>\)_,GU/>>GJXH--YL=R7`]7NJ(/.2#%:IJ&T;*.C=%J& MI5CJR.KW#;O3[1C'E8(^-Q&=C!?V(>NO$.?4GF7YLYA&]XT@0O`D!UE@,-%W MU_-\01E"*=OCZ$[P)&#:7=>9^ZE#Q"LRTH'D2;8=/^:']#,DJV#(L\!X`4J= M2UER!3/,E31@1"]1)#B&*IS*33$JA^WZ'A3D'"64%#N-'0RP"A)J2#.63J,R M6_Z;DE,"R[!Q%DB!?U>FI\[3]?*TH%=2+_,#S)"9"#MXN5`LK_0>M%Z@X.,( MC;?`FXE":<5:JMOE MW+7Y'[]*",>5L3/S@\6[%6](/R8PL-^A[ZPFJUU)<;N<`E=D3]54]:<:`%Z? MV;;UTT5M(9WC^8"-TP*^WM+ZC_?O[8.8MEIR[>*\X#7CCX)W)%DG)N4G M9[-Y$"T8BA5E:0(!$#PQ.#C*QRZH`#`EN4/<:\)E\_SPRMR)B27*\>[\)*+T M[[SFG+5K@>GFR4S,JUBE(IZ@:'LCJ%#&/CEG/!%"5@(2&CRQ2)P?1F'Y5/TW M\M[XA3.ON&=^;X_<91K[1!7!=2\H13AJH._>_*O"[+1J+F(DP``R"6&@4#@& M;,';$3@#PW8A")>LZ$?1O!"2F\E/DDP`E;P71!0INP"K6,(A1*56DO80T4H" MX%9*6'SGNT3T0Z\V%#P9V!R,C$A">9/Q0I`#L=CU.0]B-"\`&!*"H5Q02PB# M?EEVRM\?HN6(-0"?I.<20%W(K>6(\>%@YOJ";TC\&O&P"[$H%*1FCZ3WK\Q; MGOW\928NT1;7NP]A:)5='I;"#QLF3=.C,!1UM]Y&D)%]58DA!=E`!.`!L)=A&Q!TA$;@X0'D%]G,N" M:N,-,D!`=S`I=;Z#OPC96)"-Q(S#?FZ'VJS*#9)(7B9X*#@'W(-,:KL>5OV5 M`066>JO)G8XMH)NLM3O545:=630]!.`K?(PGE%O?EX_UI'!EZ_KR(W&3AHQH M!`ON&^E.4%@2=\R*9/(VDD!%2Z-*4_D@U72]J+@JG2RX4G.F)*CAKB#\>6L: M'6Y)6[-6RN$DP,)3%N2Q,Z5[EL0VQMV>X^:8?>:'_BR;T8BC4A%?YT2W@)X$ MZ-\`56^,CTN:OBZ&=P3>H\"9[)N>3[OX,':"A'%FOIHHI82"X&Q$1##X;MQ+ MD/X?V`K?;4/&%_K=A2[W>LJ_='(TKJF").\O%&-%7W-@#'J]CJ6H6MM2 M6CVSK_14W5+ZG5Y;[?8-51OI-]"`?O&A#04L:+:<&T_4J6Z0H1.'N%'RA<7T M)$!^WWT!M0&EMG3-NOGK>G`#D>)FU0SZME;0;!BOZI7:*DVP5HNZHB-.\M,7 M##]?D>"'NZD$5NE?2[Z?9&?[D-I0-4$3!13I*2TPCP(]V59,58=ZNMU!V]2. M:Q]2V$S*C295S%3N1I8K0[XD*LF8H=(J+:6@`A-T2Y5M']IGRBF7*))`T!:T MCQXRX>`"*2W9A+\+PJB8LWX5VX"W3D"KC&3*`!WA7I,LQ*CR6!3V%#,3W`72`H=B5.3\7#28BM4/4C+3XX1P"PHOM+]8\W(><0Y]Q7ZD M6+;!)V[NM*`A0RDXQ=H&N&1KK[),!(:R?76^[W+';VA9EF&KFC(:#E2E-1CH MG`-L9'55RQJT>JJIO[(=O_;+[/CQ[I.@_]BCV0$.N[DW*!<6Z31FFZ]Q:",B MW]!_\Z_"@7MLS&)ZPPK`?;XQ0VLQ]:K:VA,7Q[7FUC-J53MT M/D];0!E/:)GKJ5M\G639ILQ7\D221.IG!]A!Z,L\)+?2=T M/!_\&_),.S$X*W0]Q01;C,9XXA%O=#Q);$_@H'Q.U M#2(Q0!(8G?[8=W%_O0`9.51#S$-[>&L[<['!N1O?A*%ZUMJLL,E#%BM)A%&= M)=YS$W"""R) M3)9\TYS05$K@6:!B[.U:IY!I9'%*G_/DYNROB:"VK=:/YBQ:\/'4`FE7<4\_ MFL?H'38[5:69\B`O:X('#(*PV!7CW?5C0,&X&G4)\G$2<6)'%OZ[E(MH>Y'X MF$,SK[9!2CN;PAYCYB$Y/-'GXD'.PQN=I7.OQPJ4I(@6^>;F$_:>-T&+C\&\ M.B#\'$^<4%R9Z!='Y_`!4.47C`=A2A\_CT?Y.+_.C]2378)(M=T9FN9HH-C# MSE!I]7%GQFIK2K?;LBU5[=D#L_?*0*3V,B`2O7&^TW^T&/(;RP&(C'XFPVD- MXTP69TPT&Q*P.TS$_V_OVIK;-I+UNZO\'UBNI"JI(F3B0A!PLJGB->MSDMAK M.4F=)Q=$0A+6),#%13;WUY^^S.!&BJ(H$01I[,/&DH#!]&5ZNGMZ^D-H[WGB M@#30%Z2_`=G^!NA1\`PWNX"7!I$)H\MDAN#%LK#8O+ MG0:."T>]#A[0H`F3L6'VW?2K;1$1\CF&MU@D?@"6TUE%N0/)-`\"V\N=%X=! MKMHJ-R:C?A,B.SM/"974^/)84](6KY98F/,NV3@C&:+R<"]?I`/FX>CQ8#)T MED`R;Y8"!'X9P.ZH!-?*U!&%1^N#X`%7%/%>Z;3F#JP7!`!?T1DK28JQR,.( MA1?X'EC!-VJFB(*]O&_5LHQ+1`1!-B/[8QNT!O9?_ MBC&`%\`'^/*<$U0WL%F@?-#!#=%[X-3/(H"WD[D3$@>H4"NK:R)"Q8OMUG3N M^1XBNXO?H#CX'=#1J3-S%S"\=.G;K>6M$RX<X@5[C?HDA M2_092`2N4![F:D61Q0IWE1LW7!%0_35LG?\%NEBYLY4MR\X$B_[$JQS^'7 M#>>B4(BK"(3D^,5L7'!]C9QNB^J.Q0*/4H$R%HKGSQ(<&WZ!11@8`#`G82W0 M8J.W!,^)(WD6XZJX@Z5%>ZH3RX4FU,ES9<5F!#KB8FV`#Y2XH9A,P)^!0?!# MLOD2FA9<:20]$(E4[EP)!`MN4S7!NKOSW$Y,J61.!)_OKC=F_^$;X@3D([+H M`.G\2<<:]4>6HJF&IAB=#GA"QF2L6,.!-1P->W;?'%:=SL\AU7^\E86L(L>. M*YL.=RB+P*QIN8)UK1\P8OP1;0^?%TL5P]PWNN/1F_USRA0]W3/-+87K!7?Q MD4PI>Y=D_YUEY*Z[A66W4?A_MO9]^=I\SME\V'\TK?O!W=>N"8EW].-!T3>? M/LBGO]U&P6E;57-K6]6/%'__3BG:8MBS"9-]O"4IY=(*?N>/ZD=9C[>1Z'M(\^Y9/;BPST.Q8KT=+![[MNV\K MZC;$.SN]6J.&2WMW-&A;^V,%U[D3-5!F[]_#L]Z4]=I&YS"@I:?49:E M(_'&LH_38/H4>-/5&SRK@M7M;K6Z5&^`][BXPCF]J)4V$-C4H>+LK;1IG+6) M?F#>>XRPSD)\-:TK,O9FRVG9L(:Q#6._C?ZYNR1JSJ=1>L._TTE(-ES[MKEV M[GD242%\]CYXUVR;^R.FGH(;_EP1;Y,I:3(EIYHI.25_]IR..AL.GI)WUO"M MX=NIY9VW%R>,[[O$U90@-#2>]D']^5)V[J'U:90@[%F&W+GHG$"<>!36_`"\ M.4Q]]K%LP1,842F.'`.UH**AF_GPK=3"XK/XVBG M\4`;#[3Q0!L/M/&?&@_TY#A8"RH:OIT+WQX-/;YG#\!2(T$O;8'>9UQC&(C@ M.CPW>OZ^@=:X;YN=OJ$,[>Y(,7JJIMCC45_I=_KV8#SH]@>C_DX=E"MOB4>= MDW=K@I?W^_,=E<6OUYLH:P\U42Z,>.\PE\EB07V"KULYL;8RN<*`4K3;/KAK ME^5G[M]H;D>%]_RI)QO5%AIJTLV2@0`70!)SW36)@#78^(\E3.Y7#$R`6!1?;D$)5TKPQE_8=2+5G\^Y_ZD4VZC7802PD\*@"ALD4RM MY:\09L"=>P)B"&&=4A2"6_@'=K`-"G#`7]QV_JLHJ-Q?DZCPU\+?@B0L_E%T MWLT_LX;T25]8N(Z?,EQRKB"\E',DA<0''8D*D.^>C[U_D<0U(UT)-)30'J). MX.H]H'K8@S3QG60FF@<#W6W943A8>K[$ETS!#MII*VT'NX!G2%RH.01L(G`W M_3G9!T;6%7>R$#6*$"*RUWX4R`1H3K@)M-.Z=CQL=)PMKA33+"5!XJ[*RU[) M/!:+,H=W)KHN1Z*?KK=(T52150AOO($E,$1T&R3S&4(]AZXC$53^+>"O,HC1 MS0QEC(,@9CB(T$7XX1P^%I+1]_T$WOI`B!G8=WP"3`+)*_\KIPQ#7!/`8FOE M.J'`1[@?`4("I3&B2($!PJ@\'JQ'X"Z$A`SQ\D4J)@]1DEG/\1*>@!<)-WX? MT8KH#EXV$8+'0**.LT36[?V?C*8T%G`[T?V&'#22<.*$0N87%\EKHV7'Q[#! M/`*Y,!ALNDG"@'*K@?>QUWA(7;KA"91(J;.W[.L-7^XO0(VG#@-E,\YN#HTD MQA[NGS,`(;;)3A0E"WE!\BI(8I`$M2Y'R+XXNF#S$95?(XSS.1F3P@A\]9*V MJX7K)L@F'WQYO,"D@(L=&Q[3X/33%),Y90[::]QF'&8 M4'MVX`,:6K0RTJ(A#^X7>RA!I@(_IS#9-HB`UU?P_MHH_TYF-_CH1>OW3,]< M9B1R%V@KO,"23#],9AK^_R9`WA"X0EL@3]QZB`U`;==1>,!M@N*A(1CA`5OL M(VX\`PAN1-T)A*G&?O[(;E):848+.#@Y8`J&%9!0E\!FA`4`@WCGA8'/M#(F M`FU5L/47]*G,VB^WX.'<#[X#UA(7[T7K[7SN_8=0%!@J2N`*M%MW`8H?YL[0 MDC2*0#5[F4-;3)^'UQ/A<8$.YKKE7R<,J5#`N$A'JUH5]7>)20<2` MD$-7"'4"F_."YD`6$NSLU(L(5)T1U>7N0D3@SLPP5GE4+3";$EP^;\,N6D,& MO61;&I162`DNDQ=;0IY3_C4W51!\.U.1')I)JJ4([W15A"0M.@OH7Q0V")J6 M9-C#<.^5;HZ7MV!RE8\@'H@.)`+>/5ODWVX*;$>^843OHFA)?=*WQ7I-8144 MT',E`U83-AAWJZ;=]K<=I93B5S\G*_ M7#JKU.TC]\K-.Y,,Q/25M@RQAV4(I#FY1IES14]Q("DFU/+1[KC'$=(DT[T% M;.\PCX6$GT1#G44NF]WOESFDJRL7&2]&F17]<@+0RNFY0-$BA!,1JLR$\9_. MX5.P:L00(BH0$;*?1I4,BL+Y1(Y@<9G=D%/^!*24QY9`&-_?FS_\#6':6NH; M"-+84P0:A-UG@T^(8*PJPGG+@YEAJ`>,$.!"2').0`2MSJ'$#*&+P$ENT[XA M6]MD`1,\DQ-8)09W1]9H;UK_*O.CS`C"GF0F$>*5YR\3\O;8Y\+&1T_>D/^U!:Y!LS5@?\=>PQ\)3,/M!:%=A'O\JQ;_83:6"/FZ6]: M[YEK09B+6PF1#^((5[!0+"[!-_J=<%*N8-.%.63@AN7&:.7_#D"4=0HQY(5/0VUFQ2"BFPT"5QY6\(/]6#E+TE[*!Q`[U=-!'=;,NGOK;+,.YV2-_FT^!(MQD3"M`>"K@F8'\2:LPSL'M0"R%7$*' M?4+$/54\ORW^A6E?X1RBG2%/J!#8%WR_;PT2KV<^$1+/>#PDGJH=#QWN\-]N MD+,0>NB>;G(Y*"+Q02[QV(QHEOYPGF!;C^/11N^BP*(&T.E15^P_.%]22.AH MK\JZI]2=[EGV;+9[O>-<$C@*K9T#`U>=VOV8!Q`M@O`S^L4"(;YRG7[<&^L" MM_7C=*,Z(LF6OO>UEBHUO+Y6?.+Y'L1W7.MP>BK?:ZN';C-6/Z+UMJWN?7?G M^=3^E"[QG$__T89_];_2N[/4YK6_.:H:;MD4L5F>D5*!A"E#B)7V'=(GS7FQ6.QZ(X=-"L*7.Z<>#&M\&LA86JXKQ1 MEF'B.^YU,F_-O;OL`$W60/-YU$5KD'CS&1]%$A]F+.\"77M?8RY:#]W\MV$4 M\?6`SM9=GS^<37A=*%E]&+[Z,BV,W*C/Q>!R+98E4'1%$=%8().,I1'J< M73K92XM:BW=`+O!68%J$.,NK$CRWS*DZJD2F[+L<\&XYWH7!Z(`7'C<[.I_P M:E9;MSO%0]ZSK'U,K<[;[`I"GQ0H9W!:;]?N)XAJ1[$$7[[X=L_@;.V)9W#J MX\_@NH\_!GO&H9I//_S[DS]'/+43.;6SZ0@.A]]R1MEZ_J/)DQ?\WJ+8POU^ MS@`O]OX9!M+6[P>E(>4>* M*^PJXBKPI@5P-O- M+6)GM0?(&\R%KE1C,)YZA*MVVH9AGYKE>"K5/\!*V_^\I!(3\E02M;;9Z9Z" M+:FO_]&?RNN'LI'6ZMAF9:>ZJF.O+JMM'@FJ\9@F16^;UMY4GX1)Z;8[NVUJ MQS8I=3$@'T-GYN(%OF.;#76GG>#82\AH:]:WYXI8=J4-T8]0)*C;!X8W/J72 ME"J^4;9PYUU(U_#O=#IBGP_7CA/\/,;*U!%#L^9UE+K1-@^=@3M9YOR@=MN] M_1VT/4-!6I=75KOBD.UH**^O%M)\L3ERS/K8O6\1^O5/-^ MBY![)G]H_KCGU?M>./EZFU.K^WB@T$K6V;9D>2U-XVK/_>+\Q%U%>56NVH9K MJ9H*JM.CN*F@:BJHF@JJ`T=T:KMG'_B\O#;$_J"U>YW#@&X>N8+*;G?L&MR# M/9TCRJ:"JJF@VLN$]-J&N?>QWDD<7&IMVVJ:^C055$=0/;NMFM]>!14LN.YY M5U"9;:VIH&HJJ`ZF7T:[JQWX6*I^1/_0VTTX)VLU]+;5J4$%U2D[(G\$OD)@ M#@B%_3%*KP_UGY5^Q46SH1HS9?NNV MW*\(89)UAY2PZ@Q]B$C52\?+6KQN@'#TW;B5-9VDEI\,;7OM4;M';ZTEI2./ MG4J8Q/CW9"&1T0G*#Y^,/-E9=/1'_U?L5-I/;I(HQJ)%]2*CS(L8N=[);;EN_+/L7I$*5W5W@E7`D\3 M`0Q;]+C0Z1UG@(B?P1P;'!,X9BB_OKY(G.5R#DIS)7LUYUE(L)S(-^<&6'F# M<+!%-/2V@.ADQ%`IX0L4ZCIT^D8IX2IW9Y%8X\4_"D,'B\G^*33RQ?,*60#R"^%A\P!TDKB;4A)%&5MF.'5_TGFJVR7$U7@1BN)P1S_ESA_K_'Q9ZDM MF;U\D9H3[,Z\JSV1:*UHT]?7Q`YFY0)IEX:9C,NM0X#L,[0L3A3XM/W(#MP" MEQ1WF"7W5@>M32&`96_DM>D5YT5KSID*K&-J)`X*D4+V7$964V* M`_)S;NA$HZAV]\ZLS>0LG!63A#W(:3OP\Q+EKNZR<7\"-C&Z-:H("$(B1#>HR#P<:-%^Q-# M*'CCAFRQW#O:7J?3!'NH]Q_J`M[.[[A^@`M\^XY[E(6'E@M$X+,(TFV7NJ]_ MI^GMGJ6)AN=;\*ICI.X["):[IK9#>W0$UQ4*AX^"B%QPC%'ER.68KA!8VH_F MM$KK@DC\`<4/FO4!S/R-[Z6U\&L0"7^[U(X>GOFOFQ4[\MN(U_T%O0C<\5UD M!*AHE#@16R9T.*?"K2'`[1`%DZE(U);N+7FU\/JU]]6ECOMRXT)C`4]Y,=@, M<(#![8TBX:)BIW&T^6#YO(ALE;`N*UJUX,%<(+Y#8;ZB)[_HKH\^,N[+V'D= M81EP%/0^<6^;P7KB-OX!FILKQA,GUX9M'S[(B_E=Z/PK\::?D6E1LNE@0[02LJ?N:Y/UD%Z[+Q]+R3: M*,$4@`!@%!SXBROA+]9F@6:.@--Q'R#)MDV$DNVR^01'QT^#+F%B9^#1 MS#'VSQQVCO%25X+7(;S*[Z5&+P4UN6@-W*D#%!W2/FUDM8,[H0]*+PDEVW+K M@0*AZ?(XQB0KX;1N4_LB+#+[OX+`=OZ-S)\$X6"HFB,["W$<\2X.`GP@GT9N MS!BL@6*2G'(#9SN;%,F7-"B.;KWEDITVAGF)'6^.6_D,AIX$E'B)LBT1'Z?Z M&.$G8LP$^C_+O8R+*\2=!?RPJP2(;V=[TX:/PG`AJ<>^'Y4BT@7EMMVZ#+_#]L)U/HLS8W?CBLII%R?6U-_5< M6D4S)W:(;W>PAU%Z"]UGL3&FC,"9HPOINW,.H>_<>;`D2C8$,#*DG>-C^`-N M9B*VY:T4U3!*IK=M"D(6H"-3PBKR4Q>4C2G..54^T%IT?+E/Q^Q:'"$(E9F[=.4-;P;@Q%G M6R4GV&[1+H9NOW2O2=_D\LA;>C)E\M)EYHW3\]-``%SAGC&#U1Z3_\F**'&T MA'\N1J((_`KV;M3/^5PP!DQU;FA&-LMB??@7+&O&4@8KF24'VD)+T"AP!AEW M^CM8$2)M"'XNQ.19!H9@QV;_3B(1\(?N-88IK<]^\,47L:G45HJY)R#01[,`$Y[#S8:`@0AJ!E,9$H48D::YW2??VD5!V/]B0 M,3?@-=>!W87#R%QBE,+(?.2934%\61C>W/(#UO/?."DZRVVY8N<@6YI^N\SY M.O#];ZE,[/,(2F`#]6<4D_"*BEJP9<[3+%8620(/^ZW_27PW"S[5?)J-BIUIG0*OG=;O3H2!V?LP M@)6P:%VZX9W'V0ID\C!0X"^+@)9^7Y9I<]C5O[KZRW-;`^?660"O?HMG%\`3 M6!,!.,(*&"3&$TRN(F_F.>$*I2+>>>M/+UH_9+G1X4_\A^PWHY]^;%.Z-E"6 M-('#!AS_'/[5^N`LP7/_6(A>_P3''GAU&:>V,I4QY?X@2J+HCC`C(SXHO/-F MB3,G#L9*Z$6?A2\$7J.[A*4(FTQK"&YBF$1%'L`D"@P@KUA\AK:T:(EY9K(= M>'+I^`E:>'EF,DOC_#@W318SG71`./H903B/HI0!))_C:%V3E5QC4MSB7H/!W?#_",_HXGB$QBP-C#99B*@KC@ MG859/H^"UK\#C[TGYG_>0!W#BMRG++!$;T0@CW?HYJLW8!3`+[F=YM!WPTAN M0)SB6:#QY`=N5Q%$G`XZMC=@N,.`K#E>X^64-UD8^:,LS?"O*8,+Y@;<6A?U M`O-EGH,M2**?6B[H9[!R!9*P^`F789`L<0:XN8:>B"PQM7)S2Y1B$`G[(SK? MF!+)=DWR:0+_1KEU$K0[<9A,/W-8RCFNG^A+/FD=96@H^[$$3V#A3#UQ.L:_ MQ9`,;)HW%5ZL/)V&R<48A>6X%TU!]#Y^)Q*;V'$LW5L?5RN?$UVGJ9QT`4L+ MAC02]F\Z73*!XE0:?"87'P;=!/W]KM=M8WT3Z-'260G?[BYG3]/#;VE.Z?`$ MG5.0GH>`QX%__ZF4G>TT:TDK.K<0GFHD?5]OFLTC1&.#$7HZH;EW[69)HG1* M"%7;<@3.-54$R+4AA(KAA\(1T0*L%'B`?AI-(<0S8AVWLSP=V#5W[O&I/2?_10Y6BMBST@P_0:YQ&$,)2+:=X.G[84!>J_`6 M-AKA-N>A;F!NE&#`)3-S0L*7!G_IFN"LJ5B#UQ>^,^>J"I#;;9IM(:(I_4B* M18>.>KL+6H$*TNW2/].3VX>%D97!;&&_C'5@RJA",,*]2M3E(=,OL%W&4V80 M<21EC>:`0R"A!>`6+'SO&@][993+JX*,8<2'X_%J2;E<2O%DMP69+BSS6BUA M(WR?JB2K`J:[V>G`4]3\RA#;XKV!U@-AECB:>(Y`ZV0.D]9/>=-65I<4)7V0 MAWC`OGZ:3;CWW)?/&BD-[1!SMYTGIB>G0B[Y\T4AC(.GIDASL02M?,)(3DBF M2GXA?5O.V&Y)J%1!03E`E3F#/`C\_7I-KF8NM27S3Q&-D3MSX;@Y=1R$?9:I M7G9+9,X3`VFPPA"Z4#D$K7WA$8C\53M+C-QY[A>1W[M)YDZ(%4[X_-'U;9"!P]W;%X3[3'>960BZOQD#VMB50['MV M"<+^Y8MM MRUMZ1&Q5S(CT[*/,D3OTBB/OAC"TE"OU M*#(&XQ1$*6%=ZFH^YJ1YZ<8QAY6;J[_?^>EY>J:[6JJ[=(PHM4/4$>(1V*JP MY6$9C',5\/KGH.I#,"7QC#SGQ@^`R]-2%H,>*.4QWB=8N` MFZO/(5CYSFKKX-*((UZGF!?-6=!"?ADD+).!6TU;T;*)Y8L+6E8J@,?C;EO^ M%V*V:<#/UA7CM]2OI=(LZ8RF9[G)$NL+4Z\?>9*PL:!!\G5Y^.P\75:IDX]R MBJ2@57$:?(2+U')H<8T^,_JBS`0T5VE%=2:G"XZV1=85-VF: M'NP]7"?,\V3WC&<'<2MRE,^W7'^6^FKX004_*'U+ICSSWTDI,B=>..J\N)GG M,)2(B]CKG;D@<7*?@=[;X`NN?]H;R"\':[?VS?RDKR"($`KN1"QWM,6C+.$O MRI6+12R<3:7B)%X^:%7FZ6T*U,H0Q8*LODXP)>HD6!)"11R21[ECV$W"S"W0 MHERY?)2/?DL.B.`)KA&RPSD_X_%K!*DX\@'"NADXM;8PW%#^@$=6 MJ.T)1C7BN(L#AH+6YDN.LJ47P,81Y\_++UJC]?J*AQR+;9&4+HK_\9*!]+%! M5;+(_[KU70^>XF&^4]NJ6O8E-DP)H[%TW._43MO2>FQ<\^>MG+WY3N5\@UQ[ M*7\\GVK(1=EX25/3I"YFAS9L'9R/DX>W"ZZ`+!RRB5P"?D8RMR8ZEP8[N/+^ M`B,!:C(,?&P=(U;'O5J(9I-JFG/."I649.^V?BB4OJN=[W^DK`'7>D5I/LCA M&PH/.*X7L/FGU>Q932:,(B4@!L9C*PRLEK`W?25W"7BO:M_+=PM%`6*#I'H9 MV/)D_0/ODUMGD_(@SP'>Z1[FP:8Y4`$&'FCL.(7TO)!G#H/D*CAPLWA@`/UH M1Z=964!Z2R]-FLD#3DH.X&L<-QV\R=XT;)>2.LUG'G8(?X++%`6CEC@-494=`6T4!V"-FFVR=M M/!&)\,X7UZ/UURLALJ"9RS53C#L<4295QS(LD,L'9NO M,G>( MZBG(**0ALP=Z<9K!AIAOF22J.PO?Q1DWD+;RY M0Y[(U7WDBD%$)DS>M\K1TKJ?EFSN.(EL%<9\]X:OC-*O17F$>#&M69'W=N\P MT$;'&Y/8;CCUZ&R2D@A`/?KSX#PGY;J*(B/%Y2S4U,2_DR>,\+DX]*;LD<)S M[7SQLBAFPKPN&`KY+(945RC) MG!4F7)@N?XB>YK^V13F%.)CGFYELC1,ZH^$AZ3Z(Y"B]GJ1"$3>H[]-&<=E. M2ER<-O(=#M9-84&SVVU"3\\Q64TWM6AE"=\"V,7K"*4P>W!ABC.G2`3$T9O] MB=#P%_?EU.]G$C48V+,+H^B,,'SWVV_]]Y?P$OGBR\A]!<[#''$]\"CW'Z\Z M_/,2@VWQ\Q=O%M_^XY6M?5_NCMBZHG`6G\I/L]"/92;?-ZWO=^Z!(M_1[W_E MN7[??+K23W^[>%`I>HZY%3WG(X4COU,80A.X2O^<(0JE3X^W1"G%MX_2X/+0 MS/H#0[;Z\:I1\@<@HC``KU@]CT[P,P/K'6D]UDZNYR'-L^_L78ZRUYS;0S=U MVQ=QK*T:QX$:KY[6']2V9=<;VF-_RNS]H5KJ35FO;73V[A*^E;13ZJQ9-F7G MWGNPX>#!.5@+*AJ^G0O?S@ORZ>_R><+#)R+K"=.Z-?P^YG,-C0UEQZ/L].-/ M?:NYHO/A^MN?1VVBZ\%`UVQWU+V!!TX%EN')7.JVN_N'N=5QZ4B\L>SCX(B= M`F^Z>@-;7K"ZW:U6=R3K/62UTO6&\HYR37L._TTE(-ES[MKEV[GD249]^]CYXUVR; MYH&!"<^`2TVFI,F4G'"FY)3\V7,ZZFPX>$K>6<.WAF^GEG?>7IPPON\25U." MT-!XV@?UYTO9N8?6IU&"L&<9BR!4]@Q-Y!X9DQ M0E:.,_-1[H MR7&P%E0T?#L7OA6MZ6MJ`+=I5@=LS2F`Q[E-KD+M<467P%V;[!*XP,L7A2Z* M#S9[7&_U^#+7D1J'T-JFT:-WNFW#ML4%U&+/Z[9LS\B`G"\SV*I\*T"\E_!@ M_[^V0#'SL*4H=<.,,B@,ZM)ZY;H^M9Y4LMZ3DUQSXD)K8AAD)[X]R+67+Q[@ M6Y%K>EOG+N'`-5TS)-=>OMC$-]%Q=+XJ09JN\^_EBXVW2`3%Y9Y:TA] ME*>KUD?$0I@3*33%$FR&P+"*(C>%SYM[W.?7<]/^YM=BU*R5+G61C\78$ESU MSXM+!!*88?=%;*<7,"U(W0O47LK#N$_<.VQ`S9@OCER_2NT$(;N:&458L;__4 MPE[2\>HX^D/*X3!I1;`O%B.\*YHJ2;"Y#2C4/`V^(ZF%!:[#M<[8:2^WSIW-8CMXUXO%X8$-Y$=ZC>J*?LQMA[.(5D M?T#OL5MRBM8!EJ9@#X[6A9ZV/*04<=,9(JZ(A8E`RKF/0`!%E/PCHK;+Q(T1Q#TM)T^$B_GF#?. MK!0P0,K+E"]Y78J*:A.M\Z@NAN&#BRWW"%$O89_E?1CX\.\IX\]M-@IO_=;O MSDI@\/"RFJ2=[W-C7:(OY83@O`X"^$\1IFK2OQQD/X]^^E%`^;PD7`K81&]` MJC>)-V,#X:=`)3AR!@5)<$VA@TW\$>.$E$P";K3ZEW_2+!50II1X`5K#N\BP M_+;$&8G*/@G(4,!6D8\)W(X$>:3I`;9$#P-&HLO!F\EFWXP@ND!3)E`+8"1) MQLT\N$+(LPO1.#MDR&W8;[SE7**'%KY'L"$\H+\2Z$U%W-A20WOJK3YSE]Y4 M0,R07E]S5_J;`".,(,QC8N4Y25@HOH",X:%2C#_V3\%>SUR)-2.WPYN_ M#HO5O?%\PBUF,-AU7""U2Z&"24`:B*3C!P+@RIEQ:("#+;P8L>I2*%]$9T[0 M.2$$+IIMA+"[-)>5-)/I"!*?*]5Y&H1,?[".$E50LPPP#"'/?(7>+_U\\SUWHSA@7@U)*28^5L( MJ+[^K[NB=0?/?G"O__'*#>:?WH][IM4S%451#;6C_`N"]=ZGRX^C3UI/_X2+ ML&/KG4^=5RUO]H]7WNR3:>I=R]8^C09C^._(4H:=H:48:M]6K.Z@KPPGDY[: M-\W!V+(^J9^T5[_`B*JJFH:I__SZWGGQM"6I8!1S)!9,&Q&\XO]/B7XVJB:6 MKDU&EJ&,^R,-J+(G2G]D#!3=''8'8]WN6L,)4-5Y]0O*2(BHV0J:K:#9"IJM MH+JMX+'V,=L41@'$8/#^#>!WT7/9D)[O6%75\=]96)TNHIA]@QE M,-`ZRF`$PXPUHV.-53"AQJM?_B4VA'OG5-P4^CG$FLL4'&^@J4X]1;.//K'*T5?XT*W,QCT+%-3!N.1 MJ1C=@:;88P/,F-$?Z<`$5>V./NFXD>BZJL-',^$^"YU%UDT<+_P+5-E]=YV: M^;=^%(=)3F>>30/Z$\/6S`GX`CU[J!A#NZ?T.P-5Z0P-N]NW.Y:F6?7:1)$_ M+6(0KN%L)\SQ:/,^VA?@8%ORU!R93YTP7*&!0HLB>D`Z$83MT2W8,@5A("EG MCAEJ^EX*-ACE,`QSOUPZ*T8UQ!S`=!KROILE.#-L0I'9R8+GUC62*R9R1?A5 M@9_F[;,)B630<8+>23K'UL)U$*<\!?&$?39G.;.D.B`C!>C MS$1#)=Q"F'`GQP\!\\LX1BD^'Z*)I0DU3PPATV.4PPC\=(]/L8!?2L3'*0CA M)@AA5D_`0WILH9/Q?9&W9L;:WP@:7'W3^M/GG(R+&+U!S#BN4T:W=UA5&!`K M2IG):3P7&$'*Q^A9.0%1[IVV<_`F?,)61`"R[,3EY0LI,7@F)[#U@\#CL49[ MT_I7F1]E1H`#$0LF,7"\#R89U4[X!/!$<(4>$*];UZ,\Z0ST:8JPE/2&_*DM MCAER"(XBIX4`R(01FP/2=>,\ZU8_H3;6B'GZ&XA`B&L!+RIV*6-W>NM[_T&3 M([Q/QF5COM'O4#5PN0;@GN4Q7P6L\/5&BR!.]C)>PR@_>!?N15LBAC-:';`J M9CA./Y`P;R0^8.&/1\L0!]?HOSLP)_\_X-JR=4EQE]'U!G/.#%S.\<`#YB^` M3-':S[T;6H?N8CD/5JXXY5K03I2>NG'D!C^,2-T"!/G\R"E]L1!9M>@#*(!; M=YXF9GUGX9;2OG1:1L8M0P#-S+$'6Z87)PQ^?BE/L=)M"\=?P.R1`G:!$0'1 M@16#`WD0+0F)B^B$E5Y@'J>,2>$G\R_13HA.NSQ`P#MPRM$8%/&613V/D\SF%4L"W9J6I`T*MHSPD5=I[W3M+#-,FH_.88 M860J\#TS%$NAFG(3CN0V1!HCG*R+=3:BD'-,9-3-]&B/3Y_$WRBNHS`;E98% M_/+%AN?S1]."$%10DBC7$!2BM.*IP'%L!?)?K&?GSO'F:.D46#M*Y,SS6*%< ME%!T5>#U!_B^`S;V#E'I3E%&*=%'F*/OKC^0/X9$7;HW/*6G!VIBJ'RD]O:/ MR5JXHJNC@='OZ(HY-#N*T9],E($VG"CCT;@_L4QK-!D,.5S1YO$"^1I%:]"ZK6V%PWHJ"4W.DCP8#",LZ:K>G&`-SJ`PZ6D\9VH-NIS_4 M.^H$V/))4U_]TH47>H7P]%$4%9E!9]B%(^RW=#2/Y]BBXD06G.1*"OK^+%=] MTD]/$?]PXW?7'YVOS\`U+PH,3>U]^O-R]`#K.MV>K4TFAJ)J=E/E?Y0,Y2Q M"2M"&PQ-S1J#8=#!,AA:@:+UB9?R,?=*^U?PBU`?_H20"?S!_Y(76#N208R] M8M+J,105>7$)&U@D,OJ_8NJX:C'OJ+HJTFSBBLZ1O6GR1?+$'S]PB.AR#RL:;H`\T:C":37K_7X^U/ MMXOK=A_2BLQY[ZQHS_P8]!FF^Q*33Q\AWGV;\S5KN`!4\]4OMM$I[HP[4;.9 M`<"E]P+?'!.\)\.&'NQSAJ%K&_FP`U&[^P=RNWN/1S^P#\9QZ%TEY'E]#-X[ M5!Y:0T=`?ZPCL`.=:YLD&-;(A;"1_OO6?Q^Z6$6=Y*]R#O(1:A"OHQY63KR`D;C*UA&`\P(D=$:1UQ=9M_DZE5+7=4 M\I(UW2XNCO7)%ZG[S9L*@?_NT)$^!N>R)*"&9`*5AEIRE[;14*1V@YFH<^!C MT(90.M'<0L,FAY_B(3KFQ//M!%3A75K&.G#Q$D'.O_[=\V$%Q*NW6#,`VPJP MM#C*F`J$?W?CVV!VK.UTUP6!W%-MN[LAF*B$*?T@V; MR_A)=5>'LYT:K#>S9%,>IF2#(_)'X`=%6R2VFEJJ#C@:6FG'V$[%QC"EELL" M2.OU>I:^*?AX**``!Q2HCU?OYU@VZ<]0\9>+RIW%'1T@"X2H=_7M4<6]))5K M*..:;_\F63NS&#P4IOV0&R>*H*(/:85$'<6*4E55]0%O;IV64F9/Y%'>^;+B M$6,IO"&%IX-UE&\'T\>=8L)D*Q5%@J6##SN:,%D41:*U?L?W.L=?W7#J18?, MD6TZ,+`[=F\`[RO#GH[U3>.^TA_9`V5DC?6)VC$&/5T5I<\9X8^@ILP&\)VF M'C$(_CUW15*XO\`(\;_5BW]'K0=?!OY67-R[T%*D?DQ%E^^NQZ+.](,3NZ`[ M3G0+K^%_T/K=.?.Z9D@T=.DTN^B./(:HATR@U*MC!$"[;FNP$F!9Z/H#%K!$ MRCTQ[5B6N-71Y.&)6<>R>ILC6CGULNL5N0ZXI"#[$1[-!K29U]C7[+WZQ=)* M)QY;B2@E_-WY')A!L2]6(62,J2.QL'GK'4LK9K[O)Z$4O&]YHH/>Z+-Z\@F^GH)R>BV`CIZ._ MRV!>[6'MCJ($#T2S5;V85"K->RUTQ.4-@>:=-W-G@]6?X)6^]451#]@]KIOT MW&A3-JJ6A@S/86R]'&D^@=[48SLN:MS8AET0>WI:C&B>8".7=-V M[\4=IAH*&R,Y1;-V,`YY2DJ!#I9$#O!^U3!?R%]#:G6L8"L1NWGV3&$0)>&; M#U@'&O5O0M<5L9['BWW$?:N>J<_`:#+L]X=#F/*HQ^>.MM'3E%Z_;VFV.>CU MQCI3@#U<%%53=/7GUP]/,$=(+@-YZ>(M$7SZ4!T&8+\Q1I/N$)QK>-N8Z)8R M&/9TI6];UF1@V<-NIV8=!O)IYHP_%YO:P+7>^:T_@KM2#;DFKB]@QSR\-R+& MP]MW"17O.RO0XC1I`*R>SYVK0-Y%QZK^#\&4[GN,/.?&!]?5FT;%7@3T0*$9 MP47K?1)&B;A.XJ2?%6SJ/-5*HM9W5AL\)'&+"^];I*V*'.S+!A%? M,A5C8#V^3.W(FY=TR:!TT3N[W)U[A=L2RGOO_TF<$"^N<[?(^V^`7(C9TO1G M?,=_R3NRO!?$;0'2AEIA@!.6=Z'R[0&06KR3P8T">,]V\??X['R5CI?=#G%6 MD1047BJ!N89IDX"\R.A296$:?*T2J4V6^(EKO%NXF5?/R@@A^43068\K25@<,= MJG*-R.C4C5M,,,]A*)[\=]TV!%/8BL'EGI-`[VWP!2]D44B1],59]JHE2&*!5F- MEP=7BI/$P8*['$H>N7=>D$3SU3W"S"W0HEP+_<:HK4&Z.`1/<(W0S5FQ2O9; M(R_SC.Q8>F=R_M&I?OTCKL<[`H]/E'K M".)WI2;'@#&83U*(/K73R,Z7!ZX6]T_J\0HSQ$1BWHAD>,_>C6 MD&[P`-^KITAWU]#WI%M'NM63I=O6[/WH-L1R?R+=$XA<8_N/SX<\&8S'F@FA&1BW+A#>'2L#?60K]M#NCDS;L`<3"Q5= M6R=\%SJ.;?^!">;A[+\F%H)^@N8?.?-LYI_.,MYKIV`.RG0_R?QK9/ZU$R3[ M2=:?TO>G2?93C#_;P">1797MEW0_W?:GXM;W,OV%M![=2H50X:/S]6\OOL6^ MVA"?8>SPK"E+)+RCJ\0(55,??4^]-^IH8W,X4?K68*(8D[ZN]`<=3)V-.Z.! M/E;[6&@G;+_:,=?SEX\DM-1P+FM8_<&E1AH?@^-Q;/V;2B5?P+1A\Q^ M5\P8V$55NW3==1>B#W:PE:>_:Z+MW(/^W0I7Q7IZXE'7X<1?`?G8ZT.S-MB3 M!\3_U%L42*8._Z.=PM3W\YBUB6[`YS1EU,&;6@/54BQSJ"JC<4>?6+V!-=)L M)%-GJVF7*D,V7ZQX3LI4^.#A*-.0,BP]M^Q2'>:A*=/-CJH>4&8Z4@8FNV>9 MZ@Z$/>,M4/+<=-L&&JV>:FI[T3@$KZX_PK:@FJHJ8%UZBCV96,K`'NG=KCT9 M=.T.ZR55+.E%Z_O@M=#GD&.%-.+:ZX&36(M+3573CAU3K*+9V?>:TR&O1U3, MEA[>_BKMNH^_,3$,_"GUUL<_??"BSY=XXN012,_^7+#-SE?5Z)H0P*U1:(PM MO3<:CI1!3[45B-I496#T-<54QY.>90T'8W6PUD#KWFE6&J=E<9G1W3,NVY!Y M?GQ45A69\"]KS_"3R.R=!)5&SUK7TIVH-%B8W2>1>9";>DB?;7>LKUC)V]6, MO6R1:HS&@ZZF*;HY&"B&;H`M`@\#*U"TKM$=V6K'XC2BMM_=/3Z034_^+T6U M05J#P]<$?G>^>HMD\7RLV)M,S*>@L!\U[T.Z69:JJQ8YR>#_'VZ_(2<9"V"[ M:N^>RTH']+.J)!)V';.CF9VZ^%E5THZUFY9IG8*?525;3/2SK*?Z6:7;BGU1 M._2(=:&KS`-,.Q`/.KJA@5$#3U/?KUAB,.P:>-%2,CHN;X9F\G8J>.Z>':M3?G3>?!\+=UKF^ M,J)4[`S9U4JW.Q]L7%]9,^[*5%Y_G,H_NA/WDS+!U:D#=5WNE#*B%75=KHQ* M;#EF%#/;%?=<]]*I,IA`_JZ96K*]Z_`'7$SIN5B=1/,HR[5)GKVH:;E9&)-:%8;^6(_;; MK(Q64%W+MHI6=]=NF\_=7_+I1._47I)J%!3,^!^]OV1UZ[:[@>1J^TL^DM:] M6^SI1VDO69DDP8&V>Z5:[:W-)9^Y56)U8GQRI\1GZ_Y6F7#M5[]T]5*GYT?U M?GNB@U_I?1C.E'6-74K%GI&N@]^&T?@V6Z=;[MA]4,(JN`Q#61Z]L[F,YSDO MPZR16-FE`+*O1M?<[-X^7XGF,2F$56?8I2;C1PJTJZ:\0W@_-:S//"97$%Y` M+=!T]5KQ M53+%Q!7_U'35,]4X;>WB][R5+MQINW/1R5V+VZG$B?H0HT(X?*3E4<_;XU@?#)5&QCA,78MJ7TN_I`&:H6[B3=WLCH M\P4ZTRB&D$\GL=*JL#WYLZ.:4%68"?^K6558M6O%>FBMU*4H;$]EV*DHC*_1 MFJ6C[5,K"COPUQ@>=SEH550",F M#/527Z^CU(55H-=4%Z9VR[A?IU\75L5:`.:I?$?V[,K"JF`?5D^5+IY741=6 M`6E(6<\R=NF9=KCDGU855H:XFKO;2P5_%96$5B)3+ MPHH'+4Y M"6WY'.QH16%5K-KN&L''*`D[/.JJ>L22L`KDB"5AY=VT^I*P*L18MY*P"H2+ M)6'F4^!`UQH_OG=#_(5SXZI[THL%"EK'Z#*>@J52YX4.]E*"GS4K7["P3$)W M^W$$'DV-[-Y(Z>D=$+W=[RG]3J>O6-H0(D*SW[?&:EJXTKE0M_6TS)'VK`%. MI75QC*RB';1\[!A=HD6;;\/)8FX'77LGE63!5\EZ3;F,NK8J/283,&R.&W?0EA!(7W]"1328#`< ML-F+5^(G^-F;X6^NL:U\-+UU%^X_7MW&\?+-Z]=?OGRYB-SIQ4UP]WKX]G_! M1P9:P.4Q3/WGU]EKV5"1>T-2_/GK53B?>6_#5SO3>_N3?.?$RSZ7_UHE>_9/J"P1>>;SG^BM_]^?7&(7_Y^;7\IJ#N=8&\ MGQFN.3?#V`EC`HU'3BD=C)%@C/2WZ8.N/\L]9D.XB$//<@_]_#HW^,^OA92> M*++B+E0KD:7).@GO/$@BSW>CZ)*'B%B(U'][Y#LWWYC@"C%!O07WJQONI27%*0EN]^?/RFY,7I4Y.35YI]6N" M_M`WMM*V9OEJ*W""3\7!=J?TE*,&)L8J\D>$.Y3YO!QM72+ MGQ\F40Q!5+CV\#>D8@=7H=/DSGVW@FJUX&H1'.B[B4RO4&1-<'"J@FN"@_.1 M8A,?N],X<>:R"J!1ID,ITT:,Q?-1IJHM$V-&-\K46*9& MF?90IMH%]D=GSU;4Z%HNK3*T=-:E*SN&I'QQ_^KJSJO'F7;O4/)[`/J\5@*L MQ9F:L=N:.^0QZ)K,>K;=`9F!9]35:KJ?X=)Z=YU;:[EU-@SF<^ZA1![MF87"E%]= M/XC=`Q?*U5!R36'1B4JNJ2PZ(S$VI44G)["FMNCD1-?154YHFYI=3]'UOSCA M;+VN?[Q8SH.5ZU[&P?3SNR5Z+]^J[%1-K:F=O$=V']P(-K8IMO-'Z7UC/LDE,D$_Y=/*.MJT.]M>+#I^M;OSO060IQPE7^PT:+*M,C0:VJ2'J5% M#!/BAHT&5:Y!\,@Y:-`D"6$+3$+L@#CQON*_3KOP[Z242#?MF@:6CU*B0>+- M$8NG49Q#*DX]%:6155E630W=:=70G80R->%/HT7/J$5-^--HT),TJ`E_&B5Z MLA(UX4^C.#LK3CT5I9%5_=HYU(<]32>N9[^I4Z',FHJYDY5<4S%W1F)L*N9. M3F!-Q=S)B:ZIF#M]V345TE0515MEUX'_-@! M)-@I=A5I8MXUB7D^2`>>SC>=D+\[H""XYP38'Z.NX=`N/2?DLW\N)R%P0B!. MY1X]!UDUU]Q/2TK??+>MTY)7TVO@E*35E$Z=F+R:A@^G(;#F9*-6XFB.*^HN MF^8,HB92,.KJO^T@A6'_A*5P]'QEE31K]:-9.S3-38O+W021U@U5((B.U3&I M6:S5Z=5+$%FU&_C.F*.+WEV/W"M9+!FO+MUI$GHQN`$Y-^'7Q`F!92YZX7=N M%./'AA`&P32F8#X/YS%4*K0FVWHJLFJRK2U$D>3O:N[;)KL74VDT&3OCB2%.F6R#DYS72HL"QG+0\M953M&O6@VL-2P M8QQ2MQM4I7U67^^1>>0$O&\2B1<%AJ;V/OUY.4J9O'`=F+7[B_@;;%:CGU_+ M7_)@^'YII.C6"=UH;1#^]0[OYV;R"2;^J33>S+L#J67TXWM_)!`,.'&027&7 MV3-O-K]/PXYS[.[F:61_WVDPTN7[1J(_WC,,+Q#XQ_\#4$L#!!0````(`+6!9T4. MCE#*H0T``$:W```5`!P`;W-U&UL550)``,&-EU4 M!C9=5'5X"P`!!"4.```$.0$``.U=ZX_;-A+_7J#_@\X%#G?`>;V/IG=9)"WV ME6"!36S83EON7G[__[MW?VFVG MWW=N.6/@^S!W?G?!!T$"<(;DA3,^G3LWQ'=#GP0XFO-`V=='(N%?COK7<_"K MWZ_[#\[YR9GC3()@=MGI/#\_GPCA+88\F;RXLWEZ=O_[O:FL_F@HXG M@?,/]Y_8^/1-&WM<./V3_LD*QK\[`\XDMI[.")L[5[[O]%4OZ?1!@G@"[R09 MU$_@.LA1)M^W5A"^/`K_A(MQ!Z>YZ"P:MK[_SHD;7[Y(FNGP?+%H?M;Y_=/# MP)W`E+0IDP%A;J:C&BROZ]G;MV\[T:]Q:TDO933*`W-^2=#KSH95\-Q$P>M_B,A2* M\S^>OKTX5?U_N.5N.`6&4+T[%M!@?L]&7$PCJEN.&O=+_SY#/A<$1X%(>H)$ M%#NJ8:=PK,ZVE/:QYQ^#`,5-S=$=?:`,UX<2O\<\\*L`-MJ!ZY3EX*\\KQ(*HF_C;[9R:0'QW[/GG`9N,`_]XUX=:J#XURVNE*-T0!I&@R>[HFDCJ7C'OEOIA`-X=$0S;R@=^\J4[0+GD6>IIW_PO10]BU'C"<8(>8D,4B1-:]S-``H.RA MW^>%/G1':S^\'I3Q##M$%9LQW&GL7%67CKQ#%->AI`RD',!86;Z5678,JNI$ M!\&8*H2-G_:!M&BZ@^#M"=PDLEBW=4=#'A"_#VC_0I0TYCUP-GY`!\V+3<'U M_"/PL2"S"2I`W,ON@R/;$;0;%_(S#T`.^7([L'0#95>,":-_1M3=H#5``^'% M(LN\+.4YG5/X0W@)KGU4NU4Y>$#*]LW*0HN[!P89SEG`G)K'MGP8;?I=KN54F83[EO\`G[98_,%;=1226.V0,EC]1'\P_[U9>O M):"FC-GUD[(=&?MFTM(?WJN(%,ZR;XBXYYS2(%X+YJ%%5ZH*F+OOYZ+BO'M7 MDK&#V(<9%XJ2_:I'@\EJ`'CG5M%XR@2\F^;05`HMPP3L`BXNL/"031\FJ$9&/4<8JE.TQ(;..DI,. M^(%:=KX)AZ#"_1)4?,9 M`C/J<[M8PK!F!TL!:-I;HCZ1@4RD<>X^28O>DR51K&"=!E$ZA'J MW;,;,J,!\95]XRQRA'7@RCM:P9.D`?)I7@W5VZ"KY!G(M+%!I4K?*7\&_U,; MGR?B1QY.<$.$F*/-^Y7X(6BH-^MK!54JDX4`UIO9H/461H#K[R71O&*!T32V M23?JL5B,2TU640_+"%:LT&?.7%,8^=UL8/G(N?=,?5]#\_)G&[2M9TYQV>]> M7#]4I6HE=!MUM8,I3H;/D2(M[2M-;-"X(IVHIC=C7!JZ2[M9QE*L9&KB3T;N MGXD+D-/0,KVE"C"_K36JJ^CN@@XVZ.^)Q):4NBIY+2U1/$/O/RD30/U@+.@F M/>T@XC,0P;SGJ^P'\Y22FZGHAEZS%W:Q@:$/`:$LK;E9V8>BMT)=JD-BT-$& MGL&$BV`(8JILJ(RCKAH$N4VMT&QJ7XLLZDK$[DID22?"70R(?VZ$Z[)EWDF+ MCE1U%&JT-@U@NN@_$GRZL4=>3,9UVU.'"R0Y.FKPG]/3EO,,JIP^^HR?9H)R M@5C>M\Y;3BB1.#Z+HP5U15?\X*=@WQX#6#,??`GZ[/080.$T6C/ MD$)_2?C@AR\>+^NSE(3<-GJ^#SPE2I56[0,K\&?%$T)F7"D4M` M>5(A946#ME&O845>JR7X\P99.'WP.<]]62\^2=>[08Z+&61=[C*%?(RKK"MS M25$WR(4Q>Y1S`]4IW@:%2,SP;A80I(JK0:$1,[`F%4$I_`;MK@WA5RW]2GG1 MH-VW&2],$@DI_-?8LSJ6JF8OL;!+9G+G@Y6B*8GSJYBI'*"<:&NFLJVL%+N@ MC*I'LJM.]`6"N%&$#-/3&R$JN.Y,78.E[B^XAA'/'"C_1%FD MR>Y9``*DRA!E1XFUZ"<()MPKSU,>D@)['$:Z$T&\1CG5RX.NM9W2(C>)2WY" M'8$Z7-W4E>QHM$5&!5UL8$#G)!4-#='9-E;*=6)99^/T'HM<2C?;6:6VE+-Y M+:V50WU&OR)+3[%!*>EDIYQ%`OJV*NMWBP^5SZ.T?#&,XCYV4,37,V@)3GZV M4JQ"?)`)!9$OIR]VRFUJA6;P<9:@V]AE:'*>[7JCM.!09E(M>;:ID44NMAE98C(;65*3ZPUFJPX.R/1&YC\, M69BSW]'D/FJNS[2N>=8R%?IEC:QG,`)>Y'HTLK;!"'5I@*J1!<%FT(LCC)KB MX*8\X\6:+>/`-;(LRQ!HCB1H"J!KOK#K.\V,ZLK=Z36R6+8(9G$0;[MZ66NY M(.V-X':.U*^347(91E&/;S'2PAA>20JZI^XCP@",(F;&63Y8H?SA:%4^?1/T!5\ M5!KB6^:Y(N691_N>K=40ZS&4]*L7FO1`5V5`*UUK@VFM_K<*IO6N]<"T5L9M M#&B]7SW09%Z)8XAD\]TVME$DA^86+,X]/&<,SV@P2WLR929[@C]1]`:OYU\D MH,>3U&JR\14:FJ>XRCXG2:'?Q&TS:(WX$.=1=LP'TT%KQ(=EI&Z7?#`=]%NL M0GMU#IE'.3YT$9&Y+H`790(KW-Y2903+"/LP"P6Z^1)PWUEZ6:I!1YMXAOS* MQ:V)`.TE*"6X#`:H!;Y7R&)Q7TM75*6/AI*=;A1_D7#<*P(^:P'*K8Q<(VM2]L0T8P^ID:?P]\0T8_>Z MD2<\MV5:M;A@(\^%[F;;M7:96IF):N05$'O@E(%+J;DBHN9E"+O9Q.;QJL2= MTU08_F799;0?:V:=X@%DK&!+I+GAH9D\JQA4.;84^^ZYHMO8-/*VOMVSQRR' MW,@S+[MG5K7$;3//T.R>:^5%^4TJ8]T+?PQ2M)HZ_K^B-!6E%C6%_]_89)B[ MU)P>^,:_S2J01EY&?@A.;50N-/(&\P/)U$;=RG8'1@];]9F^?'6@."KFW5'A M6\O32\TLORVU*N&K-L;FBZT^J!-?$_"B0R/:2I/R%5"8Y\\?R(!"$K\ M4M9FVEJE^C7I9%1#6.L:XO9R!B%,=@U M7=:DTPY5S<>RU?H;7VP8$\7W`![HDW)GLN2LW"QI<(C@%0-9*;?7DQF=JJV. M+NYVU&_MM*,YS,%EPG*E"]Q0J[%S=FB?;XVE,=WVUUO[JL!_&,3[LN[HFDCJ MJLLRJ!\&Z:6Z*GK;`Q&E"^RX^+@I5`FMY1W/BA*9/1F8)C.2!-F5$*H:HN2. MRVT'MJ'I?HM$$.7T";?48_@<3A]!=$?)JL48NF$@4<#5`Z$!7W64&B'=("X2 MW&HX-6-856NO7-A5#5>18XW4_CM@TRY42I,N:5BQ"QOWJM_^W>$&K+_UBY1[2&WM%U*"E#>1O`6+FB*W0U MBM@T0K'Q4UU)[N$>06T:U-_=T9#C]F%QR=L5\QXX&T>QI3BB=#W_"'PLR&Q" MW2L!Q`:HSSP`.>3+=PDM[R*273$F+`ERW7`FN4\]DE0X9F'F=$YY-43BKGUU M"*!6Z`J#7HVF>?%%$VD?JGUUW2C?V`^KMK47\+62*U66O&&$CQ5$'<5HZ3'4 MGNDJWD7C0S7J?&!4H#4&YC9!8!*+W(>9RM"P\3$07";-[SJ*G$`L``00E#@``!#D!``#M75MOVS@6?A]@_H/7 M`RQV@76<2]N9!NT,D^8"\+H^_[1P6&_AZG%;$)G[_N?'@9G#QO>G]:V,$\<%1KS=WW>7I`KM/>FX/CHX.3Q)LQ\ZA]VCM./+K@&/D=VT`1O#H\>C4X.AH7UZ^/:_R=)LN>)D-G=[_[+^#84/7P^@QDEO?#`^2$#\9^^!40&E%TM$5[TS MQ^F-92W1&V.!^1.V#\)&G1!N#QA*Q?M^`N'S(W<.&)\-H9N3852P_^,/O:#P MZ;,@J0I?3Z+B1\,_/]X^6'.\0`-"A8NHE:HH&\NJ>O3V[=NA_S99&NBPW77Q M)%FOA\'+H+0@I\+O\Y99/D\UX/1R2\C_!E&Q@7PT.#H>G!P=/`N[_ZOL\!UG M#A[C:<^G^-1=+?'[OB"+I8/[X;,YQ]/W?28\+L?IU>';DT-9_Z=+9GD+3($Q M]A5UB;NZH5/&%S[5_9YL]]/X)D4^XPA:P?Y<<\-Y.Y0%A\JVAMM2.H::GQ]< MF)RRC]'TFE`838*<>R;\%7/A("'(E&"[+.&:K>X2PCWBN/0`E&C:G6.76,BI M']0-B+\%WH+TL(':"1L!9BXE$<=S3`5YPEN3FMMD[<1?(#&_=MA7<4-MPK'E M;D'U9EM;DWM)A.7(Q_C!6RP07XVF#V1&8;Y9B+IGE@7[C0M[XCUSB$6P.+-M M?U8B9QMY4TNG.\=^0Y]@&!B'GTTC3G:U?"8'=QE'G=[QS M'DC9X+G^1!.CZ3D2Q#JC]B5Q/!?;5XA3*"MNF1#WF#_,03`WS9OR!-7),Y=9 M7^;,L4$OO?J?!QI"W7)`LX,:,0&+N0>L>U["!@!S#_0^VW/P:/KB1750VCW4 MB"K8QN!84KNH+FRY1A3GGB`4"_&`9W+G2_12,ZBR'>T$8RP0-EXU@535W4[P MWG,X4M)`MHVF$^8B9XQA__-@IE'[EM'9+2AH=K`5G*\^8#;C:#D'`0@GWR8X MLAU!]:B0=\S%8L+6QX&U&BA&?(8H^=NG[@)V`]@@[&#*4CM->4;E&/X$/[OG M#HC=LAS<(65-LU*YXS;`(,W^V@$[>K!K^.M^V\&&"0(U=.=,"'MMG`4;>I5B6@I8RI>Z5L1T;33%KK MPXU.$64O34.$,^>"N,%84!MV="FJ,+6:7A4-"L>-3IK M`>#:=T7M+D/PB%NZ^',<-)'K1WIF7OML08[3[X4-)T&M:Q'J#FVR&(9EAK)" M@_1`5](XS>C`QE/D.6XYZC:K[X96MD"$5B8UJ-TDI7X/@P5>/&)>DLQ4U09I MG$,3W/(>\6#-F7*49C40TFNO7=724YVB&98:IK;TPP5/95-U^!"#CH?IGIND M1M,QV%*ZTHX^DT2&7C&3).2ZZDP2M>F)VSDU]3C1?`J!1MA@4X0Y,@""\2)% M0C[Y?/;X^$3PQU">!A4<](B=H$;Z_;!4CTDQ-T7BT9=UGAC,$%H.)25#[+@B M>N+3-C@\"F,L?@H??XX.$F-L8?(DU8A,8@N+&Z+=6W@.S#S[$L,:`(DA!PY^ M.S@TK9TMI,[T=VBZ9"#XW=6](R,?(HP%;S\J51+VT:XPF&@9C@Z<-Z!D(R?^(.( M+-_QJA8;)5OY9I!^/C:#]0D11TIO6)4/R$G,R3Q8^17:17\HD;%]P43N:M2L M70Y9G@:0V]F=)V>`]"WF,+]\?1-C<>X11X8&*Y?%BT)FZ`Q\FF<6;,S!L<+_ MR3&^#(_E.:07U=LK-(8D4A9=SR1/'.65KF7%7C`'NH/3A=_L##@C97>^#J\L M;X*7@2Z!^5H#52[-O-)F**<64!"P=P@ONBG-2%U?8(BZ'UN4G6 M:DV88J$65FL)E@GT60[&ND8K$,!)03Y`,WRD"R%9I148'KSETB$*.957OA74 MR_E0;F$G:G0>@2FIY`F7+:3-X05EZAVOH%8M6L0EGF+.Y4EB(4-9`Q.1@^@U M(OQWY'AX-)7_1M'CFVI%N09,<#^B,`P`C*RH>4(TMW@;:$\D%:8!#-,U7D%*Y'0E'T`5/FXFQIF5VFEIX#+^@?Q,89_@3T M%^.1A)Y`,T(&Q,7*2A:56[57,Z)PI+:#H=M(/;0+ERRD^?Z,4@\Y]VCE6R\G M[!P';,3VB$K3TV@:Y#EGTEZZ$1-K[]KCE+@R_X3:U^19_E*;+T?02/T8. M4W>5,,;G*V&ZM5N*3*FZZ-??:W2&M+./Z)DLO$7!6DJ6,4(EH<54ILK4(DO7 M'JA6&TU];[R,6%%75,(0@.X*FT#ZK4[-5B`H/L#HU]PZ1(9F?2]DG@:>> MQ61!"^Y$X<$QA M%.ARY\Q>_YL'0;^!=N"3>RWLO7`(IR*\:BW<@:.GVD@UFJI%VPCT@750P-7S MD@0:SB6<(+-4#'4%$^,0W\VQJ2],,A0\_7JU<-B/J0O&%$:16#AFWCWF!&9Q MH*UG,5N[K@F^RVUQ-$U8KA7R/+NL":H_+:\Y`_8%FG*"(J4T+:JU1A+G"YSQ M-";$K:CQ,-&G;,Y26'O*V:)ZY&I$$],)#NHQ;F,NK]@\_OGPL-];PIR#,_#J M??^XW_,$(&#+("_!(`>T(\W6F#<="VN<)T>&<&ZF"^IB3:PZB;`$6]:H#P^- MHTZ-5'.@01=J`>SB2:T;G)4$GY\J$T]O\P.MFMZZ05Q)U,6<,C_>6M.\"?#M MF.Z5!_^E544)/7G`;Q/F$7([!KJ"7-LTRZ00%\5/Q0K*V]9B+@I#6NLE M%O`JZHS<4@<^XPB,^ZK\R/M%5B[UD?%5RJ$N$^)B?\5K+ M?A?,Z(H`*!W`M5X(NI&4L20PM$10'%J:QJX1(I,<>PW/5X3U\#`<\^"VLE-Y M_1"VW_==[N'X(0A0_.Q>.;[(>=\7P<5^+9TH)9FE?25#O$C:JVK7ACT)M[TJ MM";<"O=9Q.A-Z<;UHB^9U1?#-Z4MU#[7M8*E8MRO]P5W?9>-Q@,H@KY`6%K.@O0;3,BPHB-Z*[Z/$Y?L*8K"F ME#(]NUZ)'!DMK;V#1OSF6-`5&UZ)))QT]%[ZIL;84-?J!5X%:NX5>+']OM5[ M=17,RJ3P&/?>C;7J4H<8=KO%^D;"5DHK368CF9=/6D):%U!71&Y&1EAZ[:72 MQF/)VEX33Q&B=(IYO)`,:?R9GWW)PJ6=KU04V.Y/7N-SLUG4Z3% MX=\A`T[VE`':3O"0#Z_VE`_*H/`0^^L]Q:YU=`IY\&9/>9"35QFB_GE/4>M$ MOH4L^*4-JJ5*659FQJ9\=F63-XWO]GK*=5,,J**,M_F[7C).B;I`/Q;M_PC9 MNM2-_%+@C,C/^@9A!`8O5A[C(.Y9S,E2?5.BJH:1JQ[ED.);Z:9\R="$*S_I MLL\!5J&AEN$]7P6Y'O(CBHI+!,JTT#*$'S@3%6`%U5J&9<.!H8_GUNCU70K" MXMESAQ;J:Z+*MO+-(#5TS5`^E86W8VE5-8'I);OOL!ND1L%V7'`YK5950YBP MXV#+E;$ZX3%/N6$K*GR_>-/4Q9OU4`EZOB4#5%V\#F-0*V^*"D8NY`.-"F:G M/<'6G#*'S=0S.;?X]ZOWNG?U7FS=4.R/>O>.%39@Y%HOCFPL=W7UBMPH9M;D M4N%TD7+1EE68.F*(V2U;6N$KS4VN*G.DRYQN595]>OIY%X+3Z^=` M9!?H0EQZ`^AS[5Q="%ROR@^]LUT78M^X35ZF)T?0<"6*=4?M27K^&[>AJ-9E- M%UVO9C08P676%WG3'^8BB/^+LJ"0DP@D,A%T$%^N)GR%%106-D'/?Q!W+@D& M+LK42\E`X''Z#H8<*]HV+9HP#IY]1=Q^F<3T$E.JC`DJHU@RX.35LV08EA<* M^A-KY*]:*KF?-96IP43"*\62X>M,$Y0I+36YI78MGTCW"DC MQ%LDGPMYG2'[ES+][%J"VCT0NC91KIZCO/2G=E*`S))U/< M(R)OX-E.*:S4E%GW:Z9>F'*B-3*IC)]+]2Q$1KC3"F=LA7-[3>I(*LL@S7_C M7,EU4=>W?6<[L+?F[1[[MQOB?8[@[X)OJQF.:!S^NN#U:H8YI2P77?"--;BJ M2BM;77"I-<.OK0R7YMUP-;!MBS-+^OZ]3%M/%]Q@NV*1PC19UK=FQ@%Q9EF@ MQ=BA_!6Q]O3BA4DG2?`I&%C"6"B\(V9HBZXJ>0C4O015'2(U=JQMO#+B>0KO MZ\YVN`0OS7A:BF^:SG6Q:%2MY0OMHF8KJYHN/;=XAIR@UPS_8E8)$W-^M,3R;A8ZB[_'E3/% MLTJ:25>2%Z;*;1_1HDRES9)F*(XN\PX_WZRXKCX'B'8#9GR&_BTGN3E8T6O# MGL%@[QOCI13)SCIZRNXN*0N@>D%^,_S(G"O&;\K4,4=E[6;Q9ZP21S;CWH!\=UV)G2[' M(:<_YOOL>JO(QUB+[H0KI"+*S/-F)WP9%0'K&94ZX9:HR($RQ]].^!XJ\F'S M,X6F/MJF%P:E=4Q([03I7="XVJ(7S[0=S.Y7MV3:"R52KC]K*Z MX!5K;ATR^^A-3ZFL&S?M:-L[-3>LM,FNFM3ZAJR?E;BZ:0CMCE6L`F#U@[22#)5NJ"`-X):@1]BLY&<)]Q-"^R;0.NNAY0R_8(L%"=*M@-D@ MZN4"Q=1J_U1YJ9IUG]R"6?QN**EY1`+#/_\'4$L#!!0````(`+6!9T76O7GW MZT(``)*``P`5`!P`;W-U&UL550)``,&-EU4!C9= M5'5X"P`!!"4.```$.0$``-1=;9/B.)+^OA'['_)J-^YZ(J`*FX*"CIG9H"FJ MA[AJJ`!Z=NXF+CI4MJ"\8VS6-M55^^M/DE^PC5]D,)*W/W2[C93*3.>3>DNE M?OS;V]:$5^RXAFW]=*5<=ZX`6YJM&];FIZNOR_9H.9Y.K_[V\Y__].-_M-NP M6,"];5G8-/$[_*9A$SO(P[!";[9E;]_A$3UCTX5'P_KC&;FX!?1O'6P+?ONT M>`3U6@%X\;S=QYN;[]^_7SN.'E*[UNSM#;3;84N_^CQ]A/ZUJEQW8[\L[+VE M?P0U]FKL8.21TJ`3;LA/'>6VK2CM3G_5Z7WL]CYVAO\;+VWOWAUC\^+!!^T' M4KC3:Y,:75A<+ZYCXOTG+&W+):6W.V2]P\@T84%KN;#`+G9>L7X=$#4#<8$H MTW)_NHI)^/;LF->VL[DAS71OPH)7?_X3^(4_OKE&HL+W;EA\%; MU#8LUT.6EJA(B65558;#X0W[U2_M&A]=1N71UIB6.!B$W!+T?^VP6)N^:BMJ MNZMOL[DP'>>&UK^Q M\(9\2YVV,*0M*'W:PE^"U\S.KH"6_+J8Y@HT3-#R*]WX3)KT/]1.$VSB-P]; M.M9#1FGU`G4QZDS3C"@E:VL)@B;5N>TD!;?=O4--[K8S[':86/3-M]'S\ZN! MO^#M,XXJ,#;]&LG?;Z(6:8E$FPYV[;VCX2I"Z+:VWV++8P92UO@W\YDHGY@A M*4']!+;:7Y=78.@_71GZMWZ_VQL,U6]*5^FKW<&W[C?EZF>_^O6/-XQFO;R; MOC'4R;-RX!E^]PG\WT5X]XB;PX_U"Z`&`OQ:(L#(2=HK>W$AU@[]C;+<,/F[#P9;RIA*6".,;9&[C/C;N^V-PCM;BC&;K#IN>$; MAKIV1PDD^V:6@&=D?/KN<@S4M]%HX*-2,SR[K+N>"T M%O6N/QCT`G./B$%(#7X/Z0FV_KH%5$\3\-+HX#<_"A=.I4C$C_N$WM&SB4>6 M3MXX>]+G&NC9,`V/,'EON)I)(8]7I)O]1+CYH_BK5Z8F'GE56>2UVOZ`/"=@ MZ4+0%"!+AZ`QB+4&A^;@=]H@L!;E`O>R^@E1S50Q>=MAR\5N`W!\*@PR0'Z2 M`AO@`<9[QR'#23[K"`O+PV_``:_Y#=3AG9H-SQ8$M!J!NY/D4A-R[7Q*#8)5 MRK8*4!,77R8H%EC#QBOE*'-V5UI<`C#2/'"/MWK$BE+0.-"2-)FJ5SCU%.%$ M8R7/Y++0DJF.9N!EACV^KB2SBE3<'/C@=K\#]6Z8BYT6$(H-Z5[.ES()(B`3-/^3M<\86T[H-O[9V^]-P&%54B1OQ):;#C\5W4X;!;HCNVV&'@I M-4H"7VI\68J\G/)B89?-!+G")1D,_KD6@1E4$L(N,;25S`YK#`#447ZD`BGA?V.3.ZQ M[%%I\0!*L\!M4+=W2@HY$:EF(.8\R1A4(A(-@$B>965@(U-R2:#8;_LB+ MA5TM//,OL7=N#_/-L&F(M]V"J'5_LR_6?@M"#L@3Y:'%BD1L2$.X!"6J:27J ML;;IP'47M,-4A(M4)-!WU`K`E+.I[R-(]DYS[P4[-/+2P2]DSF&\XJFEV5O\ M:+ON@^U@8V/YOE1[7SG(FI'/79?C`U(\`$^(_"!LO)#"P)N(&0'8OS`@2&VRDW!2YB2[LSD:/?(KZT# MU6FAZE#4@@N&I9E[G90RB,]CGT%+?`:3\`IH2]>;L=X0WU ML1YOUV!/5AE'ZK!_=Y*7^C=Q/J@B(@J4*NW=`KHM\"D#(RT) MIC6+K*9$WA&J;2*RYM.5BD=N(TU`D$]!H\R">(^M@3!T4A>+T9#:YK?F.=#0A@`]CU*`Y\&S:LT*L M11; MD;F7O/AY/GB2;N(\74OV'RM[@:G2#!;`'/O5(#.S3^]?">]3 M:[ZCIV6)3"/-,U[9YF/9OOHEFI+C<6KCO\)F=O_VV!41%Q0QPD;[B0D`_9GR M`R%#\/P.'RA/9`#R`T1LP8$O^=O_TI6L9BC9B91,X_G8(@1Y2Y\UJM]=7+_[ M4+]VI%\4L?2Q(>ZN=JSG^,%ZOZ$4!QE&;A+??1_$;1Y'/)9LR%:B(=*E56&, M?]U/&82;MXFPU[`%R(P'EKNK>SE%J,>*.(K_E>H53C'P!-PKZ^YT'+M8N][8 MKSL#)2`6 M*&?RK_+Q?VF;SS4-:L_9(DKI3-WQMY(*+0N MSV\Q7T^08Y%.TWW"_NQBQ/9'\CQ=+;1%]E%U,,SMLCM*/\P@$&L7#@U#V#)0 MDX)8VW2N&[8.I'E_):`%/@>2^C7QRF-0G^WIT2MV\H5PT([TZ![TB!-ZG#PM MV=)]P(K4#K%.]"4ZRMH^AA2GY#CDZV,VK!]9^LRVT.$-VW&DTQS;8;3 M()#P`2>H50K:71=[;IYM^#^*Q"9KD7]%^FX8SD!914D0.H%IA@QV\@O0!5DO M/=EV`NOL&-MJOAH]PFBYG*R64J&:L-\$`@^BR0-6V5)YLI!PH%5>.>WV^X,X MX.2O(Y\AA]\[-<2$"Q=:CX649](E2Z"),L(-NO*I_H&BQNWYPLN3?.[X)"'Z MAPY%"XYXYG%,YB@'^5;J@JF0;?$$]^EES,H8^_ M+A:3V2H8F\C=B"NRJUP8R/?SK\@PZ5H^#6-`9FP-(^_3Y5<0"8Q<+O@WYN5T-9^U&8"S!$O_0I:LH'(!K040>*'WXA%RC<3`\0P4\F$21"C1" MOYFXS#1K/I`>:Z\:8O/RT^YW5OU^L+SVU=@CM,@>]V^JO:#_/7H.#I9)3$*P]S-?7[IGS')(%Q9?:9#X)=GV+Z:#^1M#+LF@W\4YATP_^PBUQC"`E>?QN/4I\K]H,` MNS^TQFT'RNU=$!XT'LU&]R.QUGPJP_ZV,;*0CJ0.GXZ_.[7+E%0R7#4]PSFR M=/H/3;CWBDP6UNJ-D>.\DU'U\-45Z,:Y&*J0^ZP?!!"Q$]AT M8J1;@#P(J<.O>9NJ9PN]PXYAZQ-++_+T%Y#^UL?[\I<63&;W,'^`I\EB.K^_ MH)!+#SF>8#%[!S$_33Y/9[/I[/.%A2WMMR\@IAK:LLSNNI+#B7?>_`IICA]] M8B8]M30'(Q??8__?2E\\AX1TKYK-%[=!]M5AI]2Y^FU`V`A\")OY04X,Y^4T MP4(\9Y,53&?CQ62TG!!9)_[3#^0=4.?4/-06FW`LT5TN`P-@VB4RVXZ?1 MW)"),=URS[_0OK"\Z`"`(F9X[U[O=7KJK;_AGR`'$;W++H[F;N_7)YPB3;CB MS?OZ)%1/E5#(?CT/QJ+]^5*E2.FZ[>W6\,+C?&.;;=5@2\L/BBVJ(;)CSF>C M0AY6M1MB**+F=\=Q>I+&P'4)Z$-H_N7+=/5E,ELM841F,^/Y;$4&^I/9>#I9 MPH>9[6'H9XXLA/6RY9:8Z%1+U-,P,!UN!R\YAU&-1C,`=\P8]T*5VE&''!"$ M0Q/2#W1<4!%JC8IH`&[SC9X3R3GZ;"RVRP)]*A)I&KI/"'T9='I5X2T]_.>2 MNBA'>..Q7!CV1&L56XV)'61ZWJ$&'!6K8*AI&/+H1S+V M&"/N:.^]V`X](E/^M8]JR,%:F@W^*.O;^)3S@#&?(!PH2L?5>2)FX"G(J(X* M192`JSPCS,%3IEX:@:.IZ^[Y,124EHD?GX4J`ZA!/G9:X)-K"'!.D2T?-$:N M:-(`D[2V0K#$=-$(H,SWGNN1@3<9FO)^SG@5F9")\5'%MH9%N(G1;`AX3I8R M'T%VL9#28)1ABX582JM&,J`*0Z32Q>0`IUJPB!HEDDF"A5%I3!]S@DQ%,QSX MZW6'_E%:H*B=%GDZ'JVUH-=O=7HJ6['H]5K]KIKLG=@/S8-9?DQ-ECHEP2E] M(U[))9)%-<2"+(^-"C>NW1XZ)YZK(%LP\CS'>-Y[[`B[9]/U"6F9S6I303_8 MI7M:3'Z9S);37R?P.%]*3>#'89Z=S+*.#H.M:L^VD?)5_'6M6<2^#9K".Y?O)X[-`8N5UNK%I9:<%(S&"! M/Y7X;??V`#Q*"2)2DL_MUB*:>H)H(I%48&QIX.3I0@Y.B'26Y\>1+0SWCT_8 MTEZVR/FC\&QO:36AR"GFI8KKCD:/,9)`:4)$5/*YWGJE5<^25AR^^(PT"30. M/34#<>\1:P5G>TNK245F:QVB3,`U5#DHYQF&`)E*0G)#OBZ0D[]`7: M8(7WZ\:KR,11C`_^%$)W_5P@L<-U`<6&`.ED$?V\8E%M_\+ZN,`.H=XH+&48 M8B&8TJII!)J6^]W.-`I6)_+*R\11R$2%/54U=[#7@I!<0R!TFG2IZQZ]%\/1 MVSOD>._@!@399>E;9.W72/-HB/+];/3YOUQZ;;J^U^3>1%)JF(702JBL$;BB M_6:U98Q8#9G8.K!183JO#$K&>LU:MSA5QN+17A-7*X[-L!!'*<7(09+KS=>? M;5MWE[:9'P68+"44,8FF^5,$#&ZCB%F7;0(S&D")R,+%&9($IS&7*Y9C93&_ M_SI>+6$Y?\Q,M2(.`)G6DS3Z8ZFE&+I_F]`#UK&#S!5ZF[SML.7B3]C":R/W M6&5)+9%`*&:EBCF%@[/@JJN`)(V2@(`H?`C(7BAK2"E6ZA268>?K]?(:UH&D MAA\EXA&!GWV*4@#B[R*N#!<#9G_@Y$SL?1[ MY*4C^PJ+"H!04?O\21U[41AYB!M&"R@Q(-2`DA,+E_H$4T\1[-+XX#$Q"HI2 M-4CL<-@1JI&E/Y*6JG8[)77%=S[%#/'?F]R]ZR:AQ`BS2%!&NH%=49VB'SHD ME\G=S.Z(SW(S.B4.58](PZ#0DD/2%KZ(GH^`$9 M#CM#,E_3__K7'J>^VPD$1&==K,0=IY'=WO;O^D$:QI`^:+$&8$?JQR[FI2M\ M[)5_S?NUV-R,%U2!DE!!O`&@)($V$637F*_]5Z/T M5(XG03O*[5A=7S*Z\Y#+!]O!QL;R#P'P3F4Y*POLY/DXXE]B[':5%$@#RN%A MM`9-9B\ANX_,0&0]U`&=S.)0Z'!6*S539#4SC@\2*FA-)CX7^!5;>SS2=79- M2U[88VYQ"1A,\\!M>F=G81RL8>-5 M;FJ/,K/+0E"F3IJ`&<,LWV2+DY:BK>1@L#.?BJMH8'%8,?NKUE/2T+S1+N9%=]4N9#;XF MQ'95,4Y^O$F.]DHQ%^S7\'WML+`\5`4<<+OW6[4[S!LC!K0:@:.3Y,H<'S8( M,"G;*H!(7'R9H"`3.G^A988]/F1DU9``CPPV^/>C!^'5WY$MT>4*GUZ4/X>N M106WJ)BF_1T18V@(A,Z6/8FCPTZ\W(S:'#:9A:@\;4B&5;!.\D!$9'FSYCLV M^9N\84:F0BBT\DI.`;XPHZTK)7Q%MZ;"M06*_[YP\ M3!:+R3V]AG'^90*KT6\3J?GG>`TS!W#Y>I&#LIV#-8,-OLBSB=DM<)8^VMJ. M9_PK:T^^4E6A:"OGIT)?T8O62`YD6Q`19L&D<=*R`%>WT&I::"8I*I%4'/CX M[34)0$X]20%A=`7-?!W?JF=!0W3WWO5^@F&8E"MVK1.9?"9"7H(V@34:Y")OLW8A;%CZ36\B]:5>7%_"/$_Z2A"G-QM!0$-P]-U9O/LN MQT(A[S)O0#Y/$C7U%>3?=)QG^H<(N"R!ZT+=IA!O&WE(VU2[TWIPI_35"&.? M1<>VGLAOB*N-9$"=Q'P(I<^-P-`F'SV;VG$3V"\9?$\LS_#>I];:=K;^]>/9 M0UK^>L*QQL$4KX_M=LB0*T!A0)9-O3`C#,:!LFB`UBZDDA"2T`6?,,0H2QMF M7TAF]7R9Q;B#"O@\.`I>=5T^9T#(BG]2^XDMU3^0=^F`N^*R@K(&Y#+`/4L; M]N_N4G@*CM?[U("1$Y\VH";)U%,D$Y$WH-3,PL0!Q8H0C0>:N8`/#8>24K`0 M-5\ASX32R48"2S31"!R<*%4F"HJE$H^!(]/*1D!2!>+LWT=>?@*9['*";3_1 M.+>-W`X&Z3%5X"+EI8VI02*UJD0B;3[3G-(6?RR\.'NGX:`%WX7]+-BZ:9O< M:5"'@WYZ8$/KR[/DZMRK7-R+M-JX4:2--9)/QA;8!#F686W<\!KXDLVMW.(" MMZWR>*@0H3X,'?@#/$T6L/QE MM)A\E+D?5&9Q\9V>0F4T`2Z?D&MHG%_2+RL1*(P!_MM.5*6;AY(6,%K-0,@) M8C%X?!HMI^,F(2%A3$4P.$CRPWVS2LM$0MPB6$5(2(N=Q,PP7>?;%DMB1@Y\?)4:E"#?*PT[>[8 M6J56$U+[-U4?A&\2L#BNA^71C!2@K==8\^;KR9OV0@]@+L@$?VZ-D?LRLG3Z M#[V6\Q69-.(G[Z-7(2$2@A7XJA!:V@_QR,C30+*P`:`M@&T!)_M0R]D\9-YHA"B9N0-IG;/A/(XU*03+C%3IT5IG#-+R\!7D=, M\"^+]=5A$E:)@Y>2L[?6)!_#4?(\:1-RMY::7!9RLE5Q^7TRRPG:V6"9\AC%I)&''VG&E`2;,^EEJ4=2_PQJ#1`Y8W0]NL"*W,8D+M M.]EVA9BGN^1P_D`'*"%9%GZ..&HU<<39>+89)8T\0_!:CG#YU/]NZ'BD:?;> M\MP%RQ>-GDW\!?W#=L);3U:$C/MBF_H3=N@-0FB3-OCSZ8D^\G4.LYRV1U.7 M#H++20+;H^W!_U=W=<^-XSC^7^'#5>U,57HO5AS'OC=WQSV3NG22C=VSNS4/ M5XK-.+JU)9\D=W?VKS]^Z-.2*%"6"/:\3"<100#"#X1($$@G)/F,1$Q)LCXY MV:0DG]7L;3%S^AG9K!_U]3)S2JII%2LMMH9VNW M9R^9%"(]SS5"B>#Y0R"'4/N=W$Q'3M4)ID6<+79\@RBBXNVP%0'U<(-H0^'6 M?!JG]8KQ^C9U!G^-$]-1(,I)WO\=&:=M&?OEATR>V95FAH?_EQGH!`'\C/PS MY'#`?M;E*/;V_#!\[OM'=Y?695H%'^ESTO;FT5^Z._KX M^NQMW^H[)NH3,;XNZW((=<"SZ>7T)EF7TSF(G"2O^14'Y(62="*>W,6GXNY9 M3F9X:1Y6%R,+==&R.@^K$.%NTB9,+D^E$1HYE#62-IDBKRQ^B1*5T!_KW3%B MOR9AHW+,K.!=W42^@G=2,LH*?@R#`U6GWQ0?,;EZ%^:%-Q">7*6Y:V(X=E9- M9QD28EASH;OI9\]W_;7'DQE8&"$6S$BFD#>\*MA8@_8/ M8@C>D>SZ*@EJ"VU]F=?-2),";?ON20R@#`>H#$S4:1ET$8YP?:'@U/.]F-[S M=?".!;+^UGO94=E?9+YFT>U1I*P"*I%W(&02P=KO! M,D3=>SZ]B^F^`ZKRH78@*^,'?I]B-H4MAW]RVD00MV\5["@W9/EKD]L"-%8, M&(C(LM8L0V6^$O/4.F4O<5TJ=F"UCC6P^3I7-S/8HEB,W?A$R!W(!U4(`,^: M"K$`W2H@`('>J%F[,/\UHJ_'W;WW>IJHI374"G3G_.A\D%T!('U!)&W"B=N& MX:YBR^/,PEY*6HSV%U[,./K53FA6[16&QQ,MH8`P"*FW]66)@O7[*G3]R%US MS?_&?`.O:/353QOV-EF!#@F3H-3@"_Q9-IJF30`2\B2E3PH3$#Y#4A"*X32; M!FT/>#A5B-W??#3/,!!J6:=JV6%_O7:P\!)\=75G%XRCN;\1/^Z$/XU@=>JZ MT[,"X"U,:JQ)XTD[VB-1P*8XGWW'N694Y32K:H=_''0N1F!>`:)0%!=Q#%D< M<@PIX^^S]X/_*U+F(2D&F`1Y(Q?P%@>7L^0*4T9,(#8EAYRSU)>$3D<)C>&O MU0!+`%-K!0-!Z7K_Z'\*?)$JO:+AWO-5"1/J,09QI&0$7KOM>I*U4^>&C?YWL=GRFO*4\"`F+1 MF;0K"<6?4)^&[HXYN/F&,2,ND,?>-[KXP1M<-^U]M8TRZ5/4K("M;SI.SYX2 MBF+Q*M,D"5$DI]*GI,ZII&Z))BJR8"99PA9`-2CH"H+-=V_7^$;3/YO$2S(G MO(3QV$D*V:1#DU2DGIAW"9)%V3"QQYS"Z1'4K1>M=_S23EOC*3T:""@&,::Q?W+C ME*$NEH9J'D(^!_H]V0$UX?2I"=.8U#+[.N#"%6H9NM,_*6_^P,?;@>HR4_#Z MS#>3"031%R3]NWW7@`;2BM,6TEB`V'I3!J*U1CDH2.6IED]A\.HUKK*%)TRB M+9]6X[QQG.X]\=%$#A\&%T'L[I2XZ,K_).?_T,B_,>NOFD?)OD^$[*4FQ&]' MEY?)HSP9XAN-8KZ7](F&L??J,2(-1Q(Z(TU7?X"Q!;22J]%D>IF4?,@)DYPR M*9(>]N"B#K^#23RR06)U)8T"*?6[D_&,>>'X1>_,Y6?,IL+!:+?Y&*+*;S MA<9O04'HICL%)CDPN+X;%`M^6W62IFY)NNGI%;=RDK-(6#0XJ<.P6['R:?RX00NUKZ82?'% M[,2+2;3OR5_&G!?,:`G!612C,=-O#L\?+UFP)L"#R<,X^#==-4(XWBI94/'L*8ES#!R M-NV*]R:CTU5&LPA2FF$51W2C!A+X%W9^8)WBR M(9I4&UX+>/!SB@NQYI/K;1YHZ_*3/XB!E&QVG4W;T2D^:$0X&?9E1Y&:\9XK M4!$)EGQ7U1E1K?V714:U^B3%Z:-L6=SVKDZ>QK#_,@M@FYF,IQ40I/EXY)>$ M6NW=3(-0.$>[%>I]VA88U8*_1AM('B"D;D1OJ?S_G9^V/WERWWGOD^:WVC+. MK%=0,P//:KU.NPNG-,DO*=5?&9SR=D$)9317T:?`3E+W4$IV:);,(*!@5GD" M+8!2[`)9WF-(^TT7AEH!M9P?C;L:XRL8VIZ5W::Z2PR_G3*`X.,2['`;:G4Q M51CX3M1C#?["(WOAGOOB[;S8HXI3S?:AV/@[X0=LAC=9T_!F_'':I$#FFK,3XVD4T78@:(D2\7??G(/ M7NSNVH^KH010\=7$%?A@:G8YNU2"+9N!)%/8<+X]B!9DH]$W]B0+*9GDKKSE MQ8-+:\/*-K-60U6I-SMP^Q32@^MMTN4YV7^=^YM''N_+RRY@.P$10\4SA$.- MY64R56([F2T[2N&F+B9*;H;9L[H.H!>Q[*8:J/F4=!M5@`=W'32HH0]6*)H; M$)=>=I^"_3[PEV\N,[5Y'(?>RS'FNU*K0/SN(Q-FD[1;G([G$C;M M'L[B5B/?:SHKN`HY*9&S$CDM*<[+^WK>>KNCK(SR^DK7HL2">/+#"^+\@\^5RL5I>$'^H),CVJVQ]BRCNH#4D=6*Y$A7V5-ZD M41M(#H7N=BP,X\W9>=_JD-\Z4]0>5@PPZSP:N(#W%I^.L\WTG!A)J2&7'NY+ M0.$;GMR8QXLBL&;$-D<6=3][V[?8CO+#[39X`B>59G!`)#?VWWF@$+W1#8=U M\Y=V[<-&P5/'`3R!]=K)LBP20C+,Y:3$ZHK;Z+$/\;(V54(F7A\1.8I5&5@9 M'8W"HR)#=0&E\`@&"G3N:$POKZ\KMH]XV:2K"`[@9-5$G-B5_XE5)\-5&Z^% M).[-F)R)UA/>FD>1@*E[7CF]O+ETZ@!JP=GLN5*=8M::J\;-EM4$`PN.4Q-F M8$V7&A_'@$7'/D"3F7,YK4##O@W)/J2$+&_&\0'H7:24'A4GS^[W+^PK,O3< M7>N'3>E9#(04&=!(XLRO4F;P8)1(1LJ.KYKNP@E4<(GVZ7@K<%%G6K6@J$B. MBHB_!^&_>+9`L*91*R3*#V-@HL2!QN;K=77-X*1DDHP@9@BQLR$)E\+"J_GG#"*EE0F.C-4_+3FG9&5GU(*<`R_(M".,/ MO%-3L>8B-F:4IG<*FV95=$=.1-=_W0;?_G-#/0D:]H]3K+!?_<\]W;J[A1][ M\?O\AW>Z>-0]80`/-=/"2Y=$W1)QI%5H724=YI'2S<\4I M+&5K.=Z6:VW-]M0`BZ+\=@``OAZ=#D`%A'Y=X.O)=3,P;%IQSI)07@7]^OR\ M>%B1PEKS7W;!!+B*U*D"!S;KY)+9%]?S8^J[3&9U[1#E$*/0:>8#_D4QFERE MX%EG%RX+!'$KA?0GHY/+R%/1N92')"%SP^CM@@-V!W>(*9;1U*(;##Q]<==O MGD_#=\86#PV%5I5IS:H1!M&D8`/^+3!SDAN+&;7LV^<@NSR@IC;W)J/35493 M6`*881%*;8K!0=+_!N&G8Q0'>_9>Y78Y['`',M(HLEK9`5O?V)DY*<(859*1 MM>_4IW>Q90"8$!28^X/Z&ZX$C@<_3CH>X<(.;+-E^,%4A0;#%9LE>GR]I2]Q MXB'B]R5EGZQR1Z1ZDJ0[VC0AQ%;A<= MZ&)7H0.+T%LV<4W\%M2(@^`?WOZX;_EL+#YC%(F%B34^F\;3%&UB//JG8&/;D9Z_G:]C[YO<\J]I MS]OP'L\D:A`WYW$*+S0_&B6'O_Q&'9^1I%.2EW?R"Y^5>/ZO))N8Y#-?U'?R MQCDR-JFPM'8)67.%':6.R&NF(C>;"Q/H_2"HZ!EZT/'/YTI:CKM[(O[3N!;= M0V;V+91>L._/Q:`?OF/H4%:PN'N8/WRZ>_B-S#^M[O[`/ZGO%US]>1OT#(`& M]N5-A9X#&"A1?"\#Y%2C4\X,YEVRB7^R`&80A=4',%ZF(JL#&$T$`5R*CHY_ M/E?2+8#1)?[3N!;M+#F&F%G?+L;6`&90'295+?]8+%?V!S`=P=6?M[$U@,D: M:?09P$")XGL9(*?P'-S)=`SR+GESFI\K@!E$8>4`YE!4V#%56)`IS.IP1A-/ M``>CH_&?S[%T"V=TB?\TCJ;+7L*D;X=C:S@SJ`Y%.//XM'B>_P3A3$=P]>=M M;`AG[OQUL*?W06-UG_(S9GU`/C&\2??XYB:'LB1`?N$D?JUTL'ERA[O.!T!G M5^D$R!X6*W+W\.GQRX))][A<#E3G'Q#@=!5C8DZ,;S1\"09['R,G-;==0X4H M@XZNBN<3?W4B)8[;^9[TF6?ND/E.G_US+;O]Z.3>:Y,QZKST>(.WJG2NLV^C M[R2?@Y0GL2]'?UB-R*I_="TZCC4I!1>:W6R^C-X.*D0!>,"=S('&=+X-J>10 MF8NE&&`2M(U`3B+@!TT)C8&MU?Y*L%)K!05` M1S[]X^LS/02AB%>7=*OJ;*D88!)`C5QH7/'(#B\%,9XAGI,C*3TD_/0DGU.6 M+\SEBQ)Z_-?<*%T?M:A4NQV6@*16CQZ0@N@8"GAO'Y3MY=WZR1D8\'/"^<39.7N<9A'H&TR98'T5W3#YC;UQ"C7$VXS7.KLK& M&.4SD75I*M$4/9F,V6PZVU\'P6*=FS&ED:+[>7PEA9E.[G^2.S^--B.2SV;6 M.9G2RHG36N?7@1.CH!OR&H0*`\+P9.<[#>[ASM0Q1@B1[4$FO;V;(H?JQ#LY75K\XVGQL$0^6VHU-R5*T$^`,HY:SX'J MGL1`2(==^JN1,SK%1NED"!D5745RRB)YB4B[X40"KX%=19IHBF0.[GY#JIK51D0622Y$PDG8QS-OAG5\8(R3DA.2OD3_2# M'ERE"I^X>J-,E>B[9T,AL.1QAM`VBKN*WVC(OI_#(]V`*TRW##+I2I2A**(QB#8E!XT#I7B[/!. M9I/130D>@HH5B.@N3XZ"K#*[*ZCA@Z+.EJI`J(B.;/S\0!=J_X5G<2"0,Z!C M-=,Z%.2DT('052J)A=7OBVUI=@7;^O0M>/^%40$2^*GW8R>MS\[U$VCWN@\>/KROVA>N?]3V8: MB[U+`&_'=N-<%L%?3TRQA!=`[*2 MDZ*^B>;B@J;$.P"J0-P`ZV"R$JB4^ M#,"J1BGY\7OBX?EW1^+]HM7/XGK41ZY M]ZCQ7A)8!4-IC,63Q4*/UE^.:'W<=#*J@A>@15Y-+D>CB4PYE8#@=JN=`X_[DJ[6&6#KBLV,CL0;["REOH(HF^TBH-KK)X-NL!#3&,CZ"< M:9,DU*G>9_,@T\AIY`1^[_SR-`B:FNG!7T"CR[3I:O()F)!!OHE[MD@2$LNOSU9< MN%684A$(35+C6'],^9VE%5V_^<$NV+9!H.%QHSBHYP%>)^[F9IJ"09(B.2UT M1/0AG(#%?/U_1R^$"V<.)6J3*T-%H0X&I% M&$2LKKF?(%A+E\B(?J8'9E!O;D0?7UF@NP_\9=Q\>08P$`>_#=S`M[]F>:19 M@&U.EMNJ)$P$90N@VH_,8UF)K"CG6LH9-G?DIW?/WO:MLB[JC35];`9E#&AHU[/IY70JS]`R<*6T!YV*^"9)^!A24'&L;O3^P=IAV>#_OF,SP-`@B+?SM7&M5QK\8G@(T#DI`G M*?T+(F:XR'J`BTG0OJ,'48),/78/'B_O(HJZ;#P6M?==JD8_[.G];+]4]7Y-QT%P!-?%0T#56>&B.NPMJ,=B.J8S/Z-O1LT^R0U"HB)H[+YM6&HH!1\_(@U$_1&Y9-HB!'3:WR97#2.38#*5<9$H(.KK=) MDFWG_@9<)0DRTBS"VM@!V^5DY%QEB.-4TUK!8I/.HMI*O0OM%(6VH;RVAGV> M0`RD&!S(%?(TN`=X/(CZ^(L?-%Q[D2+V:QMG%&XMS(#M[F8RRW8VBHD[@BI) MR)*,+A;0>A4W:XF8-J,NR,T,E2%/DA4;D$(/P6&X/MV`_H]]OVZG^KZU9#;G M?H!8+3L?B+*07,_FN([O_-<@W(N,C'O/IW>=RA&F'4W36QH9/#.1IFC MX=1(@1SYDQ,D@B)6EG)?,CI=932(JC8S/,&34C%(2*H_U?SXOF)SSW]X"D2U MCC2+K#9VP/N'D]%5OI07LQ?*R0L7A%,F?W+:>%CK5VKG?*D-H@]JNB MGW0AS[R#S^J?9/YP2Q9_^WKW]&7QL+H@?OV+0_<9!8"!G$6J%JN\!*RA.GBX M#=ZC:[OPR6A\!?(DMC50'T83I66]/043'8Z`-NE:BK(*ICS,N`WVKG=ZCT!G MI`W@S-F!-Q8O?KRV!YF2NFU0["HW/+A6R(V.S:KY@F!YHC2K$/DUHJ_'W;WW MVGSLVC[2!D3F[.BL#V,0(B5MPHE;AL>N4@L\+J+8VXN4PZ,4D(?C(F46OSV' MAL&",'BB*`P,/K/WHMI6RO]N$$_9I/`-RNOT:%6,1=T$ZLB]`^'>E*57S*)H MSV4!T:Q663FH^(1IR]4LH3,;7SHEVT6-LCI+X,`D,&K!S95^3L5$L6+*Y?!V M7M(K\)E^H_Z1BO,]NDWN5.3M!>EFQ:NJ-+VW;L1,8J,3AQI&F'8I*T_$0X=D MJB0#()F,7T$J3D?^%!-BX-T M%XCP45U^53W&*.X5C&AL9D_&*;PE/?%!5*"89M-AX;.DXR9=5Q9.VS9M%390!>M=0976:H2>@D*7"XA2=[$,O1%LL@ M3IH-[`0?#5K`P47,HG:Z6;BA[_G;:+Y>'_?''5_^;NFKM_::#KT!`XTBIHT; M>'&I2V>4PD<2)2E5\DN!+DD((U7][EOBI)YK+MY&4L'%%-0XRP`#:08';2+D MY)'HUO=X&'J;W-](_M+XLMO&&<5:"S,:>V"S=! M52"P=RHM+O"`=EK&'40I=L#NB[=CRW#@TR\T?@LVV8_@]]U(`!6(35S!2WO/ M)B,%(C."1$Y0^(TM0.Q'!4Y1!6%1!?M,!7LQ`5LGHW7HB;1\NR#;9N-J["KU M:`>(8;E6[>-0(=LUIXB9Z5B!5-MRJGH6W&D0W"X$`E*H8'JQ`V^\.F3$HNMC MZ#<>':L'H2*MR(G&KH,S4\!,T"0)49O1UEWXI)D[<_Y[&IX(+-H6[';!=Y>A M`S5-`V:M:N15=&0?[/CF:OB-)J5:SP)C`REK(%K/GT9!B)%J?2S9\05))LNJ M&V=_LA&_?6@F.V](I8Z$U*&@)7#M_@2X5L,!CG:%1A%]0`NN,;`*M[+QUHJ4Y M6.4Q!*^AVR+KAI]*E+T'>N>O\V21#F6Q(L^+/Q8/7Q?+_[+!KE4-O6KE[:7W MB&PK,-^&E":I`5XH6,\O4[V!"%N.@=:=Q`0UK*6(.V:P5CH MDIA[IBFF,/AJT<-!0RFA MLL1W5X)YA$/-O![4($7:C6/XH@^G9"6R.P2PDY'3$>(VK?(#*4;"_KC?N^$[ MUTM%%3\'P('+MYX2<2'/6]_Y;);WI"R\)LY;AJ.`6\V3SGHUK2(Z(YZU/K`0 MQ7UJ0$`W)>C9\@T.,]MZ>`*T@XO):L%G6!3=-`X%A0W,P`L!7%^-JO"K+>MM M1Z#@BJ=(6+O?0$F5=86/Q@K]]W=VDB:<0^P7GE7;&R MR_7\X_MO--B&[N'-6[M,^]35C91[GQ`%[7U+`;^+-AG7Q-VE2B$I/R1C2&PK MB1K*,C)/FQF]O),B7T0P9N'ZCJOMM$E2E"8<<(W+U*TL\:56P67]"NW:X<.& M`GV]\QOD[>%ZS:06S3,]!&'L^=N"8__XGOP1%L/`*:'X.3![&M_'US5Q3D** M9!,5`P#AJ-(G+(E^!E),)1[J13'F/8PV0.I=AYZ6?P*?``Z3]*C9ZQLZ[)]= MUP0XNC"P*7H94$^G^XRI$@I3_$3^`!9.Z*L3V2\D)YITPX]\J1\)5N=AR"M= MBHIVC.WLF2?WG?]N_MT-E64E^Z./XSO.8UIC2^]F4N--..4/+YPT*7NO,@'O MZ'"5-FTL;?U98?_GBN5HB648#\V&5H.-!DT@XB2+MUNN,C8^;AXE%1XTSJ;& MT]("4?CPQ+[CV(]P3A?A#".FT>1J`%.O#AOP3Z/(N@T:N*VJ,->D)!O@I^HZWO+N M:X7LR8$ZC2--P_!\\5N6.QTQ,9"I,I\59!L5)H-F"P4^A'- M/AB[C#]=>+91041J"VOPZT(SIRD.OS6?H`PO;0!BH M8`Y1+`[B=YR9N;_YXH;_HIQ5=5<44Z>S40*4\G"^OP9\M&FC[%!%2,W MVZ-8.+=&(ZIYU"BZJ_/#/[N=<89>1N8#@\R>%`AAX?)X8I#06CLQO+#/TD$2A.VYS^\QF5+ M.<8D'E6,:"3HSF:G.?><`!;2^A/*`0IE#$408RN!IU47J)@IE0,`X*7R/`96 M3IF`)RRQ_^KR\VW`RGE"U63GVX.5)B.KQ4FM'E`Q\OCZR8W>/N^"[VVMAI1# M,)!2PP?\!I23-A#,R/$0AQ,D@B)^MGYO8CK=Q32.)H4YU@*J23G(F/KL^:Z_ M]MS=4Q")?H1P;#4/Q<%8(S\:V>R3JQJL981)2MDFS/4D=A5[VF(C8+#5?!NP MJ%8:,B;O_'6PY\<4?!LRI&_4C[QO-/DM&)X@*CA(A;"F8[VU"V21-)&T;8)M M_SJH63WU=8"`81US;X`S6)DXR`[6_^*G#,PZY+EMHW54'C2*S]/9P<';U3@K M[%H@\A>2GE+'<>B]'&-1M2@.R)/+:_3BM+(]5\I"4]NH)"L5Q'`AU61G9=34 M*L`.8+2N;HT#4(&B[:\GX]&5-F`L6+WZ$5PN5*O'3__]^^/][>)YR03_V]>[ MU3_M0H]Z[5&JP@XT/00QU;B:#1Z/BK4&IG0L<*R`'B=OV77M853@-*G`+A"V MV+`:DRI%H4#T>#CL1,CJ[M+=H,(MUK;5#SC:)#QA+&E\QTRO$W`6*.>[@.7[ MS-C+X1#"R\9Y7-Y#DL.&VJ%=TV)+<-103R_]W'FNBN<+XDL:QW)N<4#^WK3V MP<>9[NX.80K:(WPVO626)9J\%\B2G*[,C'@??K&K\R4#B3NR0%QU__?^97:: M94;K_*Z#RJP!/%@U&*OX*G0WE&>/1U_H_H6&#3)+S+2).4-LF($TF=).0-!WB#"#VR0NB6,&\0R9,&Z[[X MAB+B6^N=1'("XF;2'\0,>,&?)G[S`%!':2A!()O@\;5P[U"1MEG_K,EPL(X! M>#'5V652H8O3X>?*Q3OP_,;80^!_<`N_$V^/V26_-H::UMF#X,X`@AL+-%5& M6HHV&_6$@:VOA\\A\VSIY=V<*^7W5MLH@WAK806>4SP>)6OA76DL.1S)V%-X0IHH$6$0;1T_N>=N!84OG.H7:4_<)1=%5"6_/I_ M^%LHO=#"'PQ@)9\-OD%^?9E\T7U]N%LM;LER-5\MEF;-OBO?TK)Y%_D-$9E+ MZFV5H4VY:@7<6D^$0W'^$5N)%E'L[;F.FGQ.^2&3KKTT,WPK:IJ6)F8$>"21 MD;C(=J.3_Z,?.)\CHE,G(JJKKC6GDF>NBHMA]W^GWO:-.8?Y-QJZ6_IPY*[A M\?76VQW9;V7A@L=C',4L[O3\;<.[TZ5B$#F:K,&S&6Y&R:J0SD"2*8B<(VOC M%9$"_0N2S(P#LD&U(5!X>W?_E2V2.&F6@XHG?B.+^?,#^_^2_'+_N%S^2IX6ST0\7)L6<[8N`$5F![83IV0H;F(HLE`3 M-Y1UL-\'ODP^)T$^'6J:4%?W`'"%:KW:[`L_NI&W/M.()`T+O:!@#'Z[]_KZ MNI,+%-/8[?4Z:$(V3)HO[S[]#*`MV7$7Q.8:DH:<"'W/Z+&?V4_L'[R"+OOA M_P%02P,$%`````@`M8%G10DCH^T%(@``C%8"`!4`'`!O!$H6"^['A$-=G_$I;O1W?CU[Z]+?_0,,($H^'1T]N[T:`0"%WDPF'\Z M^O9X?/%X=7=W]/>__?YWO_[7\?%H,AE=HR``O@_6HW^ZP`?8"<%HZKRB`"W7 MHP<,"`A")Z3=C>YA\./)(>#/(_9?;T1_^N?EY'[T_MW9:+0(P]7'DY.7EY=W M&'M9G^];%'>:*/ M3L]^.CX[.S[]97KZ\\?SGS^>?OB_8FNT6F,X7X2C/[I_HHU/?SZF%.>CR;O) MNX*0_SUZ1`&AK9=;\[.2?7^X?W058.L^3&*"DP..*V8/\ZSIH=LY^.S]X?GY^]>R7> MT=_8"W_%R`<3,!O%/'P,UROPZ8C`YGC/X/ MU\B-EFP4!=Y-$,)P?1?,$%[&7!^-6+_?)GP6!O3[0,=_0`2R5USY#B%P!H&GR[ABK[L4X<'!0/L# M:'0=+D`(7!!S%PPQ9<5_MJS>XU)*[/?@:/T7+IX/5X]@CG`1UOKA.$%ZY+=Y"0 M[G,/R(^"9_H9$*9_]BUQ\54[EW/3ZHYM"7/X MY(,+0D#8N]3\%^\<`[8V1(F*1L:S2X=`]R+PKJ$?A<"[<7!`VY)[1,@#P(\+ MNC#WC8T^0UUB%B+WQP+Y'M4T;_X=40VAZW5`\04=RD0AQA&%[G5%-P`Z]JC> MYT4^&,^V'C072OD-'4J5;&/4U.A\J9;VW*$4EQ&!`2#D$%YGM[7R03 M!7$"5@@S3OI='A5>-@"!.]\5E5^9"K\JZ)/L#*V$`B4!@?"1'@OINCYQ,/P!/V)=@?\2U6P%;\N']NDE%_15^(F2O+`Z__`]8U M;-6WVQE_=,='06P:Q,YK,HY"=HS/0BSXS(J(=L7Y+?0!OJ(C:XXP']=RJUWQ M-@%SR):X(/SJ+.O&8FVS_KF;8H=]H\?U\@GY-6R5GV_X*6[Y%[C,FX/=K"/Z M9V6_+P=FI"U.5O&!^K&[@/Y&59AAM-39.S(N4,WL'B%,K=PX8NCL]/1H1`68 M`;I+>O>)K%P&8^Y":B"#N"6CA`A3#CX=O3\:180*AU:)=WJ_X-G2;W)\WA_P M$>QM.4[G!YR$>DJ.U$\'I"2:9X[5SP>L:O:E')]?#OCPM8H MSYB>=#HZ'FVH2W^CV6C3URCK[,^C0G>-C<690YYB>"-R/'><56(Q`C\DV2_; MIF/Z\_>M`!?`9\;-5Q"J<5]+8DB&K1,XJ0"<]H:X MCY:13T>WQXL`9R&4%./Q;.J\\F72ZL6(I)OPM0<'>G?!E;."H>,7UD:><')" M(_*D`#A$WPQ3F!X#0RQZ=DKI;:&.=2"=3MMB:X9FD9[)R:_H\%M#P[ M?GQR'5XY&*^ITO$/QX^VO:]ZM$:DXA_"\V014)B2(%VSA)]@NYD)7J]3-32- M,Q5/5$YCDWS3?2Z9D%*51D1A6(*"EO(5!:ZJ&/5D)F3YC)#W`OWM,Y7*8Q.\ M;>?TT,]^\^KZ$3/+)'PKD9J1*4G36E..N+P7FIC@L3`ZZ:IY M9.]2(C4CDZ(^-Q`-3EMG4]'2=G@V)?;[L8,HB2_+UI`P=6#$RWFKD+!G@)_0 M_B.D9BK;&A2FCE,=%@W"OBP9-1P#P=8H+]V5N&T\%ZL"L`](<(SQ(B"*!Q9Y MJ(1=43C:>-4KNQMXWML5?J,-CSBN(8?)9H5'`::RLSB'Q:[0=VU8E/P5.5HV MZSH*:`G/VW*4[`I^UT9)/(1LUH-4EFL>+G9J1;IG1D6H1&<PT[>EK\27@_9S?.ST:NGAHY+8 ME2-FIZM+$S'=I+\&A&@H<@@GB(#`ZJ#R/7(/:.ZUMH=$-X51=>FRM8IFM_A5ETC;`ZB[Q"U; MDFVMK]D6,R7%V_90[`[`$\U26[TQ'8%6G:*V.F,Z`JR^+F#O84D&'339O=EI MSVD)P/>R$H`)V>B/]/])$M+H,T:$C+XX>`Z#/YEPYUPA0N5A"4#D$?E\8[K< MRH2!D/E-LVU`8A1PFP^!]_C:847&D[9#X#J])%F1[ZRUD?H]#@S86<2879\9 M?W:6=4(7.;8F`5PDC.++X#J8)X\O7^7')A#>+,?2I9O7FMSG%/$TRET26<8?R3S6INI+>2F MR4!?Z.I&-1_F3$KCX3CL"TE,R/`5A/F@YC!=;F.D/D\R2X-Y?MU]+:?5=H/@ M5C(;^>V-9-,R$HS(T9*=K= M#%E6D=]`KP^3CD>9)Z?H;.1X3FQW9K>!:..FL=V!+;$HR\&7V]NJ[?EX&N!4 M?,#MLNVLPJ;DN6J783#\=!\-7`06I.UY!DU0*EJJ[;(*[!I%$KO8]@P"#:AV MZJ!NEX=@U1#E.G];92+L1:E$#92VG+3M*MY9-7[XFKSM=>\T0-*W]6VOAB?U MT)>M&Z%;UO:X8"VL1`Y`VP.`M8"21A_8'O:KAY8XXJ19N.^'!*L`S%D0K$5H MU9R6MHOI';[*P#O8*:U-M0S$W%83R0\UV%=J&/Y.:'@PU M43BWCQLL+3+<(Z3\D\G=U2(V&"G.JY2Q'3O^TU]_$L>.E_I((\G-!(Q79)%< M\RVB.`24"4.&."56;A&FDRU($C_=]10[`:&SDJT7@1?_RT]6#^]?4>+3DWRB MGEXV--PRQAX0CCD.0PR?HI`ET4Y14EFC`4`JO>XA$K*0P(YZ-YQKGC`=E[FM MB**>=J[4BU'KK-NQ4#G#Z6&ALMYK9>:3**V!MCO"&BX`*B<>ECK#.D"LLP'_ MAG+GFV(MU-)WYVHS:'BQ2[EN??1"[JBYB4$!IM3B^IG9\D*+B_8PBKLP4F=M MLR62*9H`%P4NC"^$RB?-%#$6'S!ZAA2NR_4W`KR[8.-;O:`;[7-26U:LR/3R M*B-UMM3N8ZNW4I5HK93J^_L!R?4`Z*+"XE0P<`BX!LG_M<3C=&%"QFM`ESH7 MQ@L=_=L'J>Y[L60;W7]$^O[L()YF!"U\QQ4/\I.+)I M=6%"1K[ADAWT?0OHJ/(%->*TNC":U@H(*X',3]ZI:7A(P]7DO+04W05;-WCP M99#0#4N:O":=MD`%TL'(M'4OAHY,VZ3#D&GK1A1E@;;IAB%-=@^HSJ29D.H]GI295F5.C-TIE1G(*5UM8H&4EWD-O\0 MJDVG^X>#9.QWU/F`<$F"[CL>'ZJ=[A\.S<:';N<#PJ7&P=)^?*AVNG\X-!L? MNIT?8A:X-Q%I*8O!=D%P(O3C!X7",?AL/(B6#H]&)9P`E81=A=4+QG/ M2K<&R03C$9J49XHNW']'$`.*.AWQX?K!=P*6,,8<,7$V@40NA0X&(5^#L2BF M-5/KOS`UV-@9Q\,5$F,R!"M5G[,D>-G'-T%,X273ET9X&UQ%*E-'J;V>8Y6BMWGC&+;PUAV MA:_:28KM@2N[0EOO_*-9\,L^93?M"G=YMKFE,2_ZCM$MV!2.))K%O>S3,.T: MQ9*+O5G-K;<,GYKONUF9KK>,:^7TU/84R:X!K!P$VIY!V<,(K)P.M\N['#Z& MW9[ME"_*DOHS6I7KVXMJ.SW"J^"T;%;R;Y\VH?[P;7OX:WM9P6X/_>I&ML2] MVZPBH06#NT.(EQ33K"[B`>![Z-B7MM=]['4!:14EU:YHY/"7;I43Z>[PK!O1=IZZ=82K MMO*RNPI)>XVKM@F?XVKG89HNKGH9?3EZUM^^KH2>7AYKCEZ3DO;V[4&*V,#:ZA>LT:VKV\28CB-%) MZ;$BOI3M1^!&.#:PJ*G@1W0532XC6JZB9+6E-L3V?2=+-C%X&'72MQ%4,&:6 M4NR!I8/Z*UWD\U\*X;)$O&QH]F)$TF<'^FQ%HR.5%:C/OQ-/*#[!L/A/5RD6 ML4^X(U216D\RWJ[.?=FF(C:S.-";U@4* M(Q)04X=:1+C"EWA]E5!ULF=EP?+%O$YFS-XZ$,<.UO&,_;.VE%&##LR4J2SE M`V1^*]X"Q&T^!-X+!I1X&54@')X\PDFM1#H`F1)G!\_DXC3N9BX'SF<0H!#4 MKROU;3IY\TT0PG#]&_1`C:_0^1?"V5HVI=V0!?*]?$NLX[)5?QU+E'ZI=F*H M=M(-[R2$2^::NPB"R/'SV-M+D,`(O''`3.CQ;,*NM:I=U_4[,5+*-L(!#"/, M\@YOX2O[2^R4$A"8X%]RLV:M"&(:(U(@Y+U`W^`7QUW``.!U\0Q!.)!%%&8DH$L;VXG)>'8-GK+#D'!= M<"KRU155ZH%*)E1LL:( M0GGH%AUU(D.V[=NH^CP/B_(B=U_&5`&5:0X7"O,@-"]$']W1!O`O!DEOT M3$!A2(+ZTV.IETR%Z$ZWRQA1$.$UN.)2;1Q9RM(E^@3]5)%%"NP@7R-O_D":#>P3#D2Z]NI\92 M0/]'`'[.#F&S7Y4E5>BJDUTOV9$AZ>:HUU8"O3FL"=;3CC6<&_*%@K MZ]N:X/K;ZA8C"E^BL14X$JZE,BJC9>FD49:E@&?Y;,GK`-F9F]@P;(NAJ!"_ MT"I)80_04PZ+V>!5];?GT>%VUD.5!-L4YZ,"G+;/1]6@E%+N.SW>9!T-! MJS[LI7P3K`SAMS?&*JX#(6!%N_S-855U2I2PDD5MV)XZ)0NV&75I,UCZ=L5X7%+I@Z2JZRO0"+ M%J1]9/C97HE%/8BR?">'2JBB[3JS3L!F$3VI.[)5T08+@:O)?,\M?CLK^6B& M#!6'ET9,CNTS5#L\:3/:5"/I;*\HI1!(4MJ#57-N;;\=JS/<[+_:2A&J!HG2 MS:ZGLA,YS60FVZ^=TIR?2I%.S:Z9LA:S[JK1-+N`REI@\Y2"9C=(60>,9BRO M[9=&Z:#6(!_*]BNC=."3A-+9?C.4YL*E$QW:ZMZGMP"=2N!IL\N=K`51DE'8 M[CHF:]#2C&!M=L>2=:AQ?)N;C/=F-R2]%9@*!SO-KCC:*Z!4$YN4+-"W=.*B MD4)5CK`D3TW/,#F.L@)FH*$4.F9TK?R6Y ML*3@%W/[;%_':Q(9RQ.KE'??[N:,_4>CG-^?SQ([K13EU#Y91D4\T3*T3FV= M2HW@*JQ$&4#6KC6-`)(G7&2XO3_@IA=[4H;O_`"?>-CE-F$&V4\'R%3LXCKH M?CY`5X".D\R=@?7+`2SED->H7S/X$8_LU9!$Y9,*,5+Z*:H[\Y* M'/I]6RQ&,PBI#(#HW;+537V)[/7K6VJJ$3I%6(0&KRP&I[&)NA@;5N+KV\3< MLB:F>93<)%;;U"C/$^?EBT-G&G1\Z7`HM37*]6\(_[AC\5@NM:AE;)<;FUQH M12.E?'5A[=>Q/2)9&YZM86![&+(V/EN+O>W!QMKXE.\$;11'K'/K\=!UE$VK M.\I,,(=46TZ#K0W>NC$!2>HC6<"5N#BXB,)(=7,Z^T)PSP(4MP$M!!X7`XPY M@C7H:&#R7JZ3%'7?(:(ZTCH]#$S"SQAQ-1$IVKN%6[6`X%!%WU05_6ZX_(I8'8L5",$F'%>LM@D(C%0, MI[H4'9W>%+B+`/EH+A[)W.:'VN#[5QL\/SP0Z`!JQ9NE'1BIC8P=#S#-13PC M*\U,&O4-K(I2-)^N2FA[8)N.WJ\&9'V"L9V)B]VCEUF.MN>R$]05UZVUCUI^T%-!_B)3$;;SW$Z@(]O MI=A^R-,!>%4UV/9:,AV`)K+K;2\KT\@S67^]B=RPM-T`.>08"1PB*EDUEI88 M:IAQ96E=(7U7E*+15'6:O*$$I"98OLU,I(Y'W;V9>.JA1]P4*JB3\>S2(="E M.L8UJ[H.O*RB.JL'DU55-Q&)4ZGL+CZ"Y38WX?'>9B:&6)'QI.T0N$X'A"+? M66LS)\$NCFT#QZ=C>XF"F"-R$888/M&13A>$*CRM;;-.C"0WZXL7!WG;)RVV92FU,<)G5?:!(WKPRP`"[G"\>6.-XF).;5X!= M2+@>!)T>C$BXF2[C67%0I(.(W==#XF'S5%B@B<2&:]FI$;_0.::]N:C7"N7V:+6LWENJKT MQ(N=4@!TV_Z-H*.SF0UHGY)BS8/Z7I+IUT''@\2#._;RW3SP6+TN:;)@+Z\R MAAEY<""[EJ:=FM>H*Y/63:V>5XK?Z65`V1[?THW:5A]'U7K[LAW\SG?Z4B&P M\H1Y0Q$D/8#9Q>YM?Y&Z[G0<.?8MCX3VXE"C'SP5;#S;H_O[`5;+R6-[#D"/ M:X&V!FS[R5X_6+?R+=M^3MBG^5J^L:_6A67[F>&NX!5X:W=W7&CN9.O"=7$$ MO'2W(KD*O?7`R-%6PL(]=)Z@']?\W]R"5W_(PVUOY%B*QXWDQ$-.9U`:JCG. M`"'QV+T%BA^$1V10C@E:.[[RB*JT-GFLE.[$RK-"3F="FG&X`%AW@DN(C#HG M56=[W=XC^*2V1STVPHT[B6VW6MN@Q5VZ;;=#&X$F6Y]L-RC;C#0Q7DVLP?V( M$DNBU:F!#,A@PL/2#W`+*/R.G_NE+D$`9I"WTODE7 M'@FMR;"P6X0!G`>;(:0DEB*QH12SA!?EHK`B"K/UZJ62U+F`91_4=L5.$S;I M.F6[:M<,+]EJN#O=SMRV>YG>V?H(YLP'6-AP![,+9U'T$[!".,Y52)GE9IOR M"8R$'24O3[B1)UYRFQMU*$MD**4>"K[7[A;N(4ZIO&)"Y9$1%W%R\PG'>Y<\ M-*/6T8_DPA@7^KJ-PCHD2J)Q/[IC&GIQ_.3V,^V2_?KP-G7AL1O?VT M.8($N._FZ/G$`S`!C_ZQC1G]Z?M-$-*94!O#67GZR\3 M5I*CEM2(3,P&C&-\REJ;Z`XO,8T)-9VG!93KZ=;L'[8Z4@2*",.DBM<;BI77 MW0]*`83BZ?*6HN2;P%@[+-]0R<5V8T]I^WD#:0)UB@X#JF*7VN[VU?%*-1J$ MUN\*&AI=.:PVLWQLCW]HBE"M?\'VN(>F8*DY_*R/B6^(GHZ;Q?K`]X889JYP MVXM<*9F[-4K7[LVD(9[?/!3>/9Y-66!5MA/&Q\C!/*X,GE6A_PS0'#NK!70O M,'":G_!DGO>XM#9>,^?&>?8/YM2,)HY#3&-)KF+Y(>=>2&ES0]6$ZM?QKX#K,1>1F/&1NRAPH0_329/.ESBS M,UUZIN@*!03YT(N3Y`2NZ(:='\YKV0_!"[[,'/1T&FW%- M%1:Z/>LZTV6]&/6K%T>-BD^]TK[]B;7.OOGMD;-OT@=&KPYJM8[6NG"K7\9Z M]VV'*.K.Y#?CE^1O*PR_XCRS]?!)"Y!Z!?F->&[%T,AU^#?B?52;4LSD>VL> M1I''O^EB_]:<_HI*J,S_W\`INQ]5I-K#)3;DK??)RDR!&KVJ;L6SU_?X%86` MKD6W,'#HD'+\#6)DC.=.D)Z`Y$M5>O,9P!+?GFI-MD/A[FHSS^[]8O$%=:*7*V3_\KFHB*QD0H-:$F'ZP($ M!#ZGQ3!T)%,F'\)EOVHBR:A,2'+K0/P/QX]`016Y"^ATB.+IG[#(D4>-UHA4 MJ7LM3HNG$&,G('1^TU63Q37$__3C192H?;GF_9F0_C-"W@OT?F&(JS/:1`#[7M,6%[5($> M.@)]S/:X`CV@%(U>VV,/]$=7O:5B>QZ3'D[JFJGMY^2ZXTMJU]N>S*0'F(:; M)P?NKP?@5"R2'+`/!\"D1L\&K3,[`\S4T-(PPW+`#EJ]DK\C!^R@Z"NZ+G/( M#BJ_PHE=#M=!V6]U@)8#>;`&=$[!<]P.UD"3LXP/YC_UJ5+X37THRS30AHXU[`WLY(7[/!M,U-3:O6>S$J\\72EURIHBBDA MWY\U6!V1PRE%/6X:<^=PE%$/H>;":^\5)P(M@%U6S*[@INPS;W.X9FT'DBR3 M,"39]K<:F:GOH`HB9_U7IC/EW&R(.S9BL/J^E7N>9P M(#.O*:M"S5R[-T/W-,0F3\:DX\OL#A&%R?FJ(,G6E9O-/OEA*BN#92*:C7AZ&,29WOT$+,84S<1E]UZW!-"["W M.+FWJ_T,9$;;5/14PTFD0#FDTE!"I54%A<.,JP7&G`V9FQI9R3-6/NZ&XH`I MEIN8(G'U=\=G]=]U+;;.7[@'UU`J@Z/7VQ!6/=MO_6[\I6T_#&T&8O?+S>Y. M3&OWEE]/F+1/#@'T'_\/4$L#!!0````(`+6!9T5(*<6U%0H``!)6```1`!P` M;W-U?+O_F.*3?)W>"<_!]6))/+O@@J08RI`O!1;`D M`W<*`?V%C*@"CPA./MWT'\E)LT/(5.O91:OU]>O7II1>HJ3IBJ!%'">IX(_( ME`ORMGG2:9ZF2OHBY-X%.4G=NI5`-4H3#XW`HG;GC=/I..VWP_;9Q>G91?O\ MWVEI,5M*-IEJ\LI]C<+M,P<1IZ3?[#=37OV=#`17*!W,*%^2:]\G?8-2I`\* MY!R\9JQ466<)MB!75XV4?U]/FT).6EA%I_7IPV/4*(V??R*1[,5B)'VV@3!W M$LQIBW&E*7 MEBU350N%')0"R=PT]'E9#3$D^AO$Y*)V/BLKR/>.4N2H? M9HL,JI-!*>;F8[!@!T+/Y`X(EFQC-)43T!]I`&I&72@7@3C&!<#U@Y#!'8QI MZ&-S_!E2GXT9>`U"M99L%&K8$`CY6N2=T7)).1?:CE;VM[DSFS$^%O%/O&&Z MY(44/@PQ+(FY^+W?W6FDCL?M;0W;RD-\./3X.WOM4M\-?0M\ MQ-\Q.)8H`LXD#L=<[X%<6[8;%]]-V#@.20.TU@93;_S`.([PC/I/0EE3;GVJ M5!Q3AJX^`CZ7!!2SAP]1LE)$S'.0*^$S\\STR`WUS9.&#*8`6M74'4;=$\41 M6T]!,VR;RCQ:]#-DOBE/)GFU8<[KFMP2Y'8Q^0T@G[JXK)B@LR*"5@6*B#'I MS4SVC+"ZWY6AIH>1+$U:+F$*7+$Y%)&U4[J8OK?EZ=M03AZ%JFDL0^,M5=,' M7WQ57>XQ":[.YR\K5DS4\K1U*-N#;YCRO7-[`^&L-`WOG"_I.C_CI46!],_39:[0N&/X122 M%8$Z9JK'S(!-.*8X+N7ZVK538L8G3TBBRQ!1*1)*JBKF]WR;WT$8!%0NS>B0 MJH"L:R!)%37]>]"OD9*I\#V0ZO[/$.>+1G;?L:"\ML(@Z+0S09!2_`\2J:[I MKDYWW&O4$UW2D0\X1.,=&8+WR.B(^6@L[/T@V%=W<2ATMD,A5DKN%S/,[^I> MOT\81/GVD"[VY;I003&A)]N$1KK,BXJ:S'W(Q.0G8#KJ@MS#%,P\%(&[!W3E MBBJ+"3_=)CREW:Y3;NBO(V"/ASA,S/\^S(0T+;GWX[N$GF*NWVQS?1,JQD$I M$NNN5Z._1[J>W#ABVKY261P`9_NG[^15/ZM>=9,ZF?_4KA**J*Z3]@]<^,#ZL:-Z/D#C1E]5O6XT5)E\_1 M0R%7*>8A"@HCXB2[%%@E(E+UU&%P]#!8277-MTL39A(`I4#O&12[U16'2&:) ML%*(I(37]9*HXCIFCAXSYE5=&'FH>N,;JIB+2>,=\T,-WCV5'&65>6/_!'(P MI1+VBZ7JU13'6&;5LE*,I:TQ"&N/7?N*+2*)2>25,>HUF8$DUJXZ!*N$8.;] M4[E\IB2L.$0RZYQY+ZWJ+.48/,<3P60>:+[B]T(?>N.M@FVB2^.*F\]!J/)E#Z>T:>:L13! M5>'%?&>6)@L7'&K^ORG_Z]PN4U0^"HJ4%,="9L'QF5A(YX!YJU-U3!PA)C:_ M(1P*3?T^X*P^!/-N^E'PR2.;@Q=-V&Z6[T%,))U-,=^70,M'S6'5%,=5M45- MAZ1M,<%EK2&).7;>8`QRK$7)5'6T)&NCB+'J_RD`S1^SR[(/8V(W4%Z8#817 M#<6"F8]SR.@>E:[!%V^];,VDP.F7>7/12M0F"C+HS;V>-JBWVB^V*M$PE3"^ M:IA`<)*];)\1T5P$?B*BF3:UW*[U$*-(_4*H[S=:+]?S31I+.(Z`',?O5FK^ M(G[[=`1^29=1-L?E1Z/A+^+M=C&.9R?+]LI?=AXJ_-?9J7Z+J0 MFO#<3:,[MFV3:&?XHW"MH@*(^>4D.,?<;&(5"]8M7SUE6].7)WA9=JE33R8P0TS7)NFJ7S]A!+]K-B M/Q-R]ZR7C8H$8"H]JQP(V\<%'!`'YD[5,'AN^WVA.7FXY(>S5K*'(3F;^+K@\(AP*R5SOJCX]KL`9<-:Y'HSF# M#Q",0$;3-),S?-Z\'24YT1DC%YX(*.-=#8&9`#0('2DMJ:NO&EJ&)H4Q9[=< M8&K#A#>T0"^4\>(!9[YOOA5)9%6(8*9#4_I>BG!VU8C@#-7O,'B. MO$ACX]-8KG/.=;F.34F[44H\'5UXC_')#_,OLO)?S(/D,]`^N,#F1NT'^A\A M;T.E!2;)0YP4*O,F]`FD:Z9\$TCY?9B:F'!D>Q;=_6'CY=J/>*ENKS8HC7U! MCB,@,+OYK['74?^)+NTWH4-Q`Q&39B'///MZX^B\MK3CU;$'CZ_K3O#-!MCW M(978O`!>UZ:DINC6++J8[T0TJ,P85A;PDL:W50*S_@#F5G`3BO'A*5V>[=$I MG_?$OZ0C,* M6D=E]MNTY=;N0.M7.?&-F-7)_1_H)(Z=T9E=`Y!SYL*:F2=;YP>Z8$$8I!TM M#=G@,K;ZN[EZV8KFWWCY/U!+`0(>`Q0````(`+6!9T43'JWTKZH``&!0!P`1 M`!@```````$```"D@0````!O`Q0````(`+6!9T4.CE#*H0T``$:W```5`!@` M``````$```"D@?JJ``!O`L``00E#@``!#D!``!02P$"'@,4````"`"U@6=%8V3.'4,2``!9_```%0`8 M```````!````I('JN```;W-U&UL550%``,&-EU4 M=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`M8%G1=:]>??K0@``DH`#`!4` M&````````0```*2!?,L``&]S=7(M,C`Q-#`Y,S!?;&%B+GAM;%54!0`#!C9= M5'5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`+6!9T4)(Z/M!2(``(Q6`@`5 M`!@```````$```"D@;8.`0!O`L``00E#@``!#D!``!02P$"'@,4````"`"U@6=%2"G%M14*```25@`` M$0`8```````!````I($*,0$`;W-U`L``00E#@``!#D!``!02P4&``````8`!@`:`@``:CL!```` ` end XML 22 R24.htm IDEA: XBRL DOCUMENT v2.4.0.8

Income Taxes - Additional Information (Detail) (USD $)
3 Months Ended 9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Income Tax Disclosure [Abstract]

Foreign deferred tax expense (benefits) $ 10,000 $ (127,000) $ (33,000) $ (786,000)

U.S. federal income tax benefits 0 0 0 0

U.S. state income tax benefits $ 0 $ 0 $ 0 $ 0

X

- Definition

Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 6.I.7)

-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6509736

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 6

-Section I

-Paragraph Question 1-7

+ Details

Name: us-gaap_CurrentFederalTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 6.I.7)

-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6509736

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 6

-Section I

-Subsection 7

+ Details

Name: us-gaap_CurrentStateAndLocalTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 6.I.7)

-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 6

-Section I

-Subsection 7

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Deferred Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6510177

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

+ Details

Name: us-gaap_DeferredForeignIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 23 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 24 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8

The Company
9 Months Ended

Sep. 30, 2014

Accounting Policies [Abstract]

The Company

1. The Company

We develop, manufacture, market and sell oral fluid diagnostic products and specimen collection devices using our proprietary oral fluid technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types. Our diagnostic products include tests that are performed on a rapid basis at the point-of-care and tests that are processed in a laboratory. We sell the first and only rapid point-of-care HIV test approved for use in the domestic consumer retail or over-the-counter (“OTC”) market. We also manufacture and sell oral fluid collection devices used to collect, stabilize and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic testing, academic research, pharmacogenomics, personalized medicine, and animal genetics markets. Lastly, we manufacture and sell medical devices used for the removal of benign skin lesions by cryosurgery, or freezing. Our products are sold in the United States and internationally to various clinical laboratories, hospitals, clinics, community-based organizations, public health organizations, research and academic institutions, distributors, government agencies, physicians’ offices, and commercial and industrial entities. Our OTC HIV and cryosurgical products are available at retail pharmacies and mass merchandisers, and our OTC HIV product is also sold to consumers over the internet.

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=35735333&loc=d3e288-107754

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 235

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 272

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 25 R3.htm IDEA: XBRL DOCUMENT v2.4.0.8

Consolidated Balance Sheets (Parenthetical) (USD $)
In Thousands, except Per Share data, unless otherwise specified

Sep. 30, 2014

Dec. 31, 2013

Statement of Financial Position [Abstract]

Allowance for doubtful accounts $ 288 $ 299

Preferred stock, par value $ 0.000001 $ 0.000001

Preferred stock, shares authorized 25,000 25,000

Preferred stock, shares issued

Common stock, par value $ 0.000001 $ 0.000001

Common stock, shares authorized 120,000 120,000

Common stock, shares issued 56,052 55,632

Common stock, shares outstanding 56,052 55,632

X

- Definition

A valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=35738203&loc=d3e5074-111524

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Face amount or stated value per share of common stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 26 R17.htm IDEA: XBRL DOCUMENT v2.4.0.8

Business Segment Information (Tables)
9 Months Ended

Sep. 30, 2014

Segment Reporting [Abstract]

Summary of Segment Information

The following table summarizes segment information for the three and nine months ended September 30, 2014 and 2013:

 Three Months Ended September 30, Nine Months Ended September 30,

 2014 2013 2014 2013

Net revenues:


OSUR
 $ 20,978 $ 19,707 $ 60,260 $ 56,622

DNAG
 6,867 4,964 17,523 13,550



Total
 $ 27,845 $ 24,671 $ 77,783 $ 70,172



Operating income (loss):


OSUR
 $ (987 ) $ (2,516 ) $ (5,177 ) $ (18,012 )

DNAG
 1,869 456 2,938 (213 )



Total
 $ 882 $ (2,060 ) $ (2,239 ) $ (18,225 )



Depreciation and amortization:


OSUR
 $ 820 $ 815 $ 2,386 $ 2,389

DNAG
 804 810 2,346 2,457



Total
 $ 1,624 $ 1,625 $ 4,732 $ 4,846



Capital expenditures:


OSUR
 $ 298 $ 369 $ 1,868 $ 1,096

DNAG
 67 235 485 600



Total
 $ 365 $ 604 $ 2,353 $ 1,696



 September 30, 2014 December 31, 2013

Total assets:


OSUR
 $ 137,418 $ 130,848

DNAG
 53,082 53,397





Total
 $ 190,500 $ 184,245





Presentation of Total Revenues and Long-Lived Assets by Geographic Area

The following table represents total revenues by geographic area, based on the location of the customer:

 Three Months Ended September 30, Nine Months Ended September 30,

 2014 2013 2014 2013

United States
 $ 22,469 $ 19,052 $ 58,987 $ 54,052

Europe
 3,252 2,540 10,935 7,823

Other regions
 2,124 3,079 7,861 8,297









 $ 27,845 $ 24,671 $ 77,783 $ 70,172









The following table represents total long-lived assets by geographic area:

 September 30, 2014 December 31, 2013

United States
 $ 16,802 $ 16,925

Canada
 1,139 975

Other regions
 17 33





 $ 17,958 $ 17,933





X

- Definition

Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 41

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599

+ Details

Name: us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 21

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8721-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8813-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 22

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8736-108599

+ Details

Name: us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 27 R1.htm IDEA: XBRL DOCUMENT v2.4.0.8

Document and Entity Information
9 Months Ended

Sep. 30, 2014

Nov. 04, 2014

Document And Entity Information [Abstract]

Document Type 10-Q

Amendment Flag false

Document Period End Date Sep. 30, 2014

Document Fiscal Year Focus 2014

Document Fiscal Period Focus Q3

Trading Symbol OSUR

Entity Registrant Name ORASURE TECHNOLOGIES INC

Entity Central Index Key 0001116463

Current Fiscal Year End Date --12-31

Entity Filer Category Accelerated Filer

Entity Common Stock, Shares Outstanding 56,056,813

X

- Definition

If the value is true, then the document is an amendment to previously-filed/accepted document.

+ References

No definition available.

+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition

The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.

+ References

No definition available.

+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".

+ References

No definition available.

+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.

+ References

No definition available.

+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: osur_DocumentAndEntityInformationAbstract

Namespace Prefix: osur_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 28 R18.htm IDEA: XBRL DOCUMENT v2.4.0.8

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 9 Months Ended 12 Months Ended 1 Months Ended 0 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended

Sep. 30, 2014

Customer

Sep. 30, 2013

Sep. 30, 2014

Customer

Securities

Sep. 30, 2013

Dec. 31, 2013

Securities

Sep. 30, 2014

Up Front Payment Arrangement [Member]

Dec. 31, 2013

Up Front Payment Arrangement [Member]

Jul. 31, 2014

AbbVie [Member]

Nov. 21, 2013

Collaboration Agreement [Member]

Sep. 30, 2014

Collaboration Agreement [Member]

Sep. 30, 2014

Guaranteed Investment Certificates [Member]

Sep. 30, 2014

Accounts Receivable [Member]

Customer Concentration Risk [Member]

Sep. 30, 2014

Maximum [Member]

Sep. 30, 2014

Maximum [Member]

Building [Member]

Sep. 30, 2014

Maximum [Member]

Computer Equipment [Member]

Sep. 30, 2014

Maximum [Member]

Machinery and Equipment [Member]

Sep. 30, 2014

Maximum [Member]

Furniture and Fixtures [Member]

Sep. 30, 2014

Minimum [Member]

Sep. 30, 2014

Minimum [Member]

Building [Member]

Sep. 30, 2014

Minimum [Member]

Computer Equipment [Member]

Sep. 30, 2014

Minimum [Member]

Machinery and Equipment [Member]

Sep. 30, 2014

Minimum [Member]

Furniture and Fixtures [Member]

Sep. 30, 2014

DNA Genotek [Member]

Product Information [Line Items]

Available-for-sale securities, amortized cost $ 5,000

Available-for-sale securities, fair value 5,000

Available-for-sale securities 0

Fair value of plan assets 1,090 1,090 677

Estimated useful lives of assets 40 years 10 years 10 years 10 years 20 years 2 years 2 years 2 years

Accumulated depreciation of property and equipment 30,603 30,603 28,390

Amount of goodwill at period end 22,562 22,562 23,782

Payments received for sale of exclusive rights 75,000

Additional annual payments to be received for sale of exclusive rights 55,500 3,500

Expiration date of rights agreement Dec. 31, 2019

Revenue recognition, milestone method description We could be eligible to receive additional milestone payments. These payments would be based upon the aggregate number of new patients enrolled in the patient care database, in a given calendar year, after exceeding a baseline threshold, and could range from $3,500 to $55,500 annually over the life of the agreement. The first performance-based milestone period ends on December 31,2015.

Reserve for sales return and allowances 398 279

Gain on contract termination settlement 5,500 8,300 5,500

Contract Supply service agreement period 5 years

Deferred revenue 11,540 11,540 1,119 713 1,119 10,827

Deferred revenue payment received 15,000

Number of customers, accounted for significant concentrations 1 1

Percentage of concentration risk 12.00%

Concentration rate of accounts receivable 10.00% 10.00%

Concentration rate of net revenues 10.00% 10.00%

Number of third-party suppliers to manufacture DNAG's products 2

Number of anti-dilutive securities excluded from EPS computation 2,647 5,499 3,313 5,324

Accumulated foreign currency adjustments included in other comprehensive loss amounted $ 2,451 $ 1,709 $ 2,451 $ 1,709

X

- Definition

Available For Sale Securities Number Of Securities

+ References

No definition available.

+ Details

Name: osur_AvailableForSaleSecuritiesNumberOfSecurities

Namespace Prefix: osur_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- Definition

Deferred compensation plan fair value of plan assets.

+ References

No definition available.

+ Details

Name: osur_DeferredCompensationPlanFairValueOfPlanAssets

Namespace Prefix: osur_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Entity Wide Accounts Receivable Major Customer Threshold Percentage

+ References

No definition available.

+ Details

Name: osur_EntityWideAccountsReceivableMajorCustomerThresholdPercentage

Namespace Prefix: osur_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition

Entity Wide Revenue Major Customer Threshold Percentage

+ References

No definition available.

+ Details

Name: osur_EntityWideRevenueMajorCustomerThresholdPercentage

Namespace Prefix: osur_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition

Estimated Annual Payments to be Received on Sale of Rights

+ References

No definition available.

+ Details

Name: osur_EstimatedAnnualPaymentsToBeReceivedOnSaleOfRights

Namespace Prefix: osur_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Number of significant concentrations in accounts receivable.

+ References

No definition available.

+ Details

Name: osur_NumberOfSignificantConcentrationsInAccountsReceivable

Namespace Prefix: osur_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- Definition

Payments Received for Sale of Exclusive Rights

+ References

No definition available.

+ Details

Name: osur_PaymentsReceivedForSaleOfExclusiveRights

Namespace Prefix: osur_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Rights Agreement Expiration Date

+ References

No definition available.

+ Details

Name: osur_RightsAgreementExpirationDate

Namespace Prefix: osur_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

Transition Services Agreement Period Maximum

+ References

No definition available.

+ Details

Name: osur_TransitionServicesAgreementPeriodMaximum

Namespace Prefix: osur_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.14)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 14

-Article 5

+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e681-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14A

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669686-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 10A

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669646-108580

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section 45

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6915805&loc=d3e32022-110900

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Antidilution

-URI http://asc.fasb.org/extlink&oid=6505113

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Diluted Earnings Per Share

-URI http://asc.fasb.org/extlink&oid=6510752

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Contingent Stock Agreement

-URI http://asc.fasb.org/extlink&oid=6508534

+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 25

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28360136&loc=d3e22054-111558

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 5

-Subparagraph (aa)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27232-111563

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26610-111562

+ Details

Name: us-gaap_AvailableForSaleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.2)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AvailableForSaleSecuritiesAmortizedCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13537-108611

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6404-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13531-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 18

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6351-108592

+ Details

Name: us-gaap_ConcentrationRiskPercentage1

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Description of risks that arise due to the volume of business transacted with a particular supplier or reliance placed on that supplier. At a minimum, the description informs financial statement users of the general nature of the risk.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6327-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6404-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 18

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6351-108592

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 55

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6374342&loc=d3e7102-108593

+ Details

Name: us-gaap_ConcentrationRiskSupplier

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueAdditions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Gain (loss) related to the termination of a contract between the parties. The termination may be due to many causes including early termination of a lease by a lessee, a breach of contract by one party, or a failure to perform.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)(1)

-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

+ Details

Name: us-gaap_GainLossOnContractTermination

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_ProductInformationLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.

+ References

No definition available.

+ Details

Name: us-gaap_PropertyPlantAndEquipmentUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

A description of each milestone and related contingent consideration as well as a description of whether or not each milestone(s) is considered substantive.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 28

-Section 50

-Paragraph 2

-Subparagraph (b,c)

-URI http://asc.fasb.org/extlink&oid=19771982&loc=SL6892177-166501

+ Details

Name: us-gaap_RevenueRecognitionMilestoneMethodMilestone

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of estimated sales returns.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 15

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6406750&loc=d3e47468-111626

+ Details

Name: us-gaap_RevenueRecognitionSalesReturnsReserveForSalesReturns

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 29 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8

Consolidated Statements of Operations (USD $)
In Thousands, except Per Share data, unless otherwise specified
3 Months Ended 9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

NET REVENUES:

Product $ 24,447 $ 24,524 $ 73,610 $ 69,549

Licensing and product development 3,398 147 4,173 623

Total revenue 27,845 24,671 77,783 70,172

COST OF PRODUCTS SOLD 9,140 9,738 29,135 28,711

Gross profit 18,705 14,933 48,648 41,461

OPERATING EXPENSES:

Research and development 2,990 2,670 8,242 8,720

Sales and marketing 9,216 8,981 30,828 35,224

General and administrative 5,617 5,342 17,317 15,742

Gain on contract termination settlement (5,500)

Total operating expenses 17,823 16,993 50,887 59,686

Operating income (loss) 882 (2,060) (2,239) (18,225)

OTHER INCOME 268 41 244 36

Income (loss) before income taxes 1,150 (2,019) (1,995) (18,189)

INCOME TAX EXPENSE (BENEFIT) 10 (127) (33) (786)

NET INCOME (LOSS) $ 1,140 $ (1,892) $ (1,962) $ (17,403)

EARNINGS (LOSS) PER SHARE:

BASIC $ 0.02 $ (0.03) $ (0.04) $ (0.31)

DILUTED $ 0.02 $ (0.03) $ (0.04) $ (0.31)

SHARES USED IN COMPUTING EARNINGS (LOSS) PER SHARE:

BASIC 56,018 55,592 55,897 55,534

DILUTED 56,666 55,592 55,897 55,534

X

- Definition

Total costs related to goods produced and sold during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 2

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2(a))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_CostOfGoodsSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.23)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Gain (loss) related to the termination of a contract between the parties. The termination may be due to many causes including early termination of a lease by a lessee, a breach of contract by one party, or a failure to perform.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)(1)

-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

+ Details

Name: us-gaap_GainLossOnContractTermination

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1,2)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_GrossProfit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Sum of operating profit and nonoperating income or expense before Income or Loss from equity method investments, income taxes, extraordinary items, and noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h)(1)(i))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Income Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6515339

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Revenue from multiple-deliverable arrangements that include licensing fees and maintenance revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Maintenance revenue is derived from maintenance services provided under contracts or arrangements with clients. Services may include the maintenance of software, plant and equipment, and facilities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(d),(e))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_LicenseAndMaintenanceRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net result for the period of deducting operating expenses from operating revenues.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 9

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.9)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_OtherNonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_RevenuesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(a))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_SalesRevenueGoodsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate total amount of expenses directly related to the marketing or selling of products or services.

+ References

No definition available.

+ Details

Name: us-gaap_SellingAndMarketingExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1505-109256

+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Weighted-Average Number of Common Shares Outstanding

-URI http://asc.fasb.org/extlink&oid=6528421

+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 30 R12.htm IDEA: XBRL DOCUMENT v2.4.0.8

Commitments and Contingencies
9 Months Ended

Sep. 30, 2014

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

6. Commitments and Contingencies

From time-to-time, we are involved in certain legal actions arising in the ordinary course of business. In management’s opinion, based upon the advice of counsel, the outcomes of such actions are not expected to have a material adverse effect on our future financial position or results of operations.

X

- Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 31 R11.htm IDEA: XBRL DOCUMENT v2.4.0.8

Income Taxes
9 Months Ended

Sep. 30, 2014

Income Tax Disclosure [Abstract]

Income Taxes

5. Income Taxes

During the three months ended September 30, 2014, we recorded foreign deferred tax expense of $10. During the nine months ended September 30, 2014, we recorded foreign deferred tax benefits of $33. During the three and nine months ended September 30, 2013, we recorded foreign deferred tax benefits of $127 and $786, respectively. The foreign deferred tax benefits are associated with certain Canadian research and development and investment tax credits. The income tax benefits associated with DNAG are considered realizable based upon the estimated scheduled reversal of the deferred tax liabilities recorded in connection with the acquisition of DNAG.

Deferred income taxes reflect the tax effects of temporary differences between the basis of assets and liabilities recognized for financial reporting and tax purposes, and net operating loss and tax credit carryforwards. The significant components of our total deferred tax liability as of September 30, 2014 relate to the tax effects of the basis differences between the intangible assets acquired in the DNAG acquisition for financial reporting and tax purposes.

In 2008, we established a full valuation allowance against our U.S. net deferred tax asset, and management believes the full valuation allowance is still appropriate as of September 30, 2014 and December 31, 2013 since the facts and circumstances necessitating the allowance have not changed. As a result, no U.S. federal or state income tax benefit was recorded for the three and nine month periods ended September 30, 2014 and 2013.

X

- Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 32 R23.htm IDEA: XBRL DOCUMENT v2.4.0.8

Accrued Expenses - Schedule of Accrued Expenses (Detail) (USD $)
In Thousands, unless otherwise specified

Sep. 30, 2014

Dec. 31, 2013

Accrued Liabilities, Current [Abstract]

Payroll and related benefits $ 5,093 $ 5,827

Royalties 1,703 4,374

Professional fees 484 749

Other 1,923 2,082

Accrued Expenses, Total $ 9,203 $ 13,032

X

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_AccruedLiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

+ Details

Name: us-gaap_AccruedProfessionalFeesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

+ Details

Name: us-gaap_AccruedRoyaltiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_EmployeeRelatedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e7018-107765

+ Details

Name: us-gaap_OtherAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 33 R19.htm IDEA: XBRL DOCUMENT v2.4.0.8

Summary of Significant Accounting Policies - Inventories (Detail) (USD $)
In Thousands, unless otherwise specified

Sep. 30, 2014

Dec. 31, 2013

Inventory, Net [Abstract]

Raw materials $ 6,772 $ 6,700

Work in process 937 833

Finished goods 7,134 3,911

Inventories $ 14,843 $ 11,444

X

- Definition

Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_InventoryFinishedGoods

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6386567&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_InventoryNetAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a)(4))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_InventoryRawMaterials

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_InventoryWorkInProcess

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 34 R15.htm IDEA: XBRL DOCUMENT v2.4.0.8

Summary of Significant Accounting Policies (Tables)
9 Months Ended

Sep. 30, 2014

Accounting Policies [Abstract]

Inventories

Inventories. Inventories are stated at the lower of cost or market determined on a first-in, first-out basis and are comprised of the following:

 September 30, 2014 December 31, 2013

Raw materials
 $ 6,772 $ 6,700

Work in process
 937 833

Finished goods
 7,134 3,911





 $ 14,843 $ 11,444





Summary of Intangible Assets

Intangible assets consist of the following:

 September 30, 2014

 Amortization
Period (Years) Gross Accumulated
Amortization Net

Customer list
 10 $ 11,190 $ (3,370 ) $ 7,820

Patents and product rights
 3-10 10,449 (7,844 ) 2,605

Acquired technology
 7 8,692 (3,682 ) 5,010

Tradename
 15 4,289 (893 ) 3,396





 $ 34,620 $ (15,789 ) $ 18,831





 December 31, 2013

 Amortization
Period(Years) Gross Accumulated
Amortization Net

Customer list
 10 $ 11,795 $ (2,701 ) $ 9,094

Patents and product rights
 3-10 10,449 (7,466 ) 2,983

Acquired technology
 7 9,162 (2,952 ) 6,210

Tradename
 15 4,521 (715 ) 3,806

Non-compete agreements
 1-3 787 (654 ) 133





 $ 36,714 $ (14,488 ) $ 22,226





Computations of Basic and Diluted Earnings (Loss) per Share

The computations of basic and diluted earnings (loss) per share are as follows:

 Three Months
Ended September 30, Nine Months
Ended September 30,

 2014 2013 2014 2013

Net income (loss)
 $ 1,140 $ (1,892 ) $ (1,962 ) $ (17,403 )





Weighted average shares of common stock outstanding:


Basic
 56,018 55,592 55,897 55,534

Dilutive effect of stock options and restricted stock
 648 — — —





Diluted
 56,666 55,592 55,897 55,534





Earnings (loss) per share:


Basic
 $ 0.02 $ (0.03 ) $ (0.04 ) $ (0.31 )





Diluted
 $ 0.02 $ (0.03 ) $ (0.04 ) $ (0.31 )





X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16265-109275

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 2

-Paragraph 6

-Subparagraph a,b,c

-Article 5

+ Details

Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 35 R13.htm IDEA: XBRL DOCUMENT v2.4.0.8

Business Segment Information
9 Months Ended

Sep. 30, 2014

Segment Reporting [Abstract]

Business Segment Information

7. Business Segment Information

We operate our business within two reportable segments: our “OSUR” business, which consists of the development, manufacture and sale of oral fluid diagnostic products and specimen collection devices and the manufacture and sale of medical devices used for the removal of benign skin lesions by cryosurgery; and our molecular collection systems or “DNAG” business, which consists of the manufacture, development and sale of oral fluid collection devices that are used to collect, stabilize and store samples of genetic material for molecular testing. OSUR revenues are derived primarily from products sold in the United States and internationally to various clinical laboratories, hospitals, clinics, community-based organizations, public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities. Revenues from OSUR’s OTC products result from sales to retail pharmacies and mass merchandisers, and to consumers over the internet. OSUR also derives revenues from licensing and product development activities. DNAG revenues result primarily from products sold into the commercial market which consists of companies and other entities engaged in consumer genetics, clinical genetic testing, pharmacogenomics, personalized medicine, and animal and livestock genetic testing. DNAG products are also sold into the academic research market, which consists of research laboratories, universities and hospitals.

We organized our operating segments according to the nature of the products included in those segments. The accounting policies of the segments are the same as those described in the summary of significant accounting policies (see Note 2). We evaluate performance of our operating segments based on revenue and operating income (loss). We do not allocate interest income, interest expense, other income, other expenses or income taxes to our operating segments. Reportable segments have no inter-segment revenues.

The following table summarizes segment information for the three and nine months ended September 30, 2014 and 2013:

 Three Months Ended September 30, Nine Months Ended September 30,

 2014 2013 2014 2013

Net revenues:


OSUR
 $ 20,978 $ 19,707 $ 60,260 $ 56,622

DNAG
 6,867 4,964 17,523 13,550



Total
 $ 27,845 $ 24,671 $ 77,783 $ 70,172



Operating income (loss):


OSUR
 $ (987 ) $ (2,516 ) $ (5,177 ) $ (18,012 )

DNAG
 1,869 456 2,938 (213 )



Total
 $ 882 $ (2,060 ) $ (2,239 ) $ (18,225 )



Depreciation and amortization:


OSUR
 $ 820 $ 815 $ 2,386 $ 2,389

DNAG
 804 810 2,346 2,457



Total
 $ 1,624 $ 1,625 $ 4,732 $ 4,846



Capital expenditures:


OSUR
 $ 298 $ 369 $ 1,868 $ 1,096

DNAG
 67 235 485 600



Total
 $ 365 $ 604 $ 2,353 $ 1,696



 September 30, 2014 December 31, 2013

Total assets:


OSUR
 $ 137,418 $ 130,848

DNAG
 53,082 53,397





Total
 $ 190,500 $ 184,245





Our products are sold principally in the United States and Europe.

The following table represents total revenues by geographic area, based on the location of the customer:

 Three Months Ended September 30, Nine Months Ended September 30,

 2014 2013 2014 2013

United States
 $ 22,469 $ 19,052 $ 58,987 $ 54,052

Europe
 3,252 2,540 10,935 7,823

Other regions
 2,124 3,079 7,861 8,297









 $ 27,845 $ 24,671 $ 77,783 $ 70,172









The following table represents total long-lived assets by geographic area:

 September 30, 2014 December 31, 2013

United States
 $ 16,802 $ 16,925

Canada
 1,139 975

Other regions
 17 33





 $ 17,958 $ 17,933





X

- Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 29

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 32

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 34

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 35

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 41

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 42

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 31

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 40

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 33

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599

+ Details

Name: us-gaap_SegmentReportingDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 R14.htm IDEA: XBRL DOCUMENT v2.4.0.8

Summary of Significant Accounting Policies (Policies)
9 Months Ended

Sep. 30, 2014

Accounting Policies [Abstract]

Principles of Consolidation and Basis of Presentation

Principles of Consolidation and Basis of Presentation. The consolidated financial statements include the accounts of OraSure Technologies, Inc. (“OraSure”) and its wholly-owned subsidiary, DNA Genotek, Inc. (“DNAG”). All intercompany transactions and balances have been eliminated. References herein to “we,” “us,” “our,” or the “Company” mean OraSure and its consolidated subsidiaries, unless otherwise indicated.

The accompanying consolidated financial statements are unaudited and, in the opinion of management, include all adjustments (consisting only of normal and recurring adjustments) necessary for a fair presentation of our financial position and results of operations for these interim periods. These financial statements should be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013. Results of operations for the three and nine months ended September 30, 2014 are not necessarily indicative of the results of operations expected for the full year.

Use of Estimates

Use of Estimates. The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Such estimates include the valuation of accounts receivable and inventories and assumptions utilized in impairment testing for intangible assets and goodwill, as well as calculations related to contingencies and accruals, among others. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis, using historical experience and other factors which management believes to be reasonable under the circumstances, including the current economic environment. We adjust such estimates and assumptions when facts and circumstances dictate. Illiquid credit markets, volatile equity and foreign currency markets, reductions in government funding and declines in consumer spending have combined to increase the uncertainty inherent in such estimates and assumptions. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic environment and other factors will be reflected in the financial statements in those future periods.

Short-Term Investments

Short-Term Investments. We consider all short-term investments to be available-for-sale securities. These securities are comprised of guaranteed investment certificates with purchased maturities greater than ninety days. Available-for-sale securities are carried at fair value, based upon quoted market prices, with unrealized gains and losses, if any, reported in stockholders’ equity as a component of accumulated other comprehensive loss.

Our available-for-sale securities as of September 30, 2014 consisted of guaranteed investment certificates with amortized cost and fair value of $5,000. As of December 31, 2013, we had no available-for-sale securities.

Fair Value of Financial Instruments

Fair Value of Financial Instruments. As of September 30, 2014, the carrying values of cash, short-term investments, accounts receivable, accounts payable and accrued expenses approximate their respective fair values based on their short-term nature.

Fair value measurements of all financial assets and liabilities that are being measured and reported on a fair value basis are required to be classified and disclosed in one of the following three categories:

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

We offer a nonqualified deferred compensation plan for certain eligible employees and members of our Board of Directors. The assets of the plan are held in the name of the Company at a third-party financial institution. Separate accounts are maintained for each participant to reflect the amounts deferred by the participant and all earnings and losses on those deferred amounts. The assets of the plan are held in mutual funds and Company stock. The fair value of the plan assets as of September 30, 2014 and December 31, 2013 was $1,090 and $677, respectively, and was calculated using the quoted market prices of the assets as of those dates. All investments in the plan are classified as trading securities and measured as Level 1 instruments. The fair value of plan assets is included in other assets with the same amount included in other liabilities in the accompanying consolidated balance sheets.

All of our available-for-sale securities were classified and measured as Level 1 instruments as of September 30, 2014.

Inventories

Inventories. Inventories are stated at the lower of cost or market determined on a first-in, first-out basis and are comprised of the following:

 September 30, 2014 December 31, 2013

Raw materials
 $ 6,772 $ 6,700

Work in process
 937 833

Finished goods
 7,134 3,911





 $ 14,843 $ 11,444





Property and Equipment

Property and Equipment. Property and equipment are stated at cost. Additions or improvements are capitalized, while repairs and maintenance are charged to expense. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. Buildings are depreciated over twenty to forty years, while computer equipment, machinery and equipment, and furniture and fixtures are depreciated over two to ten years. Building improvements are amortized over their estimated useful lives. When assets are sold or otherwise disposed of, the related property amounts are relieved from the accounts, and any gain or loss is recorded in the consolidated statement of operations. Accumulated depreciation of property and equipment as of September 30, 2014 and December 31, 2013 was $30,603 and $28,390, respectively.

Intangible Assets

Intangible Assets. Intangible assets consist of the following:

 September 30, 2014

 Amortization
Period (Years) Gross Accumulated
Amortization Net

Customer list
 10 $ 11,190 $ (3,370 ) $ 7,820

Patents and product rights
 3-10 10,449 (7,844 ) 2,605

Acquired technology
 7 8,692 (3,682 ) 5,010

Tradename
 15 4,289 (893 ) 3,396





 $ 34,620 $ (15,789 ) $ 18,831





 December 31, 2013

 Amortization
Period(Years) Gross Accumulated
Amortization Net

Customer list
 10 $ 11,795 $ (2,701 ) $ 9,094

Patents and product rights
 3-10 10,449 (7,466 ) 2,983

Acquired technology
 7 9,162 (2,952 ) 6,210

Tradename
 15 4,521 (715 ) 3,806

Non-compete agreements
 1-3 787 (654 ) 133





 $ 36,714 $ (14,488 ) $ 22,226





Goodwill

Goodwill. Goodwill represents the excess of the purchase price we paid over the fair value of the net tangible and identifiable intangible assets acquired and liabilities assumed in our acquisition of DNAG in August 2011. Goodwill is not amortized but rather is tested annually for impairment or more frequently if we believe that indicators of impairment exist. Current U.S. generally accepted accounting principles permit us to make a qualitative evaluation about the likelihood of goodwill impairment. If we conclude that it is more likely than not that the fair value of a reporting unit is greater than its carrying amount, then we would not be required to perform the two-step quantitative impairment test. Otherwise, performing the two-step impairment test is necessary. The first step of the two-step quantitative impairment test involves comparing the fair value of the applicable reporting unit with its aggregate carrying value, including goodwill. If the carrying value of a reporting unit exceeds the reporting unit’s fair value, we perform the second step of the test to determine the amount of the impairment loss, if any. The second step involves measuring any impairment by comparing the implied fair values of the affected reporting unit’s goodwill and intangible assets with their respective carrying values.

We performed our last annual impairment assessment as of July 31, 2014 utilizing a qualitative evaluation and concluded that it was more likely than not that the fair value of our DNAG reporting unit is greater than its carrying amount. We believe we have made reasonable estimates and assumptions to calculate the fair value of our reporting unit. If actual future results are not consistent with management’s estimates and assumptions, we may have to take an impairment charge in the future related to our goodwill. Future impairment tests will continue to be performed annually in the fiscal third quarter, or sooner if a triggering event occurs. As of September 30, 2014, we believe no indicators of impairment exist.

The change in goodwill from $23,782 as of December 31, 2013 to $22,562 as of September 30, 2014 is a result of foreign currency translation.

Revenue Recognition

Revenue Recognition. We recognize product revenues when there is persuasive evidence that an arrangement exists, the price is fixed or determinable, title has passed and collection is reasonably assured. Product revenues are recorded net of allowances for any discounts or rebates. Other than for our OraQuick^® In-Home HIV test, we do not grant price protection or product return rights to our customers, except for warranty returns. Historically, returns arising from warranty issues have been infrequent and immaterial. Accordingly, we expense warranty returns as incurred.

We began selling our OraQuick^® In-Home HIV test in the third quarter of 2012. From launch through November 2013, our revenue recognition practices with respect to the OraQuick^® In-Home HIV test were different than those customarily used in the consumer package goods industry. Under U.S. generally accepted accounting principles, product revenue cannot be recognized unless the amount of future returns can be reasonably estimated. Because our OraQuick^® In-Home HIV test was a new product for which we did not have a historical record of returns, we did not believe we could reasonably determine a return rate. As a result, initially we did not recognize revenue when we shipped to the retail trade. For these product shipments, we invoiced the retailer or distributor, recorded deferred revenue at gross invoice sales price, and classified the cost basis of the product held by the retailer or distributor as a component of inventory. We then recognized revenue upon the consummation of a sale to the consumer either in a store or over the internet. With the passage of time, however, we concluded that we have sufficient data and visibility into our distribution channel to develop a reasonable estimate of the level of expected returns. As such, commencing in December 2013, we recognized previously deferred revenue and its related cost of goods sold, and began to recognize revenue for this product upon shipment to the retailers or distributors. Accordingly, revenues in the first nine months of 2014 were recorded based upon shipments into the distribution channel, while revenues in the first nine months of 2013 were recorded based upon the consummation of a sale to the consumer.

Our net revenues recorded on sales of the OraQuick^® In-Home HIV test represent total gross revenues, less an allowance for expected returns, and customer allowances for cooperative advertising discounts, rebates, and chargebacks. All of these allowances are estimates established by management, based on currently available information and are adjusted to reflect known changes in the factors that impact those estimates. These allowances are recorded as a reduction of gross revenue when recognized in our statements of operations.

Royalty income from the grant of license rights is recognized during the period in which the revenue is earned and the amount is determinable from the licensee and is recorded as licensing and product development revenue in our statements of operations.

We record shipping and handling charges billed to our customers as product revenue and the related expense as cost of products sold. Taxes assessed by governmental authorities, such as sales or value-added taxes, are excluded from product revenues.

On June 10, 2014, we entered into a Master Program Services and Co-Promotion Agreement with AbbVie Bahamas Ltd., a wholly-owned subsidiary of AbbVie Inc. (“AbbVie”), to co-promote our OraQuick^® HCV Rapid Test in the United States. The product will be used to test individuals at-risk for the hepatitis C virus (“HCV”). We will be responsible for manufacturing and selling the product into all markets.

Under the terms of our agreement, we have granted exclusive promotion rights to AbbVie for the OraQuick^® HCV Rapid test in certain markets and we have agreed to develop, implement, administer and maintain a patient care database for the exclusive use of AbbVie. This patient care database will be used to compile patient information regarding new individuals who have tested positive for HCV using our OraQuick^® HCV Rapid test. We have also jointly agreed with AbbVie to co-promote our OraQuick^® HCV Rapid test in certain market segments, namely: healthcare providers such as primary care physicians, gastroenterologists, hepatologists and infectious disease specialists; employers and employee groups experiencing a high HCV prevalence rate, such as the long-haul trucking industry; and national retail pharmacies and retail clinics that perform routine healthcare screening services.

In exchange for these exclusive rights and other services, we will receive up to $75,000 in payments over the term of the agreement which expires on December 31, 2019. We will recognize revenues from these periodic payments ratably, over the life of the agreement. In addition, if certain performance-based milestones are achieved, we could be eligible to receive additional milestone payments. These payments would be based upon the aggregate number of new patients enrolled in the patient care database, in a given calendar year, after exceeding a baseline threshold, and could range from $3,500 to $55,500 annually over the life of the agreement. The first performance-based milestone period ends on December 31, 2015. The agreement also contains certain termination, indemnification and other provisions, typical of agreements of this type. Payments received under this agreement will be recorded as licensing and product development revenue in our statements of operations.

Customer Sales Returns and Allowances

Customer Sales Returns and Allowances. We do not grant return rights to our customers for any product, except for our OraQuick^® In-Home HIV test. Accordingly, we have recorded an estimate of expected returns as a reduction of gross OraQuick^® In-Home HIV product revenues in our consolidated statements of operations. This estimate reflects our historical sales experience to retailers and consumers, as well as other retail factors, and is reviewed regularly to ensure that it reflects potential product returns. As of September 30, 2014 and December 31, 2013, the reserve for sales returns and allowances was $398 and $279, respectively. If actual product returns differ materially from our reserve amount, or if a determination is made that this product’s distribution would be discontinued in whole or in part by certain retailers, then we would need to adjust our reserve. Should the actual level of product returns vary significantly from our estimates, our operating and financial results could be materially affected.

Termination Settlement

Termination Settlement. On November 21, 2013, we terminated our assay development collaboration with Roche Diagnostics (“Roche”). Pursuant to a termination agreement, Roche paid us $8,300 which was recorded as a reduction of operating expense in our consolidated statement of operations for the quarter ended December 31, 2013. Roche agreed to provide certain transitional product support services to us and to continue to supply certain of the assays developed under the collaboration on a transitional basis for up to five years following the termination. We had the right to stop the supply of assays prior to the end of this five-year period and to receive an additional payment from Roche of up to $5,500 depending on how early in that five-year period the supply obligation was ended. During the second quarter of 2014, we issued our final purchase order for fully-automated assays previously developed under the terminated collaboration and as such, have recorded $5,500 as a reduction of operating expense in our consolidated statement of operations.

Deferred Revenue

Deferred Revenue. We record deferred revenue when funds are received prior to the recognition of the associated revenue. Deferred revenue at September 30, 2014 and December 31, 2013 includes customer prepayments of $713 and $1,119, respectively. Deferred revenue also includes $10,827 which represents the $15,000 payment received in July 2014 under the terms of our HCV collaboration with AbbVie, less amounts recognized ratably in revenue.

Customer and Vendor Concentrations

Customer and Vendor Concentrations. We had no significant concentrations (greater than 10%) in accounts receivable as of September 30, 2014. One of our customers, AbbVie, accounted for approximately 12% of our net revenues for the three months ended September 30, 2014. We had no significant concentrations (greater than 10%) in net revenues for the nine months ended September 30, 2014 and the three or nine months ended September 30, 2013.

We currently purchase certain products and critical components of our products from sole-supply vendors, and if these vendors are unable or unwilling to supply the required components and products, we could be subject to increased costs and substantial delays in the delivery of our products to our customers. Also, our subsidiary, DNAG, uses two third-party suppliers to manufacture its products. Our inability to have a timely supply of any of these components and products could have a material adverse effect on our business, as well as our financial condition and results of operations.

Earnings (Loss) Per Share

Earnings (Loss) Per Share. Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings (loss) per share is computed in a manner similar to basic earnings (loss) per share except that the weighted average number of shares outstanding is increased to include incremental shares from the assumed vesting or exercise of dilutive securities, such as common stock options and unvested restricted stock, unless the impact is antidilutive. The number of incremental shares is calculated by assuming that outstanding stock options were exercised and unvested restricted shares were vested, and the proceeds from such exercises or vesting were used to acquire shares of common stock at the average market price during the reporting period.

The computations of basic and diluted earnings (loss) per share are as follows:

 Three Months
Ended September 30, Nine Months
Ended September 30,

 2014 2013 2014 2013

Net income (loss)
 $ 1,140 $ (1,892 ) $ (1,962 ) $ (17,403 )





Weighted average shares of common stock outstanding:


Basic
 56,018 55,592 55,897 55,534

Dilutive effect of stock options and restricted stock
 648 — — —





Diluted
 56,666 55,592 55,897 55,534





Earnings (loss) per share:


Basic
 $ 0.02 $ (0.03 ) $ (0.04 ) $ (0.31 )





Diluted
 $ 0.02 $ (0.03 ) $ (0.04 ) $ (0.31 )





For the three-month periods ended September 30, 2014 and 2013, outstanding common stock options and unvested restricted stock, representing 2,647 and 5,499 shares, respectively, were excluded from the computation of diluted earnings (loss) per share, as their inclusion would have been anti-dilutive. For the nine months ended September 30, 2014 and 2013, outstanding common stock options and unvested restricted stock, representing 3,313 and 5,324 shares, respectively, were similarly excluded from the computation of diluted earnings (loss) per share.

Foreign Currency Translation

Foreign Currency Translation. The assets and liabilities of our foreign operations are translated into U.S. dollars at current exchange rates as of the balance sheet date, and revenues and expenses are translated at average exchange rates for the period. Resulting translation adjustments are reflected in accumulated other comprehensive loss, which is a separate component of stockholders’ equity.

Transaction gains and losses resulting from exchange rate changes on transactions denominated in currencies other than functional currency are included in income in the period in which the change occurs.

Accumulated Other Comprehensive Loss

Accumulated Other Comprehensive Loss. We classify items of other comprehensive loss by their nature and disclose the accumulated balance of other comprehensive loss separately from accumulated deficit and additional paid-in capital in the stockholders’ equity section of our balance sheet.

We have defined the Canadian dollar as the functional currency of our Canadian subsidiary, DNAG, and as such, the results of its operations are translated into U.S. dollars, which is the reporting currency of the Company. The $2,451 and $1,709 currency translation adjustments recorded in the first nine months of 2014 and 2013, respectively, are largely the result of the translation of our Canadian operation’s balance sheets into U.S. dollars.

Recent Accounting Pronouncements

Recent Accounting Pronouncements. In May 2014, the Financial Accounting Standards Board (“FASB”) issued converged guidance on recognizing revenue in contracts with customers, ASU 2014-09 Revenue from Contracts with Customers. The intent of the new standard is to improve financial reporting and comparability of revenue globally. The core principle of the standard is for a company to recognize revenue in a manner that depicts the transfer of goods or services to customers in an amount that reflects the consideration which the company expects to receive in exchange for those goods or services. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2016, with no early adoption permitted. We will evaluate the effects, if any, which adoption of this guidance will have on our consolidated financial statements.

X

- Definition

Termination Settlement Policy [Text Block]

+ References

No definition available.

+ Details

Name: osur_TerminationSettlementPolicyTextBlock

Namespace Prefix: osur_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).

+ References

No definition available.

+ Details

Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for comprehensive income.

+ References

No definition available.

+ Details

Name: us-gaap_ComprehensiveIncomePolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257

+ Details

Name: us-gaap_EarningsPerSharePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for determining the fair value of financial instruments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13279-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 60

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260

+ Details

Name: us-gaap_FairValueOfFinancialInstrumentsPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895

+ Details

Name: us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_IntangibleAssetsFiniteLivedPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for major classes of inventories, bases of stating inventories (for example, lower of cost or market), methods by which amounts are added and removed from inventory classes (for example, FIFO, LIFO, or average cost), loss recognition on impairment of inventories, and situations in which inventories are stated above cost. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28360613&loc=d3e4492-108314

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=28360613&loc=d3e4556-108314

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Financial Reporting Release (FRR)

-Number 206

-Paragraph b

-Subparagraph i, ii

-Chapter 2

+ Details

Name: us-gaap_InventoryPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for investments in financial assets, including marketable securities (debt and equity securities with readily determinable fair values), investments accounted for under the equity method and cost method, securities borrowed and loaned, and repurchase and resale agreements. For marketable securities, the disclosure may include the entity's accounting treatment for transfers between investment categories and how the fair values for such securities are determined. Also, for all investments, an entity may describe its policy for assessing, recognizing and measuring impairment of the investment.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 325

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6872867&loc=d3e40691-111596

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13433-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 323

-SubTopic 10

-Section 50

-Paragraph 3

-Subparagraph (a)(2)

-URI http://asc.fasb.org/extlink&oid=6382943&loc=d3e33918-111571

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 6

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27290-111563

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section M

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.2,12)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 2, 12

-Article 5

+ Details

Name: us-gaap_InvestmentPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for major customers. Major customers are those that the loss of such customers would have a material adverse effect on the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6327-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6404-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 18

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6351-108592

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 42

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599

+ Details

Name: us-gaap_MajorCustomersPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.

+ References

No definition available.

+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

+ Details

Name: us-gaap_PropertyPlantAndEquipmentPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for recognizing unearned income or deferred revenue related to transactions involving the sale of a product or performance of services.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section B

-Paragraph Question 1

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.B.Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

+ Details

Name: us-gaap_RevenueRecognitionDeferredRevenue

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18726-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section B

-Paragraph Question 1

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.B.Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18823-107790

+ Details

Name: us-gaap_RevenueRecognitionPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for sales returns.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section B

-Paragraph Question 1

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 15

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6406750&loc=d3e47468-111626

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.B.Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

+ Details

Name: us-gaap_RevenueRecognitionSalesReturns

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6143-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6132-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6061-108592

+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 37 R16.htm IDEA: XBRL DOCUMENT v2.4.0.8

Accrued Expenses (Tables)
9 Months Ended

Sep. 30, 2014

Payables and Accruals [Abstract]

Schedule of Accrued Expenses

 September 30, 2014 December 31, 2013

Payroll and related benefits
 $ 5,093 $ 5,827

Royalties
 1,703 4,374

Professional fees
 484 749

Other
 1,923 2,082





 $ 9,203 $ 13,032





X

- Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the components of accrued liabilities.

+ References

No definition available.

+ Details

Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 38 R21.htm IDEA: XBRL DOCUMENT v2.4.0.8

Summary of Significant Accounting Policies - Computations of Basic and Diluted Earnings (Loss) per Share (Detail) (USD $)
In Thousands, except Per Share data, unless otherwise specified
3 Months Ended 9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Earnings Per Share [Abstract]

NET INCOME (LOSS) $ 1,140 $ (1,892) $ (1,962) $ (17,403)

Weighted average shares of common stock outstanding:

BASIC 56,018 55,592 55,897 55,534

Dilutive effect of stock options and restricted stock 648

Diluted 56,666 55,592 55,897 55,534

BASIC $ 0.02 $ (0.03) $ (0.04) $ (0.31)

DILUTED $ 0.02 $ (0.03) $ (0.04) $ (0.31)

X

- Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.23)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 28A

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1500-109256

+ Details

Name: us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1505-109256

+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Weighted-Average Number of Common Shares Outstanding

-URI http://asc.fasb.org/extlink&oid=6528421

+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 39 R26.htm IDEA: XBRL DOCUMENT v2.4.0.8

Business Segment Information - Summary of Segment Information (Detail) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2013

Segment Reporting Information [Line Items]

Net revenues $ 27,845 $ 24,671 $ 77,783 $ 70,172

Operating income (loss) 882 (2,060) (2,239) (18,225)

Depreciation and amortization 1,624 1,625 4,732 4,846

Capital expenditures 365 604 2,353 1,696

Total assets 190,500 190,500 184,245

OSUR [Member]

Segment Reporting Information [Line Items]

Net revenues 20,978 19,707 60,260 56,622

Operating income (loss) (987) (2,516) (5,177) (18,012)

Depreciation and amortization 820 815 2,386 2,389

Capital expenditures 298 369 1,868 1,096

Total assets 137,418 137,418 130,848

DNAG [Member]

Segment Reporting Information [Line Items]

Net revenues 6,867 4,964 17,523 13,550

Operating income (loss) 1,869 456 2,938 (213)

Depreciation and amortization 804 810 2,346 2,457

Capital expenditures 67 235 485 600

Total assets $ 53,082 $ 53,082 $ 53,397

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The net result for the period of deducting operating expenses from operating revenues.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_SegmentReportingInformationLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 40 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8

Consolidated Statements of Comprehensive Loss (USD $)
In Thousands, unless otherwise specified
3 Months Ended 9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Statement of Comprehensive Income [Abstract]

NET INCOME (LOSS) $ 1,140 $ (1,892) $ (1,962) $ (17,403)

OTHER COMPREHENSIVE INCOME (LOSS)

Currency translation adjustments (2,295) 876 (2,451) (1,709)

Other comprehensive income (loss) (2,295) 876 (2,451) (1,709)

COMPREHENSIVE LOSS $ (1,155) $ (1,016) $ (4,413) $ (19,112)

X

- Definition

Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=35737396

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e557-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 10A

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669646-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section 45

-Paragraph 20

-Subparagraph (b,c)

-URI http://asc.fasb.org/extlink&oid=6915805&loc=d3e32211-110900

+ Details

Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount after tax of other comprehensive income (loss) attributable to parent entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569643-111683

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569616-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1A

-Subparagraph (c)(3)

-URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684

+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 41 R10.htm IDEA: XBRL DOCUMENT v2.4.0.8

Accrued Expenses
9 Months Ended

Sep. 30, 2014

Payables and Accruals [Abstract]

Accrued Expenses

4. Accrued Expenses

 September 30, 2014 December 31, 2013

Payroll and related benefits
 $ 5,093 $ 5,827

Royalties
 1,703 4,374

Professional fees
 484 749

Other
 1,923 2,082





 $ 9,203 $ 13,032





X

- Definition

The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a),20,24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20, 24

-Article 5

+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 42 R27.htm IDEA: XBRL DOCUMENT v2.4.0.8

Business Segment Information - Presentation of Total Revenues and Long-Lived Assets by Geographic Area (Detail) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2013

Segment Reporting, Revenue Reconciling Item [Line Items]

Revenues $ 27,845 $ 24,671 $ 77,783 $ 70,172

Long-lived assets 17,958 17,958 17,933

United States [Member]

Segment Reporting, Revenue Reconciling Item [Line Items]

Revenues 22,469 19,052 58,987 54,052

Long-lived assets 16,802 16,802 16,925

Europe [Member]

Segment Reporting, Revenue Reconciling Item [Line Items]

Revenues 3,252 2,540 10,935 7,823

Other Regions [Member]

Segment Reporting, Revenue Reconciling Item [Line Items]

Revenues 2,124 3,079 7,861 8,297

Long-lived assets 17 17 33

Canada [Member]

Segment Reporting, Revenue Reconciling Item [Line Items]

Long-lived assets $ 1,139 $ 1,139 $ 975

X

- Definition

Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_SegmentReportingRevenueReconcilingItemLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 43 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.8 Html 84 156 1 false 26 0 false 7 false false R1.htm 101 - Document - Document and Entity Information Sheet http://www.orasure.com/taxonomy/role/DocumentandEntityInformation Document and Entity Information true false R2.htm 103 - Statement - Consolidated Balance Sheets Sheet http://www.orasure.com/taxonomy/role/StatementOfFinancialPositionClassified Consolidated Balance Sheets false false R3.htm 104 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.orasure.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical Consolidated Balance Sheets (Parenthetical) false false R4.htm 105 - Statement - Consolidated Statements of Operations Sheet http://www.orasure.com/taxonomy/role/StatementOfIncome Consolidated Statements of Operations false false R5.htm 106 - Statement - Consolidated Statements of Comprehensive Loss Sheet http://www.orasure.com/taxonomy/role/StatementOfOtherComprehensiveIncome Consolidated Statements of Comprehensive Loss false false R6.htm 107 - Statement - Consolidated Statements of Cash Flows Sheet http://www.orasure.com/taxonomy/role/StatementOfCashFlowsIndirect Consolidated Statements of Cash Flows false false R7.htm 108 - Disclosure - The Company Sheet http://www.orasure.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock The Company false false R8.htm 109 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.orasure.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock Summary of Significant Accounting Policies false false R9.htm 110 - Disclosure - Stockholders' Equity Sheet http://www.orasure.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock Stockholders' Equity false false R10.htm 111 - Disclosure - Accrued Expenses Sheet http://www.orasure.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock Accrued Expenses false false R11.htm 112 - Disclosure - Income Taxes Sheet http://www.orasure.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock Income Taxes false false R12.htm 113 - Disclosure - Commitments and Contingencies Sheet http://www.orasure.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock Commitments and Contingencies false false R13.htm 114 - Disclosure - Business Segment Information Sheet http://www.orasure.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock Business Segment Information false false R14.htm 115 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.orasure.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies Summary of Significant Accounting Policies (Policies) false false R15.htm 116 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.orasure.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables Summary of Significant Accounting Policies (Tables) false false R16.htm 117 - Disclosure - Accrued Expenses (Tables) Sheet http://www.orasure.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables Accrued Expenses (Tables) false false R17.htm 118 - Disclosure - Business Segment Information (Tables) Sheet http://www.orasure.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlockTables Business Segment Information (Tables) false false R18.htm 119 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://www.orasure.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation Summary of Significant Accounting Policies - Additional Information (Detail) false false R19.htm 120 - Disclosure - Summary of Significant Accounting Policies - Inventories (Detail) Sheet http://www.orasure.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesInventories Summary of Significant Accounting Policies - Inventories (Detail) false false R20.htm 121 - Disclosure - Summary of Significant Accounting Policies - Summary of Intangible Assets (Detail) Sheet http://www.orasure.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfIntangibleAssets Summary of Significant Accounting Policies - Summary of Intangible Assets (Detail) false false R21.htm 122 - Disclosure - Summary of Significant Accounting Policies - Computations of Basic and Diluted Earnings (Loss) per Share (Detail) Sheet http://www.orasure.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesComputationsOfBasicAndDilutedEarningsLossPerShare Summary of Significant Accounting Policies - Computations of Basic and Diluted Earnings (Loss) per Share (Detail) false false R22.htm 123 - Disclosure - Stockholders' Equity - Additional Information (Detail) Sheet http://www.orasure.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation Stockholders' Equity - Additional Information (Detail) false false R23.htm 124 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail) Sheet http://www.orasure.com/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpenses Accrued Expenses - Schedule of Accrued Expenses (Detail) false false R24.htm 125 - Disclosure - Income Taxes - Additional Information (Detail) Sheet http://www.orasure.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation Income Taxes - Additional Information (Detail) false false R25.htm 126 - Disclosure - Business Segment Information - Additional Information (Detail) Sheet http://www.orasure.com/taxonomy/role/DisclosureBusinessSegmentInformationAdditionalInformation Business Segment Information - Additional Information (Detail) false false R26.htm 127 - Disclosure - Business Segment Information - Summary of Segment Information (Detail) Sheet http://www.orasure.com/taxonomy/role/DisclosureBusinessSegmentInformationSummaryOfSegmentInformation Business Segment Information - Summary of Segment Information (Detail) false false R27.htm 128 - Disclosure - Business Segment Information - Presentation of Total Revenues and Long-Lived Assets by Geographic Area (Detail) Sheet http://www.orasure.com/taxonomy/role/DisclosureBusinessSegmentInformationPresentationOfTotalRevenuesAndLongLivedAssetsByGeographicArea Business Segment Information - Presentation of Total Revenues and Long-Lived Assets by Geographic Area (Detail) false false All Reports Book All Reports 'Monetary' elements on report '123 - Disclosure - Stockholders' Equity - Additional Information (Detail)' had a mix of different decimal attribute values. 'Monetary' elements on report '125 - Disclosure - Income Taxes - Additional Information (Detail)' had a mix of different decimal attribute values. Process Flow-Through: 103 - Statement - Consolidated Balance Sheets Process Flow-Through: Removing column 'Sep. 30, 2013' Process Flow-Through: Removing column 'Dec. 31, 2012' Process Flow-Through: 104 - Statement - Consolidated Balance Sheets (Parenthetical) Process Flow-Through: 105 - Statement - Consolidated Statements of Operations Process Flow-Through: 106 - Statement - Consolidated Statements of Comprehensive Loss Process Flow-Through: 107 - Statement - Consolidated Statements of Cash Flows osur-20140930.xml osur-20140930.xsd osur-20140930_cal.xml osur-20140930_def.xml osur-20140930_lab.xml osur-20140930_pre.xml true true XML 44 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8

Summary of Significant Accounting Policies - Summary of Intangible Assets (Detail) (USD $)
In Thousands, unless otherwise specified
9 Months Ended 12 Months Ended

Sep. 30, 2014

Dec. 31, 2013

Finite-Lived Intangible Assets [Line Items]

Gross $ 34,620 $ 36,714

Accumulated Amortization (15,789) (14,488)

Net 18,831 22,226

Customer List [Member]

Finite-Lived Intangible Assets [Line Items]

Amortization Period (Years) 10 years 10 years

Gross 11,190 11,795

Accumulated Amortization (3,370) (2,701)

Net 7,820 9,094

Patents and Product Rights [Member]

Finite-Lived Intangible Assets [Line Items]

Gross 10,449 10,449

Accumulated Amortization (7,844) (7,466)

Net 2,605 2,983

Patents and Product Rights [Member] | Minimum [Member]

Finite-Lived Intangible Assets [Line Items]

Amortization Period (Years) 3 years 3 years

Patents and Product Rights [Member] | Maximum [Member]

Finite-Lived Intangible Assets [Line Items]

Amortization Period (Years) 10 years 10 years

Acquired Technology [Member]

Finite-Lived Intangible Assets [Line Items]

Amortization Period (Years) 7 years 7 years

Gross 8,692 9,162

Accumulated Amortization (3,682) (2,952)

Net 5,010 6,210

Tradename [Member]

Finite-Lived Intangible Assets [Line Items]

Amortization Period (Years) 15 years 15 years

Gross 4,289 4,521

Accumulated Amortization (893) (715)

Net 3,396 3,806

Non-compete Agreements [Member]

Finite-Lived Intangible Assets [Line Items]

Gross 787

Accumulated Amortization (654)

Net $ 133

Non-compete Agreements [Member] | Minimum [Member]

Finite-Lived Intangible Assets [Line Items]

Amortization Period (Years) 1 year

Non-compete Agreements [Member] | Maximum [Member]

Finite-Lived Intangible Assets [Line Items]

Amortization Period (Years) 3 years

X

- Definition

Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph ((a)(1),(b))

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Business Segment Information - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2014 Segment
Segment Reporting [Abstract]
Number of reportable segments of company	2

Consolidated Balance Sheets (USD $) In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
CURRENT ASSETS:
Cash	$ 93,855	$ 93,191
Short-term investments	5,000
Accounts receivable, net of allowance for doubtful accounts of $288 and $299	14,920	12,957
Inventories	14,843	11,444
Prepaid expenses	1,089	1,712
Deferred income taxes	67	71
Other current assets	273	200
Total current assets	130,047	119,575
PROPERTY AND EQUIPMENT, net	17,958	17,933
INTANGIBLE ASSETS, net	18,831	22,226
GOODWILL	22,562	23,782
OTHER ASSETS	1,102	729
TOTAL ASSETS	190,500	184,245
CURRENT LIABILITIES:
Accounts payable	4,510	4,834
Deferred revenue	11,540	1,119
Accrued expenses	9,203	13,032
Total current liabilities	25,253	18,985
OTHER LIABILITIES	1,090	677
DEFERRED INCOME TAXES	3,233	3,437
COMMITMENTS AND CONTINGENCIES (Note 6)
STOCKHOLDERS' EQUITY
Preferred stock, par value $.000001, 25,000 shares authorized, none issued
Common stock, par value $.000001, 120,000 shares authorized, 56,052 and 55,632 shares issued and outstanding
Additional paid-in capital	342,865	338,674
Accumulated other comprehensive loss	(6,248)	(3,797)
Accumulated deficit	(175,693)	(173,731)
Total stockholders' equity	160,924	161,146
Total liabilities and stockholders' equity	$ 190,500	$ 184,245

Consolidated Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
OPERATING ACTIVITIES:
Net loss	$ (1,962)	$ (17,403)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Stock-based compensation	4,284	4,187
Depreciation and amortization	4,732	4,846
Unrealized foreign currency loss	(73)
Deferred income taxes	(33)	(786)
Changes in assets and liabilities
Accounts receivable	(2,111)	3,127
Inventories	(3,444)	745
Prepaid expenses and other assets	576	(554)
Accounts payable	(284)	497
Deferred revenue	10,433	(1,098)
Accrued expenses and other liabilities	(3,734)	3,297
Net cash provided by (used in) operating activities	8,384	(3,142)
INVESTING ACTIVITIES:
Purchases of short term investments	(9,407)
Proceeds from maturities of short term investments	4,432
Purchases of property and equipment	(2,353)	(1,696)
Net cash used in investing activities	(7,328)	(1,696)
FINANCING ACTIVITIES:
Proceeds from exercise of stock options	546	317
Repurchase of common stock	(639)	(817)
Net cash used in financing activities	(93)	(500)
EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH	(299)	40
NET INCREASE (DECREASE) IN CASH	664	(5,298)
CASH, BEGINNING OF PERIOD	93,191	87,888
CASH, END OF PERIOD	93,855	82,590
Cash paid for:
Income taxes	$ 42	$ 28

Stockholders' Equity - Additional Information (Detail) (USD $) Share data in Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost	$ 4,284,000	$ 4,187,000
Net cash proceeds from the exercise of stock options	546,000	317,000
Income tax benefit realized from stock option exercises during period	0	0
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost	1,998,000	2,159,000
Vesting of restricted shares, withheld and withholding obligations	106	122
Restricted shares of common stock, aggregate values	639,000	817,000
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost	2,286,000	2,028,000
Net cash proceeds from the exercise of stock options	$ 546,000	$ 317,000

Income Taxes - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
Income Taxes - Additional Information (Detail) (USD $)	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Income Tax Disclosure [Abstract]
Foreign deferred tax expense (benefits)	$ 10,000	$ (127,000)	$ (33,000)	$ (786,000)
U.S. federal income tax benefits	0	0	0	0
U.S. state income tax benefits	$ 0	$ 0	$ 0	$ 0

Consolidated Balance Sheets (Parenthetical) (USD $) In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 288	$ 299
Preferred stock, par value	$ 0.000001	$ 0.000001
Preferred stock, shares authorized	25,000	25,000
Preferred stock, shares issued
Common stock, par value	$ 0.000001	$ 0.000001
Common stock, shares authorized	120,000	120,000
Common stock, shares issued	56,052	55,632
Common stock, shares outstanding	56,052	55,632

Document and Entity Information	9 Months Ended
Document and Entity Information	Sep. 30, 2014	Nov. 04, 2014
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2014
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q3
Trading Symbol	OSUR
Entity Registrant Name	ORASURE TECHNOLOGIES INC
Entity Central Index Key	0001116463
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		56,056,813

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended		12 Months Ended			1 Months Ended	0 Months Ended	9 Months Ended		3 Months Ended	9 Months Ended
	Sep. 30, 2014 Customer	Sep. 30, 2013	Sep. 30, 2014 Customer Securities	Sep. 30, 2013	Dec. 31, 2013 Securities	Sep. 30, 2014 Up Front Payment Arrangement [Member]	Dec. 31, 2013 Up Front Payment Arrangement [Member]	Jul. 31, 2014 AbbVie [Member]	Nov. 21, 2013 Collaboration Agreement [Member]	Sep. 30, 2014 Collaboration Agreement [Member]	Sep. 30, 2014 Guaranteed Investment Certificates [Member]	Sep. 30, 2014 Accounts Receivable [Member] Customer Concentration Risk [Member]	Sep. 30, 2014 Maximum [Member]	Sep. 30, 2014 Maximum [Member] Building [Member]	Sep. 30, 2014 Maximum [Member] Computer Equipment [Member]	Sep. 30, 2014 Maximum [Member] Machinery and Equipment [Member]	Sep. 30, 2014 Maximum [Member] Furniture and Fixtures [Member]	Sep. 30, 2014 Minimum [Member]	Sep. 30, 2014 Minimum [Member] Building [Member]	Sep. 30, 2014 Minimum [Member] Computer Equipment [Member]	Sep. 30, 2014 Minimum [Member] Machinery and Equipment [Member]	Sep. 30, 2014 Minimum [Member] Furniture and Fixtures [Member]	Sep. 30, 2014 DNA Genotek [Member]
Product Information [Line Items]
Available-for-sale securities, amortized cost											$ 5,000
Available-for-sale securities, fair value											5,000
Available-for-sale securities					0
Fair value of plan assets	1,090		1,090		677
Estimated useful lives of assets														40 years	10 years	10 years	10 years		20 years	2 years	2 years	2 years
Accumulated depreciation of property and equipment	30,603		30,603		28,390
Amount of goodwill at period end	22,562		22,562		23,782
Payments received for sale of exclusive rights			75,000
Additional annual payments to be received for sale of exclusive rights													55,500					3,500
Expiration date of rights agreement			Dec. 31, 2019
Revenue recognition, milestone method description			We could be eligible to receive additional milestone payments. These payments would be based upon the aggregate number of new patients enrolled in the patient care database, in a given calendar year, after exceeding a baseline threshold, and could range from $3,500 to $55,500 annually over the life of the agreement. The first performance-based milestone period ends on December 31,2015.
Reserve for sales return and allowances			398		279
Gain on contract termination settlement			5,500						8,300	5,500
Contract Supply service agreement period										5 years
Deferred revenue	11,540		11,540		1,119	713	1,119	10,827
Deferred revenue payment received								15,000
Number of customers, accounted for significant concentrations	1		1
Percentage of concentration risk												12.00%
Concentration rate of accounts receivable	10.00%		10.00%
Concentration rate of net revenues	10.00%		10.00%
Number of third-party suppliers to manufacture DNAG's products																							2
Number of anti-dilutive securities excluded from EPS computation	2,647	5,499	3,313	5,324
Accumulated foreign currency adjustments included in other comprehensive loss amounted	$ 2,451	$ 1,709	$ 2,451	$ 1,709

Accrued Expenses - Schedule of Accrued Expenses (Detail) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Accrued Liabilities, Current [Abstract]
Payroll and related benefits	$ 5,093	$ 5,827
Royalties	1,703	4,374
Professional fees	484	749
Other	1,923	2,082
Accrued Expenses, Total	$ 9,203	$ 13,032

Summary of Significant Accounting Policies - Inventories (Detail) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Inventory, Net [Abstract]
Raw materials	$ 6,772	$ 6,700
Work in process	937	833
Finished goods	7,134	3,911
Inventories	$ 14,843	$ 11,444

Summary of Significant Accounting Policies - Summary of Intangible Assets (Detail) (USD $) In Thousands, unless otherwise specified	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]
Gross	$ 34,620	$ 36,714
Accumulated Amortization	(15,789)	(14,488)
Net	18,831	22,226
Customer List [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period (Years)	10 years	10 years
Gross	11,190	11,795
Accumulated Amortization	(3,370)	(2,701)
Net	7,820	9,094
Patents and Product Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Gross	10,449	10,449
Accumulated Amortization	(7,844)	(7,466)
Net	2,605	2,983
Patents and Product Rights [Member] \| Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period (Years)	3 years	3 years
Patents and Product Rights [Member] \| Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period (Years)	10 years	10 years
Acquired Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period (Years)	7 years	7 years
Gross	8,692	9,162
Accumulated Amortization	(3,682)	(2,952)
Net	5,010	6,210
Tradename [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period (Years)	15 years	15 years
Gross	4,289	4,521
Accumulated Amortization	(893)	(715)
Net	3,396	3,806
Non-compete Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Gross		787
Accumulated Amortization		(654)
Net		$ 133
Non-compete Agreements [Member] \| Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period (Years)		1 year
Non-compete Agreements [Member] \| Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period (Years)		3 years